prednisone and Precursor Cell Lymphoblastic Leukemia-Lymphoma
prednisone has been researched along with Precursor Cell Lymphoblastic Leukemia-Lymphoma in 601 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
Precursor Cell Lymphoblastic Leukemia-Lymphoma: A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"In the present prospective trial, 15 children with acute lymphoblastic leukemia and hyperleukocytosis (range 101-838 x 10(9)/l) were treated with intravenous low-dose prednisone continuous infusion (6 mg/m(2)/24 h)." | 9.14 | Management of hyperleukocytosis and prevention of tumor lysis syndrome with low-dose prednisone continuous infusion in children with acute lymphoblastic leukemia. ( Karakukcu, M; Kose, M; Ozdemir, MA; Patiroglu, T; Torun, YA, 2009) |
"In 1971, Cancer and Leukemia Group B (CALGB) mounted a study of acute lymphocytic leukemia (ALL) that compared the effects of the two steroid hormones dexamethasone and prednisone." | 9.07 | Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. ( Chevalier, L; Freeman, AI; Jacquillat, C; Jones, B; Koch, K; Maurer, HM; Pochedly, C; Shuster, JJ; Sinks, L; Weil, M, 1991) |
"Lubiprostone was more effective than stimulant laxatives at treating vinca alkaloid-induced intractable constipation in patients with hematological malignancies, and its use could enable safe vinca alkaloid chemotherapy." | 5.56 | Effect of lubiprostone on vinca alkaloid-induced constipation in patients with hematological malignancies: a propensity score-matched analysis. ( Fukuda, H; Hayashi, T; Imai, T; Kawada, K; Miyamura, M; Morita, Y; Ohta, T; Tanaka, K, 2020) |
"Ponatinib treatment was well tolerated and considered safe with easily manageable side effects." | 5.46 | Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic Transplant. ( Bossio, S; De Stefano, L; Gentile, M; Greco, R; Mazzone, C; Morabito, F; Morelli, R; Musolino, C; Palummo, A; Petrungaro, A; Recchia, AG; Uccello, G; Vigna, E, 2017) |
"We describe a 57-year-old woman with acute lymphoblastic leukemia who had a cavitary lesion develop in the right upper lobe caused by Cunninghamella bertholletiae, a zygomycete." | 5.33 | Treatment of cavitary pulmonary zygomycosis with surgical resection and posaconazole. ( Colson, YL; Marty, FM; Paul, S, 2006) |
"During treatment Hepatitis B was reactivated and after termination, of chemotherapy she developed fulminant hepatitis with hyperbilirubinemia, coagulopathy, hypoalbuminemia and ascites." | 5.31 | [Effective treatment with Lamivudine of patients with reactivation of hepatitis B following chemotherapy administration]. ( Haran, M; Klepfish, A; Lurie, Y; Malnick, S; Shtalrid, M, 2001) |
"In the present prospective trial, 15 children with acute lymphoblastic leukemia and hyperleukocytosis (range 101-838 x 10(9)/l) were treated with intravenous low-dose prednisone continuous infusion (6 mg/m(2)/24 h)." | 5.14 | Management of hyperleukocytosis and prevention of tumor lysis syndrome with low-dose prednisone continuous infusion in children with acute lymphoblastic leukemia. ( Karakukcu, M; Kose, M; Ozdemir, MA; Patiroglu, T; Torun, YA, 2009) |
" In this study, adrenal function and signs and symptoms of adrenal insufficiency were prospectively assessed in children with acute lymphoblastic leukemia (ALL) after induction treatment including high-dose prednisone (PDN) or dexamethasone (DXM)." | 5.13 | Adrenal axis function after high-dose steroid therapy for childhood acute lymphoblastic leukemia. ( Barisone, E; Bertorello, N; Corrias, A; Einaudi, S; Farinasso, L; Masera, N; Pastore, G; Riva, F; Rizzari, C; Saracco, P; Villa, A, 2008) |
"In 1971, Cancer and Leukemia Group B (CALGB) mounted a study of acute lymphocytic leukemia (ALL) that compared the effects of the two steroid hormones dexamethasone and prednisone." | 5.07 | Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. ( Chevalier, L; Freeman, AI; Jacquillat, C; Jones, B; Koch, K; Maurer, HM; Pochedly, C; Shuster, JJ; Sinks, L; Weil, M, 1991) |
"The hyper-CVAD/methotrexate-cytarabine (H-CVAD/ MTX-AraC) chemotherapy protocol has been one of the standard treatments for hematological malignancies, such as mantle cell lymphoma (MCL), Burkitt lymphoma (BL), and B-cell and T-cell acute lymphoblastic leukemia." | 4.02 | Efficacy of chemotherapy protocols for hematological malignancies: H-CVAD versus GELA/BURKIMAB/PETHEMA LAL. ( Algarra-Algarra, JL; Gómez-Catalán, I; Hernández-Fernández, F; Ibañez-García, Á; Marín-Sánchez, A; Martínez-Fernández, G; Montoya-Morcillo, MC; Romero-Macías, JR, 2021) |
"The authors report the occurrence of fatal or near-fatal sepsis in 16 of 38 children with newly diagnosed acute lymphoblastic leukemia (ALL) treated with a new induction regimen that differed from its predecessor by the substitution of dexamethasone for prednisone." | 3.70 | Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia. ( Clavell, LA; Dalton, VK; Gelber, RD; Glick, KM; Hurwitz, CA; Sallan, SE; Schorin, MA; Silverman, LB, 2000) |
" Patients treated with a combination of prednisone and dexamethasone had as a late effect the highest prevalence of obesity (44%)." | 3.69 | Obesity after successful treatment of acute lymphoblastic leukemia in childhood. ( De Groot, A; Egeler, RM; Hählen, K; Hokken-Koelega, AC; Tromp, CG; Van Dongen-Melman, JE, 1995) |
"Outpatient adherence to oral medication regimens was evaluated in 50 adolescents and young adults with cancer: 21 patients with acute lymphoblastic leukemia or Hodgkin disease who were to take prednisone as a component of their chemotherapy regimen, and 29 patients with Hodgkin disease whose chemotherapy had been discontinued and who were to take penicillin for postsplenectomy prophylaxis." | 3.68 | Therapeutic adherence to oral medication regimens by adolescents with cancer. I. Laboratory assessment. ( Chasalow, F; Festa, RS; Lanzkowsky, P; Tamaroff, MH, 1992) |
"Two children with bone marrow necrosis at diagnosis or at relapse of acute lymphoblastic leukemia (ALL) had thrombotic complications 15 and 17 days after starting remission induction therapy including prednisone, vincristine, and L-asparaginase." | 3.68 | Bone marrow necrosis and thrombotic complications in childhood acute lymphoblastic leukemia. ( Eguiguren, JM; Pui, CH, 1992) |
"The protocol included minimal residual disease (MRD) analysis at two different time-points (TP), that is, at the end of induction IA and consolidation IB, and a modulation in post-consolidation intensity according to MRD." | 3.01 | Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL-1308 trial. ( Candoni, A; Canichella, M; Cavalli, M; Chiaretti, S; Conter, V; D'Aloisio, M; De Propris, MS; Elia, L; Fazi, P; Foà, R; Guarini, A; Luppi, M; Martino, B; Messina, M; Moleti, ML; Piciocchi, A; Starza, ID; Testi, AM; Vignetti, M; Vitale, A, 2021) |
"Pentoxifylline is a xanthine that possesses antitumor properties and that can induce higher apoptosis in the leukemic cells of pediatric patients with acute lymphoblastic leukemia (ALL) during treatment with prednisone." | 2.87 | Pentoxifylline Added to Steroid Window Treatment Phase Modified Apoptotic Gene Expression in Pediatric Patients With Acute Lymphoblastic Leukemia. ( Aguilar-Lemarroy, A; Bravo-Cuellar, A; Gonzalez-Ramella, O; Hernández-Flores, G; Jave-Suárez, LF; Meza-Arroyo, J; Ortiz-Lazareno, P; Padilla-Corona, M; Sanchez-Zubieta, F, 2018) |
"Approximately 30% of childhood acute lymphoblastic leukemia (ALL) cases are high hyperdiploid (HD)." | 2.84 | High hyperdiploid acute lymphoblastic leukemia (ALL)-A 25-year population-based survey of the Austrian ALL-BFM (Berlin-Frankfurt-Münster) Study Group. ( Attarbaschi, A; Dworzak, M; Haas, OA; König, M; Mann, G; Meister, B; Pichler, H; Pötschger, U; Reismüller, B; Schmitt, K; Steiner, M; Urban, C, 2017) |
"The idarubicin dose was adjusted according to the degree of myelosuppression." | 2.84 | Outcome of Reinduction Chemotherapy with a Modified Dose of Idarubicin for Children with Marrow-Relapsed Acute Lymphoblastic Leukemia: Results of the Childhood Acute Lymphoblastic Leukemia (CALL)-0603 Study. ( Ahn, HS; Im, HJ; Kang, HJ; Kim, H; Koh, KN; Koo, HH; Lee, JW; Lim, YT; Park, BK; Park, HJ; Park, JE; Park, KD; Seo, JJ; Shin, HY; Sung, KW; Yoo, KH, 2017) |
"Pentoxifylline (PTX) has been shown to increase chemotherapy-induced apoptosis." | 2.82 | Pentoxifylline during steroid window phase at induction to remission increases apoptosis in childhood with acute lymphoblastic leukemia. ( Bravo-Cuellar, A; Gallegos-Castorena, S; Gonzalez-Ramella, O; Hernández-Flores, G; Jave-Suárez, LF; Jiménez-López, X; Lerma-Díaz, JM; Medina-Barajas, F; Meza-Arroyo, J; Ortiz-Lazareno, PC; Sánchez-Zubieta, F, 2016) |
"Induction therapy for childhood acute lymphoblastic leukemia (ALL) traditionally includes prednisone; yet, dexamethasone may have higher antileukemic potency, leading to fewer relapses and improved survival." | 2.82 | Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. ( Aricò, M; Attarbaschi, A; Barisone, E; Bartram, CR; Basso, G; Beier, R; Biondi, A; Caruso, R; Cazzaniga, G; Conter, V; Greiner, J; Harbott, J; Kremens, B; Kulozik, AE; Lo Nigro, L; Locatelli, F; Mann, G; Möricke, A; Niggli, F; Parasole, R; Ratei, R; Rössig, C; Schrappe, M; Silvestri, D; Stanulla, M; Valsecchi, MG; von Stackelberg, A; Zimmermann, M, 2016) |
"Methyprednisone was administrated and the symptoms relieved gradually." | 2.82 | Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy. ( Cui, Q; Hu, Y; Huang, H; Jin, A; Liang, B; Luo, Y; Pu, C; Shi, J; Sun, J; Wu, Z; Xiao, L; Yu, J, 2016) |
"The level of minimal residual disease during remission induction is the most important prognostic indicator in patients with acute lymphoblastic leukaemia (ALL)." | 2.80 | Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. ( Bhojwani, D; Bowman, WP; Campana, D; Cheng, C; Coustan-Smith, E; Downing, JR; Evans, WE; Gruber, TA; Inaba, H; Jeha, S; Leung, WH; Pei, D; Pui, CH; Relling, MV; Ribeiro, RC; Rubnitz, JE; Sandlund, JT, 2015) |
"Acute lymphoblastic leukemia (ALL) is the most frequent childhood malignancy." | 2.80 | [The prospects for children with acute lymphoblastic leukemia of being cured has increased in the Czech Republic in the 21st century to 90% - outcome of the ALL-IC BFM 2002 trial]. ( Blažek, B; Černá, Z; Domanský, J; Hak, J; Houdková, A; Hrušák, O; Jabali, Y; Janotová, I; Jarošová, M; Mejstříková, E; Mihál, V; Novák, Z; Procházková, D; Ptoszková, H; Sedláček, P; Smíšek, P; Starý, J; Štěrba, J; Timr, P; Trka, J; Zdráhalová, K; Zemanová, Z; Zuna, J, 2015) |
"Children with acute lymphoblastic leukemia (ALL) and high minimal residual disease (MRD) levels after initial chemotherapy have a poor clinical outcome." | 2.78 | High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation. ( Alvaro, F; Bierings, MB; Cross, S; Dalla Pozza, L; de Bont, ES; de Groot-Kruseman, HA; de Haas, V; Haber, M; Hoogerbrugge, PM; Kaspers, GJ; Law, T; Maarten Egeler, R; Marshall, GM; Mueller, H; Ng, A; Norris, MD; Pieters, R; Révész, T; Suppiah, R; Sutton, R; van den Berg, H; van der Schoot, E; van der Velden, VH; van Dongen, J; Venn, NC, 2013) |
"The detection of minimal residual disease (MRD) via molecular genetic methods provides - in comparison with conventional clinical and biological parameters - much more sensitive approaches to monitor individual treatment response." | 2.78 | [Molecular genetic detection of minimal residual disease (MRD) in children with acute lymphoblastic leukemia]. ( Bartram, CR; Koehler, R, 2013) |
"In the ALL-BFM studies for treatment of acute lymphoblastic leukemia, reduction of leukemic blasts in peripheral blood after a one-week prednisone pre-phase - the so-called prednisone response - has been used for risk stratification since the 1980s and has been one of the most relevant factors for identification of high-risk patients." | 2.78 | Prediction of outcome by early response in childhood acute lymphoblastic leukemia. ( Attarbaschi, A; Beier, R; Lauten, M; Möricke, A; Niggli, F; Odenwald, E; Schrappe, M; Stanulla, M; Zimmermann, M, 2013) |
"Localized lymphoblastic lymphoma (LL) is rare in pediatric patients." | 2.77 | Outcome of newly diagnosed children and adolescents with localized lymphoblastic lymphoma treated on Children's Oncology Group trial A5971: a report from the Children's Oncology Group. ( Abromowitch, M; Finlay, JL; Gross, TG; Lones, M; Perkins, SL; Smith, LM; Termuhlen, AM; Weinstein, H, 2012) |
"Treatment of acute lymphoblastic leukemia (ALL) has included the use of prophylactic cranial irradiation in up to 20% of children with high-risk disease despite known cognitive risks of this treatment modality." | 2.77 | Cognitive outcomes following contemporary treatment without cranial irradiation for childhood acute lymphoblastic leukemia. ( Cheng, C; Conklin, HM; Krull, KR; Pei, D; Pui, CH; Reddick, WE, 2012) |
"Osteonecrosis is a severe glucocorticoid-induced complication of acute lymphoblastic leukemia treatment." | 2.76 | Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. ( Cai, X; Cheng, C; Evans, WE; Howard, SC; Kaste, SC; Kawedia, JD; Neale, G; Panetta, JC; Pei, D; Pui, CH; Relling, MV, 2011) |
"coli asparaginase in children with acute lymphoblastic leukemia in second bone marrow relapse." | 2.76 | Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866). ( Asselin, B; Bernstein, M; Buchanan, GR; Camitta, BM; Kurtzberg, J; Pollock, BH, 2011) |
"A total of 201 pediatric cases of acute lymphoblastic leukemia were treated with the ALL-96 protocol by the Kyushu-Yamaguchi Children's Cancer Study Group." | 2.75 | Randomized trial to compare LSA2L2-type maintenance therapy to daily 6-mercaptopurine and weekly methotrexate with vincristine and dexamethasone pulse for children with acute lymphoblastic leukemia. ( Fujita, K; Hidaka, Y; Hotta, N; Inada, H; Itonaga, N; Kawakami, K; Kawano, Y; Matsuzaki, A; Moritake, H; Nagatoshi, Y; Nakayama, H; Okamura, J; Suminoe, A; Ueda, K; Yamanaka, T; Yanai, F, 2010) |
"Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy." | 2.75 | [Long-term observations of children with acute lymphoblastic leukemia and high leukocytosis treated according to modified "New York" protocols (1987-2003)]. ( Balcerska, A; Balwierz, W; Chybicka, A; Derwich, K; Dobaczewski, G; Kowalczyk, JR; Kwiecińska, K; Matysiak, M; Moryl-Bujakowska, A; Pawelec, K; Płoszyńska, A; Sońta-Jakimczyk, D; Styczyński, J; Szczepański, T; Tomaszewska, R; Wachowiak, J; Wiśniewska-Slusarz, H; Wysocki, M, 2010) |
"Treatment of childhood relapsed acute lymphoblastic leukemia (ALL) remains a significant challenge." | 2.73 | Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected]. ( Borowitz, MJ; Camitta, BM; Carroll, WL; Devidas, M; Gaynon, PS; Hunger, SP; Linda, SB; Raetz, EA; Winick, NJ, 2008) |
"To improve the outcome of children with acute lymphoblastic leukemia (ALL) treated at the National Cancer Institute, Bogota, Colombia, a protocol based on the BFM-90 (Berlin, Frankfurt, Munster study) and the LSA2L2 regimens was implemented in the year 1993." | 2.73 | The impact of acute lymphoblastic leukemia treatment on central nervous system results in Bogota, Colombia. ( Buendia, MT; Guevara, G; Lozano, JM; Saavedra, C; Suarez, GE, 2008) |
"Two toxic deaths were observed, and infections and neuropathy were the most common toxicities." | 2.73 | Augmented and standard Berlin-Frankfurt-Munster chemotherapy for treatment of adult acute lymphoblastic leukemia. ( Chang, JE; Esterberg, E; Juckett, MB; Kahl, BS; Kim, J; Kim, K; Lionberger, J; Longo, WL; Medlin, SC; Williams, EC, 2008) |
"Only 20-30% of elderly patients with acute lymphoblastic leukemia (ALL) are enrolled in clinical trials because of co-morbid disorders or poor performance status." | 2.73 | Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. ( Abella, E; Bethencourt, C; Brunet, S; Debén, G; del Potro, E; Feliu, E; Hernández-Rivas, JM; López, R; Morgades, M; Novo, A; Oriol, A; Ortega-Rivas, F; Ortín, X; Ribera, JM; Sancho, JM; Sanz, MA; Tormo, M; Xicoy, B, 2007) |
" The population mean peak serum concentration of asparaginase enzymatic activity was 1 IU/mL, the elimination half-life was 7 days, and the volume of distribution was 2." | 2.73 | Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. ( Avramis, VI; Cohen, LJ; Douer, D; Levine, AM; Periclou, AP; Watkins, K; Yampolsky, H, 2007) |
"Thirty-six untreated lymphoblastic lymphoma patients aged from 3 to 18 years were included, with 1 patient in stage II , 9 in stage III and 26 in stage IV." | 2.73 | [Modified BFM-90 regimen greatly improves treatment outcomes of chinese childhood and adolescent lymphoblastic lymphoma]. ( Guan, ZZ; Huang, HQ; Li, YH; Ling, JY; Liu, DG; Sun, XF; Xia, Y; Xia, ZJ; Zhang, L; Zhen, ZJ; Zhou, ZM, 2007) |
"Cure rates for adult acute lymphoblastic leukemia (ALL) in developing countries are significantly lower because of problems unique to these countries." | 2.73 | Outcome of adult acute lymphoblastic leukemia with BFM protocol in a resource-constrained setting. ( Ahluwalia, J; Das, R; Jain, S; Kumari, S; Mahi, S; Malhotra, P; Radhika, S; Sharma, SC; Varma, N; Varma, S, 2007) |
"Fifty-two infants with acute lymphoblastic leukemia (ALL) enrolled in the AIEOP ALL-91 and ALL-95 studies were treated with the intermediate or high risk protocols according to their presenting features and early response to treatment." | 2.72 | Role of treatment intensification in infants with acute lymphoblastic leukemia: results of two consecutive AIEOP studies. ( Aricò, M; Basso, G; Biondi, A; De Lorenzo, P; De Rossi, G; Lo Nigro, L; Locatelli, F; Masera, G; Rizzari, C; Valsecchi, MG, 2006) |
"The regimen for acute lymphocytic leukemia was idarubicin 8 mg/m2, dl - 3; vincristine 2 mg/mr, dl; cyclophosphamide 750 mg/m2, dl ; plus prednisone 60 mg/m(2),dl - 14 for 1-2 cycles." | 2.72 | [Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia]. ( Du, X; Ke, XY; Liu, Y; Lu, ZS; Lv, JQ; Ma, J; Shen, ZX; Xu, XH; Zeng, XY; Zhan, ZM; Zhang, XH; Zhao, YM, 2006) |
" During delayed intensification, all patients received a dexamethasone dosage of 10 mg/m(2)/d for 21 days, with taper." | 2.71 | Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. ( Bostrom, BC; Erdmann, GR; Gaynon, PS; Gold, S; Heerema, NA; Hutchinson, RJ; Johnston, K; La, MK; Provisor, AJ; Sather, HN; Sensel, MR; Trigg, ME, 2003) |
"Relapse was diagnosed in 17." | 2.71 | [Improved results in children with acute lymphoblastic leukemia treated with the ALL-BFM 90 protocol in the Czech Republic]. ( Blazek, B; Cerná, Z; Dembická, D; Gajdos, P; Hak, J; Hrstková, H; Hrusák, O; Jabali, Y; Kopecná, L; Mihál, V; Mydlil, J; Pospísilová, D; Procházková, D; Ptoszková, H; Slavík, Z; Starý, J; Timr, P; Trka, J; Vávra, V; Zahálka, F, 2003) |
"In all, 236 adults with newly diagnosed acute lymphoblastic leukemia (ALL) were randomly assigned to receive either granulocyte colony-stimulating factor (G-CSF), or granulocyte-macrophage CSF (GM-CSF), or no CSF during a 4-week 4-drugs induction chemotherapy." | 2.71 | Efficacy of granulocyte and granulocyte-macrophage colony-stimulating factors in the induction treatment of adult acute lymphoblastic leukemia: a multicenter randomized study. ( Boiron, JM; Boulat, O; Espinouse, D; Fiere, D; Garban, F; Gardin, C; Huguet, F; Lhéritier, V; Reman, O; Sutton, L; Thomas, X; Turlure, P, 2004) |
"Children with acute lymphoblastic leukemia (ALL) receive as part of induction therapy a 4-week course of high-dose glucocorticoid, which is either abruptly discontinued or shortly tapered." | 2.71 | Steroid withdrawal syndrome during steroid tapering in childhood acute lymphoblastic leukemia: a controlled study comparing prednisone versus dexamethasone in induction phase. ( Altare, F; Barisone, E; Bertorello, N; Corrias, A; Einaudi, S; Farinasso, L; Pastore, G; Saracco, P, 2005) |
" Gender, ALL-immunophenotype, steroid-type or ASP dosing schedule did not alter the risk but older age and HR-disease were factors predisposing to TE associated with DFCI-ALL protocols." | 2.71 | Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease. ( Athale, UH; Barr, RD; Chan, AK; Crowther, M; Siciliano, SA, 2005) |
"Patients with advanced-stage Burkitt lymphoma, including those with bone marrow and/or central nervous system involvement, can be cured with a short-term intensive chemotherapy regime tailored to the tumor burden." | 2.71 | Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol. ( Bosq, J; Casassus, P; Diviné, M; Dupriez, B; Koscielny, S; Le Maignan, C; Pico, JL; Raphaël, M; Ribrag, V; Sebban, C; Stamattoulas, A, 2005) |
" The distribution of adverse prognostic factors was comparable in the two-induction arm." | 2.70 | Daunorubicin continuous infusion induces more toxicity than bolus infusion in acute lymphoblastic leukemia induction regimen: a randomized study. ( Bernard, M; Casassus, P; Delain, M; Desablens, B; Guilhot, F; Hunault-Berger, M; Ifrah, N; Jouet, JP; Milpied, N; Sadoun, A, 2001) |
"Glucocorticoid treatment in childhood acute lymphoblastic leukemia increases energy intake markedly, and this effect contributes to the excess weight gain and obesity characteristic of patients being treated for acute lymphoblastic leukemia." | 2.70 | Effect of glucocorticoid therapy on energy intake in children treated for acute lymphoblastic leukemia. ( Brougham, M; Gibson, BE; Kelly, A; Montgomery, C; Reilly, JJ; Richardson, F, 2001) |
" These results suggest that increasing DNM dosage in induction is one of the possible approaches to improve the outcome of adult ALL by decreasing the relapse occurrence." | 2.69 | Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin. ( April, F; Meneghini, V; Perona, G; Pizzolo, G; Ricetti, MM; Solero, P; Tecchio, C; Todeschini, G; Veneri, D; Zanotti, R, 1998) |
"Twenty-one patients (ALL:10, NHL:8, ATLL:2, ATL:1) were assessable for response and toxicity." | 2.69 | [EPOCH therapy for relapsed/refractory lymphoid malignancies]. ( Asai, O; Dobashi, N; Kato, A; Katori, M; Kobayashi, T; Kuraishi, Y; Nagamine, M; Tajima, N; Usui, N; Watanabe, H; Yamazaki, H; Yano, S, 1998) |
"CD45 was detected on the surface of childhood ALL cells (cut-off > or = 20% positive cells) in only 88." | 2.69 | Immunophenotype and clinical characteristics of CD45-negative and CD45-positive childhood acute lymphoblastic leukemia. ( Harbott, J; Karawajew, L; Ludwig, WD; Ratei, R; Riehm, H; Schott, G; Schrappe, M; Sperling, C, 1998) |
"The prednisone response was defined as the cytoreduction (number of blood blasts per microliter at day 8) to a 7-day prednisone prephase and 1 intrathecal dose of methotrexate on day 1." | 2.69 | Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. ( Borkhardt, A; Dördelmann, M; Gadner, H; Götz, N; Ludwig, WD; Reiter, A; Riehm, H; Schrappe, M; Viehmann, S, 1999) |
"Patients with refractory or recurrent acute lymphoblastic leukemia (ALL) were treated with a combination of methotrexate (MTX), vincristine, PEG-asparaginase, and prednisone (MOAP)." | 2.69 | Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia. ( Aguayo, A; Cortes, J; Kantarjian, H; Keating, M; Pierce, S; Thomas, D, 1999) |
"Children with acute lymphoblastic leukemia (ALL) who experience hematologic recurrence while receiving chemotherapy or within 6 months after its cessation have a low cure rate." | 2.69 | Alternating drug pairs with or without periodic reinduction in children with acute lymphoblastic leukemia in second bone marrow remission: a Pediatric Oncology Group Study. ( Boyett, JM; Buchanan, GR; Chauvenet, AR; Crist, WM; Maybee, DA; Pinkel, D; Pollock, BH; Rivera, GK; Wagner, H, 2000) |
"G-CSF can increase CDI in high-risk childhood ALL." | 2.69 | Use of recombinant human granulocyte colony-stimulating factor to increase chemotherapy dose-intensity: a randomized trial in very high-risk childhood acute lymphoblastic leukemia. ( Auclerc, MF; Auvrignon, A; Baruchel, A; Bauduer, F; Berthou, C; Bordigoni, P; Demeocq, F; Lamagnere, JP; Landman-Parker, J; Leblanc, T; Legall, E; Leverger, G; Mathey, C; Michel, G; Pautard, B; Perel, Y; Schaison, G; Schneider, P, 2000) |
" There was a highly significant difference in CR rates between weekly (69 of 71; 97%) and biweekly (60 of 73; 82%) PEG-Asp dosing (P =." | 2.69 | Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study. ( Abshire, TC; Billett, AL; Bradley, P; Buchanan, GR; Pollock, BH, 2000) |
"Disease progression, which includes recurrence at the primary tumor site, is a major cause of treatment failure in patients with mediastinal presentations." | 2.68 | Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: a Childrens Cancer Group study. ( Kadin, M; Kersey, JH; King, D; Krailo, MD; Meadows, AT; Morse, M; Rosenstock, J; Steinherz, PG; Tubergen, DG, 1995) |
"673 of them suffered from acute lymphoblastic leukemia (ALL) at primary diagnosis and a transcription of the chimeric gene was detected in 21 of 648 with a successful analysis (3." | 2.68 | Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92. ( Bartram, CR; Borkhardt, A; Harbott, J; Janka-Schaub, G; Janssen, JW; Kabisch, H; Lampert, F; Ludwig, WD; Ratei, R; Reinisch, I; Repp, R; Riehm, H; Ritterbach, J; Schlieben, S; Schrappe, M; Zimmermann, M, 1996) |
"The cure rate of childhood acute lymphoblastic leukemia (ALL) has improved dramatically." | 2.68 | Intermediate-dose methotrexate versus cranial irradiation in childhood acute lymphoblastic leukemia: a ten-year follow-up. ( Boyett, JM; Brecher, ML; Freeman, AI; Glicksman, AS; Holland, JF; Leventhal, BG; Sinks, LF, 1997) |
"A total of 119 children (1990-95) with acute lymphoblastic leukemia (ALL) B-lineage either CD10+ or CD10- were registered into a single non-randomized chemotherapy protocol." | 2.68 | B-lineage acute lymphoblastic leukemia of childhood. An institutional experience. ( Cardenas-Cardos, R; Gómez-Martínez, R; Leal-Leal, C; Meza-Coria, C; Navarro-Alegría, I; Rivera-Luna, R; Vega-Vega, L, 1997) |
"Improved survival of children with acute lymphoblastic leukemia (ALL) has made it more difficult to develop new protocols to further improve results." | 2.67 | Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan-Kettering-New York-II protocol. ( Heller, G; Meyers, P; Redner, A; Steinherz, L; Steinherz, PG; Tan, C, 1993) |
" Gastrointestinal morbidity was less in the cohort treated without Ara-C; however, infectious morbidity persisted at unacceptable levels and this program was terminated as too toxic to administer." | 2.67 | Severe toxicity limits intensification of induction therapy for acute lymphoblastic leukemia. ( Berman, E; Gaynor, J; Gee, T; Kempin, S; Kritz, A; Little, C; Scheinberg, D; Sogoloff, H; Telford, P; Weiss, M, 1993) |
"Vindesine was more toxic than Vincristine." | 2.67 | A study of toxicity and comparative therapeutic efficacy of vindesine-prednisone vs. vincristine-prednisone in children with acute lymphoblastic leukemia in relapse. A Pediatric Oncology Group study. ( Beardsley, GP; Buchanan, G; Hvizdale, E; Krischer, J; Link, M; Maybee, D; Mehta, P; Nitschke, R; Ragab, A; Vats, T, 1992) |
"Initial treatment and relapse therapy were similar in all patients according to the BFM- and CoALL-protocols (front line: 38 patients according to BFM-protocols and 13 patients according to CoALL-protocols; relapse: 12 patients in study ALL-REZ-BFM 83, 17 in ALL-REZ-BFM 85, 20 in ALL-REZ-BFM 87, and two in ALL-REZ-BFM 90)." | 2.67 | Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: results of the German Cooperative Study. ( Bender-Götze, C; Dopfer, R; Ebell, W; Ehninger, G; Friedrich, W; Gadner, H; Henze, G; Klingebiel, T; Peters, C; Riehm, H, 1991) |
"58% of the non-Hodgkin's lymphomas occurred in patients with marked immunodeficiency, 85% were high grade malignancies and 47% had primary extranodal disease." | 2.67 | [Malignant lymphoma associated with HIV infection]. ( Becker, K; Clemens, MR; Fischer, T; Helm, EB; Knauf, W; Mitrou, PS; Pohl, C; Schrappe-Bächer, M; Serke, M; Westerhausen, M, 1991) |
"Boys with acute lymphoblastic leukemia (ALL) who have overt testicular relapse (OTR) during initial continuation chemotherapy or within 6 months thereafter have poor outcomes, with long-term survival similar to patients with marrow relapse during treatment." | 2.67 | Improved treatment results in boys with overt testicular relapse during or shortly after initial therapy for acute lymphoblastic leukemia. A Pediatric Oncology group study. ( Boyett, JM; Buchanan, GR; Crist, WM; Ghim, T; Johnson, W; Pollock, BH; Smith, SD; Vietti, TJ; Wharam, MD; Yanofsky, RA, 1991) |
"Daunorubicin was associated with more early deaths but improved disease-free survival for those achieving remission." | 2.67 | Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood). ( Eden, OB; Lilleyman, JS; Peto, J; Richards, S; Shaw, MP, 1991) |
"Among 3,638 children with acute lymphoblastic leukemia (ALL) entered on Pediatric Oncology Group (POG) protocols between June 1981 and April 1989, successful cytogenetic studies were available for 2,519, 58 (2." | 2.67 | Philadelphia chromosome positive childhood acute lymphoblastic leukemia: clinical and cytogenetic characteristics and treatment outcome. A Pediatric Oncology Group study. ( Behm, F; Borowitz, M; Carroll, A; Crist, W; Head, D; Jackson, J; Link, M; Ragab, A; Shuster, J; Steuber, P, 1990) |
" It is generally agreed that dexamethasone is the steroid of choice for groups using a delayed intensification phase, but dosing schedules (intermittent versus continuous) vary." | 2.46 | The optimal use of steroids in paediatric acute lymphoblastic leukaemia: no easy answers. ( McNeer, JL; Nachman, JB, 2010) |
"By contrast, B-cell lymphoblastic lymphoma/leukemia is a rare high-grade malignancy that comprises approximately 10% of all lymphoblastic lymphomas." | 2.44 | Rare oral cavity presentation of a B-cell lymphoblastic lymphoma. A case report and review of the literature. ( Cox, DP; Dong, R; Jordan, RC; Treseler, P, 2007) |
"The risk of thrombosis in children with acute lymphoblastic leukemia (ALL) reportedly ranges between 1% and 37%." | 2.43 | Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. ( Caruso, V; de Gaetano, G; Di Castelnuovo, A; Donati, MB; Iacoviello, L; Mariani, G; Storti, S, 2006) |
"The poor prognosis of lymphoblastic leukemia in children under 1 year of age is attributed largely to rearrangements involving the mixed lineage leukemia (mll, also known as all1, htrx, trx1, or hrx) gene that occur with increased frequency in this population." | 2.42 | Lymphoblastic leukemia with mature B-cell phenotype in infancy. ( Batanian, JR; Frater, JL; Grosso, LE; O'Connor, DM, 2004) |
"Acute lymphoblastic leukemia (ALL) is one of the few malignant disease for which substantial improvement was achieved during the last two decades." | 2.40 | [Treatment of acute lymphoblastic leukemias in adults]. ( Krykowski, E; Wrzesień-Kuś, A, 1997) |
"Among 4,760 acute lymphoblastic leukemia (ALL) patients enrolled from 1986 to 1995 in two subsequent trials of the BFM and AIEOP study group, 61 patients were found to have Philadelphia chromosome-positive (Ph+) ALL." | 2.40 | Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome. ( Aricò, M; Bartram, CR; Basso, G; Biondi, A; Conter, V; Gadner, H; Harbott, J; Lampert, F; Masera, G; Reiter, A; Riehm, H; Schrappe, M; Valsecchi, MG; Zimmermann, M, 1998) |
"Treatment of childhood acute lymphoblastic leukemia has included glucocorticosteroids for almost 50 years." | 2.40 | Glucocorticosteroid therapy in childhood acute lymphoblastic leukemia. ( Carrel, AL; Gaynon, PS, 1999) |
"Acute myelofibrosis (AMF), as defined by an acute panmyelopathy associated with marked megakaryocytic hyperplasia and marrow fibrosis, appears to be a stem cell disorder." | 2.39 | Acute myelofibrosis terminating in acute lymphoblastic leukemia: case report and review of the literature. ( Dunphy, CH; Kitchen, S; Saravia, O; Velasquez, WS, 1996) |
"We reviewed all reported cases of Burkitt's lymphoma and/or Burkitt's leukemia (BLL) occurring following therapy for Hodgkin's disease." | 2.39 | Burkitt's lymphoma-leukemia in patients treated for Hodgkin's disease. ( Cooper, DL; Levy, A; Salloum, E; Tallini, G, 1996) |
"Chemotherapeutic regimens for childhood acute lymphoblastic leukemia (ALL) include a remission induction period with high, daily doses of prednisone among other agents." | 2.38 | Reduced incidence of the somnolence syndrome in leukemic children with steroid coverage during prophylactic cranial radiation therapy. Results of a pilot study. ( Fuks, Z; Mandell, LR; Steinherz, P; Walker, RW, 1989) |
"Besides, the PLK4 expression in childhood ALL patients was also determined at day 15 after the initiation of induction therapy (D15)." | 1.91 | Polo-like Kinase 4: the Variation During Therapy and its Relation to Treatment Response and Prognostic Risk Stratification in Childhood Acute Lymphoblastic Leukemia Patients. ( Xu, J; Zhao, L, 2023) |
"The prognosis of childhood acute lymphoblastic leukemia (ALL) in Indonesia, a lower-middle-income country (LMIC), is lower than in high income countries (HICs)." | 1.72 | Childhood acute lymphoblastic leukemia: Four years evaluation of protocols 2013 and 2016 in a single center in Indonesia, a lower-middle-income country. ( Adelin, CP; Ardianto, B; Christian, SD; Kaspers, GJL; Kors, WA; Lestari, RP; Mulatsih, S; Pangarso, AWS; Purwanto, I; Sabrina, DS; Sagoro, L; Supriyadi, E; Sutaryo, S; Veerman, AJP; Verena, N; Widjajanto, PH, 2022) |
"We represent here an atypical case of lymphoblastic lymphoma revealed by an isolated third cranial nerve palsy." | 1.62 | Disseminated lymphoblastic lymphoma revealed by an isolated third cranial nerve palsy. ( Bahloul, Z; Ben Salah, R; Bouattour, Y; Chabchoub, I; Feki, J; Frikha, F; Kammoun, S, 2021) |
"The prognosis of childhood acute lymphoblastic leukemia (ALL) is optimistic with a 5-year event-free survival (EFS) rate of 70-85%." | 1.62 | Reduced intensity of early intensification does not increase the risk of relapse in children with standard risk acute lymphoblastic leukemia - a multi-centric clinical study of GD-2008-ALL protocol. ( Chen, HQ; Fang, JP; Li, CG; Li, CK; Li, JQ; Li, XY; Lin, YD; Liu, RY; Luo, XQ; Sun, X; Sun, XF; Wu, XD; Xu, HG, 2021) |
"Childhood acute lymphoblastic leukemia (cALL) is a common hematological malignancy in children with unfavorable prognosis." | 1.62 | Long non-coding RNA MEG3 as a candidate prognostic factor for induction therapy response and survival profile in childhood acute lymphoblastic leukemia patients. ( Gao, W, 2021) |
"Therapy for childhood acute lymphoblastic leukemia (ALL) is associated with substantial health care utilization and burden on families." | 1.62 | Phase-specific risks of outpatient visits, emergency visits, and hospitalizations during Children's Oncology Group-based treatment for childhood acute lymphoblastic leukemia: A population-based study. ( Athale, U; Bassal, M; Breakey, VR; Gibson, PJ; Gupta, S; Li, Q; Mittmann, N; Patel, S; Pechlivanoglou, P; Pole, JD; Silva, M; Sutradhar, R; Zabih, V, 2021) |
"In contrast to previous studies, childhood ALL patients with TCF3-PBX1 transcripts do not appear to show a better outcome than their negative counterparts." | 1.62 | Clinical features and prognostic impact of TCF3-PBX1 in childhood acute lymphoblastic leukemia: A single-center retrospective study of 837 patients from China. ( Hu, BF; Jia, M; Li, SS; Tang, YM; Xu, XJ; Zhang, JY, 2021) |
"Lubiprostone was more effective than stimulant laxatives at treating vinca alkaloid-induced intractable constipation in patients with hematological malignancies, and its use could enable safe vinca alkaloid chemotherapy." | 1.56 | Effect of lubiprostone on vinca alkaloid-induced constipation in patients with hematological malignancies: a propensity score-matched analysis. ( Fukuda, H; Hayashi, T; Imai, T; Kawada, K; Miyamura, M; Morita, Y; Ohta, T; Tanaka, K, 2020) |
"Four children suffered from oral mucositis graded 1 or higher between days 8 and 22." | 1.56 | Salivary immunoglobulin A level during steroids and chemotherapy treatment administered in remission induction phase among pediatric patients with acute lymphoblastic leukemia. ( Młynarski, W; Proc, P; Szczepańska, J; Wyka, K; Zubowska, M, 2020) |
"Acute lymphoblastic leukemia (ALL) is characterized by abnormal lymphoblasts accumulation in the bone marrow and blood." | 1.51 | TCF7L2 activated HOXA-AS2 decreased the glucocorticoid sensitivity in acute lymphoblastic leukemia through regulating HOXA3/EGFR/Ras/Raf/MEK/ERK pathway. ( Li, J; Liu, J; Qian, C; Wang, H; Zhang, H; Zhao, Q; Zhao, S; Zhao, Y, 2019) |
"Thromboembolism is one of the most common complications during induction therapy of pediatric acute lymphoblastic leukemia (ALL)." | 1.51 | Analysis of apoptotic, platelet-derived, endothelial-derived, and tissue factor-positive microparticles of children with acute lymphoblastic leukemia during induction therapy. ( Ateş, H; Erdem, M; Kızmazoğlu, D; Ören, H; Tüfekçi, Ö; Yenigürbüz, FD; Yılmaz, Ş, 2019) |
"Although childhood acute lymphoblastic leukemia (ALL) is characterized by high remission rates, there are still patients who experience poor response to therapy or toxic effects due to intensive treatment." | 1.48 | Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia. ( Avgeris, M; Baka, M; Drakaki, I; Gourgiotis, D; Kossiva, L; Marmarinos, A; Piatopoulou, D; Pourtsidis, A; Scorilas, A; Xagorari, M, 2018) |
"In childhood B-precursor acute lymphoblastic leukemia (B-ALL), the ETV6/RUNX1 fusion transcript is considered to have an excellent outcome." | 1.48 | ETV6/RUNX1-positive childhood acute lymphoblastic leukemia in China: excellent prognosis with improved BFM protocol. ( Wang, Y; Zeng, HM; Zhang, LP, 2018) |
"Children with acute lymphoblastic leukemia (ALL) in low-income countries have disproportionately lower cure rates than those in high-income countries." | 1.48 | Outcomes of Low-Intensity Treatment of Acute Lymphoblastic Leukemia at Butaro Cancer Center of Excellence in Rwanda. ( Driscoll, C; Elmore, S; Fehr, AE; Gilbert, UD; Hategekimana, V; Larrabee, K; Lehmann, L; May, L; Moore, M; Mpunga, T; Muhayimana, C; Rubagumya, F; Shulman, LN; Shyirambere, C; Uwizeye, FR; Xu, MJ, 2018) |
"Although cure rates in pediatric acute lymphoblastic leukemia (ALL) are quite high with combined chemotherapy regimens, complete response (CR) and long-term survival rates in adults are 80-90 and 30-40%, respectively." | 1.48 | Comparison between Hyper-CVAD and PETHEMA ALL-93 in Adult Acute Lymphoblastic Leukemia: A Single-Center Study. ( Akidan, O; Erkut, N; Karabacak, V; Selim Batur, D; Sonmez, M, 2018) |
"Ponatinib treatment was well tolerated and considered safe with easily manageable side effects." | 1.46 | Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic Transplant. ( Bossio, S; De Stefano, L; Gentile, M; Greco, R; Mazzone, C; Morabito, F; Morelli, R; Musolino, C; Palummo, A; Petrungaro, A; Recchia, AG; Uccello, G; Vigna, E, 2017) |
"Patients ages 1 to 17 years with acute lymphoblastic leukemia (ALL) were treated according to modified ALL Intercontinental Berlin-Frankfurt-Münster (IC-BFM) 2002 protocol." | 1.46 | The treatment of childhood acute lymphoblastic leukemia in Guatemala: Biologic features, treatment hurdles, and results. ( Antillón, FG; Blanco, JG; Borrayo, DA; Castellanos, M; Conter, V; Garrido, CP; Girón, V; Letona, TR; Lorenzana, R; Mack, RA; Melgar, MA; Metzger, M; Osorio, EJ; Ribeiro, RC; Rossi, E; Valsecchi, MG; Valverde, PD, 2017) |
"Precursor B-cell lymphoblastic lymphoma arising from the ovary is extremely rare and to our knowledge, only 5 cases have been reported in the literature." | 1.46 | Lymphoblastic Lymphoma Presenting as Bilateral Ovarian Mass in an Adolescent Girl. ( Narayanan, G; Soman, LV, 2017) |
"(2) Burkitt's lymphoma was the most common (34/43, 79." | 1.43 | [Clinical and Prognostic analysis of 43 Children with Mature B-cell Non-Hodgkin's Lymphoma/Acute Lymphoblastic Leukemia]. ( Gao, J; Guo, J; Guo, X; Jia, CS; Li, Q; Zhou, CY; Zhu, YP, 2016) |
"In total, 346 pediatric patients with acute lymphoblastic leukemia were enrolled in our study." | 1.43 | Some GCR Polymorphisms (N363S, ER22/23EK, and Bcl-1) May Influence Steroid-induced Toxicities and Survival Rates in Children With ALL. ( Csóka, M; Csordás, K; Eipel, O; Erdélyi, D; Hegyi, M; Kovács, G; Luczay, A; Németh, K; Török, D, 2016) |
"Survival for childhood acute lymphoblastic leukemia (ALL) has improved significantly, but these benefits may not be available to many children from low and middle income countries, where reasons for treatment failure may be unique to their environment." | 1.43 | The Impact of Socioeconomic Factors on the Outcome of Childhood Acute Lymphoblastic Leukemia (ALL) Treatment in a Low/Middle Income Country (LMIC). ( Ashraf, MS; Belgaumi, AF; Iftikhar, S; Jabeen, K, 2016) |
"B cell acute lymphoblastic leukemia (B-ALL) exhibits phenotypes reminiscent of normal stages of B-cell development." | 1.43 | Development-associated immunophenotypes reveal the heterogeneous and individualized early responses of adult B-acute lymphoblastic leukemia. ( Huang, QR; Jia, YQ; Jiang, NG; Jin, YM; Li, HF; Li, X; Meng, WT; Mo, XM; Xu, H; Zeng, TT, 2016) |
"The identification of childhood acute lymphoblastic leukemia (ch-ALL) patients who are at a higher risk of chemotherapy resistance and relapse is essential for successful treatment decisions, despite the application of novel therapies." | 1.42 | Overexpression of BCL2 and BAX following BFM induction therapy predicts ch-ALL patients' poor response to treatment and short-term relapse. ( Anastasiou, T; Avgeris, M; Baka, M; Gourgiotis, D; Kosmidis, H; Piatopoulou, D; Scorilas, A; Stamati, L, 2015) |
"Prednisone response has been confirmed to be still great prognostic value and PPR children patients have poor outcomes generally." | 1.42 | [Prognostic Value of Prednisone Response in CCLG-ALL 2008]. ( An, WB; Chang, LX; Liu, TF; Ren, YY; Wan, Y; Zhang, JL; Zhu, XF; Zou, Y, 2015) |
"Cataract was prospectively assessed by serial slip lamp tests in 517 patients." | 1.40 | Prevalence and risk factors of cataract after chemotherapy with or without central nervous system irradiation for childhood acute lymphoblastic leukaemia: an LEA study. ( Alloin, AL; Auquier, P; Barlogis, V; Bertrand, Y; Chambost, H; Chastagner, P; Contet, A; Demeocq, F; Herrmann, I; Kanold, J; Michel, G; Plantaz, D; Poiree, M; Sirvent, N; Villes, V, 2014) |
"Mitoxantrone is a reasonable replacement for daunorubicin in times of drug shortage." | 1.40 | Mitoxantrone as a substitute for daunorubicin during induction in newly diagnosed lymphoblastic leukemia and lymphoma. ( Bergsagel, J; Cooper, T; Daves, M; Keller, F; Lew, G; Nickel, RS; Sabnis, H, 2014) |
"Being obese or underweight at diagnosis and for ≥ 50% of the time between end of induction and start of maintenance therapy resulted in inferior EFS (hazard ratios, 1." | 1.40 | Impact on survival and toxicity by duration of weight extremes during treatment for pediatric acute lymphoblastic leukemia: A report from the Children's Oncology Group. ( Freyer, DR; Gaynon, PS; Ladas, E; Malvar, J; Orgel, E; Seibel, NL; Sposto, R, 2014) |
" Population pharmacokinetic parameters were estimated by the NLME software." | 1.40 | [SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ( Chen, Y; Gao, P; He, X; Li, J; Niu, C; Wang, C; Wang, Y; Zhang, H, 2014) |
"The prognosis of acute lymphoblastic leukemia is poorer in adults than in children." | 1.39 | Risk group assignment differs for children and adults 1-45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol. ( Abrahamsson, J; Åsberg, A; Bernell, P; Birgens, H; Griškevičius, L; Hallböök, H; Heyman, M; Holm, MS; Hulegårdh, E; Jónsson, OG; Klausen, TW; Marquart, HV; Nielsen, OJ; Quist-Paulsen, P; Schmiegelow, K; Taskinen, M; Toft, N; Vaitkeviciene, G; Vettenranta, K, 2013) |
"The BFM studies for relapsed childhood acute lymphoblastic leukemia (ALL) were started in 1983, at a time when cure rates for ALL were still lower and the number of children with ALL relapse equaled about the number of children with newly diagnosed neuroblastoma." | 1.39 | ALL-REZ BFM--the consecutive trials for children with relapsed acute lymphoblastic leukemia. ( Eckert, C; Henze, G; v Stackelberg, A, 2013) |
"Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer." | 1.39 | The BCL2-938 C > A promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia. ( Bachmann, HS; Eggert, A; Grosse-Lordemann, A; Künkele, A; Schramm, A; Schulte, JH, 2013) |
"MLL-rearranged acute lymphoblastic leukemia (ALL) in infants is characterized by a poor clinical outcome and resistance to glucocorticoids (for example, prednisone and dexamethasone)." | 1.38 | Elevated S100A8/S100A9 expression causes glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia. ( de Boer, J; Hulleman, E; Pieters, R; Schneider, P; Spijkers-Hagelstein, JA; Stam, RW; Williams, O, 2012) |
"Acute lymphoblastic leukemia (ALL) with distinct fusion transcripts has unique clinical features." | 1.38 | Clinical features, early treatment responses, and outcomes of pediatric acute lymphoblastic leukemia in China with or without specific fusion transcripts: a single institutional study of 1,004 patients. ( Cui, L; Gao, C; Jiao, Y; Li, WJ; Li, ZG; Liu, SG; Wu, MY; Yue, ZX; Zhao, W; Zhao, XX, 2012) |
"We report a girl with acute lymphoblastic leukemia of B-cell type who initially presented with numb chin syndrome resulting from skull base infiltration." | 1.37 | Numb chin syndrome in acute lymphoblastic leukemia. ( Benesch, M; Lackner, H; Pansy, J; Urban, C, 2011) |
"Methotrexate is a key drug in acute lymphoblastic leukemia (ALL) treatment; it inhibits DNA replication by blocking the conversion of 5,10 methylene tetrahydrofolate to 5-methylene tetrahydrofolate by methylene tetrahydrofolate reductase (MTHFR)." | 1.36 | Methylene tetrahydrofolate reductase gene polymorphism in Egyptian children with acute lymphoblastic leukemia. ( Abdulghaffar, EE; Abou El Asrar, M; Adly, AA; El-Bostany, EA; El-Ghouroury, EA; Tantawy, AA, 2010) |
"MLL-rearranged acute lymphoblastic leukemia (ALL) represents an unfavorable type of leukemia that often is highly resistant to glucocorticoids such as prednisone and dexamethasone." | 1.36 | Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia. ( Armstrong, SA; Brady, HJ; de Boer, J; de Lorenzo, P; Den Boer, ML; Hagelstein, J; Pieters, R; Sallan, SE; Schneider, P; Stam, RW; Valsecchi, MG, 2010) |
"Risperidone is an effective short-term pharmacologic agent for controlling steroid-related psychiatric adverse effects when cessation or dose reduction of steroid therapy is not an option." | 1.36 | Concurrent treatment of steroid-related mood and psychotic symptoms with risperidone. ( Dahl, G; Shaw, RJ; Tzuang, D; Ularntinon, S, 2010) |
"In a group of newly diagnosed acute lymphocytic leukemia (ALL) children we evaluated a number of hemostatic and inflammatory markers at diagnosis and at different time points during chemotherapy for the remission induction to identify alterations in the plasma levels of prothrombotic markers before and during the course of chemotherapy." | 1.36 | Prospective study of hemostatic alterations in children with acute lymphoblastic leukemia. ( Altomare, M; Crescenzio, N; De Mattia, D; Del Vecchio, GC; Falanga, A; Giordano, P; Marchetti, M; Molinari, AC; Perutelli, P; Russo, G; Santoro, N; Saracco, P, 2010) |
"A 4-year-old boy with acute lymphoblastic leukemia (ALL) was inserted a central venous catheter into right vena jugularis interna, whereas on BFM-ALL (Protocol 1) therapy." | 1.36 | Schistocytic hemolytic anemia owing to central venous catheter in a child with acute lymphoblastic leukemia. ( Akyay, A; Bçakç, Z; Cetin, II; Olcay, L; Oztürkmen, S; Paç, A; Polat, TB; Senayl, A, 2010) |
"Overt hyperglycemia was seen in 56 (34%) patients." | 1.35 | Hyperglycemia during induction therapy is associated with poorer survival in children with acute lymphocytic leukemia. ( Haymond, MW; Margolin, JF; McKay, SV; Okcu, MF; Sonabend, RY; Yan, J, 2009) |
"Treatment for childhood acute lymphoblastic leukemia (ALL) regularly includes the use of thiopurine drugs." | 1.35 | Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Münster protocols. ( Cario, G; Coulthard, SA; Dördelmann, M; Eichelbaum, M; Kaatsch, P; Möricke, A; Reiter, A; Riehm, H; Schaeffeler, E; Schrappe, M; Schrauder, A; Schwab, M; Stanulla, M; Welte, K; Zimmermann, M, 2009) |
"In previous clinical trials of childhood acute lymphoblastic leukemia (ALL), dexamethasone resulted in higher event-free survival rates than prednisone, presumably due to greater central nervous system penetration." | 1.35 | A comparison of neurocognitive functioning in children previously randomized to dexamethasone or prednisone in the treatment of childhood acute lymphoblastic leukemia. ( Bostrom, B; Breiger, D; Brouwers, P; Chen, L; Dziura, J; Kadan-Lottick, NS; Kaleita, T; Liu, H; Neglia, JP; Nicoletti, M; Stork, L, 2009) |
"Successful treatment of higher risk childhood ALL was associated with obesity, independent of cranial irradiation." | 1.35 | Weight patterns in children with higher risk ALL: A report from the Children's Oncology Group (COG) for CCG 1961. ( Hawks, RG; Meza, JL; Post-White, JE; Sacks, N; Seibel, NL; Smith, LM; Withycombe, JS, 2009) |
"To retrospectively analyze and compare the treatment efficiency of CHOP-based regimens with or without high-dose consolidation treatment combined with hematopoietic stem cell transplantation (HDT-HSCT) in the patients with lymphoblastic lymphoma (LBL)." | 1.35 | [Comparison of the efficiency of CHOP-based regimen with or without high dose consolidation treatment combined with hematopoietic stem cell transplantation in 63 lymphoblastic lymphoma patients]. ( Dong, M; Feng, FY; Han, XH; He, XH; Liu, P; Qin, Y; Shi, YK; Sun, Y; Wang, JW; Yang, JL; Yang, S; Zhang, CG; Zhou, LQ; Zhou, SY, 2009) |
"The occurrence rates of peripheral leukocytosis and hepatosplenomegaly were significantly higher in the patients with EBV infection than in the patients without EBV infection (P <0." | 1.34 | [Infection status and clinical significance of Epstein-Barr virus in pediatric leukemia---a report of 35 cases]. ( Lu, Y; Lu, ZH; Pang, XY; Sui, AH; Sun, LR, 2007) |
"In childhood acute lymphoblastic leukemia (ALL), persistence of leukemic blasts during therapy is of crucial prognostic significance." | 1.34 | Gene expression shift towards normal B cells, decreased proliferative capacity and distinct surface receptors characterize leukemic blasts persisting during induction therapy in childhood acute lymphoblastic leukemia. ( Hagemeier, C; Karawajew, L; Kirschner-Schwabe, R; Ludwig, WD; Moericke, A; Ratei, R; Rhein, P; Scheid, S; Schrappe, M; Seeger, K; Spang, R, 2007) |
"Ninety-seven consecutive patients with childhood ALL were studied prospectively by magnetic resonance imaging (MRI) of the lower extremities at the end of the treatment." | 1.34 | High body mass index increases the risk for osteonecrosis in children with acute lymphoblastic leukemia. ( Harila-Saari, AH; Jartti, AE; Lanning, M; Möttönen, MI; Niinimäki, RA; Pääkkö, EL; Riikonen, PV; Seuri, RM, 2007) |
"Disseminated intravascular coagulation was defined by International Society of Thrombosis and Hemostasis criteria." | 1.34 | Disseminated intravascular coagulation in acute leukemia at presentation and during induction therapy. ( Chatterjee, T; Choudhry, DR; Choudhry, VP; Dixit, A; Kannan, M; Mahapatra, M; Mishra, P; Saxena, R, 2007) |
"Between 15% and 30% of children with acute lymphoblastic leukemia (ALL) experience disease recurrence." | 1.33 | Second induction in pediatric patients with recurrent acute lymphoid leukemia using DFCI-ALL protocols. ( Barrette, S; Bernstein, ML; Champagne, J; Champagne, MA; Dalle, JH; David, M; Demers, J; Duval, M; Hume, H; Leclerc, JM; Meyer, P; Moghrabi, A; Rousseau, P, 2005) |
"Children with acute lymphoblastic leukemia (ALL) are treated with intermittent steroid therapy." | 1.33 | Recent steroid therapy increases severity of varicella infections in children with acute lymphoblastic leukemia. ( Chauvenet, AR; Hill, G; Lovato, J; McLean, TW, 2005) |
"Philadelphia chromosome positive (Ph(+)) acute lymphoblastic leukemia (ALL) includes at least one-quarter of all adults with ALL." | 1.33 | Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. ( Ottmann, OG; Wassmann, B, 2005) |
"The authors describe an adolescent with acute lymphocytic leukemia and WNV encephalitis." | 1.33 | West Nile virus infection in a teenage boy with acute lymphocytic leukemia in remission. ( Buescher, ES; Byrd, R; Dory, C; Frank, LM; Hindo, H; Pettit, D, 2005) |
"We describe a 57-year-old woman with acute lymphoblastic leukemia who had a cavitary lesion develop in the right upper lobe caused by Cunninghamella bertholletiae, a zygomycete." | 1.33 | Treatment of cavitary pulmonary zygomycosis with surgical resection and posaconazole. ( Colson, YL; Marty, FM; Paul, S, 2006) |
"From 1981 to 1986, children with acute lymphoblastic leukemia (ALL) and initial WBC above 50,000/mm3, achieved significantly worse treatment results than children with lower WBC: over 6-year disease-free survival were respectively 33% and 60%." | 1.33 | [Acute lymphoblastic leukemia in children with initial leucocytosis above 50,000/mm3: summary of treatment results of Polish Pediatric Leukemia/Lymphoma Study Group]. ( Balcerska, A; Balwierz, W; Chybicka, A; Derwich, K; Dobaczewski, G; Juszczak, K; Kowalczyk, J; Krauze, A; Luszczyńska, A; Matysiak, M; Moryl-Bujakowska, A; Pawelec, K; Pawińska, K; Płoszyńska, A; Skoczeń, S; Sońta-Jakimczyk, D; Styczyńskii, J; Swiatkiewicz, V; Tomaszewska, R; Wachowiak, J; Wiśniewska-Slusarz, H; Wysocki, M, 2006) |
" All errors were due to incorrect dosing or failure to administer an indicated medication." | 1.33 | Oral outpatient chemotherapy medication errors in children with acute lymphoblastic leukemia. ( Geyer, LJ; Hawkins, DS; Taylor, JA; Winter, L, 2006) |
"Prednisone treatment induced a decrease in Bcl-2 and Bcl-xl levels in 17 and 16 of the 28 patients, respectively, while Bax protein increased in 14 of the 21 patients." | 1.32 | Determination of the in vivo effects of prednisone on Bcl-2 family protein expression in childhood acute lymphoblastic leukemia. ( Addeo, R; Casale, F; Crisci, S; D'Angelo, V; Di Tullio, MT; Indolfi, P; Morgera, C; Poggi, V, 2003) |
"Acute pneumonitis was diagnosed, and MTX was stopped." | 1.32 | Successful reintroduction of methotrexate after acute pneumonitis in a patient with acute lymphoblastic leukemia. ( Bächli, EB; Fehr, T; Jacky, E, 2003) |
"Etoposide is a substrate for P-glycoprotein, CYP3A4, CYP3A5, and UGT1A1." | 1.32 | Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. ( Boureau, B; Chen, P; Cook, EH; Das, S; Kishi, S; Morand, S; Pui, CH; Relling, MV; Rosner, GL; Schuetz, E; Yang, W, 2004) |
" In addition, before the modification, patients with Stage IV disease received a cumulative dose of 15,600 mg/m(2) of cyclophosphamide for 3 years; after 1980, these patients received the same dosage as the other patients (i." | 1.32 | Lymphoblastic lymphoma of childhood and the LSA2-L2 protocol: the 30-year experience at Memorial-Sloan-Kettering Cancer Center. ( Filippa, DA; Mora, J; Qin, J; Wollner, N, 2003) |
"Childhood Acute Lymphoblastic Leukemia (ALL) represents approximately 40% of pediatric cancers, but molecular mechanisms involved in the therapeutic resistance of ALL are still unclear." | 1.32 | Glucocorticoids induce G1 arrest of lymphoblastic cells through retinoblastoma protein Rb1 dephosphorylation in childhood acute lymphoblastic leukemia in vivo. ( Abbruzzese, A; Addeo, R; Caraglia, M; Casale, F; Crisci, S; D'Angelo, V; Di Tullio, MT; Indolfi, P, 2004) |
"Up to 80% of pediatric patients with acute lymphoblastic leukemia (ALL) can be cured if intensive therapy is applied." | 1.32 | Evolution of BFM trials for childhood ALL. ( Schrappe, M, 2004) |
"A final diagnosis of acute lymphoblastic leukemia (ALL) was established in a fourth, repeated bone marrow biopsy performed more than 2 months after the first presenting symptom appeared." | 1.32 | Prolonged fever of unknown origin and hemophagocytosis evolving into acute lymphoblastic leukemia. ( Goldschmidt, N; Gural, A; Kornberg, A; Paltiel, O; Shopen, A; Spectre, G, 2004) |
"Twenty cases had additional cytogenetic aberrations, such as t(9;22) with -7, +8, -5." | 1.32 | [Analysis of 32 cases of acute leukemia with abnormality of chromosome 7]. ( Chen, ZM; Jin, J; Lou, JY; Lu, Y; Xu, WL, 2004) |
"T-cell lymphoblastic lymphoma in childhood and adolescence is an aggressive malignant disease with higher mortality." | 1.32 | [Efficacy of modified BFM-90 regimen on children and adolescents with T cell lymphoblastic lymphoma: a report of 20 cases]. ( Guan, ZZ; He, YJ; Huang, HQ; Jiang, WQ; Li, YH; Liu, DG; Sun, XF; Xia, Y; Xia, ZJ; Zhang, L; Zhen, ZJ; Zhou, ZM, 2004) |
"Extending the principle of conventional acute lymphoblastic leukemia (ALL) therapy to transplantation, 77 adult patients receiving autografts in first remission after melphalan with or without total body irradiation were scheduled to receive 6-mercaptopurine (6MP), methotrexate (MTX), and vincristine-prednisone (VP) for 2 years after transplantation to reduce relapse." | 1.31 | The role of posttransplantation maintenance chemotherapy in improving the outcome of autotransplantation in adult acute lymphoblastic leukemia. ( Kulkarni, S; Mehta, J; Powles, R; Singhal, S; Sirohi, B; Tait, D; Treleaven, J, 2002) |
"Precursor B-cell lymphoblastic lymphoma (PBLL) is a rare subtype of childhood non-Hodgkin lymphoma (NHL)." | 1.31 | Precursor B-cell lymphoblastic lymphoma in childhood and adolescence: clinical features, treatment, and results in trials NHL-BFM 86 and 90. ( Jansen, P; Ludwig, WD; Mann, G; Neth, O; Reiter, A; Riehm, H; Seidemann, K; Tiemann, M, 2000) |
"The acute treatment of hypercalcemia is independent of the underlying cause (rehydration with physiologic saline, renal excretion with furosemide, inhibition of osteoclastic activity)." | 1.31 | [Life threatening hypercalcemia in a young man with ALL]. ( Boesken, WH; Schneider, T; Seydlitz, F; Sontag, B; Zimmermann, U, 2001) |
"Prednisone was used as the corticosteroid during postremission therapy from 1987 to 1991, and dexamethasone was used from 1991 to 1995." | 1.31 | Bony morbidity in children treated for acute lymphoblastic leukemia. ( Dalton, VM; Gelber, RD; Sallan, SE; Silverman, LB; Strauss, AJ; Su, JT, 2001) |
"Acute lymphoblastic leukemia (ALL) is a bone marrow disease." | 1.31 | Intact T-cell regenerative capacity in childhood acute lymphoblastic leukemia after remission induction therapy. ( Eder, J; Heitger, A; Meister, B; Moritz, B, 2001) |
"During treatment Hepatitis B was reactivated and after termination, of chemotherapy she developed fulminant hepatitis with hyperbilirubinemia, coagulopathy, hypoalbuminemia and ascites." | 1.31 | [Effective treatment with Lamivudine of patients with reactivation of hepatitis B following chemotherapy administration]. ( Haran, M; Klepfish, A; Lurie, Y; Malnick, S; Shtalrid, M, 2001) |
"Prednisone good response was defined as a blast count of less than 1,000/microL and a prednisone poor response (PPR) as a blast count of at least 1,000/microL, both in peripheral smears, after 7 days of oral prednisone (60 mg/m2 per day) and one intrathecal dose of methotrexate." | 1.31 | Childhood acute lymphoblastic leukemia: prognostic value of initial peripheral blast count in good responders to prednisone. ( Alfaro, EM; Felice, MS; Sackmann-Muriel, F; Zubizarreta, PA, 2001) |
"Precursor B cell lymphoblastic lymphoma has not been previously reported as a form of posttransplant lymphoproliferative disease." | 1.31 | Epstein-Barr virus-negative precursor B cell lymphoblastic lymphoma after liver transplantation: a unique form of posttransplant lymphoproliferative disease. ( Borges, E; Ferry, JA; Friedmann, AM, 2002) |
"Concerning ANLL, the MOPP regimen was significantly associated with a higher risk: 3." | 1.31 | Fifteen-year secondary leukaemia risk observed in 761 patients with Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy plus high-dose irradiation. ( Andrieu, JM; Colonna, P; Delwail, V; Jais, JP, 2002) |
"Childhood acute lymphoblastic leukemia (ALL) has a 5-year disease-free survival (DFS) of more than 70%." | 1.30 | Modified BFM protocol for childhood acute lymphoblastic leukemia: a retrospective analysis. ( Aziz, Z; Mahmood, R; Maqbool, S; Zahid, M, 1997) |
"Initial and relapsed childhood acute lymphoblastic leukemias (ALL) were investigated for mutations and expression of deoxycytidine kinase (dCK)." | 1.30 | Deoxycytidine kinase mRNA expression in childhood acute lymphoblastic leukemia. ( Sauerbrey, A; Stammler, G; Volm, M; Zintl, F, 1997) |
"We prospectively assessed the pharmacokinetics of methotrexate, mercaptopurine, and erythrocyte thioguanine nucleotide levels in a homogenous population of children with lower risk acute lymphoblastic leukemia and correlated pharmacokinetic parameters with disease outcome." | 1.30 | Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study. ( Ames, MM; Balis, FM; Bleyer, WA; Ge, J; Gilchrist, GS; Holcenberg, JS; Murphy, RF; Poplack, DG; Sather, HN; Tubergen, DG; Waskerwitz, MJ; Zimm, S, 1998) |
"Infants diagnosed with acute lymphoblastic leukemia (ALL) are considered the patient subgroup at the highest risk for central nervous system (CNS) disease, both at presentation and as an isolated extramedullary relapse." | 1.30 | Neurodevelopmental outcome of infants with acute lymphoblastic leukemia: a Children's Cancer Group report. ( Kaleita, TA; MacLean, WE; Reaman, GH; Sather, HN; Whitt, JK, 1999) |
"We studied 95 survivors of childhood acute lymphoblastic leukemia a median of 11 yr (range, 3-23 yr) after diagnosis." | 1.30 | Degree of fatness after treatment for acute lymphoblastic leukemia in childhood. ( Hertz, H; Holm, K; Michaelsen, KF; Müller, J; Mølgaard, C; Nysom, K, 1999) |
"Lymphoblastic lymphoma (LBL) and Burkitt's lymphoma belong to the very aggressive lymphomas requiring intensive therapy." | 1.30 | Non-Hodgkin's lymphoma protocols in the treatment of patients with Burkitt's lymphoma and lymphoblastic lymphoma: a report on 58 patients. ( Havemann, K; Kaiser, U; Uebelacker, I, 1999) |
"To report four acute lymphoblastic leukemia(ALL) patients who developed tumor lysis syndrome(TLS) after initial chemotherapy." | 1.30 | [Acute lymphoblastic leukemia complicated with tumor lysis syndrome--four cases report]. ( Han, M; He, H; Li, C, 1999) |
"Four of these patients had an isolated recurrence, in 3 patients < or = 3 months and in 1 patient < or = 6 months after the initial event." | 1.29 | Prognosis and treatment of seizures in children with acute lymphoblastic leukemia. ( Eviatar, L; Grossman, R; Karayalycin, G; Lanzkowsky, P; Maytal, J; Schaul, N; Shende, AC; Yusuf, FH, 1995) |
"The incidence of severe hyperlipidemia during therapy of patients with acute lymphoblastic leukemia (ALL) who received prednisone and asparaginase was evaluated." | 1.29 | Transient, severe hyperlipidemia in patients with acute lymphoblastic leukemia treated with prednisone and asparaginase. ( Steinherz, PG, 1994) |
" This was associated with delivery of 100% of the planned dosage of vincristine, prednisone, and daunorubicin at induction." | 1.29 | Poor outcome of intensive chemotherapy for adult acute lymphoblastic leukemia: a possible dose effect. ( Chan, LC; Chan, TK; Chiu, EK; Kwong, YL; Liang, R; Lie, A; Todd, D, 1994) |
"In the past 16 years, 2004 children with acute lymphoblastic leukemia (ALL) have been treated in the Polish Pediatric Group centers." | 1.29 | Relapses after termination of therapy of acute lymphoblastic leukemia in children. ( Armata, J; Balwierz, W; Bogusławska-Jaworska, J; Chybicka, A; Jackowska, T; Jakowicka, M; Kulus, M; Matysiak, M; Michalewska, D; Ochocka, M, 1993) |
"We describe a case of a recurrence of ALL in the uterine cervix during hematopoietic remission." | 1.29 | Childhood acute lymphoblastic leukemia relapse in the uterine cervix. ( Okamura, J; Tsuruchi, N, 1996) |
"Two boys with acute lymphocytic leukemia (ALL) who presented with muscle pain, shortly after receiving induction chemotherapy, were evaluated." | 1.29 | Pyomyositis during induction chemotherapy for acute lymphocytic leukemia. ( Corden, TE; Morgan, ER, 1996) |
"Relapsed acute lymphoblastic leukemia (ALL) usually carries a dire prognosis." | 1.29 | Effectiveness of intensified rotational combination chemotherapy for late hematologic relapse of childhood acute lymphoblastic leukemia. ( Benaim, E; Crist, WM; Hudson, MM; Liu, Q; Pui, CH; Ribeiro, RC; Rivera, GK, 1996) |
" The bioavailability of both IGF-I and IGF-II is regulated by specific IGF-binding proteins (IGFBPs)." | 1.29 | Serum levels of insulin-like growth factor-I, -II and insulin-like growth factor binding proteins -2 and -3 in children with acute lymphoblastic leukaemia. ( Aumann, V; Blum, WF; Kluba, U; Mittler, U; Mohnike, KL; Vorwerk, P, 1996) |
"Information about elderly patients with acute lymphoblastic leukemia is scarce." | 1.28 | [Treatment of elderly patients with hematological malignancies]. ( Mizoguchi, H; Saito, H, 1992) |
"45 cases of acute lymphocytic leukemia (ALL) were treated with vincristine, daunorubicin, cyclophosphamide, prednisone with a CR rate of 88." | 1.28 | [Treatment of various types of acute leukemia in adult. An analysis of 98 cases. The Leukemia Cooperation Group of Beijing City]. ( , 1992) |
" coli L-asparaginase (L-ase) in the induction phase at a dosage of 6000 U/m2/day x 7 d starting on d 15, as well as vincristine, prednisone, daunorubicin and cyclophosphamide, the last-named by random 1:1." | 1.28 | Incidence of thrombotic complications in adult patients with acute lymphoblastic leukaemia receiving L-asparaginase during induction therapy: a retrospective study. The GIMEMA Group. ( Annino, L; Defazio, D; Gugliotta, L; Leone, G; Mandelli, F; Mattioli-Belmonte, M; Mazzucconi, MG; Tura, S, 1992) |
"More effective treatment for adult lymphoblastic lymphoma is required." | 1.28 | Intensive chemotherapy for adult lymphoblastic lymphomas. ( Chan, TK; Chiu, E; Ho, FC; Liang, R; Lie, A; Loke, SL; Todd, D, 1991) |
" Maintenance with the same drugs in a modified dosage schedule continued for approximately 2 years." | 1.28 | Multiagent chemotherapy in relapsed acute lymphoblastic leukemia in children. ( Belasco, JB; Luery, N; Scher, C, 1990) |
"Thirty-nine patients with relapsed acute lymphoblastic leukemia (ALL) and four with primarily refractory ALL were treated with a regimen that included cytarabine 1 gm/m2 (2-hour infusion) twice daily days 1 to 5, mitoxantrone 12mg/m2 daily days 1 to 5, prednisone 0." | 1.28 | Successful treatment of adult acute lymphoblastic leukemia after relapse with prednisone, intermediate-dose cytarabine, mitoxantrone, and etoposide (PAME) chemotherapy. ( Auzanneau, G; Gisselbrecht, C; Gratecos, N; Harousseau, JL; LeBlond, V; Michallet, M; Milpied, N; Sebban, C; Troussard, X; Witz, F, 1990) |
"Twenty children with acute lymphoblastic leukemia (ALL) in relapse were treated with various combinations of anti-leukemic agents in approach to the induction of remission." | 1.28 | [Study of reinduction chemotherapy in bone marrow relapse of childhood acute lymphoblastic leukemia]. ( Ikeda, Y; Ito, E; Ito, R; Miyano, T; Onodera, N; Saito, T; Sato, Y; Suto, Y; Tachibana, N; Tateoka, N, 1989) |
" For total prednisolone, the mean elimination half-life was relatively short (1." | 1.28 | Pharmacokinetics of prednisolone in children with acute lymphoblastic leukaemia. ( Blackburn, M; Choonara, I; Lewis, I; Rayner, P; Wheeldon, J, 1989) |
"Thirteen children with acute lymphoblastic leukemia (ALL) were investigated before and during cytotoxic therapy." | 1.27 | Changes in the EEG background activity of children with acute lymphoblastic leukemia during cytotoxic therapy. ( Benninger, C; Brandeis, WE; Lichter-Konecki, U; Matthis, P; Scheffner, D, 1987) |
"Many children with acute lymphoblastic leukemia (ALL) develop a marrow relapse during or shortly following initial continuation chemotherapy." | 1.27 | Reinduction therapy in 297 children with acute lymphoblastic leukemia in first bone marrow relapse: a Pediatric Oncology Group Study. ( Boyett, JM; Buchanan, GR; Chauvenet, AR; Crist, WM; Rivera, GK; Vietti, TJ, 1988) |
Research
Studies (601)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 40 (6.66) | 18.7374 |
1990's | 180 (29.95) | 18.2507 |
2000's | 199 (33.11) | 29.6817 |
2010's | 143 (23.79) | 24.3611 |
2020's | 39 (6.49) | 2.80 |
Authors
Authors | Studies |
---|---|
Martinelli, G | 2 |
Papayannidis, C | 1 |
Piciocchi, A | 2 |
Robustelli, V | 1 |
Soverini, S | 2 |
Terragna, C | 1 |
Marconi, G | 1 |
Lemoli, RM | 1 |
Guolo, F | 1 |
Fornaro, A | 1 |
Lunghi, M | 1 |
de Fabritiis, P | 1 |
Candoni, A | 2 |
Selleri, C | 1 |
Simonetti, F | 1 |
Bocchia, M | 1 |
Vitale, A | 2 |
Frison, L | 1 |
Tedeschi, A | 1 |
Cuneo, A | 1 |
Bonifacio, M | 1 |
Martelli, MP | 1 |
D'Ardia, S | 1 |
Trappolini, S | 1 |
Tosi, P | 1 |
Galieni, P | 1 |
Fabbiano, F | 2 |
Abbenante, MC | 1 |
Granier, M | 1 |
Zhu, Z | 1 |
Wang, M | 2 |
Sartor, C | 1 |
Paolini, S | 2 |
Cavo, M | 1 |
Foà, R | 2 |
Fazi, P | 2 |
Vignetti, M | 2 |
Baccarani, M | 3 |
Zhang, Y | 2 |
Qian, JJ | 2 |
Shen, YJ | 1 |
Hang, SJ | 1 |
Jin, J | 4 |
Zhu, HH | 4 |
Moriya, K | 1 |
Imamura, T | 1 |
Katayama, S | 1 |
Kaino, A | 1 |
Okamoto, K | 1 |
Yokoyama, N | 1 |
Uemura, S | 1 |
Kitazawa, H | 1 |
Sekimizu, M | 1 |
Hiramatsu, H | 1 |
Usami, I | 1 |
Ishida, H | 1 |
Hasegawa, D | 1 |
Hama, A | 1 |
Moriya-Saito, A | 1 |
Sato, A | 1 |
Sasahara, Y | 1 |
Suenobu, S | 1 |
Horibe, K | 1 |
Hara, J | 1 |
Kośmider, K | 1 |
Karska, K | 1 |
Kozakiewicz, A | 1 |
Lejman, M | 3 |
Zawitkowska, J | 3 |
Sutaryo, S | 1 |
Widjajanto, PH | 1 |
Mulatsih, S | 1 |
Ardianto, B | 1 |
Pangarso, AWS | 1 |
Supriyadi, E | 1 |
Purwanto, I | 1 |
Adelin, CP | 1 |
Lestari, RP | 1 |
Sagoro, L | 1 |
Christian, SD | 1 |
Sabrina, DS | 1 |
Verena, N | 1 |
Kors, WA | 1 |
Kaspers, GJL | 1 |
Veerman, AJP | 1 |
Xu, J | 1 |
Zhao, L | 1 |
García-Villaseñor, E | 1 |
Cortés, JE | 2 |
Reyes-Cisneros, OA | 1 |
Fernández-Gutiérrez, JA | 1 |
Sánchez-Bonilla, D | 1 |
Bojalil-Álvarez, L | 1 |
Murrieta-Álvarez, I | 1 |
Ruiz-Delgado, GJ | 1 |
Ruiz-Argüelles, GJ | 1 |
Advani, AS | 1 |
Moseley, A | 1 |
O'Dwyer, KM | 1 |
Wood, BL | 1 |
Park, J | 1 |
Wieduwilt, M | 1 |
Jeyakumar, D | 1 |
Yaghmour, G | 1 |
Atallah, EL | 1 |
Gerds, AT | 1 |
O'Brien, SM | 2 |
Liesveld, JL | 1 |
Othus, M | 1 |
Litzow, M | 1 |
Stone, RM | 4 |
Sharon, E | 1 |
Erba, HP | 1 |
Benarous, X | 1 |
Brocheton, C | 1 |
Bonnay, C | 1 |
Boissel, L | 1 |
Crovetto, C | 1 |
Lahaye, H | 1 |
Guilé, JM | 1 |
Theret, P | 1 |
Gondry, J | 1 |
Foulon, A | 1 |
Kim, E | 1 |
Yoo, SH | 1 |
Chen, Z | 1 |
Sousa, JA | 1 |
Batista, E | 1 |
Demeyer, S | 1 |
Fischer, N | 1 |
Pellegrino, O | 1 |
Ribeiro, AS | 1 |
Martins, LL | 1 |
Worthy, FR | 1 |
Goldberg, SD | 1 |
Ranjitkar, S | 1 |
Xu, JC | 1 |
Asmara, AAGY | 1 |
Karna, MB | 1 |
Meregawa, PF | 1 |
Deslivia, MF | 1 |
Carula, BC | 1 |
Giostri, GS | 1 |
Bebber, F | 1 |
Batista, MFDS | 1 |
Silva, FBD | 1 |
Novak, EM | 1 |
Vilela, JCS | 1 |
Franco, N | 1 |
Campos, G | 1 |
Deligne, LM | 1 |
Machado, TLA | 1 |
Degasperi, FA | 1 |
Scatigna, BF | 1 |
Falótico, GG | 1 |
Romero, V | 1 |
Basile, R | 1 |
Takata, ET | 1 |
Kaleka, CC | 1 |
Debieux, P | 1 |
Antonioli, E | 1 |
Zucconi, E | 1 |
Cohen, M | 1 |
Ferretti, M | 1 |
Bampidis, V | 2 |
Azimonti, G | 2 |
Bastos, ML | 2 |
Christensen, H | 2 |
Fašmon Durjava, M | 2 |
Kouba, M | 2 |
López-Alonso, M | 2 |
López Puente, S | 2 |
Marcon, F | 2 |
Mayo, B | 2 |
Pechová, A | 2 |
Petkova, M | 2 |
Ramos, F | 2 |
Sanz, Y | 2 |
Villa, RE | 2 |
Woutersen, R | 2 |
Brantom, P | 2 |
Chesson, A | 2 |
Westendorf, J | 2 |
Manini, P | 2 |
Pizzo, F | 2 |
Dusemund, B | 2 |
Aron, J | 1 |
Albert, PS | 1 |
Gribble, MO | 1 |
Samankul, A | 1 |
Senawong, G | 1 |
Swatsitang, P | 1 |
Sripa, B | 1 |
Phaosiri, C | 1 |
Kanokmedhakul, S | 1 |
Senawong, T | 1 |
Sirajudeen, MS | 1 |
Alzhrani, M | 1 |
Alanazi, A | 1 |
Alqahtani, M | 1 |
Waly, M | 1 |
Unnikrishnan, R | 1 |
Muthusamy, H | 1 |
Alrubaia, W | 1 |
Alanazi, N | 1 |
Seyam, MK | 1 |
Kashoo, F | 1 |
Miraj, M | 1 |
Channmgere Govindappa, S | 1 |
Alghamdi, KA | 1 |
Al-Hussinan, NM | 1 |
Wang, Z | 2 |
Qu, T | 1 |
Qi, H | 1 |
Zhao, S | 2 |
Shi, H | 2 |
Bai, W | 1 |
Yu, Y | 3 |
Wu, X | 1 |
Zhao, P | 1 |
Yakubov, S | 1 |
Stockerl, WJ | 1 |
Tian, X | 2 |
Shahin, A | 1 |
Mandigma, MJP | 1 |
Gschwind, RM | 1 |
Barham, JP | 1 |
Li, R | 1 |
Jiang, D | 1 |
Du, P | 1 |
Yuan, C | 1 |
Cui, X | 1 |
Tang, Q | 1 |
Zheng, J | 1 |
Li, Y | 4 |
Lu, K | 1 |
Ren, X | 2 |
Gao, S | 1 |
Zhan, X | 1 |
Ramgoolam, KH | 1 |
Dolphin, AC | 1 |
Shi, Q | 1 |
Zhou, YJ | 1 |
Fang, JG | 1 |
Zhong, X | 1 |
Chen, LZ | 1 |
Hou, HZ | 1 |
Ma, L | 1 |
Feng, SZ | 1 |
He, JW | 1 |
Huang, R | 1 |
Wang, YF | 1 |
Yang, Y | 1 |
Guo, FL | 1 |
Li, LJ | 2 |
Ruan, XH | 2 |
Fu, GM | 1 |
Zhao, JZ | 2 |
Hou, XK | 1 |
Gao, M | 2 |
Zheng, XQ | 2 |
Zeng, Y | 1 |
Huang, DM | 1 |
Zhang, JM | 1 |
Zhang, H | 4 |
Kang, M | 1 |
Zhu, J | 2 |
Xu, YJ | 1 |
Li, SN | 1 |
Lai, JM | 1 |
Liu, JJ | 1 |
Wen, S | 2 |
Yan, HH | 1 |
Cheng, R | 1 |
Zhu, F | 1 |
Gao, PF | 1 |
Zou, HY | 1 |
Huang, CZ | 1 |
Wang, J | 5 |
AbdElgawad, H | 1 |
Zinta, G | 1 |
Hornbacher, J | 1 |
Papenbrock, J | 1 |
Markakis, MN | 1 |
Asard, H | 1 |
Beemster, GTS | 1 |
Fukushi, Y | 1 |
Akamine, Y | 1 |
Abumiya, M | 1 |
Tozawa, N | 1 |
Yamashita, T | 1 |
Nara, M | 1 |
Kameoka, Y | 1 |
Takahashi, N | 1 |
Miura, M | 1 |
Qi, G | 1 |
Yu, T | 1 |
Li, J | 5 |
Guo, Z | 1 |
Ma, K | 1 |
Jin, Y | 1 |
Lucon-Xiccato, T | 1 |
Montalbano, G | 1 |
Gatto, E | 1 |
Frigato, E | 1 |
D'Aniello, S | 1 |
Bertolucci, C | 1 |
Shi, W | 1 |
Ge, N | 1 |
Yu, S | 1 |
Wu, J | 1 |
Hu, T | 1 |
Wei, J | 2 |
Yan, X | 1 |
Wang, X | 2 |
Lin, K | 1 |
Deng, T | 1 |
Qu, H | 1 |
Ou, H | 1 |
Huang, Q | 1 |
Gao, B | 1 |
Li, X | 4 |
Wei, N | 1 |
von Haeften, K | 1 |
Laarmann, T | 1 |
Wabnitz, H | 1 |
Möller, T | 1 |
Gries, KJ | 1 |
Hart, CR | 1 |
Kunz, HE | 1 |
Ryan, Z | 1 |
Zhang, X | 1 |
Parvizi, M | 1 |
Liu, Y | 3 |
Dasari, S | 1 |
Lanza, IR | 1 |
Perez, HL | 1 |
Andonian, C | 1 |
Wan, KX | 1 |
Potts, D | 1 |
Gonzalez, P | 1 |
Smith, I | 1 |
Kavetska, O | 1 |
Ferrari, LC | 1 |
Rivas, MM | 1 |
Navickas, AB | 1 |
Dick, H | 1 |
Mela Osorio, MJ | 1 |
Agamennoni, L | 1 |
Rey, IH | 1 |
Carnelutto, NE | 1 |
Cazap, N | 1 |
Castro, MB | 1 |
Aranguren, PN | 1 |
Fischman, LA | 1 |
Yupanki, ML | 1 |
Milone, JH | 1 |
Fernández, II | 1 |
Moirano, MM | 1 |
Belli, CB | 1 |
Zhao, Y | 3 |
Li, C | 3 |
Cai, C | 1 |
Fu, H | 1 |
Zhao, Z | 1 |
Han, J | 1 |
Zhang, F | 2 |
Cassaday, RD | 1 |
Zarling, LC | 1 |
Garcia, KA | 1 |
Sala-Torra, O | 1 |
Stevenson, PA | 1 |
Martino, CH | 1 |
Liu, YJ | 1 |
Fang, M | 1 |
Percival, MM | 1 |
Halpern, AB | 1 |
Becker, PS | 1 |
Oehler, VG | 1 |
Shustov, AR | 1 |
Cooper, JP | 1 |
Orozco, JJ | 1 |
Hendrie, PC | 1 |
Walter, RB | 1 |
Radich, JP | 1 |
Soma, LA | 1 |
Estey, EH | 1 |
Sharma Poudyal, B | 1 |
Paudel, B | 1 |
Tuladhar, S | 1 |
Neupane, S | 1 |
Bhattarai, K | 1 |
Joshi, U | 1 |
Xie, M | 1 |
Lu, Y | 3 |
Ouyang, G | 1 |
Shi, T | 1 |
Yang, M | 2 |
Le, J | 1 |
Hu, H | 1 |
Zhang, L | 5 |
Feng, W | 1 |
Meng, H | 1 |
Mai, W | 1 |
Qian, J | 1 |
Xu, G | 1 |
Yang, C | 1 |
Lin, Y | 1 |
Qian, S | 1 |
Kuang, Y | 1 |
Zhu, W | 1 |
Yao, G | 1 |
Wu, G | 1 |
Hu, S | 1 |
Huang, X | 2 |
Wang, Y | 4 |
Tong, H | 1 |
Haddad, FG | 1 |
Kourie, HR | 1 |
Saleh, K | 1 |
Trobisch, A | 1 |
Marterer, R | 1 |
Gorkiewicz, G | 1 |
Flaschberger, S | 1 |
Lackner, H | 2 |
Seidel, M | 1 |
Sperl, D | 1 |
Karastaneva, A | 1 |
Kohlmaier, B | 1 |
Egger, M | 1 |
Urban, C | 3 |
Benesch, M | 2 |
Strenger, V | 1 |
Kowalczyk, JR | 3 |
Drabko, K | 1 |
Samardakiewicz, M | 1 |
Matysiak, M | 12 |
Romiszewski, M | 2 |
Balwierz, W | 12 |
Ćwiklińska, M | 3 |
Kazanowska, B | 3 |
Owoc-Lempach, J | 2 |
Wachowiak, J | 7 |
Derwich, K | 6 |
Adamkiewicz-Drożyńska, E | 2 |
Niedźwiecki, M | 2 |
Trelińska, J | 2 |
Młynarski, W | 3 |
Wysocki, M | 10 |
Kołtan, A | 3 |
Szczepański, T | 6 |
Krawczuk-Rybak, M | 5 |
Kitszel, A | 1 |
Wieczorek, M | 4 |
Urasiński, T | 6 |
Ociepa, T | 4 |
Sobol-Milejska, G | 2 |
Mizia-Malarz, A | 2 |
Karolczyk, G | 2 |
Stary, J | 7 |
Ben Salah, R | 1 |
Kammoun, S | 1 |
Frikha, F | 1 |
Bouattour, Y | 1 |
Chabchoub, I | 1 |
Feki, J | 1 |
Bahloul, Z | 1 |
Aisyi, M | 1 |
Andriastuti, M | 1 |
Kurniati, N | 1 |
Kersten, MJ | 1 |
van Ettekoven, CN | 1 |
Heijink, DM | 1 |
Rausch, CR | 1 |
Jabbour, EJ | 1 |
Kantarjian, HM | 6 |
Kadia, TM | 1 |
Attarbaschi, A | 7 |
Mann, G | 10 |
Zimmermann, M | 15 |
Bader, P | 1 |
Barisone, E | 10 |
Basso, G | 18 |
Biondi, A | 11 |
Cario, G | 10 |
Cazzaniga, G | 5 |
Colombini, A | 2 |
Flotho, C | 1 |
Kuhlen, M | 1 |
Lang, P | 1 |
Lauten, M | 10 |
Linderkamp, C | 1 |
Locatelli, F | 11 |
Lo Nigro, L | 7 |
Möricke, A | 10 |
Niggli, F | 6 |
Panzer-Grümayer, R | 3 |
Parasole, R | 6 |
Peters, C | 2 |
Caterina Putti, M | 1 |
Rizzari, C | 12 |
Suttorp, M | 1 |
Valsecchi, MG | 16 |
Conter, V | 18 |
Schrappe, M | 37 |
Tidwell, C | 1 |
Willman, A | 1 |
Saygin, C | 1 |
Grieselhuber, N | 1 |
Blachly, J | 1 |
Byrd, JC | 1 |
Vasu, S | 1 |
Larkin, K | 1 |
Behbehani, G | 1 |
Long, M | 1 |
Walker, A | 1 |
Bhatnagar, B | 1 |
Mims, A | 1 |
Sun, JB | 1 |
Lu, YY | 1 |
Huang, LL | 1 |
Yu, QQ | 1 |
Tu, SJ | 1 |
Xie, ZW | 1 |
Pedrosa, F | 1 |
Coustan-Smith, E | 3 |
Zhou, Y | 3 |
Cheng, C | 4 |
Pedrosa, A | 1 |
Lins, MM | 1 |
Pedrosa, M | 1 |
Lucena-Silva, N | 1 |
Ramos, AML | 1 |
Vinhas, E | 1 |
Rivera, GK | 5 |
Campana, D | 5 |
Ribeiro, RC | 8 |
Schieck, M | 1 |
Lentes, J | 1 |
Thomay, K | 1 |
Hofmann, W | 1 |
Behrens, YL | 1 |
Hagedorn, M | 1 |
Ebersold, J | 1 |
Davenport, CF | 1 |
Fazio, G | 1 |
Buchmann, S | 1 |
Alten, J | 2 |
Bergmann, AK | 1 |
Stanulla, M | 12 |
Steinemann, D | 1 |
Schlegelberger, B | 3 |
Göhring, G | 2 |
Hogan, JJ | 1 |
Li, XY | 2 |
Wang, SS | 1 |
Meng, HT | 1 |
Yu, WJ | 1 |
Tong, HY | 1 |
Ye, XJ | 1 |
Mir, TH | 1 |
Sharma, A | 1 |
Nisar, S | 1 |
Khan, AA | 1 |
Shah, TA | 1 |
Wani, NA | 1 |
Jelinek, T | 1 |
Zuchnicka, J | 1 |
Kawada, K | 1 |
Ohta, T | 1 |
Fukuda, H | 1 |
Hayashi, T | 1 |
Tanaka, K | 1 |
Imai, T | 1 |
Morita, Y | 1 |
Miyamura, M | 1 |
Proc, P | 1 |
Szczepańska, J | 1 |
Zubowska, M | 1 |
Wyka, K | 1 |
Tomaszewska, R | 4 |
Płonowski, M | 1 |
Urbańska-Rakus, J | 1 |
Machnik, K | 1 |
Kowalczyk, J | 6 |
Testi, AM | 7 |
Canichella, M | 1 |
Guarini, A | 1 |
Starza, ID | 1 |
Cavalli, M | 1 |
De Propris, MS | 1 |
Messina, M | 1 |
Elia, L | 1 |
Moleti, ML | 5 |
Martino, B | 1 |
Luppi, M | 2 |
D'Aloisio, M | 1 |
Chiaretti, S | 1 |
Li, JQ | 2 |
Luo, XQ | 1 |
Wu, XD | 1 |
Sun, X | 2 |
Xu, HG | 1 |
Li, CG | 1 |
Liu, RY | 1 |
Sun, XF | 5 |
Chen, HQ | 1 |
Lin, YD | 1 |
Li, CK | 2 |
Fang, JP | 1 |
Jacola, LM | 1 |
Baran, J | 1 |
Noll, RB | 1 |
Willard, VW | 1 |
Hardy, KK | 1 |
Embry, L | 1 |
Hullmann, SE | 1 |
Larsen, EC | 1 |
Winick, N | 3 |
Kairalla, JA | 1 |
Gao, W | 1 |
Seetharam, S | 1 |
Thankamony, P | 1 |
Gopakumar, KG | 1 |
Nair, RA | 1 |
Jacob, PM | 1 |
Jagathnath Krishna, KM | 1 |
Rajeswari, B | 1 |
Nair, M | 1 |
Guruprasad, CS | 1 |
Prasanth, VR | 1 |
Bassal, M | 1 |
Silva, M | 1 |
Patel, S | 1 |
Gibson, PJ | 1 |
Breakey, VR | 1 |
Athale, U | 1 |
Zabih, V | 1 |
Li, Q | 4 |
Pechlivanoglou, P | 1 |
Pole, JD | 1 |
Mittmann, N | 1 |
Sutradhar, R | 1 |
Gupta, S | 1 |
Jia, M | 1 |
Hu, BF | 1 |
Xu, XJ | 1 |
Zhang, JY | 1 |
Li, SS | 1 |
Tang, YM | 1 |
Cao, W | 1 |
Zhang, S | 1 |
Li, L | 2 |
Jiang, Z | 1 |
Wan, D | 1 |
Yu, J | 2 |
Marín-Sánchez, A | 1 |
Martínez-Fernández, G | 1 |
Gómez-Catalán, I | 1 |
Montoya-Morcillo, MC | 1 |
Algarra-Algarra, JL | 1 |
Ibañez-García, Á | 1 |
Hernández-Fernández, F | 1 |
Romero-Macías, JR | 1 |
Schmäh, J | 1 |
Fedders, B | 1 |
Fischer, S | 1 |
Dagdan, E | 2 |
Bens, S | 1 |
Schewe, D | 1 |
Moericke, A | 2 |
Bleckmann, K | 2 |
Siebert, R | 1 |
Chen, P | 2 |
Sun, Y | 2 |
Chen, Y | 5 |
Mao, M | 1 |
Jiang, T | 1 |
Ouyang, J | 1 |
Hinze, L | 1 |
Junk, S | 1 |
Kratz, CP | 1 |
Piatopoulou, D | 3 |
Avgeris, M | 3 |
Marmarinos, A | 2 |
Xagorari, M | 2 |
Baka, M | 3 |
Doganis, D | 1 |
Kossiva, L | 2 |
Scorilas, A | 3 |
Gourgiotis, D | 3 |
Petrungaro, A | 1 |
Gentile, M | 1 |
Mazzone, C | 1 |
Greco, R | 1 |
Uccello, G | 1 |
Recchia, AG | 1 |
De Stefano, L | 1 |
Bossio, S | 1 |
Palummo, A | 1 |
Morelli, R | 1 |
Musolino, C | 1 |
Morabito, F | 1 |
Vigna, E | 1 |
Landmann, E | 1 |
Burkhardt, B | 1 |
Meyer, U | 2 |
Woessmann, W | 1 |
Klapper, W | 1 |
Wrobel, G | 2 |
Rosolen, A | 2 |
Pillon, M | 2 |
Escherich, G | 1 |
Beishuizen, A | 1 |
Mellgren, K | 1 |
Wynn, R | 1 |
Ratei, R | 7 |
Plesa, A | 2 |
Reiter, A | 10 |
Bergeron, C | 2 |
Patte, C | 5 |
Bertrand, Y | 3 |
Hong, CR | 1 |
Kang, HJ | 2 |
Park, KD | 2 |
Shin, HY | 2 |
Ahn, HS | 2 |
Rensen, N | 1 |
Gemke, RJ | 2 |
van Dalen, EC | 1 |
Rotteveel, J | 2 |
Kaspers, GJ | 3 |
Bartram, CR | 6 |
Niemeyer, C | 2 |
Ziino, O | 3 |
Schäfer, B | 1 |
Beier, R | 5 |
Ludwig, WD | 13 |
Casale, F | 4 |
Schlegel, PG | 1 |
Yamamoto, M | 1 |
Hori, T | 1 |
Igarashi, K | 1 |
Iesato, K | 1 |
Saito, M | 1 |
Miyanishi, K | 1 |
Kikuchi, N | 1 |
Fujita, H | 1 |
Tsutsumi, H | 1 |
Ceppi, F | 2 |
Gagné, V | 2 |
Douyon, L | 1 |
Quintin, CJ | 1 |
Buldini, B | 1 |
Krajinovic, M | 2 |
Sulis, ML | 1 |
Blonquist, TM | 1 |
Stevenson, KE | 2 |
Hunt, SK | 1 |
Kay-Green, S | 1 |
Athale, UH | 2 |
Clavell, LA | 3 |
Cole, PD | 1 |
Kelly, KM | 1 |
Laverdiere, C | 2 |
Leclerc, JM | 3 |
Michon, B | 1 |
Schorin, MA | 2 |
Welch, JG | 1 |
Neuberg, DS | 3 |
Sallan, SE | 9 |
Silverman, LB | 8 |
Tantawy, AAG | 1 |
Ebeid, FSE | 1 |
Adly, AAM | 1 |
El-Ghoroury, E | 1 |
Mostafa, M | 1 |
Sciumè, M | 1 |
Fracchiolla, NS | 1 |
Cortelezzi, A | 1 |
Vallacha, A | 1 |
Haider, G | 1 |
Raja, W | 1 |
Kumar, D | 1 |
Drakaki, I | 1 |
Pourtsidis, A | 1 |
Meza-Arroyo, J | 2 |
Bravo-Cuellar, A | 2 |
Jave-Suárez, LF | 2 |
Hernández-Flores, G | 2 |
Ortiz-Lazareno, P | 1 |
Aguilar-Lemarroy, A | 1 |
Padilla-Corona, M | 1 |
Sanchez-Zubieta, F | 2 |
Gonzalez-Ramella, O | 2 |
Malhotra, P | 2 |
Kapoor, G | 1 |
Jain, S | 2 |
Garg, B | 1 |
Zheng, Y | 1 |
Cai, YW | 1 |
Fu, QC | 1 |
Wang, Q | 1 |
Ji, XQ | 1 |
Cai, LL | 1 |
Pennella, CL | 1 |
Rossi, JG | 3 |
Baialardo, EM | 1 |
Alonso, CN | 3 |
Guitter, MR | 3 |
Sánchez La Rosa, CG | 1 |
Millán, NC | 1 |
Alfaro, EM | 4 |
Zubizarreta, PA | 4 |
Felice, MS | 5 |
Zeng, HM | 1 |
Zhang, LP | 1 |
Rubagumya, F | 1 |
Xu, MJ | 1 |
May, L | 1 |
Driscoll, C | 1 |
Uwizeye, FR | 1 |
Shyirambere, C | 1 |
Larrabee, K | 1 |
Fehr, AE | 1 |
Gilbert, UD | 1 |
Muhayimana, C | 1 |
Hategekimana, V | 1 |
Elmore, S | 1 |
Mpunga, T | 1 |
Moore, M | 1 |
Shulman, LN | 1 |
Lehmann, L | 1 |
Sun, YN | 1 |
Hu, YX | 1 |
Gao, L | 1 |
Xiao, PF | 1 |
Lu, J | 2 |
Wu, SY | 1 |
Shao, XJ | 1 |
Zhou, CY | 3 |
Ling, J | 1 |
Pan, J | 1 |
Gao, J | 4 |
Hu, SY | 1 |
Erkut, N | 1 |
Akidan, O | 1 |
Selim Batur, D | 1 |
Karabacak, V | 1 |
Sonmez, M | 1 |
Liu, WJ | 1 |
Zhao, Q | 1 |
Qian, C | 1 |
Wang, H | 2 |
Liu, J | 1 |
Fu, Y | 1 |
Zhai, X | 1 |
Qian, X | 1 |
Meng, J | 1 |
Miao, H | 1 |
Zhu, X | 3 |
Lu, F | 1 |
Perol, L | 1 |
Grignano, E | 1 |
Contejean, A | 1 |
Gastaud, L | 1 |
Legoff, M | 1 |
Franchi, P | 1 |
Deau-Fischer, B | 1 |
Willems, L | 1 |
Bouscary, D | 1 |
Tamburini, J | 1 |
Çifçi Sunamak, E | 1 |
Özdemir, N | 1 |
Celkan, T | 2 |
Zhang, XD | 1 |
Madjidyar, J | 1 |
Peters, S | 1 |
Yenigürbüz, FD | 1 |
Kızmazoğlu, D | 1 |
Ateş, H | 1 |
Erdem, M | 1 |
Tüfekçi, Ö | 2 |
Yılmaz, Ş | 2 |
Ören, H | 3 |
Kuang, CY | 1 |
Luo, AL | 1 |
Cai, MS | 1 |
Xu, L | 1 |
Zhang, WY | 2 |
Marshall, GM | 1 |
Dalla Pozza, L | 1 |
Sutton, R | 1 |
Ng, A | 1 |
de Groot-Kruseman, HA | 1 |
van der Velden, VH | 1 |
Venn, NC | 1 |
van den Berg, H | 1 |
de Bont, ES | 1 |
Maarten Egeler, R | 1 |
Hoogerbrugge, PM | 1 |
Bierings, MB | 3 |
van der Schoot, E | 1 |
van Dongen, J | 1 |
Law, T | 1 |
Cross, S | 1 |
Mueller, H | 1 |
de Haas, V | 1 |
Haber, M | 1 |
Révész, T | 1 |
Alvaro, F | 1 |
Suppiah, R | 2 |
Norris, MD | 1 |
Pieters, R | 9 |
Toft, N | 2 |
Birgens, H | 2 |
Abrahamsson, J | 2 |
Bernell, P | 1 |
Griškevičius, L | 2 |
Hallböök, H | 2 |
Heyman, M | 5 |
Holm, MS | 1 |
Hulegårdh, E | 1 |
Klausen, TW | 2 |
Marquart, HV | 1 |
Jónsson, OG | 2 |
Nielsen, OJ | 3 |
Quist-Paulsen, P | 2 |
Taskinen, M | 1 |
Vaitkeviciene, G | 2 |
Vettenranta, K | 3 |
Åsberg, A | 2 |
Schmiegelow, K | 5 |
Hassan, IB | 1 |
Kristensen, J | 1 |
Alizadeh, H | 1 |
Bernsen, R | 1 |
Koehler, R | 1 |
Gaynon, P | 1 |
Odenwald, E | 1 |
Henze, G | 9 |
Welte, K | 9 |
Gadner, H | 9 |
Ritter, J | 1 |
Harbott, J | 7 |
Klingebiel, T | 2 |
Gruhn, B | 3 |
Kremens, B | 2 |
Debatin, KM | 1 |
Schrauder, A | 4 |
v Stackelberg, A | 1 |
Eckert, C | 1 |
Waber, DP | 2 |
McCabe, M | 1 |
Sebree, M | 1 |
Forbes, PW | 1 |
Adams, H | 1 |
Alyman, C | 1 |
Sands, SA | 2 |
Robaey, P | 1 |
Romero, I | 1 |
Routhier, MÈ | 1 |
Girard, JM | 1 |
Ravandi, F | 2 |
Jorgensen, JL | 1 |
Thomas, DA | 2 |
O'Brien, S | 2 |
Garris, R | 1 |
Faderl, S | 2 |
Burger, JA | 1 |
Ferrajoli, A | 1 |
Kebriaei, P | 1 |
Champlin, RE | 1 |
Estrov, Z | 2 |
Challagundla, P | 1 |
Wang, SA | 1 |
Luthra, R | 1 |
Rousseau, J | 1 |
Labuda, M | 1 |
Sharif-Askari, B | 1 |
Brukner, I | 1 |
Neuberg, D | 1 |
Kutok, JL | 1 |
Sinnett, D | 1 |
Naumann, T | 1 |
Gruner, D | 1 |
Walther, M | 1 |
Wittig, S | 1 |
Becker, S | 2 |
Beck, JF | 2 |
Sonnemann, J | 1 |
Bernt, KM | 1 |
Künkele, A | 1 |
Grosse-Lordemann, A | 1 |
Schramm, A | 1 |
Eggert, A | 1 |
Schulte, JH | 1 |
Bachmann, HS | 1 |
Alloin, AL | 1 |
Barlogis, V | 2 |
Auquier, P | 2 |
Contet, A | 2 |
Poiree, M | 2 |
Demeocq, F | 3 |
Herrmann, I | 1 |
Villes, V | 2 |
Plantaz, D | 2 |
Kanold, J | 1 |
Chastagner, P | 2 |
Chambost, H | 2 |
Sirvent, N | 2 |
Michel, G | 3 |
Güttel, C | 1 |
Härtel, C | 1 |
Erdlenbruch, B | 1 |
Huang, XJ | 1 |
Jiang, B | 1 |
Jiang, Q | 1 |
Lu, XJ | 1 |
Xu, LP | 1 |
Liu, DH | 1 |
Chen, H | 1 |
Bao, L | 1 |
Jiang, H | 1 |
Nickel, RS | 1 |
Keller, F | 1 |
Bergsagel, J | 1 |
Cooper, T | 1 |
Daves, M | 1 |
Sabnis, H | 1 |
Lew, G | 1 |
Kunin-Batson, A | 1 |
Kadan-Lottick, N | 2 |
Neglia, JP | 3 |
Orgel, E | 1 |
Sposto, R | 1 |
Malvar, J | 1 |
Seibel, NL | 3 |
Ladas, E | 1 |
Gaynon, PS | 9 |
Freyer, DR | 1 |
Kletzel, M | 1 |
Powers, K | 1 |
Hayes, M | 1 |
de Ruiter, RD | 1 |
Gordijn, MS | 1 |
van den Bos, C | 1 |
Koper, JW | 1 |
van Rossum, EF | 1 |
Kaspers, GL | 1 |
Liu, F | 1 |
Wan, Y | 3 |
Chang, L | 2 |
Guo, Y | 2 |
Yang, W | 4 |
Wang, S | 2 |
Chen, X | 2 |
Liu, T | 3 |
Ruan, M | 1 |
Liu, X | 2 |
Zou, Y | 3 |
DeAngelo, DJ | 1 |
Dahlberg, SE | 2 |
Couban, S | 1 |
Supko, JG | 1 |
Amrein, PC | 1 |
Ballen, KK | 1 |
Seftel, MD | 1 |
Turner, AR | 1 |
Leber, B | 1 |
Howson-Jan, K | 1 |
Kelly, K | 1 |
Cohen, S | 1 |
Matthews, JH | 1 |
Savoie, L | 1 |
Wadleigh, M | 1 |
Sirulnik, LA | 1 |
Galinsky, I | 1 |
Malkan, AD | 1 |
Wahid, FN | 1 |
Rao, BN | 1 |
Sandoval, JA | 1 |
Pinheiro Junior, ED | 1 |
Pracchia, LF | 1 |
Beitler de Mauriño, B | 1 |
Martinez, GA | 1 |
Dorlhiac-Llacer, PE | 1 |
Medina, AB | 1 |
Velloso, ED | 1 |
Hu, Y | 2 |
Zhao, X | 1 |
Wu, LL | 1 |
Cai, CP | 1 |
Zhao, WL | 1 |
Wang, L | 2 |
Koh, K | 1 |
Fossat, C | 1 |
Roussel, M | 1 |
Arnoux, I | 1 |
Asnafi, V | 1 |
Brouzes, C | 1 |
Garnache-Ottou, F | 1 |
Jacob, MC | 1 |
Kuhlein, E | 1 |
Macintyre-Davi, E | 1 |
Robillard, N | 1 |
Tkaczuk, J | 1 |
Ifrah, N | 2 |
Dombret, H | 1 |
Béné, MC | 1 |
Baruchel, A | 6 |
Garand, R | 1 |
He, X | 1 |
Wang, C | 1 |
Niu, C | 1 |
Gao, P | 1 |
Zhen, Z | 1 |
Lu, S | 1 |
Xia, Y | 5 |
Sun, F | 1 |
Cai, R | 1 |
Li, P | 1 |
Guo, X | 4 |
Xue, L | 1 |
Sun, W | 1 |
Ma, C | 1 |
He, Y | 1 |
Cai, L | 1 |
Pui, CH | 12 |
Pei, D | 3 |
Jeha, S | 1 |
Bowman, WP | 2 |
Sandlund, JT | 5 |
Rubnitz, JE | 3 |
Inaba, H | 1 |
Bhojwani, D | 1 |
Gruber, TA | 1 |
Leung, WH | 1 |
Downing, JR | 1 |
Evans, WE | 3 |
Relling, MV | 6 |
Palk, K | 1 |
Pruunsild, K | 1 |
Helt, LR | 1 |
Frandsen, T | 1 |
Alacacioglu, I | 1 |
Medeni, SS | 1 |
Ozsan, GH | 1 |
Payzin, B | 1 |
Sevindik, OG | 1 |
Acar, C | 1 |
Katgi, A | 1 |
Ozdemirkan, F | 1 |
Piskin, O | 1 |
Ozcan, MA | 1 |
Undar, B | 1 |
Demirkan, F | 1 |
Jiménez-Hernández, E | 1 |
Jaimes-Reyes, EZ | 1 |
Arellano-Galindo, J | 1 |
García-Jiménez, X | 1 |
Tiznado-García, HM | 1 |
Dueñas-González, MT | 1 |
Martínez Villegas, O | 1 |
Sánchez-Jara, B | 1 |
Bekker-Méndez, VC | 1 |
Ortíz-Torres, MG | 1 |
Ortíz-Fernández, A | 1 |
Marín-Palomares, T | 1 |
Mejía-Aranguré, JM | 2 |
Stamati, L | 1 |
Kosmidis, H | 1 |
Anastasiou, T | 1 |
Zdráhalová, K | 1 |
Štěrba, J | 1 |
Domanský, J | 1 |
Blažek, B | 4 |
Ptoszková, H | 2 |
Mihál, V | 4 |
Novák, Z | 1 |
Hak, J | 3 |
Procházková, D | 2 |
Černá, Z | 2 |
Timr, P | 3 |
Jabali, Y | 3 |
Sedláček, P | 1 |
Smíšek, P | 1 |
Zemanová, Z | 1 |
Jarošová, M | 1 |
Houdková, A | 1 |
Mejstříková, E | 1 |
Hrušák, O | 3 |
Zuna, J | 2 |
Janotová, I | 1 |
Trka, J | 2 |
Ren, YY | 1 |
Chang, LX | 1 |
An, WB | 1 |
Zhang, JL | 1 |
Liu, TF | 1 |
Zhu, XF | 1 |
Wei, W | 1 |
An, W | 1 |
Dekking, SA | 1 |
van der Graaf, R | 1 |
de Vries, MC | 1 |
van Delden, JJ | 1 |
Kodish, E | 1 |
Lantos, JD | 1 |
Ortiz-Lazareno, PC | 1 |
Jiménez-López, X | 1 |
Gallegos-Castorena, S | 1 |
Medina-Barajas, F | 1 |
Lerma-Díaz, JM | 1 |
Listernick, R | 1 |
van der Linden, MH | 1 |
Boer, JM | 1 |
Schneider, P | 4 |
Willekes, M | 1 |
Seslija, L | 1 |
De Lorenzo, P | 4 |
den Boer, ML | 3 |
Stam, RW | 3 |
Park, HW | 1 |
Tse, S | 1 |
Kelly, HW | 1 |
Kaste, SC | 3 |
Tantisira, KG | 1 |
Aricò, M | 14 |
Silvestri, D | 4 |
Kulozik, AE | 2 |
Greiner, J | 1 |
Caruso, R | 1 |
von Stackelberg, A | 3 |
Rössig, C | 1 |
Guo, J | 1 |
Zhu, YP | 2 |
Jia, CS | 1 |
Eipel, O | 1 |
Hegyi, M | 1 |
Csordás, K | 1 |
Németh, K | 1 |
Luczay, A | 1 |
Török, D | 1 |
Csóka, M | 1 |
Erdélyi, D | 1 |
Kovács, G | 1 |
Daniel, LC | 1 |
Kloss, JD | 1 |
Reilly, AF | 1 |
Barakat, LP | 1 |
Zaliova, M | 1 |
Hovorkova, L | 1 |
Vaskova, M | 1 |
Jabeen, K | 1 |
Ashraf, MS | 1 |
Iftikhar, S | 1 |
Belgaumi, AF | 1 |
Sun, J | 1 |
Wu, Z | 1 |
Cui, Q | 1 |
Pu, C | 1 |
Liang, B | 1 |
Luo, Y | 1 |
Shi, J | 1 |
Jin, A | 1 |
Xiao, L | 1 |
Huang, H | 1 |
Li, HF | 1 |
Meng, WT | 1 |
Jia, YQ | 1 |
Jiang, NG | 1 |
Zeng, TT | 1 |
Jin, YM | 1 |
Huang, QR | 1 |
Xu, H | 1 |
Mo, XM | 1 |
Antillón, FG | 1 |
Blanco, JG | 1 |
Valverde, PD | 1 |
Castellanos, M | 1 |
Garrido, CP | 1 |
Girón, V | 1 |
Letona, TR | 1 |
Osorio, EJ | 1 |
Borrayo, DA | 1 |
Mack, RA | 1 |
Melgar, MA | 1 |
Lorenzana, R | 1 |
Metzger, M | 1 |
Rossi, E | 1 |
Reismüller, B | 1 |
Steiner, M | 1 |
Pichler, H | 1 |
Dworzak, M | 1 |
Meister, B | 4 |
Schmitt, K | 1 |
Pötschger, U | 1 |
König, M | 1 |
Haas, OA | 3 |
Narayanan, G | 1 |
Soman, LV | 1 |
El-Cheikh, J | 1 |
El Dika, I | 1 |
Massoud, R | 1 |
Charafeddine, M | 1 |
Mahfouz, R | 1 |
Kharfan-Dabaja, MA | 1 |
Bazarbachi, A | 1 |
Dujua, AC | 1 |
Hernandez, FG | 1 |
Koh, KN | 1 |
Im, HJ | 1 |
Kim, H | 1 |
Lee, JW | 1 |
Yoo, KH | 1 |
Sung, KW | 1 |
Koo, HH | 1 |
Lim, YT | 1 |
Park, JE | 1 |
Park, BK | 1 |
Park, HJ | 1 |
Seo, JJ | 1 |
Chiang, LY | 1 |
Crawford, JR | 1 |
Kuo, DJ | 1 |
Fetz, A | 1 |
Bretscher, C | 1 |
Tucci, F | 1 |
Raetz, EA | 1 |
Borowitz, MJ | 3 |
Devidas, M | 4 |
Linda, SB | 3 |
Hunger, SP | 4 |
Winick, NJ | 1 |
Camitta, BM | 4 |
Carroll, WL | 3 |
Paganin, M | 1 |
Zecca, M | 2 |
Fabbri, G | 1 |
Polato, K | 1 |
Buendia, MT | 2 |
Lozano, JM | 2 |
Suarez, GE | 1 |
Saavedra, C | 1 |
Guevara, G | 1 |
Leeper, NJ | 1 |
Dhaliwal, G | 1 |
Saint, S | 1 |
Witteles, RM | 1 |
Inthal, A | 1 |
Krapf, G | 1 |
Beck, D | 1 |
Joas, R | 1 |
Kauer, MO | 1 |
Orel, L | 1 |
Fuka, G | 1 |
Panzer-Grümayer, ER | 2 |
Chang, JE | 1 |
Medlin, SC | 1 |
Kahl, BS | 1 |
Longo, WL | 1 |
Williams, EC | 1 |
Lionberger, J | 1 |
Kim, K | 2 |
Kim, J | 1 |
Esterberg, E | 1 |
Juckett, MB | 1 |
Fernandez-Munoz, I | 2 |
Gerdes, K | 3 |
von Neuhoff, N | 2 |
Beger, C | 4 |
Gandemer, V | 1 |
Auclerc, MF | 2 |
Perel, Y | 4 |
Vannier, JP | 1 |
Le Gall, E | 1 |
Schmitt, C | 1 |
Piguet, C | 1 |
Stephan, JL | 1 |
Lejars, O | 2 |
Debre, M | 1 |
Jonveaux, P | 1 |
Cayuela, JM | 1 |
Chevret, S | 1 |
Leverger, G | 5 |
Behm, FG | 3 |
Onciu, M | 1 |
Razzouk, BI | 2 |
Hijiya, N | 1 |
Hudson, MM | 2 |
Kaushik, A | 1 |
Bansal, D | 1 |
Khandelwal, N | 1 |
Trehan, A | 1 |
Marwaha, RK | 1 |
Lowas, SR | 1 |
Marks, D | 1 |
Malempati, S | 1 |
Qiu, L | 1 |
Zou, D | 1 |
Mi, Y | 1 |
Nowak-Göttl, U | 4 |
Kenet, G | 1 |
Mitchell, LG | 1 |
Ozdemir, MA | 1 |
Karakukcu, M | 1 |
Patiroglu, T | 1 |
Torun, YA | 1 |
Kose, M | 1 |
Sonabend, RY | 1 |
McKay, SV | 1 |
Okcu, MF | 1 |
Yan, J | 1 |
Haymond, MW | 1 |
Margolin, JF | 1 |
Urasińska, E | 3 |
Grabarek, J | 1 |
Fydryk, J | 2 |
Domagała, W | 3 |
Schaeffeler, E | 1 |
Coulthard, SA | 1 |
Kaatsch, P | 1 |
Dördelmann, M | 4 |
Eichelbaum, M | 1 |
Riehm, H | 11 |
Schwab, M | 1 |
Kadan-Lottick, NS | 1 |
Brouwers, P | 1 |
Breiger, D | 1 |
Kaleita, T | 1 |
Dziura, J | 1 |
Liu, H | 1 |
Chen, L | 1 |
Nicoletti, M | 1 |
Stork, L | 1 |
Bostrom, B | 1 |
Marino, S | 1 |
Verzegnassi, F | 1 |
Tamaro, P | 3 |
Stocco, G | 1 |
Bartoli, F | 1 |
Decorti, G | 1 |
Rabusin, M | 1 |
Zhen, ZJ | 4 |
Ling, JY | 2 |
Tong, GL | 1 |
Lin, L | 1 |
Cai, Y | 1 |
Kristinsson, J | 1 |
Mogensen, UB | 1 |
Rosthøj, S | 1 |
Wesenberg, F | 1 |
Saarinen-Pihkala, U | 1 |
Withycombe, JS | 1 |
Post-White, JE | 1 |
Meza, JL | 1 |
Hawks, RG | 1 |
Smith, LM | 2 |
Sacks, N | 1 |
Santos, FP | 1 |
Rodrigues, M | 1 |
Mac-Donald Bley do Nascimento, C | 1 |
Kerbauy, FR | 1 |
Ribeiro, AA | 1 |
Mauro Kutner, J | 1 |
Hamerschlak, N | 1 |
Jaing, TH | 1 |
Lin, JL | 1 |
Lin, YP | 1 |
Yang, SH | 1 |
Lin, JJ | 1 |
Hsia, SH | 1 |
Tantawy, AA | 1 |
El-Bostany, EA | 1 |
Adly, AA | 1 |
Abou El Asrar, M | 1 |
El-Ghouroury, EA | 1 |
Abdulghaffar, EE | 1 |
Qin, Y | 1 |
Shi, YK | 1 |
He, XH | 1 |
Han, XH | 1 |
Zhou, SY | 1 |
Liu, P | 1 |
Yang, JL | 1 |
Yang, S | 1 |
Zhang, CG | 1 |
Dong, M | 1 |
Zhou, LQ | 1 |
Wang, JW | 1 |
Feng, FY | 1 |
de Boer, J | 2 |
Hagelstein, J | 1 |
Brady, HJ | 1 |
Armstrong, SA | 1 |
Ularntinon, S | 1 |
Tzuang, D | 1 |
Dahl, G | 1 |
Shaw, RJ | 1 |
McNeer, JL | 1 |
Nachman, JB | 3 |
Giordano, P | 1 |
Molinari, AC | 1 |
Del Vecchio, GC | 1 |
Saracco, P | 3 |
Russo, G | 1 |
Altomare, M | 1 |
Perutelli, P | 1 |
Crescenzio, N | 1 |
Santoro, N | 5 |
Marchetti, M | 1 |
De Mattia, D | 1 |
Falanga, A | 1 |
Petruzziello, F | 1 |
Menna, G | 1 |
Mangione, A | 1 |
Cianciulli, E | 1 |
Buffardi, S | 1 |
Marchese, L | 1 |
Nastro, A | 1 |
Misuraca, A | 1 |
Poggi, V | 3 |
Oztürkmen, S | 1 |
Paç, A | 1 |
Senayl, A | 1 |
Polat, TB | 1 |
Cetin, II | 1 |
Bçakç, Z | 1 |
Akyay, A | 1 |
Olcay, L | 1 |
Nagatoshi, Y | 1 |
Matsuzaki, A | 1 |
Suminoe, A | 1 |
Inada, H | 1 |
Ueda, K | 1 |
Kawakami, K | 1 |
Yanai, F | 1 |
Nakayama, H | 1 |
Moritake, H | 1 |
Itonaga, N | 1 |
Hotta, N | 1 |
Fujita, K | 1 |
Hidaka, Y | 1 |
Yamanaka, T | 1 |
Kawano, Y | 1 |
Okamura, J | 2 |
Canova, F | 1 |
Marino, D | 1 |
Trentin, C | 1 |
Soldà, C | 1 |
Ghiotto, C | 1 |
Aversa, SM | 1 |
Bélien-Pallet, V | 1 |
Cabrol, S | 1 |
Fasola, S | 1 |
Petit, A | 1 |
Landman-Parker, J | 2 |
Auvrignon, A | 2 |
Pillozzi, S | 1 |
Masselli, M | 1 |
De Lorenzo, E | 1 |
Accordi, B | 1 |
Cilia, E | 1 |
Crociani, O | 1 |
Amedei, A | 1 |
Veltroni, M | 1 |
D'Amico, M | 1 |
Becchetti, A | 1 |
Arcangeli, A | 1 |
Kawedia, JD | 1 |
Panetta, JC | 1 |
Cai, X | 1 |
Neale, G | 1 |
Howard, SC | 1 |
Fouda, A | 1 |
Kandil, SM | 1 |
Zalata, K | 1 |
Mansour, A | 1 |
Al-Tonbary, Y | 1 |
Maloney, E | 1 |
Kamieńska, E | 3 |
Kurylak, A | 2 |
Kwiecińska, K | 1 |
Moryl-Bujakowska, A | 2 |
Pawelec, K | 3 |
Chybicka, A | 9 |
Dobaczewski, G | 2 |
Wiśniewska-Slusarz, H | 3 |
Sońta-Jakimczyk, D | 11 |
Styczyński, J | 2 |
Balcerska, A | 5 |
Płoszyńska, A | 3 |
Larsen, EL | 1 |
Blach, L | 1 |
Carroll, AJ | 2 |
Pullen, DJ | 2 |
Shuster, J | 4 |
Willman, CL | 1 |
Gallego, MS | 2 |
Fraquelli, LE | 2 |
Scopinaro, MJ | 1 |
Renard, M | 1 |
Suciu, S | 3 |
Uyttebroeck, A | 2 |
Ferster, A | 3 |
van der Werff Ten Bosch, J | 1 |
Mazingue, F | 2 |
Plouvier, E | 3 |
Robert, A | 2 |
Boutard, P | 2 |
Millot, F | 2 |
Munzer, M | 1 |
Mechinaud, F | 2 |
Lescoeur, B | 1 |
Baila, L | 1 |
Vandecruys, E | 1 |
Benoit, Y | 2 |
Philippet, P | 2 |
Simmons, JH | 1 |
Chow, EJ | 1 |
Koehler, E | 1 |
Esbenshade, A | 1 |
Smith, LA | 1 |
Sanders, J | 1 |
Friedman, D | 1 |
Teuffel, O | 1 |
Kuster, SP | 1 |
Hitzler, J | 1 |
Ethier, MC | 1 |
Shah, PS | 1 |
Beyene, J | 1 |
Sung, L | 2 |
Amirghofran, Z | 1 |
Daneshbod, Y | 1 |
Gholijani, N | 1 |
Esmaeilbeig, M | 1 |
Bernasconi, AR | 1 |
Rubio, PL | 1 |
Mrakotsky, CM | 1 |
Alyman, MC | 1 |
Queally, JT | 1 |
Miller, TP | 1 |
Cranston, A | 1 |
Le Meignen, M | 1 |
Simeoni, MC | 1 |
Galambrun, C | 1 |
Play, B | 1 |
Berbis, J | 1 |
Bordigoni, P | 2 |
Pansy, J | 1 |
Szymon, S | 1 |
Bik-Multanowski, M | 1 |
Pietrzyk, JJ | 1 |
Surmiak, M | 1 |
Strojny, W | 3 |
Galicka-Latala, D | 1 |
Gozdzik, J | 1 |
Willer, A | 1 |
Gerss, J | 1 |
König, T | 1 |
Franke, D | 1 |
Kühnel, HJ | 1 |
Boos, J | 1 |
Lanvers-Kaminsky, C | 1 |
Dopfer, C | 1 |
Kentouche, K | 1 |
Dopfer, R | 2 |
Mentzel, HJ | 1 |
Mainz, JG | 1 |
Kurtzberg, J | 2 |
Asselin, B | 1 |
Bernstein, M | 1 |
Buchanan, GR | 6 |
Pollock, BH | 4 |
Koltin, D | 1 |
Naqvi, A | 1 |
Urbach, SL | 1 |
Tsukasaki, K | 1 |
Tobinai, K | 1 |
Hotta, T | 1 |
Shimoyama, M | 1 |
Tsukamoto, S | 1 |
Takeuchi, M | 2 |
Kawajiri, C | 1 |
Tanaka, S | 1 |
Nagao, Y | 1 |
Sugita, Y | 1 |
Yamazaki, A | 1 |
Kawaguchi, T | 1 |
Muto, T | 1 |
Sakai, S | 1 |
Takeda, Y | 1 |
Ohwada, C | 1 |
Sakaida, E | 1 |
Shimizu, N | 1 |
Yokote, K | 1 |
Iseki, T | 1 |
Nakaseko, C | 1 |
Spijkers-Hagelstein, JA | 1 |
Hulleman, E | 1 |
Williams, O | 1 |
Liang, ZY | 1 |
Degnan, AJ | 1 |
Levy, LM | 1 |
Termuhlen, AM | 1 |
Perkins, SL | 2 |
Lones, M | 1 |
Finlay, JL | 1 |
Weinstein, H | 1 |
Gross, TG | 1 |
Abromowitch, M | 1 |
Salvador, C | 1 |
Crazzolara, R | 1 |
Kropshofer, G | 2 |
Ribera, JM | 5 |
García, O | 1 |
Montesinos, P | 1 |
Brunet, S | 2 |
Abella, E | 3 |
Barrios, M | 1 |
González-Campos, J | 1 |
Bravo, P | 1 |
Amigo, ML | 1 |
Hernández-Rivas, JM | 2 |
Sang, W | 1 |
Wang, CF | 1 |
Cheng, YF | 1 |
Li, XX | 1 |
Gulinar, A | 1 |
Li, JZ | 1 |
Zhang, W | 1 |
Mattano, LA | 2 |
Sather, HN | 14 |
Steinherz, PG | 7 |
Gao, C | 1 |
Zhao, XX | 1 |
Li, WJ | 1 |
Cui, L | 1 |
Zhao, W | 1 |
Liu, SG | 1 |
Yue, ZX | 1 |
Jiao, Y | 1 |
Wu, MY | 1 |
Li, ZG | 1 |
Brackmann, F | 1 |
Dörr, HG | 1 |
Hinderhofer, K | 1 |
Holter, W | 1 |
Langer, T | 2 |
Conklin, HM | 1 |
Krull, KR | 1 |
Reddick, WE | 1 |
Lee, CS | 1 |
Shim, JW | 1 |
Yoon, JS | 1 |
Lee, SC | 1 |
Çankal, A | 1 |
Gözmen, S | 1 |
Yüksel, F | 1 |
Vergin, C | 1 |
Irken, G | 2 |
Russo, D | 1 |
Orlando, MA | 1 |
Benigno, V | 1 |
Jakab, Z | 1 |
Balogh, E | 1 |
Karászi, E | 1 |
Kappelmayer, J | 1 |
Kiss, C | 1 |
Oláh, E | 1 |
Ozkan, A | 1 |
Apak, H | 1 |
Kuruoglu, S | 1 |
Yuksel, L | 1 |
Yildiz, I | 1 |
Matthias, T | 1 |
Madkaikar, M | 1 |
Ghosh, K | 1 |
Jijina, F | 1 |
Gupta, M | 1 |
Rajpurkar, M | 1 |
Mohanty, D | 1 |
Dabaja, BS | 1 |
Ha, CS | 2 |
Wilder, RB | 2 |
Gopal, R | 1 |
Cortes, J | 4 |
Bueso-Ramos, C | 1 |
Hess, MA | 2 |
Cox, JD | 2 |
Powles, R | 1 |
Sirohi, B | 1 |
Treleaven, J | 1 |
Kulkarni, S | 1 |
Tait, D | 1 |
Singhal, S | 1 |
Mehta, J | 1 |
Messina, C | 7 |
Rondelli, R | 7 |
Lanino, E | 1 |
Sacchi, N | 1 |
Uderzo, C | 1 |
Fagioli, F | 1 |
Bonetti, F | 1 |
Favre, C | 2 |
Porta, F | 2 |
Giorgiani, G | 2 |
Pession, A | 8 |
Gülen, H | 1 |
Duman, M | 1 |
Uçar, C | 1 |
Atabay, B | 1 |
Uysal, K | 1 |
Cevik, N | 1 |
Addeo, R | 2 |
D'Angelo, V | 2 |
Indolfi, P | 3 |
Morgera, C | 1 |
Crisci, S | 2 |
Di Tullio, MT | 3 |
Minicucci, EM | 1 |
Lopes, LF | 1 |
Crocci, AJ | 1 |
Ahlke, E | 1 |
Fleischhack, G | 1 |
Schwabe, D | 1 |
Schobess, R | 1 |
Schumann, C | 1 |
Junker, R | 3 |
Bostrom, BC | 1 |
Sensel, MR | 1 |
La, MK | 1 |
Johnston, K | 1 |
Erdmann, GR | 1 |
Gold, S | 1 |
Heerema, NA | 1 |
Hutchinson, RJ | 1 |
Provisor, AJ | 1 |
Trigg, ME | 6 |
el Omri, H | 1 |
Kraiem, I | 1 |
Amara, H | 1 |
Ben Youssef, Y | 1 |
Skouri, H | 1 |
Ennabli, S | 1 |
Fehr, T | 1 |
Jacky, E | 2 |
Bächli, EB | 1 |
Corbacioglu, S | 1 |
Eber, S | 1 |
Gungor, T | 1 |
Hummerjohann, J | 1 |
Chessells, JM | 1 |
Camitta, B | 2 |
Boyett, JM | 7 |
Carroll, A | 2 |
Eden, OB | 3 |
Harms, DO | 1 |
Harrison, CJ | 1 |
Harrison, PL | 2 |
Heerema, N | 1 |
Janka-Schaub, G | 2 |
Kamps, W | 1 |
Masera, G | 8 |
Pullen, J | 2 |
Raimondi, SC | 3 |
Richards, S | 2 |
Sallan, S | 1 |
Sather, H | 3 |
Vilmer, E | 2 |
Yetgin, S | 1 |
Cetin, M | 1 |
Heath, JA | 1 |
Altman, A | 1 |
Jhanwar, S | 1 |
Halpern, S | 1 |
Shah, N | 1 |
Steinherz, L | 3 |
Tannous, R | 1 |
Terry, W | 1 |
Gupta, V | 1 |
Kamel-Reid, S | 1 |
Minden, MD | 1 |
Lipton, JH | 2 |
Brandwein, J | 1 |
Messner, HA | 2 |
Park, SR | 1 |
Kim, JH | 1 |
Kim, DY | 1 |
Lee, S | 1 |
Lee, SY | 1 |
Choi, IS | 1 |
Yoon, SS | 1 |
Park, S | 1 |
Kim, BG | 1 |
Kim, NK | 1 |
Yoshida, I | 1 |
Colović, M | 1 |
Bogdanović, A | 1 |
Janković, G | 1 |
Kraguljac, N | 1 |
Suvajdzić, N | 1 |
Wehl, G | 1 |
Högler, W | 1 |
Heitger, A | 2 |
Nussbaumer, W | 1 |
Tissing, WJ | 1 |
Efferth, T | 1 |
Sauerbrey, A | 3 |
Steinbach, D | 1 |
Gebhart, E | 1 |
Drexler, HG | 1 |
Miyachi, H | 1 |
Chitambar, CR | 1 |
Becker, CM | 1 |
Zintl, F | 3 |
Humeny, A | 1 |
Boccalatte, MF | 2 |
Chiesa, R | 1 |
Lippi, A | 2 |
Gallisai, D | 1 |
De Rossi, G | 9 |
Asgedom, G | 2 |
Kardinal, C | 2 |
Esparza, SD | 1 |
Moore, TB | 1 |
Feig, SA | 2 |
Kishi, S | 1 |
Boureau, B | 1 |
Morand, S | 1 |
Das, S | 1 |
Cook, EH | 1 |
Rosner, GL | 1 |
Schuetz, E | 1 |
Mora, J | 1 |
Filippa, DA | 1 |
Qin, J | 1 |
Wollner, N | 2 |
GUPTA, NN | 1 |
MITTAL, SP | 1 |
MILLER, JN | 1 |
MEYERS, RL | 1 |
CARPENTER, CM | 1 |
BELMUSTO, L | 1 |
REGELSON, W | 1 |
OWENS, G | 1 |
HANANIAN, J | 1 |
NIGOGOSYAN, G | 1 |
ALPERIN, JB | 1 |
LEVIN, WC | 1 |
Gajdos, P | 2 |
Pospísilová, D | 2 |
Hrstková, H | 2 |
Dembická, D | 1 |
Kopecná, L | 2 |
Slavík, Z | 1 |
Zahálka, F | 1 |
Vávra, V | 1 |
Mydlil, J | 2 |
Wiernik, PH | 1 |
Cassileth, PA | 2 |
Leong, T | 1 |
Hoagland, HC | 2 |
Bennett, JM | 2 |
Paietta, E | 2 |
Oken, MM | 1 |
Tang, W | 1 |
Ziring, D | 1 |
Gershman, G | 1 |
French, S | 1 |
Zalewska-Szewczyk, B | 1 |
Przybysz, K | 1 |
Kowalewska-Pietrzak, M | 1 |
Stolarska, M | 1 |
Bodalski, J | 1 |
Caraglia, M | 1 |
Abbruzzese, A | 1 |
Piccaluga, PP | 1 |
Malagola, M | 1 |
Rondoni, M | 1 |
Amabile, M | 1 |
Gaitani, S | 1 |
Visani, G | 2 |
Benatti, C | 1 |
Gnocchi, M | 1 |
Travaglino, E | 1 |
Invernizzi, R | 2 |
Ascari, E | 1 |
Goldschmidt, N | 1 |
Gural, A | 1 |
Kornberg, A | 1 |
Spectre, G | 1 |
Shopen, A | 1 |
Paltiel, O | 1 |
Bhatia, M | 1 |
Kher, K | 1 |
Minniti, CP | 1 |
Thomas, X | 3 |
Boiron, JM | 1 |
Huguet, F | 1 |
Reman, O | 1 |
Sutton, L | 2 |
Turlure, P | 1 |
Garban, F | 1 |
Gardin, C | 1 |
Espinouse, D | 1 |
Boulat, O | 1 |
Lhéritier, V | 1 |
Fiere, D | 2 |
Frater, JL | 1 |
Batanian, JR | 1 |
O'Connor, DM | 1 |
Grosso, LE | 1 |
Bürger, B | 1 |
Beck, JD | 2 |
Hajduch, M | 1 |
Noskova, V | 1 |
Janostakova, A | 1 |
Safarova, M | 1 |
Orel, M | 1 |
Kouzmina, G | 1 |
Holownia, A | 1 |
Trofimiuk, E | 1 |
Jakubow, P | 1 |
Kaliszewski, J | 1 |
Muszynska-Roslan, K | 2 |
Braszko, JJ | 1 |
Zhang, CQ | 1 |
Wang, ZH | 1 |
Wang, ZQ | 1 |
Chen, ZM | 1 |
Lou, JY | 1 |
Xu, WL | 1 |
Jiang, WQ | 1 |
Liu, DG | 2 |
Xia, ZJ | 2 |
Huang, HQ | 2 |
Li, YH | 2 |
Zhou, ZM | 2 |
He, YJ | 1 |
Guan, ZZ | 2 |
Janić, D | 1 |
Dokmanović, L | 1 |
Jovanović, N | 1 |
Skorić, D | 1 |
Lazić, J | 1 |
Luczyński, W | 1 |
Stasiak-Barmuta, A | 1 |
Zak, J | 1 |
Athanassiadou, F | 2 |
Kourti, M | 1 |
Papageorgiou, T | 1 |
Stamou, M | 1 |
Makedou, A | 1 |
Boufidou, A | 1 |
Kaczmarek-Kanold, M | 1 |
Chełmecka-Hanuszewicz, L | 1 |
Jackowska, T | 4 |
Odój, T | 1 |
Steczowicz, M | 1 |
Wojciechowska, V | 1 |
Wójtowicz, A | 1 |
Dalle, JH | 1 |
Moghrabi, A | 1 |
Rousseau, P | 1 |
Barrette, S | 1 |
Bernstein, ML | 1 |
Champagne, J | 2 |
David, M | 1 |
Demers, J | 1 |
Duval, M | 1 |
Hume, H | 1 |
Meyer, P | 1 |
Champagne, MA | 1 |
Bertorello, N | 2 |
Farinasso, L | 2 |
Einaudi, S | 2 |
Altare, F | 1 |
Corrias, A | 2 |
Pastore, G | 2 |
van Imhoff, GW | 1 |
van der Holt, B | 1 |
MacKenzie, MA | 1 |
Ossenkoppele, GJ | 1 |
Wijermans, PW | 1 |
Kramer, MH | 1 |
van 't Veer, MB | 2 |
Schouten, HC | 2 |
van Marwijk Kooy, M | 1 |
van Oers, MH | 1 |
Raemaekers, JM | 1 |
Sonneveld, P | 1 |
Meulendijks, LA | 1 |
Kluin, PM | 1 |
Kluin-Nelemans, HC | 1 |
Verdonck, LF | 1 |
Brodtman, DH | 1 |
Rosenthal, DW | 1 |
Redner, A | 3 |
Lanzkowsky, P | 3 |
Bonagura, VR | 1 |
Aoki, CA | 1 |
Bowlus, CL | 1 |
Rossaro, L | 1 |
Eiser, C | 1 |
Davies, H | 1 |
Jenney, M | 1 |
Stride, C | 1 |
Glaser, A | 1 |
Siciliano, SA | 1 |
Crowther, M | 1 |
Barr, RD | 4 |
Chan, AK | 1 |
Merkle, M | 1 |
Rupprecht, HD | 1 |
Mazur, B | 1 |
Karpe, J | 1 |
Bubała, H | 3 |
Torbus, M | 1 |
Ferrari, A | 2 |
Potenza, L | 1 |
Riva, G | 1 |
Morselli, M | 1 |
Imovilli, A | 1 |
Volzone, F | 1 |
Rossi, G | 1 |
Codeluppi, M | 1 |
Guaraldi, G | 1 |
Torelli, G | 1 |
Micalizzi, C | 2 |
Ji, H | 1 |
Liu, WP | 1 |
Li, GD | 1 |
Hill, G | 1 |
Chauvenet, AR | 4 |
Lovato, J | 1 |
McLean, TW | 1 |
D'Urbano, LE | 1 |
De Benedetti, F | 1 |
Rodriguez, V | 1 |
Anderson, PM | 1 |
Trotz, BA | 1 |
Arndt, CA | 1 |
Allen, JA | 1 |
Khan, SP | 1 |
Diviné, M | 1 |
Casassus, P | 2 |
Koscielny, S | 1 |
Bosq, J | 1 |
Sebban, C | 3 |
Le Maignan, C | 1 |
Stamattoulas, A | 1 |
Dupriez, B | 1 |
Raphaël, M | 2 |
Pico, JL | 1 |
Ribrag, V | 1 |
Ottmann, OG | 1 |
Wassmann, B | 1 |
Kalkanci, A | 1 |
Kokturk, N | 1 |
Senol, E | 1 |
Acar, K | 1 |
Guzel, O | 1 |
Sancak, B | 1 |
Kustimur, S | 1 |
Haznedar, R | 1 |
Hindo, H | 1 |
Buescher, ES | 1 |
Frank, LM | 1 |
Pettit, D | 1 |
Dory, C | 1 |
Byrd, R | 1 |
Papadhimitriou, SI | 1 |
Polychronopoulou, S | 1 |
Tsakiridou, AA | 1 |
Androutsos, G | 1 |
Paterakis, GS | 1 |
Abla, O | 1 |
Gassas, A | 1 |
Stevens, R | 1 |
Grant, R | 1 |
Abdelhaleem, M | 1 |
Appel, IM | 1 |
Hop, WC | 1 |
Dixit, A | 2 |
Kannan, M | 2 |
Mahapatra, M | 2 |
Choudhry, VP | 2 |
Saxena, R | 2 |
Klimza, MJ | 1 |
Sońta-Jakimczyk, DJ | 1 |
Breit, S | 1 |
Flohr, T | 1 |
Tolle, G | 1 |
Happich, M | 1 |
Muckenthaler, MU | 1 |
Kober, T | 1 |
Hülsewede, H | 1 |
Bohlius, J | 1 |
Engert, A | 1 |
Schrøder, H | 3 |
Kjeldahl, M | 1 |
Boesen, AM | 2 |
Schmidt, K | 1 |
Johnsen, HE | 2 |
Gregersen, H | 2 |
Gustafsson, G | 2 |
Paul, S | 1 |
Marty, FM | 1 |
Colson, YL | 1 |
Caruso, V | 1 |
Iacoviello, L | 1 |
Di Castelnuovo, A | 1 |
Storti, S | 1 |
Mariani, G | 1 |
de Gaetano, G | 1 |
Donati, MB | 1 |
Kjeldstad, M | 1 |
Schmidt, KG | 1 |
Skoczeń, S | 3 |
Pawińska, K | 1 |
Luszczyńska, A | 1 |
Juszczak, K | 3 |
Krauze, A | 2 |
Styczyńskii, J | 1 |
Swiatkiewicz, V | 1 |
Taylor, JA | 1 |
Winter, L | 1 |
Geyer, LJ | 1 |
Hawkins, DS | 1 |
Pérez Martínez, A | 1 |
Alonso Ojembarrena, A | 1 |
Ramírez Orellana, M | 1 |
García Castro, J | 1 |
González-Vicent, M | 1 |
Contra Gómez, T | 2 |
Madero López, L | 1 |
Díaz Pérez, MA | 1 |
Sawicka-Zukowska, M | 1 |
Kajdas, L | 1 |
Sancho, JM | 1 |
Xicoy, B | 1 |
Morgades, M | 1 |
Oriol, A | 2 |
Tormo, M | 2 |
del Potro, E | 2 |
Debén, G | 1 |
Bethencourt, C | 2 |
Ortín, X | 1 |
Ortega-Rivas, F | 1 |
Novo, A | 1 |
López, R | 1 |
Sanz, MA | 2 |
Feliu, E | 2 |
Douer, D | 1 |
Yampolsky, H | 1 |
Cohen, LJ | 1 |
Watkins, K | 1 |
Levine, AM | 1 |
Periclou, AP | 1 |
Avramis, VI | 1 |
Sun, LR | 1 |
Pang, XY | 1 |
Lu, ZH | 1 |
Sui, AH | 1 |
Ke, XY | 1 |
Ma, J | 1 |
Shen, ZX | 1 |
Zhang, XH | 1 |
Du, X | 1 |
Zhao, YM | 1 |
Lv, JQ | 1 |
Zhan, ZM | 1 |
Zeng, XY | 1 |
Xu, XH | 1 |
Lu, ZS | 1 |
Mantadakis, E | 1 |
Amoiridis, G | 1 |
Kondi, A | 1 |
Kalmanti, M | 1 |
Sakić, M | 1 |
Berbić-Fazlagić, J | 1 |
Yamanoha, A | 1 |
Nagasaki, A | 1 |
Nakachi, S | 1 |
Kinjo, S | 1 |
Takasu, N | 1 |
Rhein, P | 1 |
Scheid, S | 1 |
Hagemeier, C | 1 |
Seeger, K | 1 |
Kirschner-Schwabe, R | 1 |
Spang, R | 1 |
Karawajew, L | 2 |
Kroczka, S | 1 |
Steczkowska-Klucznik, M | 1 |
Romaniszyn, A | 1 |
Martin, PL | 1 |
Bell, BA | 1 |
Pettenati, MJ | 1 |
Shuster, JJ | 4 |
Niinimäki, RA | 1 |
Harila-Saari, AH | 1 |
Jartti, AE | 1 |
Seuri, RM | 1 |
Riikonen, PV | 1 |
Pääkkö, EL | 1 |
Möttönen, MI | 1 |
Lanning, M | 1 |
Cox, DP | 1 |
Treseler, P | 1 |
Dong, R | 1 |
Jordan, RC | 1 |
Bornhauser, BC | 1 |
Bonapace, L | 1 |
Lindholm, D | 1 |
Martinez, R | 1 |
Niggli, FK | 1 |
Schäfer, BW | 1 |
Bourquin, JP | 1 |
Varma, S | 1 |
Varma, N | 1 |
Kumari, S | 1 |
Das, R | 1 |
Ahluwalia, J | 1 |
Mahi, S | 1 |
Sharma, SC | 1 |
Radhika, S | 1 |
González Pérez, P | 1 |
Serrano-Pozo, A | 1 |
Franco-Macías, E | 1 |
Montes-Latorre, E | 1 |
Gómez-Aranda, F | 1 |
Campos, T | 1 |
Chatterjee, T | 1 |
Mishra, P | 1 |
Choudhry, DR | 1 |
Hann, I | 1 |
Felice, M | 1 |
Hovi, L | 1 |
LeBlanc, T | 3 |
Janka, G | 2 |
Rubnitz, J | 1 |
Silverman, L | 1 |
Campbell, M | 2 |
Vora, A | 1 |
Niklowitz, P | 1 |
Wiesel, T | 1 |
Andler, W | 1 |
Menke, T | 1 |
Karachunskiĭ, AI | 1 |
Miakova, NV | 1 |
Rumiantseva, IuV | 1 |
Timakov, AM | 1 |
Makhortykh, TZh | 1 |
Fechina, LG | 1 |
Shamardina, AV | 1 |
Dudkin, SA | 1 |
Lebedev, VV | 1 |
Varfolomeeva, SR | 1 |
Timofeeva, VN | 1 |
Herold, R | 2 |
Stakelberg, A | 1 |
Rumiantsev, AG | 1 |
Masera, N | 1 |
Villa, A | 1 |
Riva, F | 1 |
Li, XH | 1 |
Pan, LL | 1 |
Li, FY | 1 |
Liu, HT | 2 |
Fernández Canal, C | 1 |
Campoamor Serrano, M | 1 |
García Alcalde Fernández, ML | 1 |
Kager, L | 1 |
Lion, T | 2 |
Koenig, M | 1 |
Strehl, S | 1 |
Dworzak, MN | 1 |
Dynybil, C | 1 |
Bartels, DB | 1 |
Löning, L | 1 |
Claviez, A | 1 |
Luciani, M | 1 |
Gu, LJ | 1 |
Xue, HL | 1 |
Tang, JY | 1 |
Chen, J | 3 |
Zhao, HJ | 1 |
Ye, H | 1 |
Pan, C | 1 |
Karachunskiy, A | 1 |
Miakova, N | 1 |
Timakow, A | 1 |
Mahortih, T | 1 |
Bajdun, L | 1 |
Maschan, A | 1 |
Fechina, L | 1 |
Shamardina, A | 1 |
Dudkin, S | 1 |
Lebedev, V | 1 |
Varfolomeeva, S | 1 |
Timofeeva, V | 1 |
Roumiantseva, J | 1 |
Chipsanova, N | 1 |
Rumjanzew, A | 1 |
Akiyama, M | 1 |
Yamada, O | 2 |
Agawa, M | 1 |
Yuza, Y | 1 |
Yanagisawa, T | 1 |
Eto, Y | 1 |
Yamada, H | 1 |
Fernández-Abellán, P | 1 |
Bueno, J | 2 |
Parody, R | 1 |
Bastida, P | 1 |
Grande, C | 1 |
Heras, I | 1 |
Ortega, JJ | 1 |
Han, AR | 1 |
Jang, JH | 1 |
Kim, WS | 1 |
Ahn, JS | 1 |
Jung, CW | 1 |
Lee, MH | 1 |
Kang, WK | 1 |
Van Dongen-Melman, JE | 1 |
Hokken-Koelega, AC | 1 |
Hählen, K | 2 |
De Groot, A | 1 |
Tromp, CG | 1 |
Egeler, RM | 1 |
Safadi, R | 1 |
Or, R | 1 |
Bar Ziv, J | 1 |
Polliack, A | 2 |
Archimbaud, E | 1 |
Charrin, C | 1 |
Magaud, JP | 1 |
Jost, LM | 1 |
Dommann-Scherrer, C | 1 |
Honegger, HP | 1 |
Maurer, R | 1 |
Sauter, C | 1 |
Stahel, RA | 1 |
Holtgrave, EA | 1 |
Heinze, F | 1 |
Annino, L | 6 |
Crescenzi, S | 1 |
Romani, C | 1 |
Mandelli, F | 12 |
Hancock, ML | 2 |
Krance, RA | 1 |
Mahmoud, HH | 1 |
Benítez, H | 1 |
Arreguín, L | 1 |
Velásquez, L | 1 |
Bernaldez, R | 1 |
Juan, L | 1 |
Farfán, J | 1 |
Díaz, S | 1 |
Gaona, A | 1 |
Martínez, MC | 1 |
Mori, PG | 2 |
Miniero, R | 3 |
Colella, R | 1 |
Maytal, J | 1 |
Grossman, R | 1 |
Yusuf, FH | 1 |
Shende, AC | 1 |
Karayalycin, G | 1 |
Schaul, N | 1 |
Eviatar, L | 1 |
Inhorn, RC | 1 |
Aster, JC | 1 |
Roach, SA | 1 |
Slapak, CA | 1 |
Soiffer, R | 1 |
Tantravahi, R | 1 |
Pierce, S | 3 |
Keating, MJ | 1 |
Freireich, EJ | 1 |
de Stefano, V | 1 |
Gugliotta, L | 2 |
Mazzucconi, MG | 2 |
Leone, G | 4 |
Bartlett, NL | 1 |
Kwak, LW | 1 |
Horning, SJ | 1 |
Wu, GQ | 1 |
Slavotinek, A | 1 |
Thomson, A | 1 |
Eynaud, P | 1 |
Perry, P | 1 |
Steel, CM | 1 |
Waits, TM | 1 |
Greco, FA | 1 |
Greer, JP | 1 |
Hainsworth, JD | 1 |
Larson, RA | 1 |
Dodge, RK | 1 |
Burns, CP | 2 |
Lee, EJ | 2 |
Schulman, P | 1 |
Duggan, D | 1 |
Davey, FR | 1 |
Sobol, RE | 1 |
Frankel, SR | 1 |
Mahoney, DH | 1 |
Leventhal, BG | 2 |
Civin, CJ | 1 |
Ganick, DJ | 1 |
Lauer, SJ | 1 |
Steuber, CP | 1 |
Kamen, BA | 1 |
Peregud-Pogorzelski, J | 1 |
Krygier-Stojałowska, A | 1 |
Tubergen, DG | 2 |
Krailo, MD | 2 |
Meadows, AT | 4 |
Rosenstock, J | 1 |
Kadin, M | 1 |
Morse, M | 1 |
King, D | 1 |
Kersey, JH | 3 |
Rubio, JA | 1 |
Pulpón, LA | 1 |
Cavero, MA | 1 |
Oteo, JF | 1 |
Maicas, C | 1 |
Silva, L | 1 |
Serrano-Fiz, S | 1 |
Burgos, R | 1 |
Artaza, M | 1 |
Téllez, G | 1 |
Johnson, F | 1 |
Hunt, S | 1 |
Xiang, AH | 1 |
Azen, SP | 1 |
Sica, S | 3 |
Salutari, P | 2 |
Di Mario, A | 2 |
D'Onofrio, G | 1 |
Etuk, B | 2 |
Omura, GA | 2 |
Vogler, WR | 2 |
Martelo, O | 1 |
Gordon, DS | 2 |
Bartolucci, AA | 2 |
Colgan, JP | 1 |
Andersen, J | 1 |
Habermann, TM | 1 |
Earle, JD | 1 |
O'Connell, MJ | 1 |
Neiman, RS | 1 |
Mann, RB | 1 |
Glick, JH | 1 |
Danaïla, C | 1 |
Bach, QK | 1 |
Dufour, P | 1 |
Christian, B | 1 |
Corront, B | 1 |
Bosly, A | 1 |
Bastion, Y | 1 |
Gratecos, N | 2 |
Leblay, R | 1 |
Willemze, R | 2 |
Zijlmans, JM | 1 |
den Ottolander, GJ | 1 |
Kluin-Nelemans, JC | 1 |
Falkenburg, JH | 1 |
Starrenburg, CW | 1 |
van der Burgh, JF | 1 |
Fibbe, WE | 1 |
Mertens, R | 1 |
Rubbert, F | 1 |
Büssing, A | 1 |
Hiddemann, W | 4 |
Sauter, S | 1 |
Lampert, F | 3 |
Havers, W | 1 |
Niethammer, D | 1 |
Lepage, E | 2 |
Vernant, JP | 1 |
Gluckman, E | 1 |
Attal, M | 1 |
Reiffers, J | 1 |
Racadot, E | 1 |
Michallet, M | 2 |
Maraninchi, D | 1 |
Cheatham, BD | 1 |
Henry, RJ | 1 |
Kudva, GC | 1 |
Chandy, M | 1 |
Dennison, D | 1 |
Srivastava, A | 1 |
Bhushan, V | 1 |
Chiu, EK | 1 |
Chan, LC | 1 |
Liang, R | 2 |
Lie, A | 2 |
Kwong, YL | 1 |
Todd, D | 2 |
Chan, TK | 2 |
Zemlickis, D | 1 |
Lishner, M | 1 |
Erlich, R | 1 |
Koren, G | 1 |
Gururangan, S | 1 |
Horner, M | 1 |
Rodman, JH | 1 |
Marina, NM | 1 |
Putti, MC | 1 |
Cantù Rajnoldi, A | 1 |
Granchi, D | 1 |
Cocito, MG | 1 |
Saitta, M | 1 |
Santostasi, T | 1 |
Guglielmi, C | 3 |
Ras, E | 1 |
Michaeli, J | 1 |
Rosenmann, E | 1 |
Popovtzer, MM | 1 |
Shouval, D | 1 |
Meyers, P | 2 |
Tan, C | 2 |
Heller, G | 1 |
Ochocka, M | 2 |
Kulus, M | 1 |
Armata, J | 9 |
Bogusławska-Jaworska, J | 7 |
Jakowicka, M | 3 |
Michalewska, D | 1 |
Cherlow, JM | 2 |
Grossman, NJ | 2 |
Johnstone, HS | 2 |
Breneman, JC | 2 |
Hammond, GD | 6 |
Rivard, GE | 1 |
Infante-Rivard, C | 1 |
Dresse, MF | 2 |
Hoelzer, D | 1 |
Thiel, E | 1 |
Löffler, H | 1 |
Büchner, T | 1 |
Freund, M | 3 |
Heil, G | 3 |
Maschmeyer, G | 1 |
Völkers, B | 1 |
Brandalise, S | 1 |
Odone, V | 1 |
Pereira, W | 1 |
Andrea, M | 1 |
Zanichelli, M | 1 |
Aranega, V | 1 |
Mughal, T | 1 |
Morleda, J | 1 |
Goldman, J | 1 |
Cyklis, R | 3 |
Grześkowiak-Melanowska, J | 1 |
Radwańska, U | 1 |
Swiatły, A | 1 |
Katz, JA | 1 |
Hvizdala, E | 1 |
Falletta, JM | 2 |
Schwenn, M | 1 |
Murphy, SB | 2 |
Wolfrom, C | 1 |
Hartmann, R | 1 |
Fengler, R | 1 |
Brühmüller, S | 1 |
Ingwersen, A | 1 |
Weiss, M | 4 |
Telford, P | 1 |
Kempin, S | 2 |
Kritz, A | 1 |
Sogoloff, H | 1 |
Gee, T | 3 |
Berman, E | 3 |
Scheinberg, D | 2 |
Little, C | 1 |
Gaynor, J | 1 |
Dunphy, CH | 1 |
Kitchen, S | 1 |
Saravia, O | 1 |
Velasquez, WS | 1 |
Lange, BJ | 1 |
Blatt, J | 2 |
Chappell, R | 1 |
Hammond, D | 1 |
Bleyer, WA | 5 |
Azzi, A | 1 |
Ciappi, S | 1 |
De Santis, R | 1 |
Fanci, R | 1 |
Leoni, F | 1 |
Colli, S | 1 |
Rossi-Ferrini, PL | 1 |
Groot-Loonen, JJ | 1 |
Otten, BJ | 1 |
van't Hof, MA | 1 |
Lippens, RJ | 1 |
Stoelinga, GB | 1 |
Soslow, RA | 1 |
Davis, RE | 1 |
Warnke, RA | 1 |
Cleary, ML | 1 |
Kamel, OW | 1 |
Nordgren, A | 1 |
Jeddi-Tehrani, M | 1 |
Rasool, O | 1 |
Grander, D | 1 |
Ost, A | 1 |
Wallberg, B | 1 |
Johansson, B | 1 |
Schlieben, S | 1 |
Borkhardt, A | 2 |
Reinisch, I | 1 |
Ritterbach, J | 1 |
Janssen, JW | 1 |
Repp, R | 1 |
Kabisch, H | 1 |
Tsuruchi, N | 1 |
Corden, TE | 1 |
Morgan, ER | 1 |
Liu, Q | 1 |
Benaim, E | 1 |
Crist, WM | 5 |
Beretta, F | 1 |
Sanna, P | 1 |
Ghielmini, M | 1 |
Marini, G | 1 |
Cavalli, F | 1 |
Weisdorf, D | 1 |
Stammler, G | 2 |
Volm, M | 2 |
Mohnike, KL | 1 |
Kluba, U | 1 |
Mittler, U | 1 |
Aumann, V | 1 |
Vorwerk, P | 1 |
Blum, WF | 1 |
Maslak, P | 1 |
Feldman, E | 1 |
Bertino, J | 2 |
Megherian, L | 1 |
Seiter, K | 1 |
Golde, D | 1 |
Nishikawa, K | 1 |
Aziz, Z | 1 |
Zahid, M | 1 |
Mahmood, R | 1 |
Maqbool, S | 1 |
Salloum, E | 1 |
Tallini, G | 1 |
Levy, A | 1 |
Cooper, DL | 1 |
Terselich, G | 1 |
Viscaino, MP | 1 |
Freeman, AI | 2 |
Glicksman, AS | 1 |
Brecher, ML | 1 |
Sinks, LF | 1 |
Holland, JF | 1 |
Nachman, J | 2 |
Lukens, JN | 3 |
Wolff, L | 1 |
Rivera-Luna, R | 1 |
Cardenas-Cardos, R | 1 |
Leal-Leal, C | 1 |
Navarro-Alegría, I | 1 |
Meza-Coria, C | 1 |
Gómez-Martínez, R | 1 |
Vega-Vega, L | 1 |
Fajardo-Gutíerrez, A | 1 |
Bernáldez-Ríos, R | 1 |
Rodríguez-Zepeda, MC | 1 |
Espinoza-Hernández, L | 1 |
Martínez-García, MC | 1 |
Giona, F | 3 |
Arcese, W | 3 |
Meloni, G | 4 |
Amadori, S | 6 |
Resegotti, L | 1 |
Tabilio, A | 2 |
Ladogana, S | 2 |
Fioritoni, G | 2 |
Camera, A | 3 |
Liso, V | 1 |
Leoni, P | 2 |
Geissler, K | 1 |
Koller, E | 1 |
Hubmann, E | 1 |
Niederwieser, D | 1 |
Hinterberger, W | 1 |
Geissler, D | 1 |
Kyrle, P | 1 |
Knöbl, P | 1 |
Pabinger, I | 1 |
Thalhammer, R | 1 |
Schwarzinger, I | 1 |
Mannhalter, C | 1 |
Jaeger, U | 1 |
Heinz, R | 1 |
Linkesch, W | 1 |
Lechner, K | 1 |
Ueberall, MA | 1 |
Skirl, G | 1 |
Strassburg, HM | 1 |
Wenzel, D | 1 |
Hertzberg, H | 1 |
Meier, W | 1 |
Berger-Jones, K | 1 |
Huk, WJ | 1 |
Korinthenberg, R | 1 |
Ceci, A | 1 |
Madon, E | 2 |
Comis, M | 1 |
Wrzesień-Kuś, A | 1 |
Krykowski, E | 1 |
Todeschini, G | 1 |
Tecchio, C | 1 |
Meneghini, V | 1 |
Pizzolo, G | 1 |
Veneri, D | 1 |
Zanotti, R | 1 |
Ricetti, MM | 1 |
Solero, P | 1 |
April, F | 1 |
Perona, G | 1 |
Dobashi, N | 1 |
Usui, N | 1 |
Kobayashi, T | 1 |
Yamazaki, H | 1 |
Asai, O | 1 |
Yano, S | 1 |
Kato, A | 1 |
Watanabe, H | 1 |
Nagamine, M | 1 |
Katori, M | 1 |
Tajima, N | 1 |
Kuraishi, Y | 1 |
Mentzer, SJ | 1 |
Fingeroth, J | 1 |
Reilly, JJ | 2 |
Perrine, SP | 1 |
Faller, DV | 1 |
Sepet, E | 1 |
Aytepe, Z | 1 |
Ozerkan, AG | 1 |
Yalman, N | 1 |
Guven, Y | 1 |
Anak, S | 1 |
Devecioglu, O | 1 |
Agaoglu, L | 1 |
Gedikoglu, G | 1 |
Schott, G | 2 |
Sperling, C | 2 |
Martin, M | 1 |
Kuribara, R | 1 |
Muroi, K | 1 |
Yoshida, M | 1 |
Suzuki, T | 1 |
Izumi, T | 1 |
Hatake, K | 1 |
Amemiya, Y | 1 |
Miura, Y | 1 |
Durian, M | 1 |
van Wering, ER | 3 |
Veerman, AJ | 2 |
Balis, FM | 1 |
Holcenberg, JS | 2 |
Poplack, DG | 1 |
Ge, J | 1 |
Murphy, RF | 1 |
Ames, MM | 1 |
Waskerwitz, MJ | 1 |
Zimm, S | 1 |
Gilchrist, GS | 1 |
Testi, A | 1 |
Mauger, DC | 1 |
Skeen, JE | 1 |
Vivanco Martínez, JL | 1 |
López Pérez, J | 1 |
Melero Moreno, C | 1 |
Torres Valdivieso, MJ | 1 |
Palacios López, ME | 1 |
Martín Ramos, N | 1 |
Bernacer Borja, M | 1 |
Gil López, C | 1 |
Valverde Moreno, F | 1 |
Grossi, C | 1 |
Kaleita, TA | 1 |
Reaman, GH | 1 |
MacLean, WE | 1 |
Whitt, JK | 1 |
Salgado, C | 1 |
Quintana, J | 1 |
Becker, A | 1 |
Vargas, L | 1 |
Cabrera, ME | 1 |
Beresi, V | 1 |
Rojas, J | 1 |
Paez, E | 1 |
Tapia, S | 1 |
Zolezzi, P | 1 |
Advis, P | 1 |
Götz, N | 1 |
Viehmann, S | 1 |
Gaiger, A | 1 |
Linnerth, B | 1 |
Schmid, D | 1 |
Heinze, G | 1 |
Tisljar, K | 1 |
Carrel, AL | 1 |
Aguayo, A | 1 |
Thomas, D | 2 |
Keating, M | 1 |
Kantarjian, H | 1 |
Nysom, K | 1 |
Holm, K | 1 |
Michaelsen, KF | 1 |
Hertz, H | 1 |
Müller, J | 1 |
Mølgaard, C | 1 |
Kaiser, U | 1 |
Uebelacker, I | 1 |
Havemann, K | 1 |
Zuazu, J | 1 |
Villalba, T | 1 |
Julià, A | 1 |
Schneider, M | 1 |
Panzer, S | 1 |
Fasching, K | 1 |
Wagner, H | 1 |
Maybee, DA | 1 |
Pinkel, D | 1 |
Gorczyńska, E | 2 |
Filiks-Litwin, B | 2 |
Kołecki, P | 3 |
Lukowska, K | 2 |
Rokicka-Milewska, R | 9 |
Rola-Kurc, E | 2 |
Stencel, D | 2 |
Zelenay, E | 3 |
Dłuzniewska, A | 1 |
Sopyło, B | 1 |
Stefaniak, MJ | 1 |
Stefańska, K | 1 |
Stańczak, E | 1 |
Mathey, C | 1 |
Legall, E | 1 |
Lamagnere, JP | 2 |
Berthou, C | 1 |
Bauduer, F | 1 |
Pautard, B | 1 |
Schaison, G | 2 |
Hurwitz, CA | 1 |
Dalton, VK | 1 |
Glick, KM | 1 |
Gelber, RD | 4 |
Jiang, S | 1 |
Serke, S | 1 |
van Lessen, A | 1 |
Hummel, M | 1 |
Szczepek, A | 1 |
Huhn, D | 1 |
Stein, H | 1 |
Neth, O | 1 |
Seidemann, K | 1 |
Jansen, P | 1 |
Tiemann, M | 1 |
Mauz-Körholz, C | 1 |
Göbel, U | 1 |
Sklar, CA | 1 |
Mertens, AC | 1 |
Walter, A | 1 |
Mitchell, D | 1 |
Nesbit, ME | 2 |
O'Leary, M | 1 |
Hutchinson, R | 1 |
Robison, LL | 2 |
Gao, H | 1 |
Ruano, D | 1 |
Diaz, MA | 1 |
Tutor, O | 1 |
Garcia-Sanchez, F | 1 |
Martinez, P | 1 |
Madero, L | 1 |
Hammermuller, E | 1 |
De Dávila, MT | 1 |
Ciocca, ME | 1 |
Lorusso, AM | 1 |
Sackmann-Muriel, F | 2 |
Abshire, TC | 1 |
Billett, AL | 1 |
Bradley, P | 1 |
Lange, B | 1 |
Sancho, J | 1 |
Soriano Guillén , L | 1 |
Muñoz Calvo , MT | 1 |
Pozo Román , J | 1 |
Contra Gómez , T | 1 |
Buño Soto , M | 1 |
Argente Oliver , J | 1 |
Garcia-Manero, G | 1 |
Tucker, SL | 1 |
Rodriguez, MA | 1 |
Cabanillas, FF | 1 |
Anderer, G | 1 |
Brechlin, AM | 1 |
Muti, P | 1 |
Schneider, T | 1 |
Seydlitz, F | 1 |
Zimmermann, U | 1 |
Sontag, B | 1 |
Boesken, WH | 1 |
Philippe, N | 1 |
Lutz, P | 2 |
Marguerite, G | 1 |
Rialland, X | 1 |
Behard, C | 1 |
Norton, L | 1 |
Thyss, A | 1 |
Dastugue, N | 1 |
Waterkeyn, C | 1 |
Otten, J | 2 |
Atra, A | 1 |
Gerrard, M | 1 |
Hobson, R | 1 |
Imeson, JD | 1 |
Hann, IM | 1 |
Pinkerton, CR | 1 |
Ichikawa, M | 1 |
Okamoto, T | 1 |
Park, C | 1 |
Motoji, T | 1 |
Mizoguchi, H | 2 |
Shibuya, A | 1 |
Auperin, A | 1 |
Michon, J | 1 |
Behrendt, H | 2 |
Frappaz, D | 1 |
Coze, C | 1 |
Terrier-Lacombe, MJ | 1 |
Strauss, AJ | 1 |
Su, JT | 1 |
Dalton, VM | 1 |
Paolucci, G | 2 |
Vecchi, V | 2 |
Fletcher, BD | 1 |
Kennedy, W | 1 |
Neel, MD | 1 |
Hunault-Berger, M | 1 |
Milpied, N | 2 |
Bernard, M | 1 |
Jouet, JP | 1 |
Delain, M | 1 |
Desablens, B | 1 |
Sadoun, A | 1 |
Guilhot, F | 1 |
Moritz, B | 1 |
Eder, J | 1 |
Brougham, M | 1 |
Montgomery, C | 1 |
Richardson, F | 1 |
Kelly, A | 1 |
Gibson, BE | 1 |
Petroni, GR | 1 |
Schiffer, CA | 1 |
Freter, CE | 1 |
Johnson, JL | 1 |
Barcos, M | 1 |
Frizzera, G | 1 |
Bloomfield, CD | 1 |
Peterson, BA | 1 |
Heinecke, A | 1 |
von Kries, R | 1 |
Nürnberger, W | 1 |
Münchow, N | 1 |
He, H | 1 |
Han, M | 1 |
Grenzebach, J | 1 |
Parwaresch, R | 1 |
Chen, YC | 1 |
Ho, CL | 1 |
Kao, WY | 1 |
Hwang, JM | 1 |
Sheu, LF | 1 |
Chao, TY | 1 |
Shtalrid, M | 1 |
Haran, M | 1 |
Klepfish, A | 1 |
Lurie, Y | 1 |
Malnick, S | 1 |
Vegna, ML | 3 |
Specchia, G | 1 |
Ferrara, F | 2 |
Peta, A | 1 |
Ciolli, S | 2 |
Deplano, W | 2 |
Di Raimondo, F | 1 |
Cascavilla, N | 1 |
Rotoli, B | 1 |
Raetz, E | 1 |
Moos, PJ | 1 |
Bruggers, CS | 1 |
Smith, F | 1 |
Borges, E | 1 |
Ferry, JA | 1 |
Friedmann, AM | 1 |
Kingma, A | 1 |
Van Dommelen, RI | 1 |
Mooyaart, EL | 1 |
Wilmink, JT | 1 |
Deelman, BG | 1 |
Kamps, WA | 1 |
Giles, FJ | 1 |
Huh, YO | 1 |
Linker, C | 1 |
Damon, L | 1 |
Ries, C | 1 |
Navarro, W | 1 |
Klus, K | 1 |
Kolecki, P | 1 |
Boguslawska-Jaworska, J | 1 |
Pisarek, J | 1 |
Łuszczynska, A | 1 |
Bubala, H | 1 |
Łukowska, K | 1 |
Sakiroglu, C | 1 |
Ansoborlo, S | 1 |
Pacquement, H | 1 |
Babin-Boilletot, A | 1 |
Micalizzi, MC | 1 |
Delwail, V | 1 |
Jais, JP | 1 |
Colonna, P | 1 |
Andrieu, JM | 1 |
Pacholska, J | 1 |
Paciorkiewicz, W | 1 |
Jastrzebska, M | 1 |
Månsson-Rahemtulla, B | 1 |
Techanitiswad, T | 1 |
Rahemtulla, F | 1 |
McMillan, TO | 1 |
Bradley, EL | 1 |
Wahlin, YB | 1 |
Saito, H | 1 |
Jacobs, P | 2 |
Wood, L | 2 |
Mattioli-Belmonte, M | 1 |
Defazio, D | 1 |
Tura, S | 1 |
Huismans, DR | 1 |
Loonen, AH | 1 |
Peters, GJ | 1 |
van der Does-van den Berg, A | 2 |
Vats, T | 1 |
Buchanan, G | 1 |
Mehta, P | 1 |
Ragab, A | 2 |
Hvizdale, E | 1 |
Nitschke, R | 1 |
Link, M | 2 |
Beardsley, GP | 1 |
Maybee, D | 1 |
Krischer, J | 1 |
Tacik, J | 1 |
Martelli, M | 2 |
Papa, G | 2 |
Holowiecki, J | 2 |
Koehler, M | 1 |
Zintl, Z | 1 |
Kardos, G | 1 |
Lutz, D | 1 |
Krzemien, S | 1 |
Rewesz, T | 1 |
Brugiatelli, M | 1 |
Callea, V | 1 |
Kachel, L | 2 |
Thun-Hohenstein, L | 1 |
Frisch, H | 1 |
Schuster, E | 1 |
Rytwiński, K | 1 |
Konopacka, M | 1 |
Ciechanowska, U | 1 |
Rajagopal, S | 1 |
Yue, BB | 1 |
Komada, Y | 1 |
Zhang, SL | 1 |
Zhou, YW | 1 |
Hanada, M | 1 |
Shibata, T | 1 |
Azuma, E | 1 |
Sakurai, M | 1 |
Maschan, AA | 1 |
Samochatova, EV | 1 |
Kryzhanovskiĭ, OI | 1 |
Pagano, L | 1 |
DeVeber, LL | 2 |
Pai, KM | 1 |
Andrew, M | 2 |
Halton, J | 1 |
Cairney, AE | 1 |
Whitton, AC | 1 |
Festa, RS | 3 |
Tamaroff, MH | 2 |
Chasalow, F | 1 |
Martelo, OJ | 1 |
Raney, M | 1 |
Adesman, AR | 1 |
Walco, GA | 1 |
Sommelet, D | 1 |
Bancillon, A | 2 |
Pavlovsky, S | 1 |
Sackmann Muriel, F | 1 |
Santarelli, MT | 1 |
Svarch, E | 1 |
Jiménez, E | 1 |
Kohan, R | 1 |
Rosso, A | 1 |
Fabiano, F | 1 |
Muti, G | 1 |
Andersen, JW | 1 |
Mazza, JJ | 1 |
O'Connell, MC | 1 |
Wiernik, P | 1 |
Derulska, D | 4 |
Duczmal, B | 1 |
García Zueco, JC | 1 |
Torres Gómez, M | 1 |
López Gómez, L | 1 |
Martín Guerrero, Y | 1 |
Murakawa, M | 1 |
Okamura, T | 1 |
Shibuya, T | 1 |
Harada, M | 1 |
Otsuka, T | 1 |
Niho, Y | 1 |
Chiu, E | 1 |
Ho, FC | 1 |
Loke, SL | 1 |
Drigan, R | 1 |
Spirito, A | 1 |
Eguiguren, JM | 1 |
Diedrich, H | 2 |
Ganser, A | 2 |
Gramatzki, M | 1 |
Heyll, A | 2 |
Henke, M | 2 |
Haas, R | 1 |
Kuse, R | 1 |
Kalifa, C | 1 |
Flamant, F | 1 |
Hartmann, O | 1 |
Brugières, L | 1 |
Valteau-Couanet, D | 1 |
Bayle, C | 1 |
Caillaud, JM | 1 |
Lemerle, J | 1 |
Harris, RE | 1 |
Baum, E | 1 |
Kaizer, H | 1 |
Pendergrass, TW | 1 |
Saunders, EF | 1 |
Warkentin, PL | 1 |
Clarkson, B | 1 |
Philips, GK | 1 |
Crowell, EB | 1 |
Mani, A | 1 |
Cerezo, L | 1 |
Brock, B | 1 |
Head, DR | 1 |
Bozzola, M | 1 |
Gambarana, D | 1 |
Moretta, A | 1 |
Valtorta, A | 1 |
Cisternino, M | 1 |
Severi, F | 1 |
Niemeyer, CM | 1 |
Tarbell, NJ | 1 |
Donnelly, M | 1 |
Blattner, SR | 1 |
Donahue, K | 1 |
Cohen, HJ | 1 |
Bender-Götze, C | 1 |
Ebell, W | 1 |
Ehninger, G | 1 |
Friedrich, W | 1 |
Darmal, B | 1 |
Rudzka, E | 1 |
Lawniczek, T | 1 |
Pajak, J | 1 |
Ridgway, D | 2 |
Wolff, LJ | 1 |
Deforest, A | 1 |
Mitrou, PS | 1 |
Serke, M | 1 |
Pohl, C | 1 |
Becker, K | 1 |
Schrappe-Bächer, M | 1 |
Knauf, W | 1 |
Westerhausen, M | 1 |
Clemens, MR | 1 |
Helm, EB | 1 |
Fischer, T | 1 |
Balsom, WR | 1 |
Heyn, RM | 1 |
Sitarz, A | 1 |
Philip, T | 1 |
Rodary, C | 1 |
Zucker, JM | 1 |
Gentet, JC | 1 |
Dufillot, D | 1 |
Pein, F | 1 |
Loosveld, OJ | 1 |
Gaillard, CA | 1 |
Blijham, GH | 1 |
Nickerson, HJ | 1 |
Coccia, PF | 2 |
Finklestein, JZ | 1 |
Miller, DR | 4 |
Littman, PS | 1 |
Siegel, SE | 2 |
Yamada, S | 1 |
Miyagawa, Y | 1 |
Komiyama, A | 1 |
Smith, SD | 1 |
Yanofsky, RA | 1 |
Ghim, T | 1 |
Wharam, MD | 1 |
Vietti, TJ | 2 |
Johnson, W | 1 |
Jones, B | 1 |
Jacquillat, C | 1 |
Weil, M | 1 |
Pochedly, C | 1 |
Sinks, L | 1 |
Chevalier, L | 1 |
Maurer, HM | 1 |
Koch, K | 1 |
Lilleyman, JS | 1 |
Shaw, MP | 1 |
Peto, J | 1 |
De Salvo Cardullo, L | 1 |
Weir Madina, J | 1 |
Gómez Sánchez, O | 1 |
Plumacher, Z | 1 |
Salas, D | 1 |
Okpala, IE | 1 |
Olatunji, PO | 1 |
Okunade, MA | 1 |
Ogunsanwo, BA | 1 |
Jeje, OM | 1 |
Shokunbi, WA | 1 |
Essien, EM | 1 |
De Boben, M | 1 |
Knauf, U | 1 |
Koch, P | 1 |
Janka-Schaub, GE | 1 |
Goebel, U | 1 |
Graubner, U | 1 |
Haas, RJ | 1 |
Juergens, H | 1 |
Spaar, HJ | 1 |
Winkler, K | 1 |
Belasco, JB | 1 |
Luery, N | 1 |
Scher, C | 1 |
Leikin, SL | 2 |
Albo, VC | 2 |
Palmer, NF | 1 |
Murphy, RG | 1 |
Greenberg, ML | 1 |
Novitzky, N | 1 |
Shimamoto, T | 1 |
Ohyashiki, J | 1 |
Utsumi, K | 1 |
Ohyashiki, K | 1 |
Toyama, K | 1 |
Grañena, A | 2 |
Rozman, C | 2 |
Urbano-Ispizua, A | 2 |
Bladé, J | 1 |
Carreras, E | 1 |
Cervantes, F | 1 |
Marín, P | 1 |
Sierra, J | 2 |
Nomdedeu, B | 1 |
Bader-Meunier, B | 1 |
Garel, D | 1 |
Dommergues, JP | 1 |
Venencie, PY | 1 |
Crist, W | 1 |
Jackson, J | 1 |
Head, D | 1 |
Borowitz, M | 1 |
Behm, F | 1 |
Steuber, P | 1 |
Gisselbrecht, C | 1 |
Harousseau, JL | 1 |
Witz, F | 1 |
Troussard, X | 1 |
LeBlond, V | 1 |
Auzanneau, G | 1 |
Kreitzer, PM | 1 |
Blethen, SL | 1 |
Chasalow, FI | 1 |
Iannetti, P | 1 |
Fabbri, A | 1 |
Ulisse, S | 1 |
Isidori, A | 1 |
Imperato, C | 1 |
Pulczynska, MK | 1 |
Hejl, M | 1 |
Sato, Y | 1 |
Ito, R | 1 |
Saito, T | 1 |
Suto, Y | 1 |
Tateoka, N | 1 |
Onodera, N | 1 |
Ikeda, Y | 1 |
Ito, E | 1 |
Miyano, T | 1 |
Tachibana, N | 1 |
Radford, JE | 1 |
Jones, MP | 1 |
Gingrich, RD | 1 |
Kemp, JD | 1 |
Edwards, RW | 1 |
McFadden, DB | 1 |
Dick, FR | 1 |
Wen, BC | 1 |
Neerhout, RC | 1 |
Bleyer, A | 1 |
Steinherz, P | 2 |
Mandell, LR | 1 |
Walker, RW | 1 |
Fuks, Z | 1 |
Solbu, G | 1 |
Rammeloo, JA | 1 |
de Koning, J | 1 |
van Zanen, GE | 1 |
Shi, YD | 1 |
Zhang, ZN | 1 |
Choonara, I | 1 |
Wheeldon, J | 1 |
Rayner, P | 1 |
Blackburn, M | 1 |
Lewis, I | 1 |
Desai, SJ | 1 |
Pai, MK | 1 |
Piroso, E | 1 |
Erslev, AJ | 1 |
Caro, J | 1 |
Casonato, A | 1 |
Lazzaro, AR | 1 |
Girolami, A | 1 |
Skwarska, E | 1 |
Slørdal, L | 1 |
Kolmannskog, S | 1 |
Moe, PJ | 1 |
Prytz, PS | 1 |
Aarbakke, J | 1 |
Lichter-Konecki, U | 1 |
Benninger, C | 1 |
Brandeis, WE | 1 |
Matthis, P | 1 |
Scheffner, D | 1 |
Russo, A | 1 |
Di Bella, D | 1 |
Lo Bianco, M | 1 |
Schilirò, G | 1 |
Rossi, MR | 1 |
Zurlo, MG | 1 |
Bagnulo, S | 1 |
Carli, M | 1 |
Zanesco, L | 1 |
Dini, G | 1 |
Guazzelli, C | 1 |
Pearson, AD | 1 |
Darbyshire, PJ | 1 |
Mott, MG | 1 |
Serra, L | 1 |
Rosito, P | 1 |
Paolucci, P | 1 |
Burnelli, R | 1 |
Vivarelli, F | 1 |
Mancini, AF | 1 |
Wegelius, R | 1 |
Venkatarangam, SH | 1 |
Kutcher, SP | 1 |
Notkin, RM | 1 |
Reddemann, H | 1 |
Hellwig, C | 1 |
Poller, C | 1 |
Peters, WG | 1 |
Colly, LP | 1 |
Brugués, R | 1 |
King, DJ | 1 |
Brunton, J | 1 |
Lewicki, Z | 1 |
Yu, A | 1 |
Boyett, J | 1 |
Abdalla, A | 1 |
Badrawy, F | 1 |
Khalifa, A | 1 |
Hamza, R | 1 |
Clinical Trials (30)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Front-line Treatment of Philadelphia Positive/BCR-ABL Positive Acute Lymphoblastic Leukemia With Ponatinib, a New Potent Tyrosine Kinase Inhibitor.[NCT01641107] | Phase 2 | 44 participants (Actual) | Interventional | 2014-12-04 | Completed | ||
A Phase II Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients ≥ 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone [NCT02143414] | Phase 2 | 53 participants (Actual) | Interventional | 2015-06-30 | Active, not recruiting | ||
Treatment Protocol for T-Cell and B-Precursor Cell Lymphoblastic Lymphoma of the European Inter-group Co-operation on Childhood Non-Hodgkin-Lymphoma (EICNHL)[NCT00275106] | Phase 3 | 600 participants (Anticipated) | Interventional | 2004-09-30 | Terminated (stopped due to Withdrawn due to an excess of toxic deaths) | ||
ALL-BFM 2000 Multi-Center Study for the Treatment of Children and Adolescents With Acute Lymphoblastic Leukemia[NCT00430118] | Phase 3 | 4,559 participants (Actual) | Interventional | 2000-07-31 | Completed | ||
AIEOP LLA 2000 Multicenter Study for the Diagnosis and Treatment of Childhood Acute Lymphoblastic Leukemia[NCT00613457] | Phase 3 | 2,039 participants (Actual) | Interventional | 2000-09-30 | Completed | ||
Enhancing Effect on Tumour Apoptosis With the Combined Use of Pentoxifylline Plus Chemotherapeutical Agents in Pediatrics and AYA Patients With Hodgkin´s Lymphoma[NCT05490953] | Phase 4 | 30 participants (Anticipated) | Interventional | 2022-07-11 | Recruiting | ||
Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph-positive Acute Lymphoblastic Leukemia[NCT04554459] | Phase 2 | 32 participants (Anticipated) | Interventional | 2021-02-16 | Active, not recruiting | ||
Use of Levocarnitine to Reduce Asparaginase Hepatotoxicity in Patients With Acute Lymphoblastic Leukemia[NCT05501899] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2023-03-03 | Recruiting | ||
Total XV - Total Therapy Study XV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia[NCT00137111] | Phase 3 | 501 participants (Actual) | Interventional | 2000-07-08 | Completed | ||
Metformin as an Adjunctive Therapy For Transient Hyperglycemia in Patients With Acute Lymphoblastic Leukemia During Induction Chemotherapy[NCT01486043] | 4 participants (Actual) | Interventional | 2011-12-31 | Terminated (stopped due to The research project was terminated due to lower than projected patient recruitment within the period of time allowed for the study.) | |||
Neurobehavioral Outcomes in Childhood Acute Lymphoblastic Leukemia. A Limited Non-Therapeutic Study[NCT00085176] | 286 participants (Actual) | Observational | 2004-05-31 | Completed | |||
Treatment of Patients With Acute Lymphoblastic Leukemia With Unfavorable Features: A Phase III Group-wide Study[NCT00002812] | Phase 3 | 2,078 participants (Actual) | Interventional | 1996-09-30 | Completed | ||
ALinC 17: Protocol for Patients With Newly Diagnosed High Risk Acute Lymphoblastic Leukemia (ALL) - Evaluation of the Augmented BFM Regimen: A Phase III Study[NCT00005603] | Phase 3 | 276 participants (Actual) | Interventional | 2000-03-31 | Completed | ||
ALL-REZ BFM 2002: Protocol for the Treatment of Children With Relapsed Acute Lymphoblastic Leukemia[NCT00114348] | Phase 4 | 338 participants (Actual) | Interventional | 2003-08-31 | Completed | ||
Randomized Phase III Study for the Treatment of Newly Diagnosed Disseminated Lymphoblastic Lymphoma or Localized Lymphoblastic Lymphoma[NCT00004228] | Phase 3 | 393 participants (Actual) | Interventional | 2000-06-30 | Completed | ||
International Collaborative Treatment Protocol for Infants Under One Year With Acute Lymphoblastic Leukemia[NCT00015873] | Phase 3 | 350 participants (Anticipated) | Interventional | 1999-05-31 | Completed | ||
"Precision Exercise Program in Children With Malignant Hemopathies Undergoing Therapy and/or Hematopoietic Stem Cell Transplantation: The Sport Therapy Project"[NCT04090268] | 380 participants (Anticipated) | Interventional | 2017-04-03 | Recruiting | |||
"Geriatric Assessment Adapted Therapy for Ph- ALL Elderly Patients. GIMEMA Protocol LAL1104. EudraCT Code 2005-002156-17"[NCT00475280] | Phase 2 | 102 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
Multicenter, Prospective, Open Label Trial, Uncontrolled to Determine the Efficacy and Safety of Depocyt ® for the Treatment of CNS Relapse in Adult Patients With Lymphoblastic Leucemia or Very Aggressive Lymphoma[NCT00388531] | Phase 2 | 10 participants (Anticipated) | Interventional | 2006-03-31 | Completed | ||
PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia[NCT00494897] | Phase 4 | 374 participants (Actual) | Interventional | 1996-06-30 | Completed | ||
Single Arm Phase II Study of Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia (ALL) in Older Patients Using Fludarabine and Total Body Irradiation (FluTBI) Regimen[NCT01991457] | Phase 2 | 19 participants (Actual) | Interventional | 2013-08-27 | Completed | ||
Phase 2 Study Evaluating the Efficacy of Rituximab Plus Modified VPDL for Newly Diagnosed CD20-Positive Adult Acute Lymphoblastic Leukemia[NCT01429610] | Phase 2 | 78 participants (Actual) | Interventional | 2011-11-30 | Active, not recruiting | ||
A PHASE I TRIAL OF BUTYRATE AND GANCICLOVIR IN EBV-ASSOCIATED MALIGNANCIES[NCT00006340] | Phase 1 | 0 participants | Interventional | 1994-12-31 | Completed | ||
A Pilot Study of Allopurinol As A Modifier of 6-MP Metabolism in Pediatric ALL[NCT02046694] | Early Phase 1 | 34 participants (Actual) | Interventional | 2014-01-06 | Completed | ||
NOURISH-T+: A Randomized Control Trial Targeting Parents in Promoting Healthy Eating and Exercise Behaviors in Pediatric Cancer Survivors With Overweight/Obesity[NCT04656496] | 520 participants (Anticipated) | Interventional | 2020-12-08 | Recruiting | |||
Burkimab:Study Multicenter of Optimization of the Treatment of LLA-B and the Burkitt's Lymphoma in Adult Patients (From 15 Years Old)[NCT00388193] | Phase 2 | 20 participants (Anticipated) | Interventional | 2006-08-31 | Completed | ||
HIGH INTENSITY, BRIEF DURATION CHEMOTHERAPY FOR DIFFUSE SMALL NONCLEAVED CELL LYMPHOMA AND THE L-3 SUBTYPE OF ALL: A PILOT STUDY OF A MULTIDRUG REGIMEN[NCT00002494] | Phase 2 | 134 participants (Actual) | Interventional | 1992-05-31 | Completed | ||
Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.[NCT05049473] | Phase 2 | 100 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | ||
A Phase II Study of Punctual, Cyclic, and Intensive Chemotherapy With Liposomal Cytarabine (Depocyt®) CNS Prophylaxis for Adults With Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma[NCT02043587] | Phase 2 | 31 participants (Actual) | Interventional | 2014-01-31 | Terminated (stopped due to Original investigator for the trial has left) | ||
A Pilot Study of Adherence to Oral Medication and Health Beliefs of Adolescents With HIV and Their Mothers[NCT00001699] | 45 participants | Observational | 1998-06-30 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Disease-free Survival (Cohort II)
An estimate of disease free survival in Ph-positive ALL and Ph-like DSMKF ALL (Cohort II). Disease free survival is measured by the number of years between the date the patient first achieves complete remission (CR) or complete remission with incomplete platelet recovery (CRi) until relapse from CR/CRi or death from any cause. CR is defined as having <5% marrow aspirate blasts, ANC >1,000/mcL, platelets > 100,000/mcL, no blasts in peripheral blood, and C1 extramedullary disease status. CRi is the same as CR but platelet count may be <= 100,000/mcL and/or ANC <=1,000/mcL. (NCT02143414)
Timeframe: Duration of treatment and follow up until death or date of primary analysis (about 7.5 years)
Intervention | years (Median) |
---|---|
Cohort II (Ph+/Ph-like) | 5.3 |
Incidence of Dose-limiting Toxicity (Cohort II)
Defined as any grade 4 or higher treatment-related, non-hematologic toxicity in the first cycle of post-remission therapy (blinatumomab/dasatinib) graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Only participants with Ph-positive ALL or Ph-like DSMKF ALL were evaluated. (NCT02143414)
Timeframe: Up to day 42 of post-remission therapy
Intervention | Participants (Count of Participants) |
---|---|
Cohort II (Ph+/Ph-like) | 0 |
Overall Survival Rate (Cohort I)
To evaluate the 3-year overall survival rate in elderly participants with newly diagnosed Ph-negative ALL treated with blinatumomab followed by POMP maintenance. Overall (NCT02143414)
Timeframe: From the day of registration on study until death from any cause, assessed at 3 years
Intervention | percentage of participants (Number) |
---|---|
Cohort I (Ph-) | 34 |
Complete Response Rate (Cohort I)
Complete response rate is measured by the number of participants achieving complete remission (CR) or complete remission with incomplete platelet recovery (CRi) rate. CR is defined as having <5% marrow aspirate blasts, ANC >1,000/mcL, platelets > 100,000/mcL, no blasts in peripheral blood, and C1 extramedullary disease status. CRi is the same as CR but platelet count may be <= 100,000/mcL and/or ANC <=1,000/mcL. (NCT02143414)
Timeframe: Participants are assessed after induction treatment and again after re-induction treatment, if re-induction treatment is received (i.e. up to 85 days after registration)
Intervention | Participants (Count of Participants) | |
---|---|---|
CR or CRi | No CR or CRi | |
Cohort I (Ph-) | 19 | 10 |
Minimal Residual Disease Negativity
To estimate in each cohort the rate of minimal residual disease (MRD) negativity. (NCT02143414)
Timeframe: Participants are assessed after induction treatment and again after re-induction treatment, if re-induction treatment is received (i.e. up to 85 days after registration)
Intervention | Participants (Count of Participants) | |
---|---|---|
MRD- | MRD+ | |
Cohort I (Ph-) | 12 | 1 |
Cohort II (Ph+/Ph-like) | 7 | 9 |
Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drugs
Number of participants with Grade 3-5 adverse events that are possibly, probably or definitely related to study drug are reported by given type of adverse event. Adverse Events reported using CTCAE v 4.0, whereas Serious Adverse Events were reported with CTCAE v 5.0. (NCT02143414)
Timeframe: Duration of treatment and follow up until death or date of primary analysis (about 7.5 years)
Intervention | Participants (Number) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abdominal pain | Adult respiratory distress syndrome | Agitation | Alanine aminotransferase increased | Alkaline phosphatase increased | Anemia | Anorexia | Aspartate aminotransferase increased | Atrial flutter | Blood bilirubin increased | Cataract | Catheter related infection | Colitis | Confusion | Cytokine release syndrome | Dehydration | Diarrhea | Dizziness | Dysarthria | Dyspnea | Edema limbs | Encephalopathy | Fatigue | Febrile neutropenia | Fever | Gastrointestinal pain | General disorders and admin site conditions - Other | Generalized muscle weakness | Heart failure | Hematoma | Hyperglycemia | Hypertension | Hypoalbuminemia | Hypocalcemia | Hypokalemia | Hypophosphatemia | Hypotension | Hypoxia | Infections and infestations - Other, specify | Infusion related reaction | Lung infection | Lymphocyte count decreased | Metabolism and nutrition disorders - Other, specify | Mucositis oral | Nausea | Nervous system disorders - Other, specify | Neutrophil count decreased | Non-cardiac chest pain | Pericardial effusion | Platelet count decreased | Pleural effusion | Pneumonitis | Pulmonary hypertension | Rash maculo-papular | Respiratory failure | Sepsis | Soft tissue infection | Thrombotic thrombocytopenic purpura | Urinary tract infection | Vascular access complication | Weight loss | White blood cell decreased | |
Induction: Cohort I (Ph-) | 0 | 0 | 0 | 1 | 0 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 3 | 0 | 0 | 1 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 4 | 3 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 8 | 0 | 0 | 0 | 1 | 10 | 0 | 0 | 13 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 11 |
Induction: Cohort II (Ph+/Ph-like) | 0 | 0 | 0 | 1 | 0 | 8 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 2 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 2 | 6 | 0 | 0 | 1 | 0 | 9 | 0 | 0 | 8 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 6 |
Maintenance: Cohort I (Ph-) | 1 | 0 | 0 | 2 | 0 | 4 | 0 | 2 | 0 | 2 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 3 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 2 | 0 | 1 | 4 | 0 | 1 | 0 | 0 | 11 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 1 | 2 | 1 | 0 | 0 | 1 | 0 | 5 |
Maintenance: Cohort II (Ph+/Ph-like) | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 3 | 1 | 1 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
Post-remission: Cohort I (Ph-) | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
Post-remission: Cohort II (Ph+/Ph-like) | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 10 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Circulating Leukemia Cells in Peripheral Blood Change From Prior to the Methotrexate Infusion to Three Days After Between Two Arms (4 Hours vs. 24 Hours)
"White blood cell (leukocytes) counts in peripheral blood by Complete Blood Count~Measurement: Percentage change of leukemia cells from baseline" (NCT00137111)
Timeframe: Immediately before the methotrexate infusion and three days after subsequent infusion
Intervention | Percent change (Mean) |
---|---|
4 hr | -44 |
24 hr | -50 |
Continuous Complete Remission Since Week 56 Therapy.
CCR was measured from end of week 56 therapy to the date of first treatment failure of any kind (relapse, death, lineage switch, or second malignancy) or to the last date of follow-up. Measurement was determined by Kaplan-Meyer estimate. (NCT00137111)
Timeframe: Median follow up time (range) 4.5 (1 to 7.8) years
Intervention | Percentage of participants (Number) |
---|---|
Patients With High Risk of CNS Relapse | 92.2 |
Mean Difference of Active Methotrexate Polyglutamates (MTXPG) in Leukemia Cells Between Two Arms (4 Hours vs. 24 Hours).
Children were randomly assigned to receive initial single-agent treatment with HDMTX (1g/m^2) as either a 24-hour infusion or a 4-hour infusion and the outcome measure was the accumulation of MTXPG in leukemia cells. (NCT00137111)
Timeframe: 42 hours after start of high dose methotrexate infusion (HDMTX)
Intervention | pmol/1,000,000,000 cells (Mean) |
---|---|
4 hr | 1688 |
24 hr | 2521 |
Overall Event-free Survival (EFS)
EFS was measured from the start of on-study to the date of first treatment failure of any kind (relapse, death, lineage switch, or second malignancy) or to the last date of follow-up. Failure to enter remission was considered an event at time zero. Measurement was determined by Kaplan-Meyer estimate. (NCT00137111)
Timeframe: Median follow-up time (range) 5.6 (1.3 to 8.9) years
Intervention | Percentage of Participants (Number) |
---|---|
Total Therapy | 87.3 |
Median Difference in CASP1 Gene Expression in Primary Leukemia Cells of Patients in Glucocorticoid-resistant Cells vs Glucocorticoid-sensitive Cells
Prednisolone sensitivity was measured in primary leukemia cells from bone marrow collected at diagnosis. Expression of CASP1 was determined by HG-U133A microarray. Values given are gene expression values, and the unit is arbitrary units (AU) defined as scaled fluorescence measured on microarray. (NCT00137111)
Timeframe: Pre-treatment
Intervention | arbitrary units (Median) | |
---|---|---|
Prednisolone-sensitive cells | Prednisolone-resistant cells | |
Total Therapy | 341.3 | 447.9 |
Median Difference in NLRP3 Gene Expression in Primary Leukemia Cells of Patients in Glucocorticoid-resistant Cells vs. Glucocorticoid-sensitive Cells
Prednisolone sensitivity was measured in primary leukemia cells from bone marrow collected at diagnosis. Expression of NLRP3 was determined by HG-U133A microarray. Values given are gene expression values, and the unit is arbitrary units (AU) defined as scaled fluorescence measured on microarray. (NCT00137111)
Timeframe: Pre-treatment
Intervention | arbitrary units (Median) | |
---|---|---|
Prednisolone-sensitive cells | Prednisolone-resistant cells | |
Total Therapy | 41.2 | 110.7 |
Minimal Residual Disease (MRD)
Detection of MRD at end of induction where positive MRD was defined as one or more leukemic cell per 10,000 mononuclear bone-marrow cells (>=0.01%). (NCT00137111)
Timeframe: End of Induction (Day 46 MRD measurement)
Intervention | participants (Number) | |
---|---|---|
Negative <0.01% | Positive >= 0.01% | |
Total Therapy | 390 | 102 |
Hemoglobin A1c
(NCT01486043)
Timeframe: At 1 month
Intervention | percent of hemoglobin (Mean) |
---|---|
Metformin and Insulin Therapy | 4.8 |
Length of Insulin Therapy (Days)
(NCT01486043)
Timeframe: During the 30 days of induction chemotherapy (plus or minus 2 weeks)
Intervention | days (Mean) |
---|---|
Metformin and Insulin Therapy | 7.5 |
Serum Fructosamine Level
(NCT01486043)
Timeframe: At 1 month
Intervention | uM (Mean) |
---|---|
Metformin and Insulin Therapy | 190 |
Event-free Survival
Assessed by time to treatment failure, occurrence of second malignant neoplasm, or death from any cause. Statistical analysis will be to estimate the difference in the proportion of patients treated with each therapy who are long-term event-free survivors due either to the difference between the backbone therapy regimens (CCG BFM vs NHL/BFM-95), or due to the intensification. (NCT00004228)
Timeframe: 5 years
Intervention | percentage of particpants (Number) |
---|---|
A0 (Localized Disease Stg I/II) Modified CCG BFM | 88 |
A1 (Disseminated, No CNS - CCG Mod BFM w/Out Intens | 82 |
A2 (Disseminated, No CNS - CCG Mod BFM w/ Intens | 80 |
B2 (CNS+) NHL/BFM-95 w/Intens Delayed Radiation Therapy | 63 |
B2 (Disseminated,CNS- (< Amend 7B)) NHL/BFM-95 w/Intens | 82 |
B1 (Disseminated CNS-) NHL/BFM-95 w/Out Intens | 84 |
B1 (NHL/BFM-95 w/Out Intens) Additional Enrollment | 90 |
Percentage of Patients With Overall Survival as Assessed by Time to Death
Overall survival will be computed by measuring the rate of deaths during induction due primarily to treatment toxicity and cumulative incidence of toxic deaths in induction or deaths in remission overall and separately for treatment groups defined by the two design factors. (NCT00004228)
Timeframe: 5 years
Intervention | percentage of participants (Number) |
---|---|
A0 (Localized Disease Stg I/II) Modified CCG BFM | 96 |
A1 (Disseminated, No CNS - CCG Mod BFM w/Out Intens | 84 |
A2 (Disseminated, No CNS - CCG Mod BFM w/Intens | 88 |
B2 (CNS+) NHL/BFM-95 w/Intens Delayed Radiation Therapy | 81 |
B2 (Disseminated,CNS- (< Amend 7B)) NHL/BFM-95 w/Intens | 85 |
B1 (Disseminated CNS-) NHL/BFM-95 w/Out Intens | 85 |
B1 (NHL/BFM-95 w/Out Intens) Additional Enrollment | 92 |
Number of Subjects Disease-free Survival
Percentage of patients without relapse of disease at 2 years (NCT01991457)
Timeframe: 2 years post-transplant
Intervention | percentage of participants (Number) |
---|---|
Treatment | 63.2 |
Reviews
36 reviews available for prednisone and Precursor Cell Lymphoblastic Leukemia-Lymphoma
Article | Year |
---|---|
Overcoming Steroid Resistance in Pediatric Acute Lymphoblastic Leukemia-The State-of-the-Art Knowledge and Future Prospects.
Topics: Extracellular Signal-Regulated MAP Kinases; Glucocorticoids; Humans; Precursor Cell Lymphoblastic Le | 2022 |
Overcoming Steroid Resistance in Pediatric Acute Lymphoblastic Leukemia-The State-of-the-Art Knowledge and Future Prospects.
Topics: Extracellular Signal-Regulated MAP Kinases; Glucocorticoids; Humans; Precursor Cell Lymphoblastic Le | 2022 |
Overcoming Steroid Resistance in Pediatric Acute Lymphoblastic Leukemia-The State-of-the-Art Knowledge and Future Prospects.
Topics: Extracellular Signal-Regulated MAP Kinases; Glucocorticoids; Humans; Precursor Cell Lymphoblastic Le | 2022 |
Topics: Acceptance and Commitment Therapy; Adolescent; Adult; Aged; Aldehydes; Alpinia; Animals; Antibodies, | 2023 |
Topics: Acceptance and Commitment Therapy; Adolescent; Adult; Aged; Aldehydes; Alpinia; Animals; Antibodies, | 2023 |
Topics: Acceptance and Commitment Therapy; Adolescent; Adult; Aged; Aldehydes; Alpinia; Animals; Antibodies, | 2023 |
Hypothalamic-pituitary-adrenal (HPA) axis suppression after treatment with glucocorticoid therapy for childhood acute lymphoblastic leukaemia.
Topics: Adrenal Insufficiency; Antineoplastic Agents, Hormonal; Child; Cohort Studies; Dexamethasone; Flucon | 2017 |
Hypothalamic-pituitary-adrenal (HPA) axis suppression after treatment with glucocorticoid therapy for childhood acute lymphoblastic leukaemia.
Topics: Adrenal Insufficiency; Antineoplastic Agents, Hormonal; Child; Cohort Studies; Dexamethasone; Flucon | 2017 |
Hypothalamic-pituitary-adrenal (HPA) axis suppression after treatment with glucocorticoid therapy for childhood acute lymphoblastic leukaemia.
Topics: Adrenal Insufficiency; Antineoplastic Agents, Hormonal; Child; Cohort Studies; Dexamethasone; Flucon | 2017 |
Prognostic value of the response to prednisone for children with acute lymphoblastic leukemia: a meta-analysis.
Topics: Disease-Free Survival; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis | 2018 |
Prognostic value of the response to prednisone for children with acute lymphoblastic leukemia: a meta-analysis.
Topics: Disease-Free Survival; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis | 2018 |
Prognostic value of the response to prednisone for children with acute lymphoblastic leukemia: a meta-analysis.
Topics: Disease-Free Survival; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis | 2018 |
[Current treatment of pediatric acute lymphoblastic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child, Preschool; Clinical Trials as Top | 2014 |
[Current treatment of pediatric acute lymphoblastic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child, Preschool; Clinical Trials as Top | 2014 |
[Current treatment of pediatric acute lymphoblastic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child, Preschool; Clinical Trials as Top | 2014 |
Thrombosis in childhood acute lymphoblastic leukaemia: epidemiology, aetiology, diagnosis, prevention and treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Humans; Precursor Cell Lymphoblastic L | 2009 |
Thrombosis in childhood acute lymphoblastic leukaemia: epidemiology, aetiology, diagnosis, prevention and treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Humans; Precursor Cell Lymphoblastic L | 2009 |
Thrombosis in childhood acute lymphoblastic leukaemia: epidemiology, aetiology, diagnosis, prevention and treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Humans; Precursor Cell Lymphoblastic L | 2009 |
The optimal use of steroids in paediatric acute lymphoblastic leukaemia: no easy answers.
Topics: Adolescent; Child; Child, Preschool; Dexamethasone; Drug Administration Schedule; Glucocorticoids; H | 2010 |
The optimal use of steroids in paediatric acute lymphoblastic leukaemia: no easy answers.
Topics: Adolescent; Child; Child, Preschool; Dexamethasone; Drug Administration Schedule; Glucocorticoids; H | 2010 |
The optimal use of steroids in paediatric acute lymphoblastic leukaemia: no easy answers.
Topics: Adolescent; Child; Child, Preschool; Dexamethasone; Drug Administration Schedule; Glucocorticoids; H | 2010 |
Intrathecal chemotherapy in lymphomatous meningitis.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nerv | 2011 |
Intrathecal chemotherapy in lymphomatous meningitis.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nerv | 2011 |
Intrathecal chemotherapy in lymphomatous meningitis.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nerv | 2011 |
Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis.
Topics: Child; Dexamethasone; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone | 2011 |
Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis.
Topics: Child; Dexamethasone; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone | 2011 |
Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis.
Topics: Child; Dexamethasone; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone | 2011 |
Lymphoma study group of JCOG.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2012 |
Lymphoma study group of JCOG.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2012 |
Lymphoma study group of JCOG.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2012 |
[Blastic plasmacytoid dendritic cell neoplasm: a clinicopathologic study].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; CD56 Antigen; Cyclophosphamid | 2012 |
[Blastic plasmacytoid dendritic cell neoplasm: a clinicopathologic study].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; CD56 Antigen; Cyclophosphamid | 2012 |
[Blastic plasmacytoid dendritic cell neoplasm: a clinicopathologic study].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; CD56 Antigen; Cyclophosphamid | 2012 |
Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Child; Child | 2003 |
Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Child; Child | 2003 |
Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Child; Child | 2003 |
Acute lymphoblastic leukemia in a child with nephrotic syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child, Preschool; Cyclosporine; Dexame | 2004 |
Acute lymphoblastic leukemia in a child with nephrotic syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child, Preschool; Cyclosporine; Dexame | 2004 |
Acute lymphoblastic leukemia in a child with nephrotic syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child, Preschool; Cyclosporine; Dexame | 2004 |
Lymphoblastic leukemia with mature B-cell phenotype in infancy.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; B-Lymphocytes; DNA-Bindi | 2004 |
Lymphoblastic leukemia with mature B-cell phenotype in infancy.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; B-Lymphocytes; DNA-Bindi | 2004 |
Lymphoblastic leukemia with mature B-cell phenotype in infancy.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; B-Lymphocytes; DNA-Bindi | 2004 |
Use of infliximab-daclizumab combination for the treatment of acute and chronic graft-versus-host disease of the liver and gut.
Topics: Acute Disease; Adrenal Cortex Hormones; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; A | 2007 |
Use of infliximab-daclizumab combination for the treatment of acute and chronic graft-versus-host disease of the liver and gut.
Topics: Acute Disease; Adrenal Cortex Hormones; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; A | 2007 |
Use of infliximab-daclizumab combination for the treatment of acute and chronic graft-versus-host disease of the liver and gut.
Topics: Acute Disease; Adrenal Cortex Hormones; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; A | 2007 |
Fourth biannual report of the Cochrane Haematological Malignancies Group.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2006 |
Fourth biannual report of the Cochrane Haematological Malignancies Group.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2006 |
Fourth biannual report of the Cochrane Haematological Malignancies Group.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2006 |
Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients.
Topics: Adolescent; Anthracyclines; Antineoplastic Agents, Hormonal; Asparaginase; Child; Child, Preschool; | 2006 |
Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients.
Topics: Adolescent; Anthracyclines; Antineoplastic Agents, Hormonal; Asparaginase; Child; Child, Preschool; | 2006 |
Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients.
Topics: Adolescent; Anthracyclines; Antineoplastic Agents, Hormonal; Asparaginase; Child; Child, Preschool; | 2006 |
Rare oral cavity presentation of a B-cell lymphoblastic lymphoma. A case report and review of the literature.
Topics: 12E7 Antigen; Antigens, CD; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Cell Adh | 2007 |
Rare oral cavity presentation of a B-cell lymphoblastic lymphoma. A case report and review of the literature.
Topics: 12E7 Antigen; Antigens, CD; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Cell Adh | 2007 |
Rare oral cavity presentation of a B-cell lymphoblastic lymphoma. A case report and review of the literature.
Topics: 12E7 Antigen; Antigens, CD; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Cell Adh | 2007 |
A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Prot | 1995 |
A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Prot | 1995 |
A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Prot | 1995 |
[A heart transplant in a patient with doxorubicin-induced myocardiopathy as a complication of the treatment of a lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathy, Dilated; Cyclophosphamide; Da | 1994 |
[A heart transplant in a patient with doxorubicin-induced myocardiopathy as a complication of the treatment of a lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathy, Dilated; Cyclophosphamide; Da | 1994 |
[A heart transplant in a patient with doxorubicin-induced myocardiopathy as a complication of the treatment of a lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathy, Dilated; Cyclophosphamide; Da | 1994 |
Acute myelofibrosis terminating in acute lymphoblastic leukemia: case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blast Crisis; Bone Marrow; Chro | 1996 |
Acute myelofibrosis terminating in acute lymphoblastic leukemia: case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blast Crisis; Bone Marrow; Chro | 1996 |
Acute myelofibrosis terminating in acute lymphoblastic leukemia: case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blast Crisis; Bone Marrow; Chro | 1996 |
[Chemotherapy of relapsed AML and ALL].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Etoposide; Granulocyte Col | 1996 |
[Chemotherapy of relapsed AML and ALL].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Etoposide; Granulocyte Col | 1996 |
[Chemotherapy of relapsed AML and ALL].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Etoposide; Granulocyte Col | 1996 |
Burkitt's lymphoma-leukemia in patients treated for Hodgkin's disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Burkitt Lymphoma; Cyclophosphamide | 1996 |
Burkitt's lymphoma-leukemia in patients treated for Hodgkin's disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Burkitt Lymphoma; Cyclophosphamide | 1996 |
Burkitt's lymphoma-leukemia in patients treated for Hodgkin's disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Burkitt Lymphoma; Cyclophosphamide | 1996 |
[Treatment of acute lymphoblastic leukemias in adults].
Topics: Adult; Aged; Anthracyclines; Bone Marrow Transplantation; Combined Modality Therapy; Drug Therapy, C | 1997 |
[Treatment of acute lymphoblastic leukemias in adults].
Topics: Adult; Aged; Anthracyclines; Bone Marrow Transplantation; Combined Modality Therapy; Drug Therapy, C | 1997 |
[Treatment of acute lymphoblastic leukemias in adults].
Topics: Adult; Aged; Anthracyclines; Bone Marrow Transplantation; Combined Modality Therapy; Drug Therapy, C | 1997 |
Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome.
Topics: Adolescent; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Child; | 1998 |
Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome.
Topics: Adolescent; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Child; | 1998 |
Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome.
Topics: Adolescent; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Child; | 1998 |
Glucocorticosteroid therapy in childhood acute lymphoblastic leukemia.
Topics: Antineoplastic Agents; Apoptosis; Child; Dexamethasone; Drug Resistance, Neoplasm; Glucocorticoids; | 1999 |
Glucocorticosteroid therapy in childhood acute lymphoblastic leukemia.
Topics: Antineoplastic Agents; Apoptosis; Child; Dexamethasone; Drug Resistance, Neoplasm; Glucocorticoids; | 1999 |
Glucocorticosteroid therapy in childhood acute lymphoblastic leukemia.
Topics: Antineoplastic Agents; Apoptosis; Child; Dexamethasone; Drug Resistance, Neoplasm; Glucocorticoids; | 1999 |
[Effects of chemotherapy on the changes of histology and function of the ovary].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Daunorubicin; Female; Fluorouracil; Human | 1998 |
[Effects of chemotherapy on the changes of histology and function of the ovary].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Daunorubicin; Female; Fluorouracil; Human | 1998 |
[Effects of chemotherapy on the changes of histology and function of the ovary].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Daunorubicin; Female; Fluorouracil; Human | 1998 |
The management of neoplastic disorders of haematopoiesis in children with Down's syndrome.
Topics: Acute Disease; Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemother | 2000 |
The management of neoplastic disorders of haematopoiesis in children with Down's syndrome.
Topics: Acute Disease; Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemother | 2000 |
The management of neoplastic disorders of haematopoiesis in children with Down's syndrome.
Topics: Acute Disease; Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemother | 2000 |
The hyper-CVAD regimen in adult acute lymphocytic leukemia.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Antibodies, Monoclonal; Anti | 2000 |
The hyper-CVAD regimen in adult acute lymphocytic leukemia.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Antibodies, Monoclonal; Anti | 2000 |
The hyper-CVAD regimen in adult acute lymphocytic leukemia.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Antibodies, Monoclonal; Anti | 2000 |
Induction therapy of adult acute lymphocytic leukemia without the use of vincristine or prednisone.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials | 2001 |
Induction therapy of adult acute lymphocytic leukemia without the use of vincristine or prednisone.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials | 2001 |
Induction therapy of adult acute lymphocytic leukemia without the use of vincristine or prednisone.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Aggressive chemotherapy for acute leukemia relapsed after bone marrow transplantation: a second chance?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chemotherapy, Adjuvant; | 1992 |
Aggressive chemotherapy for acute leukemia relapsed after bone marrow transplantation: a second chance?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chemotherapy, Adjuvant; | 1992 |
Aggressive chemotherapy for acute leukemia relapsed after bone marrow transplantation: a second chance?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chemotherapy, Adjuvant; | 1992 |
Intensive therapy for adult acute lymphoblastic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; Humans; Idaru | 1991 |
Intensive therapy for adult acute lymphoblastic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; Humans; Idaru | 1991 |
Intensive therapy for adult acute lymphoblastic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; Humans; Idaru | 1991 |
Therapy for childhood non-Hodgkin's lymphomas, nonlymphoblastic type. Review of recent studies and current recommendations.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Brain Neoplasms; Cell Differentiation | 1990 |
Therapy for childhood non-Hodgkin's lymphomas, nonlymphoblastic type. Review of recent studies and current recommendations.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Brain Neoplasms; Cell Differentiation | 1990 |
Therapy for childhood non-Hodgkin's lymphomas, nonlymphoblastic type. Review of recent studies and current recommendations.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Brain Neoplasms; Cell Differentiation | 1990 |
Reduced incidence of the somnolence syndrome in leukemic children with steroid coverage during prophylactic cranial radiation therapy. Results of a pilot study.
Topics: Adolescent; Brain Neoplasms; Child; Child, Preschool; Disorders of Excessive Somnolence; Female; Hea | 1989 |
Reduced incidence of the somnolence syndrome in leukemic children with steroid coverage during prophylactic cranial radiation therapy. Results of a pilot study.
Topics: Adolescent; Brain Neoplasms; Child; Child, Preschool; Disorders of Excessive Somnolence; Female; Hea | 1989 |
Reduced incidence of the somnolence syndrome in leukemic children with steroid coverage during prophylactic cranial radiation therapy. Results of a pilot study.
Topics: Adolescent; Brain Neoplasms; Child; Child, Preschool; Disorders of Excessive Somnolence; Female; Hea | 1989 |
[Current status of the treatment of acute lymphocytic leukemia in the adult].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; Doxorubicin; | 1989 |
[Current status of the treatment of acute lymphocytic leukemia in the adult].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; Doxorubicin; | 1989 |
[Current status of the treatment of acute lymphocytic leukemia in the adult].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; Doxorubicin; | 1989 |
Trials
167 trials available for prednisone and Precursor Cell Lymphoblastic Leukemia-Lymphoma
Article | Year |
---|---|
Topics: Acceptance and Commitment Therapy; Adolescent; Adult; Aged; Aldehydes; Alpinia; Animals; Antibodies, | 2023 |
Topics: Acceptance and Commitment Therapy; Adolescent; Adult; Aged; Aldehydes; Alpinia; Animals; Antibodies, | 2023 |
Topics: Acceptance and Commitment Therapy; Adolescent; Adult; Aged; Aldehydes; Alpinia; Animals; Antibodies, | 2023 |
Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Hum | 2023 |
Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Hum | 2023 |
Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Hum | 2023 |
Dasatinib plus prednisone as induction and consolidation for adults with Ph-positive acute lymphoblastic leukaemia: A single-arm, multicentre, phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Disease-Free Survival; Hemat | 2023 |
Dasatinib plus prednisone as induction and consolidation for adults with Ph-positive acute lymphoblastic leukaemia: A single-arm, multicentre, phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Disease-Free Survival; Hemat | 2023 |
Dasatinib plus prednisone as induction and consolidation for adults with Ph-positive acute lymphoblastic leukaemia: A single-arm, multicentre, phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Disease-Free Survival; Hemat | 2023 |
Long-term treatment results of Polish pediatric and adolescent patients enrolled in the ALL IC-BFM 2002 trial.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cell Lineage; Child; Chi | 2019 |
Long-term treatment results of Polish pediatric and adolescent patients enrolled in the ALL IC-BFM 2002 trial.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cell Lineage; Child; Chi | 2019 |
Long-term treatment results of Polish pediatric and adolescent patients enrolled in the ALL IC-BFM 2002 trial.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cell Lineage; Child; Chi | 2019 |
Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2020 |
Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2020 |
Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2020 |
Characteristics of Blood Transfusion During Induction Remission in Children With Acute Lymphoblastic Leukemia: A Single-Center Retrospective Investigation.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blood Transfusion; Child; | 2020 |
Characteristics of Blood Transfusion During Induction Remission in Children With Acute Lymphoblastic Leukemia: A Single-Center Retrospective Investigation.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blood Transfusion; Child; | 2020 |
Characteristics of Blood Transfusion During Induction Remission in Children With Acute Lymphoblastic Leukemia: A Single-Center Retrospective Investigation.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blood Transfusion; Child; | 2020 |
Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL-1308 trial.
Topics: Adolescent; Adult; Allografts; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Combine | 2021 |
Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL-1308 trial.
Topics: Adolescent; Adult; Allografts; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Combine | 2021 |
Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL-1308 trial.
Topics: Adolescent; Adult; Allografts; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Combine | 2021 |
Adaptive functioning and academic achievement in survivors of childhood acute lymphoblastic leukemia: A report from the Children's Oncology Group.
Topics: Academic Success; Adaptation, Psychological; Adolescent; Antineoplastic Agents; Cancer Survivors; Ch | 2021 |
Adaptive functioning and academic achievement in survivors of childhood acute lymphoblastic leukemia: A report from the Children's Oncology Group.
Topics: Academic Success; Adaptation, Psychological; Adolescent; Antineoplastic Agents; Cancer Survivors; Ch | 2021 |
Adaptive functioning and academic achievement in survivors of childhood acute lymphoblastic leukemia: A report from the Children's Oncology Group.
Topics: Academic Success; Adaptation, Psychological; Adolescent; Antineoplastic Agents; Cancer Survivors; Ch | 2021 |
Molecular characterization of acute lymphoblastic leukemia with high CRLF2 gene expression in childhood.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 2017 |
Molecular characterization of acute lymphoblastic leukemia with high CRLF2 gene expression in childhood.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 2017 |
Molecular characterization of acute lymphoblastic leukemia with high CRLF2 gene expression in childhood.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 2017 |
Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma.
Topics: Adolescent; Child; Child, Preschool; Dexamethasone; Europe; Female; Humans; Infant; Male; Precursor | 2017 |
Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma.
Topics: Adolescent; Child; Child, Preschool; Dexamethasone; Europe; Female; Humans; Infant; Male; Precursor | 2017 |
Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma.
Topics: Adolescent; Child; Child, Preschool; Dexamethasone; Europe; Female; Humans; Infant; Male; Precursor | 2017 |
Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000).
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cy | 2018 |
Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000).
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cy | 2018 |
Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000).
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cy | 2018 |
Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000).
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cy | 2018 |
Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000).
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cy | 2018 |
Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000).
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cy | 2018 |
Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000).
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cy | 2018 |
Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000).
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cy | 2018 |
Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000).
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cy | 2018 |
Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000).
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cy | 2018 |
Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000).
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cy | 2018 |
Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000).
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cy | 2018 |
Effectiveness of antibacterial prophylaxis during induction chemotherapy in children with acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Asparagin | 2018 |
Effectiveness of antibacterial prophylaxis during induction chemotherapy in children with acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Asparagin | 2018 |
Effectiveness of antibacterial prophylaxis during induction chemotherapy in children with acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Asparagin | 2018 |
Pentoxifylline Added to Steroid Window Treatment Phase Modified Apoptotic Gene Expression in Pediatric Patients With Acute Lymphoblastic Leukemia.
Topics: Adolescent; Apoptosis; Child; Child, Preschool; Female; Gene Expression Regulation, Leukemic; Humans | 2018 |
Pentoxifylline Added to Steroid Window Treatment Phase Modified Apoptotic Gene Expression in Pediatric Patients With Acute Lymphoblastic Leukemia.
Topics: Adolescent; Apoptosis; Child; Child, Preschool; Female; Gene Expression Regulation, Leukemic; Humans | 2018 |
Pentoxifylline Added to Steroid Window Treatment Phase Modified Apoptotic Gene Expression in Pediatric Patients With Acute Lymphoblastic Leukemia.
Topics: Adolescent; Apoptosis; Child; Child, Preschool; Female; Gene Expression Regulation, Leukemic; Humans | 2018 |
High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2013 |
High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2013 |
High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2013 |
[Molecular genetic detection of minimal residual disease (MRD) in children with acute lymphoblastic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Cyclophosphamide; Cytarabine; D | 2013 |
[Molecular genetic detection of minimal residual disease (MRD) in children with acute lymphoblastic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Cyclophosphamide; Cytarabine; D | 2013 |
[Molecular genetic detection of minimal residual disease (MRD) in children with acute lymphoblastic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Cyclophosphamide; Cytarabine; D | 2013 |
Prediction of outcome by early response in childhood acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biopsy; Bone Marrow; Cell Lineage; Chi | 2013 |
Prediction of outcome by early response in childhood acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biopsy; Bone Marrow; Cell Lineage; Chi | 2013 |
Prediction of outcome by early response in childhood acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biopsy; Bone Marrow; Cell Lineage; Chi | 2013 |
Neuropsychological outcomes of a randomized trial of prednisone versus dexamethasone in acute lymphoblastic leukemia: findings from Dana-Farber Cancer Institute All Consortium Protocol 00-01.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Cognition; Dexamethasone; Female; Humans | 2013 |
Neuropsychological outcomes of a randomized trial of prednisone versus dexamethasone in acute lymphoblastic leukemia: findings from Dana-Farber Cancer Institute All Consortium Protocol 00-01.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Cognition; Dexamethasone; Female; Humans | 2013 |
Neuropsychological outcomes of a randomized trial of prednisone versus dexamethasone in acute lymphoblastic leukemia: findings from Dana-Farber Cancer Institute All Consortium Protocol 00-01.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Cognition; Dexamethasone; Female; Humans | 2013 |
Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Doxorub | 2015 |
Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Doxorub | 2015 |
Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Doxorub | 2015 |
Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Child; Daunorubici | 2015 |
Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Child; Daunorubici | 2015 |
Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Child; Daunorubici | 2015 |
Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 2015 |
Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 2015 |
Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 2015 |
[The prospects for children with acute lymphoblastic leukemia of being cured has increased in the Czech Republic in the 21st century to 90% - outcome of the ALL-IC BFM 2002 trial].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2015 |
[The prospects for children with acute lymphoblastic leukemia of being cured has increased in the Czech Republic in the 21st century to 90% - outcome of the ALL-IC BFM 2002 trial].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2015 |
[The prospects for children with acute lymphoblastic leukemia of being cured has increased in the Czech Republic in the 21st century to 90% - outcome of the ALL-IC BFM 2002 trial].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2015 |
Pentoxifylline during steroid window phase at induction to remission increases apoptosis in childhood with acute lymphoblastic leukemia.
Topics: Adolescent; Anti-Inflammatory Agents; Apoptosis; Child; Child, Preschool; Drug Therapy, Combination; | 2016 |
Pentoxifylline during steroid window phase at induction to remission increases apoptosis in childhood with acute lymphoblastic leukemia.
Topics: Adolescent; Anti-Inflammatory Agents; Apoptosis; Child; Child, Preschool; Drug Therapy, Combination; | 2016 |
Pentoxifylline during steroid window phase at induction to remission increases apoptosis in childhood with acute lymphoblastic leukemia.
Topics: Adolescent; Anti-Inflammatory Agents; Apoptosis; Child; Child, Preschool; Drug Therapy, Combination; | 2016 |
A genetic factor associated with low final bone mineral density in children after a long-term glucocorticoids treatment.
Topics: Absorptiometry, Photon; Age Factors; Anti-Asthmatic Agents; Antineoplastic Agents; Asthma; Bone Dens | 2017 |
A genetic factor associated with low final bone mineral density in children after a long-term glucocorticoids treatment.
Topics: Absorptiometry, Photon; Age Factors; Anti-Asthmatic Agents; Antineoplastic Agents; Asthma; Bone Dens | 2017 |
A genetic factor associated with low final bone mineral density in children after a long-term glucocorticoids treatment.
Topics: Absorptiometry, Photon; Age Factors; Anti-Asthmatic Agents; Antineoplastic Agents; Asthma; Bone Dens | 2017 |
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modali | 2016 |
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modali | 2016 |
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modali | 2016 |
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modali | 2016 |
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modali | 2016 |
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modali | 2016 |
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modali | 2016 |
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modali | 2016 |
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modali | 2016 |
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modali | 2016 |
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modali | 2016 |
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modali | 2016 |
Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy.
Topics: Adult; Antigens, CD19; Blood-Brain Barrier; Brain Edema; Cytokines; Female; Humans; Immunotherapy, A | 2016 |
Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy.
Topics: Adult; Antigens, CD19; Blood-Brain Barrier; Brain Edema; Cytokines; Female; Humans; Immunotherapy, A | 2016 |
Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy.
Topics: Adult; Antigens, CD19; Blood-Brain Barrier; Brain Edema; Cytokines; Female; Humans; Immunotherapy, A | 2016 |
High hyperdiploid acute lymphoblastic leukemia (ALL)-A 25-year population-based survey of the Austrian ALL-BFM (Berlin-Frankfurt-Münster) Study Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2017 |
High hyperdiploid acute lymphoblastic leukemia (ALL)-A 25-year population-based survey of the Austrian ALL-BFM (Berlin-Frankfurt-Münster) Study Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2017 |
High hyperdiploid acute lymphoblastic leukemia (ALL)-A 25-year population-based survey of the Austrian ALL-BFM (Berlin-Frankfurt-Münster) Study Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2017 |
Outcome of Reinduction Chemotherapy with a Modified Dose of Idarubicin for Children with Marrow-Relapsed Acute Lymphoblastic Leukemia: Results of the Childhood Acute Lymphoblastic Leukemia (CALL)-0603 Study.
Topics: Adolescent; Antibiotics, Antineoplastic; Asparaginase; Bone Marrow; Child; Child, Preschool; Disease | 2017 |
Outcome of Reinduction Chemotherapy with a Modified Dose of Idarubicin for Children with Marrow-Relapsed Acute Lymphoblastic Leukemia: Results of the Childhood Acute Lymphoblastic Leukemia (CALL)-0603 Study.
Topics: Adolescent; Antibiotics, Antineoplastic; Asparaginase; Bone Marrow; Child; Child, Preschool; Disease | 2017 |
Outcome of Reinduction Chemotherapy with a Modified Dose of Idarubicin for Children with Marrow-Relapsed Acute Lymphoblastic Leukemia: Results of the Childhood Acute Lymphoblastic Leukemia (CALL)-0603 Study.
Topics: Adolescent; Antibiotics, Antineoplastic; Asparaginase; Bone Marrow; Child; Child, Preschool; Disease | 2017 |
Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Central Ne | 2008 |
Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Central Ne | 2008 |
Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Central Ne | 2008 |
Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2008 |
Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2008 |
Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2008 |
The impact of acute lymphoblastic leukemia treatment on central nervous system results in Bogota, Colombia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Child; | 2008 |
The impact of acute lymphoblastic leukemia treatment on central nervous system results in Bogota, Colombia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Child; | 2008 |
The impact of acute lymphoblastic leukemia treatment on central nervous system results in Bogota, Colombia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Child; | 2008 |
Augmented and standard Berlin-Frankfurt-Munster chemotherapy for treatment of adult acute lymphoblastic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Daunorubicin; Humans; Inf | 2008 |
Augmented and standard Berlin-Frankfurt-Munster chemotherapy for treatment of adult acute lymphoblastic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Daunorubicin; Humans; Inf | 2008 |
Augmented and standard Berlin-Frankfurt-Munster chemotherapy for treatment of adult acute lymphoblastic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Daunorubicin; Humans; Inf | 2008 |
Impact of age, leukocyte count and day 21-bone marrow response to chemotherapy on the long-term outcome of children with philadelphia chromosome-positive acute lymphoblastic leukemia in the pre-imatinib era: results of the FRALLE 93 study.
Topics: Acute Disease; Adolescent; Age Factors; Anthracyclines; Antineoplastic Combined Chemotherapy Protoco | 2009 |
Impact of age, leukocyte count and day 21-bone marrow response to chemotherapy on the long-term outcome of children with philadelphia chromosome-positive acute lymphoblastic leukemia in the pre-imatinib era: results of the FRALLE 93 study.
Topics: Acute Disease; Adolescent; Age Factors; Anthracyclines; Antineoplastic Combined Chemotherapy Protoco | 2009 |
Impact of age, leukocyte count and day 21-bone marrow response to chemotherapy on the long-term outcome of children with philadelphia chromosome-positive acute lymphoblastic leukemia in the pre-imatinib era: results of the FRALLE 93 study.
Topics: Acute Disease; Adolescent; Age Factors; Anthracyclines; Antineoplastic Combined Chemotherapy Protoco | 2009 |
Management of hyperleukocytosis and prevention of tumor lysis syndrome with low-dose prednisone continuous infusion in children with acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Agents, Hormonal; Child; Child, Preschool; Female; Humans; Infant; Infusi | 2009 |
Management of hyperleukocytosis and prevention of tumor lysis syndrome with low-dose prednisone continuous infusion in children with acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Agents, Hormonal; Child; Child, Preschool; Female; Humans; Infant; Infusi | 2009 |
Management of hyperleukocytosis and prevention of tumor lysis syndrome with low-dose prednisone continuous infusion in children with acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Agents, Hormonal; Child; Child, Preschool; Female; Humans; Infant; Infusi | 2009 |
Response to glucocorticoids and toxicity in childhood acute lymphoblastic leukemia: role of polymorphisms of genes involved in glucocorticoid response.
Topics: Adolescent; Child; Child, Preschool; Dexamethasone; Female; Glucocorticoids; Glutathione Transferase | 2009 |
Response to glucocorticoids and toxicity in childhood acute lymphoblastic leukemia: role of polymorphisms of genes involved in glucocorticoid response.
Topics: Adolescent; Child; Child, Preschool; Dexamethasone; Female; Glucocorticoids; Glutathione Transferase | 2009 |
Response to glucocorticoids and toxicity in childhood acute lymphoblastic leukemia: role of polymorphisms of genes involved in glucocorticoid response.
Topics: Adolescent; Child; Child, Preschool; Dexamethasone; Female; Glucocorticoids; Glutathione Transferase | 2009 |
Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
Topics: Administration, Oral; Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemother | 2009 |
Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
Topics: Administration, Oral; Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemother | 2009 |
Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
Topics: Administration, Oral; Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemother | 2009 |
Randomized trial to compare LSA2L2-type maintenance therapy to daily 6-mercaptopurine and weekly methotrexate with vincristine and dexamethasone pulse for children with acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; | 2010 |
Randomized trial to compare LSA2L2-type maintenance therapy to daily 6-mercaptopurine and weekly methotrexate with vincristine and dexamethasone pulse for children with acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; | 2010 |
Randomized trial to compare LSA2L2-type maintenance therapy to daily 6-mercaptopurine and weekly methotrexate with vincristine and dexamethasone pulse for children with acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; | 2010 |
[Is there a risk of steroid-induced adrenal deficit after induction treatment of acute lymphoblastic leukemia?].
Topics: Adolescent; Adrenal Insufficiency; Child; Child, Preschool; Cosyntropin; Dexamethasone; Female; Gluc | 2010 |
[Is there a risk of steroid-induced adrenal deficit after induction treatment of acute lymphoblastic leukemia?].
Topics: Adolescent; Adrenal Insufficiency; Child; Child, Preschool; Cosyntropin; Dexamethasone; Female; Gluc | 2010 |
[Is there a risk of steroid-induced adrenal deficit after induction treatment of acute lymphoblastic leukemia?].
Topics: Adolescent; Adrenal Insufficiency; Child; Child, Preschool; Cosyntropin; Dexamethasone; Female; Gluc | 2010 |
Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia.
Topics: Antineoplastic Agents, Hormonal; Child; Dexamethasone; Genome-Wide Association Study; Humans; Magnet | 2011 |
Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia.
Topics: Antineoplastic Agents, Hormonal; Child; Dexamethasone; Genome-Wide Association Study; Humans; Magnet | 2011 |
Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia.
Topics: Antineoplastic Agents, Hormonal; Child; Dexamethasone; Genome-Wide Association Study; Humans; Magnet | 2011 |
[Long-term observations of children with acute lymphoblastic leukemia and high leukocytosis treated according to modified "New York" protocols (1987-2003)].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2010 |
[Long-term observations of children with acute lymphoblastic leukemia and high leukocytosis treated according to modified "New York" protocols (1987-2003)].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2010 |
[Long-term observations of children with acute lymphoblastic leukemia and high leukocytosis treated according to modified "New York" protocols (1987-2003)].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2010 |
Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2011 |
Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2011 |
Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2011 |
No advantage of a rotational continuation phase in acute lymphoblastic leukemia in childhood treated with a BFM back-bone therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child, Preschool; Daunorubicin; Diseas | 2011 |
No advantage of a rotational continuation phase in acute lymphoblastic leukemia in childhood treated with a BFM back-bone therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child, Preschool; Daunorubicin; Diseas | 2011 |
No advantage of a rotational continuation phase in acute lymphoblastic leukemia in childhood treated with a BFM back-bone therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child, Preschool; Daunorubicin; Diseas | 2011 |
Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866).
Topics: Adolescent; Antibodies; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; C | 2011 |
Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866).
Topics: Adolescent; Antibodies; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; C | 2011 |
Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866).
Topics: Adolescent; Antibodies; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; C | 2011 |
Outcome of newly diagnosed children and adolescents with localized lymphoblastic lymphoma treated on Children's Oncology Group trial A5971: a report from the Children's Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Daunorubicin; Disease-Free Survival; H | 2012 |
Outcome of newly diagnosed children and adolescents with localized lymphoblastic lymphoma treated on Children's Oncology Group trial A5971: a report from the Children's Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Daunorubicin; Disease-Free Survival; H | 2012 |
Outcome of newly diagnosed children and adolescents with localized lymphoblastic lymphoma treated on Children's Oncology Group trial A5971: a report from the Children's Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Daunorubicin; Disease-Free Survival; H | 2012 |
Treatment of young patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia using increased dose of imatinib and deintensified chemotherapy before allogeneic stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Cytara | 2012 |
Treatment of young patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia using increased dose of imatinib and deintensified chemotherapy before allogeneic stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Cytara | 2012 |
Treatment of young patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia using increased dose of imatinib and deintensified chemotherapy before allogeneic stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Cytara | 2012 |
Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2012 |
Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2012 |
Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2012 |
Cognitive outcomes following contemporary treatment without cranial irradiation for childhood acute lymphoblastic leukemia.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Attention; Child; Child, Pr | 2012 |
Cognitive outcomes following contemporary treatment without cranial irradiation for childhood acute lymphoblastic leukemia.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Attention; Child; Child, Pr | 2012 |
Cognitive outcomes following contemporary treatment without cranial irradiation for childhood acute lymphoblastic leukemia.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Attention; Child; Child, Pr | 2012 |
Treatment outcome of adolescents with acute lymphoblastic leukemia.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Fe | 2002 |
Treatment outcome of adolescents with acute lymphoblastic leukemia.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Fe | 2002 |
Treatment outcome of adolescents with acute lymphoblastic leukemia.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Fe | 2002 |
Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 2003 |
Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 2003 |
Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 2003 |
Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Blood Cell Count; Child; Child, Preschool; De | 2003 |
Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Blood Cell Count; Child; Child, Preschool; De | 2003 |
Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Blood Cell Count; Child; Child, Preschool; De | 2003 |
The dose related effect of steroids on blast reduction rate and event free survival in children with acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Asparag | 2003 |
The dose related effect of steroids on blast reduction rate and event free survival in children with acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Asparag | 2003 |
The dose related effect of steroids on blast reduction rate and event free survival in children with acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Asparag | 2003 |
Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: a Children's Cancer Group Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Presc | 2003 |
Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: a Children's Cancer Group Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Presc | 2003 |
Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: a Children's Cancer Group Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Presc | 2003 |
Long-term survival in acute lymphoblastic leukaemia in adults treated according to the LALA 87 protocol.
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Pro | 2003 |
Long-term survival in acute lymphoblastic leukaemia in adults treated according to the LALA 87 protocol.
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Pro | 2003 |
Long-term survival in acute lymphoblastic leukaemia in adults treated according to the LALA 87 protocol.
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Pro | 2003 |
Osteonecrosis: An emerging complication of intensive chemotherapy for childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Agents, Hormonal; Child; Dexamethasone; Drug Therapy, Combination; Female | 2003 |
Osteonecrosis: An emerging complication of intensive chemotherapy for childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Agents, Hormonal; Child; Dexamethasone; Drug Therapy, Combination; Female | 2003 |
Osteonecrosis: An emerging complication of intensive chemotherapy for childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Agents, Hormonal; Child; Dexamethasone; Drug Therapy, Combination; Female | 2003 |
[Improved results in children with acute lymphoblastic leukemia treated with the ALL-BFM 90 protocol in the Czech Republic].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2003 |
[Improved results in children with acute lymphoblastic leukemia treated with the ALL-BFM 90 protocol in the Czech Republic].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2003 |
[Improved results in children with acute lymphoblastic leukemia treated with the ALL-BFM 90 protocol in the Czech Republic].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2003 |
A randomized trial of induction therapy (daunorubicin, vincristine, prednisone versus daunorubicin, vincristine, prednisone, cytarabine and 6-thioguanine) in adult acute lymphoblastic leukemia with long-term follow-up: an Eastern Cooperative Oncology Grou
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabin | 2003 |
A randomized trial of induction therapy (daunorubicin, vincristine, prednisone versus daunorubicin, vincristine, prednisone, cytarabine and 6-thioguanine) in adult acute lymphoblastic leukemia with long-term follow-up: an Eastern Cooperative Oncology Grou
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabin | 2003 |
A randomized trial of induction therapy (daunorubicin, vincristine, prednisone versus daunorubicin, vincristine, prednisone, cytarabine and 6-thioguanine) in adult acute lymphoblastic leukemia with long-term follow-up: an Eastern Cooperative Oncology Grou
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabin | 2003 |
Prognostic factors in childhood acute lymphoblastic leukemia.
Topics: Anti-Inflammatory Agents; Child; Child, Preschool; Combined Modality Therapy; Female; Hematopoietic | 2003 |
Prognostic factors in childhood acute lymphoblastic leukemia.
Topics: Anti-Inflammatory Agents; Child; Child, Preschool; Combined Modality Therapy; Female; Hematopoietic | 2003 |
Prognostic factors in childhood acute lymphoblastic leukemia.
Topics: Anti-Inflammatory Agents; Child; Child, Preschool; Combined Modality Therapy; Female; Hematopoietic | 2003 |
Efficacy of granulocyte and granulocyte-macrophage colony-stimulating factors in the induction treatment of adult acute lymphoblastic leukemia: a multicenter randomized study.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Combined M | 2004 |
Efficacy of granulocyte and granulocyte-macrophage colony-stimulating factors in the induction treatment of adult acute lymphoblastic leukemia: a multicenter randomized study.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Combined M | 2004 |
Efficacy of granulocyte and granulocyte-macrophage colony-stimulating factors in the induction treatment of adult acute lymphoblastic leukemia: a multicenter randomized study.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Combined M | 2004 |
Steroid withdrawal syndrome during steroid tapering in childhood acute lymphoblastic leukemia: a controlled study comparing prednisone versus dexamethasone in induction phase.
Topics: Adolescent; Antineoplastic Agents, Hormonal; Child; Child, Preschool; Dexamethasone; Female; Glucoco | 2005 |
Steroid withdrawal syndrome during steroid tapering in childhood acute lymphoblastic leukemia: a controlled study comparing prednisone versus dexamethasone in induction phase.
Topics: Adolescent; Antineoplastic Agents, Hormonal; Child; Child, Preschool; Dexamethasone; Female; Glucoco | 2005 |
Steroid withdrawal syndrome during steroid tapering in childhood acute lymphoblastic leukemia: a controlled study comparing prednisone versus dexamethasone in induction phase.
Topics: Adolescent; Antineoplastic Agents, Hormonal; Child; Child, Preschool; Dexamethasone; Female; Glucoco | 2005 |
Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Ag | 2005 |
Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Ag | 2005 |
Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Ag | 2005 |
Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, | 2005 |
Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, | 2005 |
Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, | 2005 |
Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophos | 2005 |
Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophos | 2005 |
Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophos | 2005 |
Changes in hypercoagulability by asparaginase: a randomized study between two asparaginases.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blo | 2006 |
Changes in hypercoagulability by asparaginase: a randomized study between two asparaginases.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blo | 2006 |
Changes in hypercoagulability by asparaginase: a randomized study between two asparaginases.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blo | 2006 |
Role of treatment intensification in infants with acute lymphoblastic leukemia: results of two consecutive AIEOP studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; Cytarabine; Daunorub | 2006 |
Role of treatment intensification in infants with acute lymphoblastic leukemia: results of two consecutive AIEOP studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; Cytarabine; Daunorub | 2006 |
Role of treatment intensification in infants with acute lymphoblastic leukemia: results of two consecutive AIEOP studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; Cytarabine; Daunorub | 2006 |
[Prognostic value of the initial response to corticosteroids for children with acute lymphoblastic leukemia].
Topics: Adolescent; Anti-Inflammatory Agents; Child; Child, Preschool; Disease Progression; Disease-Free Sur | 2005 |
[Prognostic value of the initial response to corticosteroids for children with acute lymphoblastic leukemia].
Topics: Adolescent; Anti-Inflammatory Agents; Child; Child, Preschool; Disease Progression; Disease-Free Sur | 2005 |
[Prognostic value of the initial response to corticosteroids for children with acute lymphoblastic leukemia].
Topics: Adolescent; Anti-Inflammatory Agents; Child; Child, Preschool; Disease Progression; Disease-Free Sur | 2005 |
Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Asparag | 2006 |
Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Asparag | 2006 |
Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Asparag | 2006 |
Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Comorbidity; Cyclophosphamide; C | 2007 |
Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Comorbidity; Cyclophosphamide; C | 2007 |
Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Comorbidity; Cyclophosphamide; C | 2007 |
Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparagina | 2007 |
Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparagina | 2007 |
Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparagina | 2007 |
[Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia].
Topics: Adolescent; Adult; Aged; Agranulocytosis; Antibiotics, Antineoplastic; Antineoplastic Combined Chemo | 2006 |
[Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia].
Topics: Adolescent; Adult; Aged; Agranulocytosis; Antibiotics, Antineoplastic; Antineoplastic Combined Chemo | 2006 |
[Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia].
Topics: Adolescent; Adult; Aged; Agranulocytosis; Antibiotics, Antineoplastic; Antineoplastic Combined Chemo | 2006 |
[Auditory evoked potentials in patients after acute children's lymphoblastic leukemia treatment].
Topics: Acoustic Stimulation; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginas | 2006 |
[Auditory evoked potentials in patients after acute children's lymphoblastic leukemia treatment].
Topics: Acoustic Stimulation; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginas | 2006 |
[Auditory evoked potentials in patients after acute children's lymphoblastic leukemia treatment].
Topics: Acoustic Stimulation; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginas | 2006 |
Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; B-Lymphocytes; Cell Lineage; Central N | 2007 |
Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; B-Lymphocytes; Cell Lineage; Central N | 2007 |
Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; B-Lymphocytes; Cell Lineage; Central N | 2007 |
[Modified BFM-90 regimen greatly improves treatment outcomes of chinese childhood and adolescent lymphoblastic lymphoma].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asian People; Asparaginase; Child; Child | 2007 |
[Modified BFM-90 regimen greatly improves treatment outcomes of chinese childhood and adolescent lymphoblastic lymphoma].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asian People; Asparaginase; Child; Child | 2007 |
[Modified BFM-90 regimen greatly improves treatment outcomes of chinese childhood and adolescent lymphoblastic lymphoma].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asian People; Asparaginase; Child; Child | 2007 |
Outcome of adult acute lymphoblastic leukemia with BFM protocol in a resource-constrained setting.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Combin | 2007 |
Outcome of adult acute lymphoblastic leukemia with BFM protocol in a resource-constrained setting.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Combin | 2007 |
Outcome of adult acute lymphoblastic leukemia with BFM protocol in a resource-constrained setting.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Combin | 2007 |
A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Follow-Up Studies; Humans; Infant; Infan | 2007 |
A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Follow-Up Studies; Humans; Infant; Infan | 2007 |
A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Follow-Up Studies; Humans; Infant; Infan | 2007 |
[The results of a multicenter trial of acute lymphoblastic leukemia treatment on ALL-MB 91/ALL-BFM 90m in children: analysis of efficacy and toxicity].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2007 |
[The results of a multicenter trial of acute lymphoblastic leukemia treatment on ALL-MB 91/ALL-BFM 90m in children: analysis of efficacy and toxicity].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2007 |
[The results of a multicenter trial of acute lymphoblastic leukemia treatment on ALL-MB 91/ALL-BFM 90m in children: analysis of efficacy and toxicity].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2007 |
Adrenal axis function after high-dose steroid therapy for childhood acute lymphoblastic leukemia.
Topics: Adrenal Cortex; Adrenal Insufficiency; Adrenocorticotropic Hormone; Antineoplastic Combined Chemothe | 2008 |
Adrenal axis function after high-dose steroid therapy for childhood acute lymphoblastic leukemia.
Topics: Adrenal Cortex; Adrenal Insufficiency; Adrenocorticotropic Hormone; Antineoplastic Combined Chemothe | 2008 |
Adrenal axis function after high-dose steroid therapy for childhood acute lymphoblastic leukemia.
Topics: Adrenal Cortex; Adrenal Insufficiency; Adrenocorticotropic Hormone; Antineoplastic Combined Chemothe | 2008 |
Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Chi-Square Distribution; Child, Presch | 2008 |
Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Chi-Square Distribution; Child, Presch | 2008 |
Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Chi-Square Distribution; Child, Presch | 2008 |
Clinical outcome of children with newly diagnosed acute lymphoblastic leukemia treated in a single center in Shanghai, China.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Central Nervous System Neo | 2008 |
Clinical outcome of children with newly diagnosed acute lymphoblastic leukemia treated in a single center in Shanghai, China.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Central Nervous System Neo | 2008 |
Clinical outcome of children with newly diagnosed acute lymphoblastic leukemia treated in a single center in Shanghai, China.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Central Nervous System Neo | 2008 |
Results of the first randomized multicentre trial on childhood acute lymphoblastic leukaemia in Russia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2008 |
Results of the first randomized multicentre trial on childhood acute lymphoblastic leukaemia in Russia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2008 |
Results of the first randomized multicentre trial on childhood acute lymphoblastic leukaemia in Russia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2008 |
Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; | 2008 |
Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; | 2008 |
Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; | 2008 |
Short-term weekly chemotherapy followed by high-dose therapy with autologous bone marrow transplantation for lymphoblastic and Burkitt's lymphomas in adult patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplant | 1995 |
Short-term weekly chemotherapy followed by high-dose therapy with autologous bone marrow transplantation for lymphoblastic and Burkitt's lymphomas in adult patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplant | 1995 |
Short-term weekly chemotherapy followed by high-dose therapy with autologous bone marrow transplantation for lymphoblastic and Burkitt's lymphomas in adult patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplant | 1995 |
L-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool | 1995 |
L-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool | 1995 |
L-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool | 1995 |
Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana d
Topics: Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asparag | 1995 |
Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana d
Topics: Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asparag | 1995 |
Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana d
Topics: Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asparag | 1995 |
Hypercoagulability during induction therapy of acute lymphoblastic leukemia is of scarce clinical relevance. Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto.
Topics: Adult; alpha-2-Antiplasmin; Antineoplastic Combined Chemotherapy Protocols; Antithrombin III; Aspara | 1993 |
Hypercoagulability during induction therapy of acute lymphoblastic leukemia is of scarce clinical relevance. Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto.
Topics: Adult; alpha-2-Antiplasmin; Antineoplastic Combined Chemotherapy Protocols; Antithrombin III; Aspara | 1993 |
Hypercoagulability during induction therapy of acute lymphoblastic leukemia is of scarce clinical relevance. Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto.
Topics: Adult; alpha-2-Antiplasmin; Antineoplastic Combined Chemotherapy Protocols; Antithrombin III; Aspara | 1993 |
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asparagi | 1995 |
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asparagi | 1995 |
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asparagi | 1995 |
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asparagi | 1995 |
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asparagi | 1995 |
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asparagi | 1995 |
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asparagi | 1995 |
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asparagi | 1995 |
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asparagi | 1995 |
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asparagi | 1995 |
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asparagi | 1995 |
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asparagi | 1995 |
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asparagi | 1995 |
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asparagi | 1995 |
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asparagi | 1995 |
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asparagi | 1995 |
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asparagi | 1995 |
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asparagi | 1995 |
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asparagi | 1995 |
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asparagi | 1995 |
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asparagi | 1995 |
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asparagi | 1995 |
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asparagi | 1995 |
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asparagi | 1995 |
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asparagi | 1995 |
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asparagi | 1995 |
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asparagi | 1995 |
Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; B-Lymphocytes; C | 1995 |
Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; B-Lymphocytes; C | 1995 |
Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; B-Lymphocytes; C | 1995 |
Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: a Childrens Cancer Group study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cause of Death; Child; Chi | 1995 |
Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: a Childrens Cancer Group study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cause of Death; Child; Chi | 1995 |
Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: a Childrens Cancer Group study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cause of Death; Child; Chi | 1995 |
Power considerations for testing an interaction in a 2 x k factorial design with a failure time outcome.
Topics: Child, Preschool; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Research Desig | 1994 |
Power considerations for testing an interaction in a 2 x k factorial design with a failure time outcome.
Topics: Child, Preschool; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Research Desig | 1994 |
Power considerations for testing an interaction in a 2 x k factorial design with a failure time outcome.
Topics: Child, Preschool; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Research Desig | 1994 |
Late intensification therapy in adult acute lymphoid leukemia: long-term follow-up of the Southeastern Cancer Study Group experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1994 |
Late intensification therapy in adult acute lymphoid leukemia: long-term follow-up of the Southeastern Cancer Study Group experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1994 |
Late intensification therapy in adult acute lymphoid leukemia: long-term follow-up of the Southeastern Cancer Study Group experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1994 |
Long-term follow-up of a CHOP-based regimen with maintenance therapy and central nervous system prophylaxis in lymphoblastic non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Central Nervous Sys | 1994 |
Long-term follow-up of a CHOP-based regimen with maintenance therapy and central nervous system prophylaxis in lymphoblastic non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Central Nervous Sys | 1994 |
Long-term follow-up of a CHOP-based regimen with maintenance therapy and central nervous system prophylaxis in lymphoblastic non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Central Nervous Sys | 1994 |
Sequential induction chemotherapy with vincristine, daunorubicin, cyclophosphamide, and prednisone in adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Confidence Intervals; Cyclo | 1995 |
Sequential induction chemotherapy with vincristine, daunorubicin, cyclophosphamide, and prednisone in adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Confidence Intervals; Cyclo | 1995 |
Sequential induction chemotherapy with vincristine, daunorubicin, cyclophosphamide, and prednisone in adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Confidence Intervals; Cyclo | 1995 |
High-dose Ara-C for remission induction and consolidation of previously untreated adults with ALL or lymphoblastic lymphoma.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplant | 1995 |
High-dose Ara-C for remission induction and consolidation of previously untreated adults with ALL or lymphoblastic lymphoma.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplant | 1995 |
High-dose Ara-C for remission induction and consolidation of previously untreated adults with ALL or lymphoblastic lymphoma.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplant | 1995 |
Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86.
Topics: Adolescent; Child; Child, Preschool; Female; Humans; Immunophenotyping; Infant; Male; Precursor Cell | 1994 |
Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86.
Topics: Adolescent; Child; Child, Preschool; Female; Humans; Immunophenotyping; Infant; Male; Precursor Cell | 1994 |
Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86.
Topics: Adolescent; Child; Child, Preschool; Female; Humans; Immunophenotyping; Infant; Male; Precursor Cell | 1994 |
Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. French Group of Therapy of Adult Acute Lymphoblastic Leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cycl | 1994 |
Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. French Group of Therapy of Adult Acute Lymphoblastic Leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cycl | 1994 |
Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. French Group of Therapy of Adult Acute Lymphoblastic Leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cycl | 1994 |
Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan-Kettering-New York-II protocol.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Examinat | 1993 |
Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan-Kettering-New York-II protocol.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Examinat | 1993 |
Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan-Kettering-New York-II protocol.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Examinat | 1993 |
The role of radiation therapy in the treatment of acute lymphoblastic leukemia with lymphomatous presentation: a report from the Childrens Cancer Group.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Brain Neoplasms; C | 1993 |
The role of radiation therapy in the treatment of acute lymphoblastic leukemia with lymphomatous presentation: a report from the Childrens Cancer Group.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Brain Neoplasms; C | 1993 |
The role of radiation therapy in the treatment of acute lymphoblastic leukemia with lymphomatous presentation: a report from the Childrens Cancer Group.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Brain Neoplasms; C | 1993 |
Circadian time-dependent response of childhood lymphoblastic leukemia to chemotherapy: a long-term follow-up study of survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Circadian Rhythm; Drug Administration Schedul | 1993 |
Circadian time-dependent response of childhood lymphoblastic leukemia to chemotherapy: a long-term follow-up study of survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Circadian Rhythm; Drug Administration Schedul | 1993 |
Circadian time-dependent response of childhood lymphoblastic leukemia to chemotherapy: a long-term follow-up study of survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Circadian Rhythm; Drug Administration Schedul | 1993 |
Follow-up of the first two successive German multicentre trials for adult ALL (01/81 and 02/84). German Adult ALL Study Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cranial Irradiation | 1993 |
Follow-up of the first two successive German multicentre trials for adult ALL (01/81 and 02/84). German Adult ALL Study Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cranial Irradiation | 1993 |
Follow-up of the first two successive German multicentre trials for adult ALL (01/81 and 02/84). German Adult ALL Study Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cranial Irradiation | 1993 |
Treatment results of three consecutive Brazilian cooperative childhood ALL protocols: GBTLI-80, GBTLI-82 and -85. ALL Brazilian Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Cranial Irradiation | 1993 |
Treatment results of three consecutive Brazilian cooperative childhood ALL protocols: GBTLI-80, GBTLI-82 and -85. ALL Brazilian Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Cranial Irradiation | 1993 |
Treatment results of three consecutive Brazilian cooperative childhood ALL protocols: GBTLI-80, GBTLI-82 and -85. ALL Brazilian Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Cranial Irradiation | 1993 |
Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Cytarabine; Dose-Re | 1993 |
Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Cytarabine; Dose-Re | 1993 |
Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Cytarabine; Dose-Re | 1993 |
Severe toxicity limits intensification of induction therapy for acute lymphoblastic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Idarubicin; | 1993 |
Severe toxicity limits intensification of induction therapy for acute lymphoblastic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Idarubicin; | 1993 |
Severe toxicity limits intensification of induction therapy for acute lymphoblastic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Idarubicin; | 1993 |
Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: a Childrens Cancer Group study.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Combined | 1996 |
Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: a Childrens Cancer Group study.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Combined | 1996 |
Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: a Childrens Cancer Group study.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Combined | 1996 |
Cytoreduction and prognosis in acute lymphoblastic leukemia--the importance of early marrow response: report from the Childrens Cancer Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Child; Combined Modality | 1996 |
Cytoreduction and prognosis in acute lymphoblastic leukemia--the importance of early marrow response: report from the Childrens Cancer Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Child; Combined Modality | 1996 |
Cytoreduction and prognosis in acute lymphoblastic leukemia--the importance of early marrow response: report from the Childrens Cancer Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Child; Combined Modality | 1996 |
Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Base Sequence; Child; Chil | 1996 |
Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Base Sequence; Child; Chil | 1996 |
Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Base Sequence; Child; Chil | 1996 |
Acute lymphoblastic leukemia in children: nonrandomized comparison of conventional vs. intensive chemotherapy at the National Cancer Institute of Colombia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 1997 |
Acute lymphoblastic leukemia in children: nonrandomized comparison of conventional vs. intensive chemotherapy at the National Cancer Institute of Colombia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 1997 |
Acute lymphoblastic leukemia in children: nonrandomized comparison of conventional vs. intensive chemotherapy at the National Cancer Institute of Colombia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 1997 |
Intermediate-dose methotrexate versus cranial irradiation in childhood acute lymphoblastic leukemia: a ten-year follow-up.
Topics: Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asparag | 1997 |
Intermediate-dose methotrexate versus cranial irradiation in childhood acute lymphoblastic leukemia: a ten-year follow-up.
Topics: Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asparag | 1997 |
Intermediate-dose methotrexate versus cranial irradiation in childhood acute lymphoblastic leukemia: a ten-year follow-up.
Topics: Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asparag | 1997 |
Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 1997 |
Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 1997 |
Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 1997 |
B-lineage acute lymphoblastic leukemia of childhood. An institutional experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; Child; Child, Presch | 1997 |
B-lineage acute lymphoblastic leukemia of childhood. An institutional experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; Child; Child, Presch | 1997 |
B-lineage acute lymphoblastic leukemia of childhood. An institutional experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; Child; Child, Presch | 1997 |
Treatment of adults with acute lymphoblastic leukaemia in first bone marrow relapse: results of the ALL R-87 protocol.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Comb | 1997 |
Treatment of adults with acute lymphoblastic leukaemia in first bone marrow relapse: results of the ALL R-87 protocol.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Comb | 1997 |
Treatment of adults with acute lymphoblastic leukaemia in first bone marrow relapse: results of the ALL R-87 protocol.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Comb | 1997 |
Granulocyte colony-stimulating factor as an adjunct to induction chemotherapy for adult acute lymphoblastic leukemia--a randomized phase-III study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blood Transfu | 1997 |
Granulocyte colony-stimulating factor as an adjunct to induction chemotherapy for adult acute lymphoblastic leukemia--a randomized phase-III study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blood Transfu | 1997 |
Granulocyte colony-stimulating factor as an adjunct to induction chemotherapy for adult acute lymphoblastic leukemia--a randomized phase-III study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blood Transfu | 1997 |
ALL R-87 protocol in the treatment of children with acute lymphoblastic leukaemia in early bone marrow relapse.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation | 1997 |
ALL R-87 protocol in the treatment of children with acute lymphoblastic leukaemia in early bone marrow relapse.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation | 1997 |
ALL R-87 protocol in the treatment of children with acute lymphoblastic leukaemia in early bone marrow relapse.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation | 1997 |
Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Combined Moda | 1998 |
Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Combined Moda | 1998 |
Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Combined Moda | 1998 |
[EPOCH therapy for relapsed/refractory lymphoid malignancies].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Dr | 1998 |
[EPOCH therapy for relapsed/refractory lymphoid malignancies].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Dr | 1998 |
[EPOCH therapy for relapsed/refractory lymphoid malignancies].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Dr | 1998 |
Immunophenotype and clinical characteristics of CD45-negative and CD45-positive childhood acute lymphoblastic leukemia.
Topics: Antineoplastic Agents, Hormonal; Cell Lineage; Child; DNA, Neoplasm; Humans; Immunophenotyping; Kary | 1998 |
Immunophenotype and clinical characteristics of CD45-negative and CD45-positive childhood acute lymphoblastic leukemia.
Topics: Antineoplastic Agents, Hormonal; Cell Lineage; Child; DNA, Neoplasm; Humans; Immunophenotyping; Kary | 1998 |
Immunophenotype and clinical characteristics of CD45-negative and CD45-positive childhood acute lymphoblastic leukemia.
Topics: Antineoplastic Agents, Hormonal; Cell Lineage; Child; DNA, Neoplasm; Humans; Immunophenotyping; Kary | 1998 |
Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantatio | 1998 |
Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantatio | 1998 |
Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantatio | 1998 |
[The treatment results in children diagnosed with non-Hodgkin's lymphomas and acute B-cell lymphoblastic leukemias treated by the BFM protocols. The report of the POGM (Pediatric Oncology Group of Madrid)].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantatio | 1998 |
[The treatment results in children diagnosed with non-Hodgkin's lymphomas and acute B-cell lymphoblastic leukemias treated by the BFM protocols. The report of the POGM (Pediatric Oncology Group of Madrid)].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantatio | 1998 |
[The treatment results in children diagnosed with non-Hodgkin's lymphomas and acute B-cell lymphoblastic leukemias treated by the BFM protocols. The report of the POGM (Pediatric Oncology Group of Madrid)].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantatio | 1998 |
Management of advanced acute lymphoblastic leukemia in children and adults: results of the ALL R-87 protocol. AIEOP and GIMEMA Cooperative Groups.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transpla | 1998 |
Management of advanced acute lymphoblastic leukemia in children and adults: results of the ALL R-87 protocol. AIEOP and GIMEMA Cooperative Groups.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transpla | 1998 |
Management of advanced acute lymphoblastic leukemia in children and adults: results of the ALL R-87 protocol. AIEOP and GIMEMA Cooperative Groups.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transpla | 1998 |
Improved outcome for acute lymphoblastic leukemia in children of a developing country: results of the Chilean National Trial PINDA 87.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 1999 |
Improved outcome for acute lymphoblastic leukemia in children of a developing country: results of the Chilean National Trial PINDA 87.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 1999 |
Improved outcome for acute lymphoblastic leukemia in children of a developing country: results of the Chilean National Trial PINDA 87.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 1999 |
Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Presc | 1999 |
Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Presc | 1999 |
Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Presc | 1999 |
Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Drug Administration Sched | 1999 |
Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Drug Administration Sched | 1999 |
Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Drug Administration Sched | 1999 |
Alternating drug pairs with or without periodic reinduction in children with acute lymphoblastic leukemia in second bone marrow remission: a Pediatric Oncology Group Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Child; Cy | 2000 |
Alternating drug pairs with or without periodic reinduction in children with acute lymphoblastic leukemia in second bone marrow remission: a Pediatric Oncology Group Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Child; Cy | 2000 |
Alternating drug pairs with or without periodic reinduction in children with acute lymphoblastic leukemia in second bone marrow remission: a Pediatric Oncology Group Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Child; Cy | 2000 |
Use of recombinant human granulocyte colony-stimulating factor to increase chemotherapy dose-intensity: a randomized trial in very high-risk childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 2000 |
Use of recombinant human granulocyte colony-stimulating factor to increase chemotherapy dose-intensity: a randomized trial in very high-risk childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 2000 |
Use of recombinant human granulocyte colony-stimulating factor to increase chemotherapy dose-intensity: a randomized trial in very high-risk childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 2000 |
Changes in body mass index and prevalence of overweight in survivors of childhood acute lymphoblastic leukemia: role of cranial irradiation.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Body Height; Body Mass Inde | 2000 |
Changes in body mass index and prevalence of overweight in survivors of childhood acute lymphoblastic leukemia: role of cranial irradiation.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Body Height; Body Mass Inde | 2000 |
Changes in body mass index and prevalence of overweight in survivors of childhood acute lymphoblastic leukemia: role of cranial irradiation.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Body Height; Body Mass Inde | 2000 |
Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Cells; | 2000 |
Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Cells; | 2000 |
Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Cells; | 2000 |
Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Presch | 2000 |
Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Presch | 2000 |
Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Presch | 2000 |
Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of
Topics: Actuarial Analysis; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Centra | 2001 |
Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of
Topics: Actuarial Analysis; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Centra | 2001 |
Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of
Topics: Actuarial Analysis; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Centra | 2001 |
The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 2001 |
The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 2001 |
The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 2001 |
Treatment of childhood acute lymphoblastic leukemia. Long-term results of the AIEOP-ALL 87 study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 2001 |
Treatment of childhood acute lymphoblastic leukemia. Long-term results of the AIEOP-ALL 87 study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 2001 |
Treatment of childhood acute lymphoblastic leukemia. Long-term results of the AIEOP-ALL 87 study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 2001 |
Daunorubicin continuous infusion induces more toxicity than bolus infusion in acute lymphoblastic leukemia induction regimen: a randomized study.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols | 2001 |
Daunorubicin continuous infusion induces more toxicity than bolus infusion in acute lymphoblastic leukemia induction regimen: a randomized study.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols | 2001 |
Daunorubicin continuous infusion induces more toxicity than bolus infusion in acute lymphoblastic leukemia induction regimen: a randomized study.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols | 2001 |
Effect of glucocorticoid therapy on energy intake in children treated for acute lymphoblastic leukemia.
Topics: Body Mass Index; Child; Confidence Intervals; Dexamethasone; Energy Intake; Female; Follow-Up Studie | 2001 |
Effect of glucocorticoid therapy on energy intake in children treated for acute lymphoblastic leukemia.
Topics: Body Mass Index; Child; Confidence Intervals; Dexamethasone; Energy Intake; Female; Follow-Up Studie | 2001 |
Effect of glucocorticoid therapy on energy intake in children treated for acute lymphoblastic leukemia.
Topics: Body Mass Index; Child; Confidence Intervals; Dexamethasone; Energy Intake; Female; Follow-Up Studie | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Favorable outcome for children and adolescents with T-cell lymphoblastic lymphoma with an intensive ALL-type therapy without local radiotherapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Austria; Child; Child, Pre | 2001 |
Favorable outcome for children and adolescents with T-cell lymphoblastic lymphoma with an intensive ALL-type therapy without local radiotherapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Austria; Child; Child, Pre | 2001 |
Favorable outcome for children and adolescents with T-cell lymphoblastic lymphoma with an intensive ALL-type therapy without local radiotherapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Austria; Child; Child, Pre | 2001 |
Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Di | 2002 |
Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Di | 2002 |
Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Di | 2002 |
Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II.
Topics: Adolescent; Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; C | 2002 |
Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II.
Topics: Adolescent; Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; C | 2002 |
Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II.
Topics: Adolescent; Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; C | 2002 |
Treatment of acute lymphoblastic leukaemia (ALL).
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclop | 1992 |
Treatment of acute lymphoblastic leukaemia (ALL).
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclop | 1992 |
Treatment of acute lymphoblastic leukaemia (ALL).
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclop | 1992 |
A study of toxicity and comparative therapeutic efficacy of vindesine-prednisone vs. vincristine-prednisone in children with acute lymphoblastic leukemia in relapse. A Pediatric Oncology Group study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Humans; Precurs | 1992 |
A study of toxicity and comparative therapeutic efficacy of vindesine-prednisone vs. vincristine-prednisone in children with acute lymphoblastic leukemia in relapse. A Pediatric Oncology Group study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Humans; Precurs | 1992 |
A study of toxicity and comparative therapeutic efficacy of vindesine-prednisone vs. vincristine-prednisone in children with acute lymphoblastic leukemia in relapse. A Pediatric Oncology Group study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Humans; Precurs | 1992 |
F-MACHOP in advanced aggressive lymphoma.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Do | 1992 |
F-MACHOP in advanced aggressive lymphoma.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Do | 1992 |
F-MACHOP in advanced aggressive lymphoma.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Do | 1992 |
Late intensification therapy in adult acute lymphoid leukemia. The Southeastern Cancer Study Group Experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 1992 |
Late intensification therapy in adult acute lymphoid leukemia. The Southeastern Cancer Study Group Experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 1992 |
Late intensification therapy in adult acute lymphoid leukemia. The Southeastern Cancer Study Group Experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 1992 |
Treatment of acute lymphoblastic leukemia French protocol Fralle 83-87.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophospham | 1992 |
Treatment of acute lymphoblastic leukemia French protocol Fralle 83-87.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophospham | 1992 |
Treatment of acute lymphoblastic leukemia French protocol Fralle 83-87.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophospham | 1992 |
An update of the results of intensive therapy in children with acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cause of Death; Child; Chi | 1992 |
An update of the results of intensive therapy in children with acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cause of Death; Child; Chi | 1992 |
An update of the results of intensive therapy in children with acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cause of Death; Child; Chi | 1992 |
GIMEMA ALL 0288: a multicentric study on adult acute lymphoblastic leukemia. Preliminary results.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Clinical Prot | 1992 |
GIMEMA ALL 0288: a multicentric study on adult acute lymphoblastic leukemia. Preliminary results.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Clinical Prot | 1992 |
GIMEMA ALL 0288: a multicentric study on adult acute lymphoblastic leukemia. Preliminary results.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Clinical Prot | 1992 |
Adult acute lymphocytic leukemia: the Eastern Cooperative Oncology Group experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabin | 1992 |
Adult acute lymphocytic leukemia: the Eastern Cooperative Oncology Group experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabin | 1992 |
Adult acute lymphocytic leukemia: the Eastern Cooperative Oncology Group experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabin | 1992 |
[Second cessation of therapy in children with acute lymphoblastic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophospham | 1992 |
[Second cessation of therapy in children with acute lymphoblastic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophospham | 1992 |
[Second cessation of therapy in children with acute lymphoblastic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophospham | 1992 |
Determination of the maximum tolerated dose of idarubicin when used in a combination chemotherapy program of reinduction of childhood ALL at first marrow relapse and a preliminary assessment of toxicity compared to that of daunorubicin: a report from the
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Child; Child, | 1992 |
Determination of the maximum tolerated dose of idarubicin when used in a combination chemotherapy program of reinduction of childhood ALL at first marrow relapse and a preliminary assessment of toxicity compared to that of daunorubicin: a report from the
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Child; Child, | 1992 |
Determination of the maximum tolerated dose of idarubicin when used in a combination chemotherapy program of reinduction of childhood ALL at first marrow relapse and a preliminary assessment of toxicity compared to that of daunorubicin: a report from the
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Child; Child, | 1992 |
[Treatment of acute lymphoblastic leukemia in children. Results of the FRALLE 83 protocol].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Clinical Prot | 1991 |
[Treatment of acute lymphoblastic leukemia in children. Results of the FRALLE 83 protocol].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Clinical Prot | 1991 |
[Treatment of acute lymphoblastic leukemia in children. Results of the FRALLE 83 protocol].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Clinical Prot | 1991 |
Intensive therapy for adult acute lymphoblastic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; Humans; Idaru | 1991 |
Intensive therapy for adult acute lymphoblastic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; Humans; Idaru | 1991 |
Intensive therapy for adult acute lymphoblastic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; Humans; Idaru | 1991 |
Low-dose versus high-dose methotrexate during remission induction in childhood acute lymphoblastic leukemia (Protocol 81-01 update).
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cytarabine; Dose-Response Relation | 1991 |
Low-dose versus high-dose methotrexate during remission induction in childhood acute lymphoblastic leukemia (Protocol 81-01 update).
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cytarabine; Dose-Response Relation | 1991 |
Low-dose versus high-dose methotrexate during remission induction in childhood acute lymphoblastic leukemia (Protocol 81-01 update).
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cytarabine; Dose-Response Relation | 1991 |
Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: results of the German Cooperative Study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantatio | 1991 |
Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: results of the German Cooperative Study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantatio | 1991 |
Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: results of the German Cooperative Study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantatio | 1991 |
[Malignant lymphoma associated with HIV infection].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modalit | 1991 |
[Malignant lymphoma associated with HIV infection].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modalit | 1991 |
[Malignant lymphoma associated with HIV infection].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modalit | 1991 |
Intellectual function in long-term survivors of childhood acute lymphoblastic leukemia: protective effect of pre-irradiation methotrexate? A Childrens Cancer Study Group study.
Topics: Asparaginase; Brain; Child; Child, Preschool; Combined Modality Therapy; Female; Follow-Up Studies; | 1991 |
Intellectual function in long-term survivors of childhood acute lymphoblastic leukemia: protective effect of pre-irradiation methotrexate? A Childrens Cancer Study Group study.
Topics: Asparaginase; Brain; Child; Child, Preschool; Combined Modality Therapy; Female; Follow-Up Studies; | 1991 |
Intellectual function in long-term survivors of childhood acute lymphoblastic leukemia: protective effect of pre-irradiation methotrexate? A Childrens Cancer Study Group study.
Topics: Asparaginase; Brain; Child; Child, Preschool; Combined Modality Therapy; Female; Follow-Up Studies; | 1991 |
High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 1991 |
High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 1991 |
High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 1991 |
Monthly pulses of vincristine and prednisone prevent bone marrow and testicular relapse in low-risk childhood acute lymphoblastic leukemia: a report of the CCG-161 study by the Childrens Cancer Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Brain Neoplasms; Child, Presch | 1991 |
Monthly pulses of vincristine and prednisone prevent bone marrow and testicular relapse in low-risk childhood acute lymphoblastic leukemia: a report of the CCG-161 study by the Childrens Cancer Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Brain Neoplasms; Child, Presch | 1991 |
Monthly pulses of vincristine and prednisone prevent bone marrow and testicular relapse in low-risk childhood acute lymphoblastic leukemia: a report of the CCG-161 study by the Childrens Cancer Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Brain Neoplasms; Child, Presch | 1991 |
Improved treatment results in boys with overt testicular relapse during or shortly after initial therapy for acute lymphoblastic leukemia. A Pediatric Oncology group study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 1991 |
Improved treatment results in boys with overt testicular relapse during or shortly after initial therapy for acute lymphoblastic leukemia. A Pediatric Oncology group study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 1991 |
Improved treatment results in boys with overt testicular relapse during or shortly after initial therapy for acute lymphoblastic leukemia. A Pediatric Oncology group study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 1991 |
Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Dexame | 1991 |
Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Dexame | 1991 |
Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Dexame | 1991 |
Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 1991 |
Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 1991 |
Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 1991 |
Treatment of relapsed acute lymphocytic leukemia in adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transpl | 1990 |
Treatment of relapsed acute lymphocytic leukemia in adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transpl | 1990 |
Treatment of relapsed acute lymphocytic leukemia in adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transpl | 1990 |
Improved prognosis for childhood acute lymphocytic leukemia with very high white blood cell count (greater than 100/nl) with rotation of non-cross-resistant drug combinations.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 1990 |
Improved prognosis for childhood acute lymphocytic leukemia with very high white blood cell count (greater than 100/nl) with rotation of non-cross-resistant drug combinations.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 1990 |
Improved prognosis for childhood acute lymphocytic leukemia with very high white blood cell count (greater than 100/nl) with rotation of non-cross-resistant drug combinations.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 1990 |
The prognostic value of testicular biopsy in childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biopsy; Child; Combined Modality Thera | 1990 |
The prognostic value of testicular biopsy in childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biopsy; Child; Combined Modality Thera | 1990 |
The prognostic value of testicular biopsy in childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biopsy; Child; Combined Modality Thera | 1990 |
Treatment of adult acute lymphoblastic leukaemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Combin | 1990 |
Treatment of adult acute lymphoblastic leukaemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Combin | 1990 |
Treatment of adult acute lymphoblastic leukaemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Combin | 1990 |
[Adult acute lymphoblastic leukemia: preliminary results of the LAL-86 protocol].
Topics: Actuarial Analysis; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; | 1990 |
[Adult acute lymphoblastic leukemia: preliminary results of the LAL-86 protocol].
Topics: Actuarial Analysis; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; | 1990 |
[Adult acute lymphoblastic leukemia: preliminary results of the LAL-86 protocol].
Topics: Actuarial Analysis; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; | 1990 |
Philadelphia chromosome positive childhood acute lymphoblastic leukemia: clinical and cytogenetic characteristics and treatment outcome. A Pediatric Oncology Group study.
Topics: Asparaginase; Child; Child, Preschool; Cohort Studies; Cross-Sectional Studies; Female; Humans; Immu | 1990 |
Philadelphia chromosome positive childhood acute lymphoblastic leukemia: clinical and cytogenetic characteristics and treatment outcome. A Pediatric Oncology Group study.
Topics: Asparaginase; Child; Child, Preschool; Cohort Studies; Cross-Sectional Studies; Female; Humans; Immu | 1990 |
Philadelphia chromosome positive childhood acute lymphoblastic leukemia: clinical and cytogenetic characteristics and treatment outcome. A Pediatric Oncology Group study.
Topics: Asparaginase; Child; Child, Preschool; Cohort Studies; Cross-Sectional Studies; Female; Humans; Immu | 1990 |
Adult acute lymphoblastic leukemia: results of the Iowa HOP-L protocol.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Clinical Tria | 1989 |
Adult acute lymphoblastic leukemia: results of the Iowa HOP-L protocol.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Clinical Tria | 1989 |
Adult acute lymphoblastic leukemia: results of the Iowa HOP-L protocol.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Clinical Tria | 1989 |
Three versus five years of maintenance therapy are equivalent in childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biopsy; Child; Clinical Tr | 1989 |
Three versus five years of maintenance therapy are equivalent in childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biopsy; Child; Clinical Tr | 1989 |
Three versus five years of maintenance therapy are equivalent in childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biopsy; Child; Clinical Tr | 1989 |
Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 1989 |
Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 1989 |
Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 1989 |
[Treatment of childhood acute lymphoblastic leukemia: randomized trials of protocols CCLSG-L 841 and I 841. (Phase III study). Children's Cancer and Leukemia Study Group].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Clinical Tria | 1989 |
[Treatment of childhood acute lymphoblastic leukemia: randomized trials of protocols CCLSG-L 841 and I 841. (Phase III study). Children's Cancer and Leukemia Study Group].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Clinical Tria | 1989 |
[Treatment of childhood acute lymphoblastic leukemia: randomized trials of protocols CCLSG-L 841 and I 841. (Phase III study). Children's Cancer and Leukemia Study Group].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Clinical Tria | 1989 |
Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Child; Humans; Methotrexa | 1989 |
Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Child; Humans; Methotrexa | 1989 |
Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Child; Humans; Methotrexa | 1989 |
Factor VIII/von Willebrand factor abnormalities during L-asparaginase treatment in patients with acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 1988 |
Factor VIII/von Willebrand factor abnormalities during L-asparaginase treatment in patients with acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 1988 |
Factor VIII/von Willebrand factor abnormalities during L-asparaginase treatment in patients with acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 1988 |
Randomized multicentric Italian study on two treatment regimens for marrow relapse in childhood acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Combined Modality Therapy | 1986 |
Randomized multicentric Italian study on two treatment regimens for marrow relapse in childhood acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Combined Modality Therapy | 1986 |
Randomized multicentric Italian study on two treatment regimens for marrow relapse in childhood acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Combined Modality Therapy | 1986 |
Other Studies
401 other studies available for prednisone and Precursor Cell Lymphoblastic Leukemia-Lymphoma
Article | Year |
---|---|
INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Imidazoles; Phi | 2022 |
INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Imidazoles; Phi | 2022 |
INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Imidazoles; Phi | 2022 |
The first report of complete remission following treatment with venetoclax plus prednisone in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Topics: Aged; Bridged Bicyclo Compounds, Heterocyclic; Hematopoietic Stem Cell Transplantation; Humans; Phil | 2022 |
The first report of complete remission following treatment with venetoclax plus prednisone in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Topics: Aged; Bridged Bicyclo Compounds, Heterocyclic; Hematopoietic Stem Cell Transplantation; Humans; Phil | 2022 |
The first report of complete remission following treatment with venetoclax plus prednisone in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Topics: Aged; Bridged Bicyclo Compounds, Heterocyclic; Hematopoietic Stem Cell Transplantation; Humans; Phil | 2022 |
The incidence of symptomatic osteonecrosis is similar between Japanese children and children in Western countries with acute lymphoblastic leukaemia treated with a Berlin-Frankfurt-Münster (BFM)95-based protocol.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2022 |
The incidence of symptomatic osteonecrosis is similar between Japanese children and children in Western countries with acute lymphoblastic leukaemia treated with a Berlin-Frankfurt-Münster (BFM)95-based protocol.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2022 |
The incidence of symptomatic osteonecrosis is similar between Japanese children and children in Western countries with acute lymphoblastic leukaemia treated with a Berlin-Frankfurt-Münster (BFM)95-based protocol.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2022 |
Childhood acute lymphoblastic leukemia: Four years evaluation of protocols 2013 and 2016 in a single center in Indonesia, a lower-middle-income country.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease-Free Surviv | 2022 |
Childhood acute lymphoblastic leukemia: Four years evaluation of protocols 2013 and 2016 in a single center in Indonesia, a lower-middle-income country.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease-Free Surviv | 2022 |
Childhood acute lymphoblastic leukemia: Four years evaluation of protocols 2013 and 2016 in a single center in Indonesia, a lower-middle-income country.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease-Free Surviv | 2022 |
Polo-like Kinase 4: the Variation During Therapy and its Relation to Treatment Response and Prognostic Risk Stratification in Childhood Acute Lymphoblastic Leukemia Patients.
Topics: Biomarkers; Humans; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic L | 2023 |
Polo-like Kinase 4: the Variation During Therapy and its Relation to Treatment Response and Prognostic Risk Stratification in Childhood Acute Lymphoblastic Leukemia Patients.
Topics: Biomarkers; Humans; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic L | 2023 |
Polo-like Kinase 4: the Variation During Therapy and its Relation to Treatment Response and Prognostic Risk Stratification in Childhood Acute Lymphoblastic Leukemia Patients.
Topics: Biomarkers; Humans; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic L | 2023 |
Long-term results of the treatment of adolescents and adults with acute lymphoblastic leukemia with a pediatric-inspired regimen delivered on an outpatient basis: A single institution experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; Cytarabine; Daunorub | 2022 |
Long-term results of the treatment of adolescents and adults with acute lymphoblastic leukemia with a pediatric-inspired regimen delivered on an outpatient basis: A single institution experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; Cytarabine; Daunorub | 2022 |
Long-term results of the treatment of adolescents and adults with acute lymphoblastic leukemia with a pediatric-inspired regimen delivered on an outpatient basis: A single institution experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; Cytarabine; Daunorub | 2022 |
Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia.
Topics: Aged; Aged, 80 and over; Dasatinib; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Predniso | 2023 |
Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia.
Topics: Aged; Aged, 80 and over; Dasatinib; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Predniso | 2023 |
Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia.
Topics: Aged; Aged, 80 and over; Dasatinib; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Predniso | 2023 |
PH negative acute lymphoblastic leukemia in adolescents and young adults treated according a MRD adapted BFM ALL IC 2009 protocol: Argentine real-world data on 171 patients.
Topics: Disease-Free Survival; Humans; Multicenter Studies as Topic; Neoplasm, Residual; Precursor Cell Lymp | 2023 |
PH negative acute lymphoblastic leukemia in adolescents and young adults treated according a MRD adapted BFM ALL IC 2009 protocol: Argentine real-world data on 171 patients.
Topics: Disease-Free Survival; Humans; Multicenter Studies as Topic; Neoplasm, Residual; Precursor Cell Lymp | 2023 |
PH negative acute lymphoblastic leukemia in adolescents and young adults treated according a MRD adapted BFM ALL IC 2009 protocol: Argentine real-world data on 171 patients.
Topics: Disease-Free Survival; Humans; Multicenter Studies as Topic; Neoplasm, Residual; Precursor Cell Lymp | 2023 |
Polo-like kinase 1 Decrease During Induction Therapy Could Indicate Good Treatment Response, Favorable Risk Stratification, and Prolonged Survival in Pediatric Acute Lymphoblastic Leukemia.
Topics: Cell Cycle Proteins; Child; Humans; Induction Chemotherapy; Polo-Like Kinase 1; Precursor Cell Lymph | 2023 |
Polo-like kinase 1 Decrease During Induction Therapy Could Indicate Good Treatment Response, Favorable Risk Stratification, and Prolonged Survival in Pediatric Acute Lymphoblastic Leukemia.
Topics: Cell Cycle Proteins; Child; Humans; Induction Chemotherapy; Polo-Like Kinase 1; Precursor Cell Lymph | 2023 |
Polo-like kinase 1 Decrease During Induction Therapy Could Indicate Good Treatment Response, Favorable Risk Stratification, and Prolonged Survival in Pediatric Acute Lymphoblastic Leukemia.
Topics: Cell Cycle Proteins; Child; Humans; Induction Chemotherapy; Polo-Like Kinase 1; Precursor Cell Lymph | 2023 |
Outcome of ALL With ALL-BFM-95 Protocol in Nepal.
Topics: Adolescent; Child; Humans; Nepal; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Treatm | 2023 |
Outcome of ALL With ALL-BFM-95 Protocol in Nepal.
Topics: Adolescent; Child; Humans; Nepal; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Treatm | 2023 |
Outcome of ALL With ALL-BFM-95 Protocol in Nepal.
Topics: Adolescent; Child; Humans; Nepal; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Treatm | 2023 |
Moving away from chemotherapy in newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukaemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Humans; Philadelphia Chromosome; P | 2023 |
Moving away from chemotherapy in newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukaemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Humans; Philadelphia Chromosome; P | 2023 |
Moving away from chemotherapy in newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukaemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Humans; Philadelphia Chromosome; P | 2023 |
Invasive mucormycosis during treatment for acute lymphoblastic leukaemia-successful management of two life-threatening diseases.
Topics: Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Chi | 2020 |
Invasive mucormycosis during treatment for acute lymphoblastic leukaemia-successful management of two life-threatening diseases.
Topics: Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Chi | 2020 |
Invasive mucormycosis during treatment for acute lymphoblastic leukaemia-successful management of two life-threatening diseases.
Topics: Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Chi | 2020 |
Disseminated lymphoblastic lymphoma revealed by an isolated third cranial nerve palsy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blepharoptosis; Cyclophosphamide; Female; Flu | 2021 |
Disseminated lymphoblastic lymphoma revealed by an isolated third cranial nerve palsy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blepharoptosis; Cyclophosphamide; Female; Flu | 2021 |
Disseminated lymphoblastic lymphoma revealed by an isolated third cranial nerve palsy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blepharoptosis; Cyclophosphamide; Female; Flu | 2021 |
The Effect of Combination of Steroid and L-Asparaginase on Hyperglycemia in Children with Acute Lymphoblastic Leukemia (ALL).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 2019 |
The Effect of Combination of Steroid and L-Asparaginase on Hyperglycemia in Children with Acute Lymphoblastic Leukemia (ALL).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 2019 |
The Effect of Combination of Steroid and L-Asparaginase on Hyperglycemia in Children with Acute Lymphoblastic Leukemia (ALL).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 2019 |
Unexpected neurologic complications following a novel lymphoma treatment 'expected' to give rise to neurologic toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnostic Errors; Doxorubicin; Hu | 2019 |
Unexpected neurologic complications following a novel lymphoma treatment 'expected' to give rise to neurologic toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnostic Errors; Doxorubicin; Hu | 2019 |
Unexpected neurologic complications following a novel lymphoma treatment 'expected' to give rise to neurologic toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnostic Errors; Doxorubicin; Hu | 2019 |
Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management.
Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2020 |
Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management.
Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2020 |
Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management.
Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2020 |
T-Cell Lymphoblastic Lymphoma Presenting as Acute Clavicular Pain.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Daunorubicin; Humans; Pain; Precursor Cell Ly | 2019 |
T-Cell Lymphoblastic Lymphoma Presenting as Acute Clavicular Pain.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Daunorubicin; Humans; Pain; Precursor Cell Ly | 2019 |
T-Cell Lymphoblastic Lymphoma Presenting as Acute Clavicular Pain.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Daunorubicin; Humans; Pain; Precursor Cell Ly | 2019 |
Outcomes of the cyclophosphamide, vincristine, prednisone (CVP) +/- rituximab (R-CVP) regimen in older patients with newly diagnosed Ph- acute lymphoblastic leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphami | 2020 |
Outcomes of the cyclophosphamide, vincristine, prednisone (CVP) +/- rituximab (R-CVP) regimen in older patients with newly diagnosed Ph- acute lymphoblastic leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphami | 2020 |
Outcomes of the cyclophosphamide, vincristine, prednisone (CVP) +/- rituximab (R-CVP) regimen in older patients with newly diagnosed Ph- acute lymphoblastic leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphami | 2020 |
Reduced-dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2020 |
Reduced-dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2020 |
Reduced-dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2020 |
Implementation of RNA sequencing and array CGH in the diagnostic workflow of the AIEOP-BFM ALL 2017 trial on acute lymphoblastic leukemia.
Topics: Abnormal Karyotype; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Comparative Genomi | 2020 |
Implementation of RNA sequencing and array CGH in the diagnostic workflow of the AIEOP-BFM ALL 2017 trial on acute lymphoblastic leukemia.
Topics: Abnormal Karyotype; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Comparative Genomi | 2020 |
Implementation of RNA sequencing and array CGH in the diagnostic workflow of the AIEOP-BFM ALL 2017 trial on acute lymphoblastic leukemia.
Topics: Abnormal Karyotype; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Comparative Genomi | 2020 |
A Case of Nephrotic Syndrome after Allogeneic Stem Cell Transplantation.
Topics: Acute Kidney Injury; Anti-Inflammatory Agents; Diuretics; Graft vs Host Disease; Hematopoietic Stem | 2020 |
A Case of Nephrotic Syndrome after Allogeneic Stem Cell Transplantation.
Topics: Acute Kidney Injury; Anti-Inflammatory Agents; Diuretics; Graft vs Host Disease; Hematopoietic Stem | 2020 |
A Case of Nephrotic Syndrome after Allogeneic Stem Cell Transplantation.
Topics: Acute Kidney Injury; Anti-Inflammatory Agents; Diuretics; Graft vs Host Disease; Hematopoietic Stem | 2020 |
An oral, chemotherapy-free regimen (dasatinib plus prednisone) as induction and consolidation for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Conso | 2020 |
An oral, chemotherapy-free regimen (dasatinib plus prednisone) as induction and consolidation for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Conso | 2020 |
An oral, chemotherapy-free regimen (dasatinib plus prednisone) as induction and consolidation for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Conso | 2020 |
Acute Kidney Injury With Massively Enlarged Noncystic Kidneys.
Topics: Acute Kidney Injury; Adolescent; Biopsy; Diagnosis, Differential; Female; Glomerular Filtration Rate | 2020 |
Acute Kidney Injury With Massively Enlarged Noncystic Kidneys.
Topics: Acute Kidney Injury; Adolescent; Biopsy; Diagnosis, Differential; Female; Glomerular Filtration Rate | 2020 |
Acute Kidney Injury With Massively Enlarged Noncystic Kidneys.
Topics: Acute Kidney Injury; Adolescent; Biopsy; Diagnosis, Differential; Female; Glomerular Filtration Rate | 2020 |
Peripheral T-cell lymphoma, NOS, with rapidly progressing leukocytosis mimicking acute lymphoblastic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Differential; Dis | 2020 |
Peripheral T-cell lymphoma, NOS, with rapidly progressing leukocytosis mimicking acute lymphoblastic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Differential; Dis | 2020 |
Peripheral T-cell lymphoma, NOS, with rapidly progressing leukocytosis mimicking acute lymphoblastic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Differential; Dis | 2020 |
Effect of lubiprostone on vinca alkaloid-induced constipation in patients with hematological malignancies: a propensity score-matched analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Pro | 2020 |
Effect of lubiprostone on vinca alkaloid-induced constipation in patients with hematological malignancies: a propensity score-matched analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Pro | 2020 |
Effect of lubiprostone on vinca alkaloid-induced constipation in patients with hematological malignancies: a propensity score-matched analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Pro | 2020 |
Salivary immunoglobulin A level during steroids and chemotherapy treatment administered in remission induction phase among pediatric patients with acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blood Proteins; Child; Chi | 2020 |
Salivary immunoglobulin A level during steroids and chemotherapy treatment administered in remission induction phase among pediatric patients with acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blood Proteins; Child; Chi | 2020 |
Salivary immunoglobulin A level during steroids and chemotherapy treatment administered in remission induction phase among pediatric patients with acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blood Proteins; Child; Chi | 2020 |
Results of two consecutive treatment protocols in Polish children with acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antineoplastic Protocols; Asparaginase; Child; Child | 2020 |
Results of two consecutive treatment protocols in Polish children with acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antineoplastic Protocols; Asparaginase; Child; Child | 2020 |
Results of two consecutive treatment protocols in Polish children with acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antineoplastic Protocols; Asparaginase; Child; Child | 2020 |
Reduced intensity of early intensification does not increase the risk of relapse in children with standard risk acute lymphoblastic leukemia - a multi-centric clinical study of GD-2008-ALL protocol.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 2021 |
Reduced intensity of early intensification does not increase the risk of relapse in children with standard risk acute lymphoblastic leukemia - a multi-centric clinical study of GD-2008-ALL protocol.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 2021 |
Reduced intensity of early intensification does not increase the risk of relapse in children with standard risk acute lymphoblastic leukemia - a multi-centric clinical study of GD-2008-ALL protocol.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 2021 |
Long non-coding RNA MEG3 as a candidate prognostic factor for induction therapy response and survival profile in childhood acute lymphoblastic leukemia patients.
Topics: Biomarkers, Tumor; Bone Marrow Cells; Case-Control Studies; Child; Child, Preschool; Gene Expression | 2021 |
Long non-coding RNA MEG3 as a candidate prognostic factor for induction therapy response and survival profile in childhood acute lymphoblastic leukemia patients.
Topics: Biomarkers, Tumor; Bone Marrow Cells; Case-Control Studies; Child; Child, Preschool; Gene Expression | 2021 |
Long non-coding RNA MEG3 as a candidate prognostic factor for induction therapy response and survival profile in childhood acute lymphoblastic leukemia patients.
Topics: Biomarkers, Tumor; Bone Marrow Cells; Case-Control Studies; Child; Child, Preschool; Gene Expression | 2021 |
Outcomes of pediatric mixed phenotype acute leukemia treated with lymphoid directed therapy: Analysis of an institutional series from India.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Daunorubicin; Femal | 2021 |
Outcomes of pediatric mixed phenotype acute leukemia treated with lymphoid directed therapy: Analysis of an institutional series from India.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Daunorubicin; Femal | 2021 |
Outcomes of pediatric mixed phenotype acute leukemia treated with lymphoid directed therapy: Analysis of an institutional series from India.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Daunorubicin; Femal | 2021 |
Phase-specific risks of outpatient visits, emergency visits, and hospitalizations during Children's Oncology Group-based treatment for childhood acute lymphoblastic leukemia: A population-based study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Dexamethasone; Emergency Service, Hospital; H | 2021 |
Phase-specific risks of outpatient visits, emergency visits, and hospitalizations during Children's Oncology Group-based treatment for childhood acute lymphoblastic leukemia: A population-based study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Dexamethasone; Emergency Service, Hospital; H | 2021 |
Phase-specific risks of outpatient visits, emergency visits, and hospitalizations during Children's Oncology Group-based treatment for childhood acute lymphoblastic leukemia: A population-based study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Dexamethasone; Emergency Service, Hospital; H | 2021 |
Clinical features and prognostic impact of TCF3-PBX1 in childhood acute lymphoblastic leukemia: A single-center retrospective study of 837 patients from China.
Topics: Adolescent; Antineoplastic Agents, Hormonal; Child; Child, Preschool; China; Female; Humans; Infant; | 2021 |
Clinical features and prognostic impact of TCF3-PBX1 in childhood acute lymphoblastic leukemia: A single-center retrospective study of 837 patients from China.
Topics: Adolescent; Antineoplastic Agents, Hormonal; Child; Child, Preschool; China; Female; Humans; Infant; | 2021 |
Clinical features and prognostic impact of TCF3-PBX1 in childhood acute lymphoblastic leukemia: A single-center retrospective study of 837 patients from China.
Topics: Adolescent; Antineoplastic Agents, Hormonal; Child; Child, Preschool; China; Female; Humans; Infant; | 2021 |
Philadelphia chromosome-positive B-lymphoblastic lymphoma successfully treated with chemotherapy regimen containing imatinib: A rare case report and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Daunorubicin; Fusion Protei | 2021 |
Philadelphia chromosome-positive B-lymphoblastic lymphoma successfully treated with chemotherapy regimen containing imatinib: A rare case report and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Daunorubicin; Fusion Protei | 2021 |
Philadelphia chromosome-positive B-lymphoblastic lymphoma successfully treated with chemotherapy regimen containing imatinib: A rare case report and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Daunorubicin; Fusion Protei | 2021 |
Efficacy of chemotherapy protocols for hematological malignancies: H-CVAD versus GELA/BURKIMAB/PETHEMA LAL.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; Cycloph | 2021 |
Efficacy of chemotherapy protocols for hematological malignancies: H-CVAD versus GELA/BURKIMAB/PETHEMA LAL.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; Cycloph | 2021 |
Efficacy of chemotherapy protocols for hematological malignancies: H-CVAD versus GELA/BURKIMAB/PETHEMA LAL.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; Cycloph | 2021 |
Diagnostic value of the dual-luciferase report assay for predicting response to glucocorticoid in children with acute lymphoblastic leukemia.
Topics: Adolescent; Child; Child, Preschool; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Glucocort | 2017 |
Diagnostic value of the dual-luciferase report assay for predicting response to glucocorticoid in children with acute lymphoblastic leukemia.
Topics: Adolescent; Child; Child, Preschool; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Glucocort | 2017 |
Diagnostic value of the dual-luciferase report assay for predicting response to glucocorticoid in children with acute lymphoblastic leukemia.
Topics: Adolescent; Child; Child, Preschool; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Glucocort | 2017 |
Prognostic impact of IKZF1 deletions in association with vincristine-dexamethasone pulses during maintenance treatment of childhood acute lymphoblastic leukemia on trial ALL-BFM 95.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2017 |
Prognostic impact of IKZF1 deletions in association with vincristine-dexamethasone pulses during maintenance treatment of childhood acute lymphoblastic leukemia on trial ALL-BFM 95.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2017 |
Prognostic impact of IKZF1 deletions in association with vincristine-dexamethasone pulses during maintenance treatment of childhood acute lymphoblastic leukemia on trial ALL-BFM 95.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2017 |
miR-125b predicts childhood acute lymphoblastic leukaemia poor response to BFM chemotherapy treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers, Tumor; Bone Marrow; Child; | 2017 |
miR-125b predicts childhood acute lymphoblastic leukaemia poor response to BFM chemotherapy treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers, Tumor; Bone Marrow; Child; | 2017 |
miR-125b predicts childhood acute lymphoblastic leukaemia poor response to BFM chemotherapy treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers, Tumor; Bone Marrow; Child; | 2017 |
Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic Transplant.
Topics: Adenine Nucleotides; Adult; Arabinonucleosides; Bone Marrow; Clofarabine; Cyclophosphamide; Disease- | 2017 |
Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic Transplant.
Topics: Adenine Nucleotides; Adult; Arabinonucleosides; Bone Marrow; Clofarabine; Cyclophosphamide; Disease- | 2017 |
Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic Transplant.
Topics: Adenine Nucleotides; Adult; Arabinonucleosides; Bone Marrow; Clofarabine; Cyclophosphamide; Disease- | 2017 |
High-dose chemotherapy and autologous peripheral blood stem cell transplantation with BCVAC regimen followed by maintenance chemotherapy for children with very high risk acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Child; Child, Preschool; Com | 2018 |
High-dose chemotherapy and autologous peripheral blood stem cell transplantation with BCVAC regimen followed by maintenance chemotherapy for children with very high risk acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Child; Child, Preschool; Com | 2018 |
High-dose chemotherapy and autologous peripheral blood stem cell transplantation with BCVAC regimen followed by maintenance chemotherapy for children with very high risk acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Child; Child, Preschool; Com | 2018 |
Non-alcoholic steatohepatitis induced by induction chemotherapy for pediatric acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers; Child; Daunorubicin; gamma | 2018 |
Non-alcoholic steatohepatitis induced by induction chemotherapy for pediatric acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers; Child; Daunorubicin; gamma | 2018 |
Non-alcoholic steatohepatitis induced by induction chemotherapy for pediatric acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers; Child; Daunorubicin; gamma | 2018 |
DNA variants in DHFR gene and response to treatment in children with childhood B ALL: revisited in AIEOP-BFM protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers, Tumor; Child; Daunorubicin | 2018 |
DNA variants in DHFR gene and response to treatment in children with childhood B ALL: revisited in AIEOP-BFM protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers, Tumor; Child; Daunorubicin | 2018 |
DNA variants in DHFR gene and response to treatment in children with childhood B ALL: revisited in AIEOP-BFM protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers, Tumor; Child; Daunorubicin | 2018 |
Influence of thiopurine methyltransferase gene polymorphism on Egyptian children with acute lymphoblastic leukaemia.
Topics: Adolescent; Alleles; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Pre | 2017 |
Influence of thiopurine methyltransferase gene polymorphism on Egyptian children with acute lymphoblastic leukaemia.
Topics: Adolescent; Alleles; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Pre | 2017 |
Influence of thiopurine methyltransferase gene polymorphism on Egyptian children with acute lymphoblastic leukaemia.
Topics: Adolescent; Alleles; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Pre | 2017 |
Severe hypofibrinogenemia associated with imatinib and prednisone therapy in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adult; Afibrinogenemia; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fibrinogen; Hu | 2018 |
Severe hypofibrinogenemia associated with imatinib and prednisone therapy in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adult; Afibrinogenemia; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fibrinogen; Hu | 2018 |
Severe hypofibrinogenemia associated with imatinib and prednisone therapy in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adult; Afibrinogenemia; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fibrinogen; Hu | 2018 |
Remission Rate of Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults (AYA).
Topics: Adolescent; Adult; Asparaginase; Bone Marrow; Daunorubicin; Female; Humans; Immunophenotyping; Male; | 2018 |
Remission Rate of Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults (AYA).
Topics: Adolescent; Adult; Asparaginase; Bone Marrow; Daunorubicin; Female; Humans; Immunophenotyping; Male; | 2018 |
Remission Rate of Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults (AYA).
Topics: Adolescent; Adult; Asparaginase; Bone Marrow; Daunorubicin; Female; Humans; Immunophenotyping; Male; | 2018 |
Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Cells; Child; | 2018 |
Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Cells; Child; | 2018 |
Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Cells; Child; | 2018 |
Incidence and Risk Factors for Hypertension During Childhood Acute Lymphoblastic Leukemia Therapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 2018 |
Incidence and Risk Factors for Hypertension During Childhood Acute Lymphoblastic Leukemia Therapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 2018 |
Incidence and Risk Factors for Hypertension During Childhood Acute Lymphoblastic Leukemia Therapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 2018 |
[Relationship between Early Treatment Response and Prognosis in Children with Acute Lymphoblastic Leukemia].
Topics: Child; Disease-Free Survival; Humans; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymp | 2018 |
[Relationship between Early Treatment Response and Prognosis in Children with Acute Lymphoblastic Leukemia].
Topics: Child; Disease-Free Survival; Humans; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymp | 2018 |
[Relationship between Early Treatment Response and Prognosis in Children with Acute Lymphoblastic Leukemia].
Topics: Child; Disease-Free Survival; Humans; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymp | 2018 |
Acute lymphoblastic leukemia in children with Down syndrome: Comparative analysis versus patients without Down syndrome.
Topics: Adolescent; Age Factors; Antineoplastic Agents, Hormonal; Child; Child, Preschool; Disease-Free Surv | 2018 |
Acute lymphoblastic leukemia in children with Down syndrome: Comparative analysis versus patients without Down syndrome.
Topics: Adolescent; Age Factors; Antineoplastic Agents, Hormonal; Child; Child, Preschool; Disease-Free Surv | 2018 |
Acute lymphoblastic leukemia in children with Down syndrome: Comparative analysis versus patients without Down syndrome.
Topics: Adolescent; Age Factors; Antineoplastic Agents, Hormonal; Child; Child, Preschool; Disease-Free Surv | 2018 |
ETV6/RUNX1-positive childhood acute lymphoblastic leukemia in China: excellent prognosis with improved BFM protocol.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2018 |
ETV6/RUNX1-positive childhood acute lymphoblastic leukemia in China: excellent prognosis with improved BFM protocol.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2018 |
ETV6/RUNX1-positive childhood acute lymphoblastic leukemia in China: excellent prognosis with improved BFM protocol.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2018 |
Outcomes of Low-Intensity Treatment of Acute Lymphoblastic Leukemia at Butaro Cancer Center of Excellence in Rwanda.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cancer Care Facilities; Child; Cycloph | 2018 |
Outcomes of Low-Intensity Treatment of Acute Lymphoblastic Leukemia at Butaro Cancer Center of Excellence in Rwanda.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cancer Care Facilities; Child; Cycloph | 2018 |
Outcomes of Low-Intensity Treatment of Acute Lymphoblastic Leukemia at Butaro Cancer Center of Excellence in Rwanda.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cancer Care Facilities; Child; Cycloph | 2018 |
The therapeutic efficacy of pediatric ALL patients with MLL gene rearrangement treated with CCLG-ALL2008 protocol.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; China; Drug Adm | 2018 |
The therapeutic efficacy of pediatric ALL patients with MLL gene rearrangement treated with CCLG-ALL2008 protocol.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; China; Drug Adm | 2018 |
The therapeutic efficacy of pediatric ALL patients with MLL gene rearrangement treated with CCLG-ALL2008 protocol.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; China; Drug Adm | 2018 |
Comparison between Hyper-CVAD and PETHEMA ALL-93 in Adult Acute Lymphoblastic Leukemia: A Single-Center Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bacterial Infection | 2018 |
Comparison between Hyper-CVAD and PETHEMA ALL-93 in Adult Acute Lymphoblastic Leukemia: A Single-Center Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bacterial Infection | 2018 |
Comparison between Hyper-CVAD and PETHEMA ALL-93 in Adult Acute Lymphoblastic Leukemia: A Single-Center Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bacterial Infection | 2018 |
TCF7L2 activated HOXA-AS2 decreased the glucocorticoid sensitivity in acute lymphoblastic leukemia through regulating HOXA3/EGFR/Ras/Raf/MEK/ERK pathway.
Topics: Adolescent; Antineoplastic Agents, Hormonal; Cell Survival; Child; Child, Preschool; Drug Resistance | 2019 |
TCF7L2 activated HOXA-AS2 decreased the glucocorticoid sensitivity in acute lymphoblastic leukemia through regulating HOXA3/EGFR/Ras/Raf/MEK/ERK pathway.
Topics: Adolescent; Antineoplastic Agents, Hormonal; Cell Survival; Child; Child, Preschool; Drug Resistance | 2019 |
TCF7L2 activated HOXA-AS2 decreased the glucocorticoid sensitivity in acute lymphoblastic leukemia through regulating HOXA3/EGFR/Ras/Raf/MEK/ERK pathway.
Topics: Adolescent; Antineoplastic Agents, Hormonal; Cell Survival; Child; Child, Preschool; Drug Resistance | 2019 |
Improved Outcome of Newly Diagnosed Childhood Mature B-Cell Lymphoma/Leukemia With High Tumor Burden Treated With BFM95-based Protocol Combining Rituximab: A Report From Shanghai, China.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Case-Control Studies; Child; China; Da | 2019 |
Improved Outcome of Newly Diagnosed Childhood Mature B-Cell Lymphoma/Leukemia With High Tumor Burden Treated With BFM95-based Protocol Combining Rituximab: A Report From Shanghai, China.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Case-Control Studies; Child; China; Da | 2019 |
Improved Outcome of Newly Diagnosed Childhood Mature B-Cell Lymphoma/Leukemia With High Tumor Burden Treated With BFM95-based Protocol Combining Rituximab: A Report From Shanghai, China.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Case-Control Studies; Child; China; Da | 2019 |
High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Cyclophosphamide; Dose-Res | 2019 |
High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Cyclophosphamide; Dose-Res | 2019 |
High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Cyclophosphamide; Dose-Res | 2019 |
Posterior reversible encephalopathy syndrome in children with acute lymphoblastic leukemia: Experience of a single center using BFM protocols.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Daunorubicin; Humans; Posterior | 2019 |
Posterior reversible encephalopathy syndrome in children with acute lymphoblastic leukemia: Experience of a single center using BFM protocols.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Daunorubicin; Humans; Posterior | 2019 |
Posterior reversible encephalopathy syndrome in children with acute lymphoblastic leukemia: Experience of a single center using BFM protocols.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Daunorubicin; Humans; Posterior | 2019 |
Visualization of Vertebral Body Deformities in Childhood by MRI in a Boy with ALL.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Density; Bone Marrow; Child, Pres | 2019 |
Visualization of Vertebral Body Deformities in Childhood by MRI in a Boy with ALL.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Density; Bone Marrow; Child, Pres | 2019 |
Visualization of Vertebral Body Deformities in Childhood by MRI in a Boy with ALL.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Density; Bone Marrow; Child, Pres | 2019 |
Analysis of apoptotic, platelet-derived, endothelial-derived, and tissue factor-positive microparticles of children with acute lymphoblastic leukemia during induction therapy.
Topics: Adolescent; Apoptosis; Asparaginase; Blood Platelets; Cell-Derived Microparticles; Child; Child, Pre | 2019 |
Analysis of apoptotic, platelet-derived, endothelial-derived, and tissue factor-positive microparticles of children with acute lymphoblastic leukemia during induction therapy.
Topics: Adolescent; Apoptosis; Asparaginase; Blood Platelets; Cell-Derived Microparticles; Child; Child, Pre | 2019 |
Analysis of apoptotic, platelet-derived, endothelial-derived, and tissue factor-positive microparticles of children with acute lymphoblastic leukemia during induction therapy.
Topics: Adolescent; Apoptosis; Asparaginase; Blood Platelets; Cell-Derived Microparticles; Child; Child, Pre | 2019 |
[Bmi-1 as A Molecular Marker for Prognosis of Pediatric ALL].
Topics: Biomarkers; Child; Humans; Kaplan-Meier Estimate; Polycomb Repressive Complex 1; Precursor Cell Lymp | 2019 |
[Bmi-1 as A Molecular Marker for Prognosis of Pediatric ALL].
Topics: Biomarkers; Child; Humans; Kaplan-Meier Estimate; Polycomb Repressive Complex 1; Precursor Cell Lymp | 2019 |
[Bmi-1 as A Molecular Marker for Prognosis of Pediatric ALL].
Topics: Biomarkers; Child; Humans; Kaplan-Meier Estimate; Polycomb Repressive Complex 1; Precursor Cell Lymp | 2019 |
Risk group assignment differs for children and adults 1-45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytogene | 2013 |
Risk group assignment differs for children and adults 1-45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytogene | 2013 |
Risk group assignment differs for children and adults 1-45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytogene | 2013 |
Outcome of patients with acute lymphoblastic leukemia (ALL) following induction therapy with a modified (pulsed dexamethasone rather than continuous prednisone) UKALL XII/ECOG E2993 protocol at Tawam Hospital, United Arab Emirates (UAE).
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cancer Care Facilit | 2013 |
Outcome of patients with acute lymphoblastic leukemia (ALL) following induction therapy with a modified (pulsed dexamethasone rather than continuous prednisone) UKALL XII/ECOG E2993 protocol at Tawam Hospital, United Arab Emirates (UAE).
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cancer Care Facilit | 2013 |
Outcome of patients with acute lymphoblastic leukemia (ALL) following induction therapy with a modified (pulsed dexamethasone rather than continuous prednisone) UKALL XII/ECOG E2993 protocol at Tawam Hospital, United Arab Emirates (UAE).
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cancer Care Facilit | 2013 |
Once upon a time--a personal view on episodes in leukemia research in Germany, and beyond.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomedical Research; Child; Daunorubic | 2013 |
Once upon a time--a personal view on episodes in leukemia research in Germany, and beyond.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomedical Research; Child; Daunorubic | 2013 |
Once upon a time--a personal view on episodes in leukemia research in Germany, and beyond.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomedical Research; Child; Daunorubic | 2013 |
Key treatment questions in childhood acute lymphoblastic leukemia: results in 5 consecutive trials performed by the ALL-BFM study group from 1981 to 2000.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Cyclophosphamide; Cytarabine; D | 2013 |
Key treatment questions in childhood acute lymphoblastic leukemia: results in 5 consecutive trials performed by the ALL-BFM study group from 1981 to 2000.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Cyclophosphamide; Cytarabine; D | 2013 |
Key treatment questions in childhood acute lymphoblastic leukemia: results in 5 consecutive trials performed by the ALL-BFM study group from 1981 to 2000.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Cyclophosphamide; Cytarabine; D | 2013 |
ALL-REZ BFM--the consecutive trials for children with relapsed acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Child; Combin | 2013 |
ALL-REZ BFM--the consecutive trials for children with relapsed acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Child; Combin | 2013 |
ALL-REZ BFM--the consecutive trials for children with relapsed acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Child; Combin | 2013 |
Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclopho | 2013 |
Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclopho | 2013 |
Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclopho | 2013 |
Bim polymorphisms: influence on function and response to treatment in children with acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like | 2013 |
Bim polymorphisms: influence on function and response to treatment in children with acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like | 2013 |
Bim polymorphisms: influence on function and response to treatment in children with acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like | 2013 |
The expression of histone deacetylase 4 is associated with prednisone poor-response in childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; | 2013 |
The expression of histone deacetylase 4 is associated with prednisone poor-response in childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; | 2013 |
The expression of histone deacetylase 4 is associated with prednisone poor-response in childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; | 2013 |
HDAC expression patterns in pediatric ALL.
Topics: Antineoplastic Agents; Female; Gene Expression; Histone Deacetylases; Humans; Male; Precursor Cell L | 2013 |
HDAC expression patterns in pediatric ALL.
Topics: Antineoplastic Agents; Female; Gene Expression; Histone Deacetylases; Humans; Male; Precursor Cell L | 2013 |
HDAC expression patterns in pediatric ALL.
Topics: Antineoplastic Agents; Female; Gene Expression; Histone Deacetylases; Humans; Male; Precursor Cell L | 2013 |
The BCL2-938 C > A promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female; Genotype; Humans; M | 2013 |
The BCL2-938 C > A promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female; Genotype; Humans; M | 2013 |
The BCL2-938 C > A promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female; Genotype; Humans; M | 2013 |
Prevalence and risk factors of cataract after chemotherapy with or without central nervous system irradiation for childhood acute lymphoblastic leukaemia: an LEA study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cataract; Child; Child, Preschool; Crani | 2014 |
Prevalence and risk factors of cataract after chemotherapy with or without central nervous system irradiation for childhood acute lymphoblastic leukaemia: an LEA study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cataract; Child; Child, Preschool; Crani | 2014 |
Prevalence and risk factors of cataract after chemotherapy with or without central nervous system irradiation for childhood acute lymphoblastic leukaemia: an LEA study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cataract; Child; Child, Preschool; Crani | 2014 |
Herpes simplex virus reactivation and disease during treatment for childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bacterial Infections; Chil | 2014 |
Herpes simplex virus reactivation and disease during treatment for childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bacterial Infections; Chil | 2014 |
Herpes simplex virus reactivation and disease during treatment for childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bacterial Infections; Chil | 2014 |
[Clinical characteristics and efficacy analysis for patients over 55 years of age with acute lymphoblastic leukemia].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; | 2013 |
[Clinical characteristics and efficacy analysis for patients over 55 years of age with acute lymphoblastic leukemia].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; | 2013 |
[Clinical characteristics and efficacy analysis for patients over 55 years of age with acute lymphoblastic leukemia].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; | 2013 |
Mitoxantrone as a substitute for daunorubicin during induction in newly diagnosed lymphoblastic leukemia and lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Daunorubicin; Dexamethasone; Dr | 2014 |
Mitoxantrone as a substitute for daunorubicin during induction in newly diagnosed lymphoblastic leukemia and lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Daunorubicin; Dexamethasone; Dr | 2014 |
Mitoxantrone as a substitute for daunorubicin during induction in newly diagnosed lymphoblastic leukemia and lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Daunorubicin; Dexamethasone; Dr | 2014 |
The contribution of neurocognitive functioning to quality of life after childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cognition; Cros | 2014 |
The contribution of neurocognitive functioning to quality of life after childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cognition; Cros | 2014 |
The contribution of neurocognitive functioning to quality of life after childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cognition; Cros | 2014 |
Impact on survival and toxicity by duration of weight extremes during treatment for pediatric acute lymphoblastic leukemia: A report from the Children's Oncology Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2014 |
Impact on survival and toxicity by duration of weight extremes during treatment for pediatric acute lymphoblastic leukemia: A report from the Children's Oncology Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2014 |
Impact on survival and toxicity by duration of weight extremes during treatment for pediatric acute lymphoblastic leukemia: A report from the Children's Oncology Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2014 |
Scurvy: a new problem for patients with chronic GVHD involving mucous membranes; an easy problem to resolve.
Topics: Administration, Oral; Adolescent; Adult; Ascorbic Acid; Ascorbic Acid Deficiency; Child; Chronic Dis | 2014 |
Scurvy: a new problem for patients with chronic GVHD involving mucous membranes; an easy problem to resolve.
Topics: Administration, Oral; Adolescent; Adult; Ascorbic Acid; Ascorbic Acid Deficiency; Child; Chronic Dis | 2014 |
Scurvy: a new problem for patients with chronic GVHD involving mucous membranes; an easy problem to resolve.
Topics: Administration, Oral; Adolescent; Adult; Ascorbic Acid; Ascorbic Acid Deficiency; Child; Chronic Dis | 2014 |
Adrenal insufficiency during treatment for childhood acute lymphoblastic leukemia is associated with glucocorticoid receptor polymorphisms ER22/23EK and BclI.
Topics: Adolescent; Adrenal Insufficiency; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Infan | 2014 |
Adrenal insufficiency during treatment for childhood acute lymphoblastic leukemia is associated with glucocorticoid receptor polymorphisms ER22/23EK and BclI.
Topics: Adolescent; Adrenal Insufficiency; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Infan | 2014 |
Adrenal insufficiency during treatment for childhood acute lymphoblastic leukemia is associated with glucocorticoid receptor polymorphisms ER22/23EK and BclI.
Topics: Adolescent; Adrenal Insufficiency; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Infan | 2014 |
[Efficacy observation of polyethylene glycol conjugated asparaginase for induction treatment of children with newly diagnosed acute lymphoblastic leukemia].
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bon | 2014 |
[Efficacy observation of polyethylene glycol conjugated asparaginase for induction treatment of children with newly diagnosed acute lymphoblastic leukemia].
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bon | 2014 |
[Efficacy observation of polyethylene glycol conjugated asparaginase for induction treatment of children with newly diagnosed acute lymphoblastic leukemia].
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bon | 2014 |
Aggressive Cunninghamella pneumonia in an adolescent.
Topics: Adolescent; Anti-Inflammatory Agents; Cunninghamella; Humans; Hyperbilirubinemia; Male; Mucormycosis | 2014 |
Aggressive Cunninghamella pneumonia in an adolescent.
Topics: Adolescent; Anti-Inflammatory Agents; Cunninghamella; Humans; Hyperbilirubinemia; Male; Mucormycosis | 2014 |
Aggressive Cunninghamella pneumonia in an adolescent.
Topics: Adolescent; Anti-Inflammatory Agents; Cunninghamella; Humans; Hyperbilirubinemia; Male; Mucormycosis | 2014 |
Prognostic factors in adolescent and adult patients with acute lymphoblastic leukemia with two protocols of chemotherapy: a cross-sectional study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Consolidatio | 2015 |
Prognostic factors in adolescent and adult patients with acute lymphoblastic leukemia with two protocols of chemotherapy: a cross-sectional study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Consolidatio | 2015 |
Prognostic factors in adolescent and adult patients with acute lymphoblastic leukemia with two protocols of chemotherapy: a cross-sectional study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Consolidatio | 2015 |
[Comparison of HyperCVAD regimen and CHOP regimen in treating patients with lymphoblastic lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease-Free Surviv | 2014 |
[Comparison of HyperCVAD regimen and CHOP regimen in treating patients with lymphoblastic lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease-Free Surviv | 2014 |
[Comparison of HyperCVAD regimen and CHOP regimen in treating patients with lymphoblastic lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease-Free Surviv | 2014 |
[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia].
Topics: Alleles; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Daunorubicin; Disease- | 2014 |
[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia].
Topics: Alleles; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Daunorubicin; Disease- | 2014 |
[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia].
Topics: Alleles; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Daunorubicin; Disease- | 2014 |
[Outcomes of modified NHL-BFM-90 protocol for children and adolescents with lymphoblastic lymphoma].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 2014 |
[Outcomes of modified NHL-BFM-90 protocol for children and adolescents with lymphoblastic lymphoma].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 2014 |
[Outcomes of modified NHL-BFM-90 protocol for children and adolescents with lymphoblastic lymphoma].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 2014 |
Single nucleotide polymorphisms in non-coding region of the glucocorticoid receptor gene and prednisone response in childhood acute lymphoblastic leukemia.
Topics: Adolescent; Child; Child, Preschool; Female; Genes, bcl-1; Glucocorticoids; Humans; Infant; Infant, | 2015 |
Single nucleotide polymorphisms in non-coding region of the glucocorticoid receptor gene and prednisone response in childhood acute lymphoblastic leukemia.
Topics: Adolescent; Child; Child, Preschool; Female; Genes, bcl-1; Glucocorticoids; Humans; Infant; Infant, | 2015 |
Single nucleotide polymorphisms in non-coding region of the glucocorticoid receptor gene and prednisone response in childhood acute lymphoblastic leukemia.
Topics: Adolescent; Child; Child, Preschool; Female; Genes, bcl-1; Glucocorticoids; Humans; Infant; Infant, | 2015 |
Toxicity profile and treatment delays in NOPHO ALL2008-comparing adults and children with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female; | 2016 |
Toxicity profile and treatment delays in NOPHO ALL2008-comparing adults and children with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female; | 2016 |
Toxicity profile and treatment delays in NOPHO ALL2008-comparing adults and children with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female; | 2016 |
Is the BFM Regimen Feasible for the Treatment of Adult Acute Lymphoblastic Leukemia? A Retrospective Analysis of the Outcomes of BFM and Hyper-CVAD Chemotherapy in Two Centers.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; D | 2014 |
Is the BFM Regimen Feasible for the Treatment of Adult Acute Lymphoblastic Leukemia? A Retrospective Analysis of the Outcomes of BFM and Hyper-CVAD Chemotherapy in Two Centers.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; D | 2014 |
Is the BFM Regimen Feasible for the Treatment of Adult Acute Lymphoblastic Leukemia? A Retrospective Analysis of the Outcomes of BFM and Hyper-CVAD Chemotherapy in Two Centers.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; D | 2014 |
Survival of Mexican Children with Acute Lymphoblastic Leukaemia under Treatment with the Protocol from the Dana-Farber Cancer Institute 00-01.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Dis | 2015 |
Survival of Mexican Children with Acute Lymphoblastic Leukaemia under Treatment with the Protocol from the Dana-Farber Cancer Institute 00-01.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Dis | 2015 |
Survival of Mexican Children with Acute Lymphoblastic Leukaemia under Treatment with the Protocol from the Dana-Farber Cancer Institute 00-01.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Dis | 2015 |
Overexpression of BCL2 and BAX following BFM induction therapy predicts ch-ALL patients' poor response to treatment and short-term relapse.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; bcl-2-Associated X Protein | 2015 |
Overexpression of BCL2 and BAX following BFM induction therapy predicts ch-ALL patients' poor response to treatment and short-term relapse.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; bcl-2-Associated X Protein | 2015 |
Overexpression of BCL2 and BAX following BFM induction therapy predicts ch-ALL patients' poor response to treatment and short-term relapse.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; bcl-2-Associated X Protein | 2015 |
[Prognostic Value of Prednisone Response in CCLG-ALL 2008].
Topics: Disease-Free Survival; Humans; Multivariate Analysis; Neoplasm, Residual; Precursor Cell Lymphoblast | 2015 |
[Prognostic Value of Prednisone Response in CCLG-ALL 2008].
Topics: Disease-Free Survival; Humans; Multivariate Analysis; Neoplasm, Residual; Precursor Cell Lymphoblast | 2015 |
[Prognostic Value of Prednisone Response in CCLG-ALL 2008].
Topics: Disease-Free Survival; Humans; Multivariate Analysis; Neoplasm, Residual; Precursor Cell Lymphoblast | 2015 |
Prediction of outcomes by early treatment responses in childhood T-cell acute lymphoblastic leukemia: a retrospective study in China.
Topics: Adolescent; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Ma | 2015 |
Prediction of outcomes by early treatment responses in childhood T-cell acute lymphoblastic leukemia: a retrospective study in China.
Topics: Adolescent; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Ma | 2015 |
Prediction of outcomes by early treatment responses in childhood T-cell acute lymphoblastic leukemia: a retrospective study in China.
Topics: Adolescent; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Ma | 2015 |
Is a New Protocol for Acute Lymphoblastic Leukemia Research or Standard Therapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Clinical Protocols; Cyclophosph | 2015 |
Is a New Protocol for Acute Lymphoblastic Leukemia Research or Standard Therapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Clinical Protocols; Cyclophosph | 2015 |
Is a New Protocol for Acute Lymphoblastic Leukemia Research or Standard Therapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Clinical Protocols; Cyclophosph | 2015 |
A 13-Year-Old Boy with Pancytopenia and a Sacrococcygeal Abscess.
Topics: Abscess; Adolescent; Anti-Bacterial Agents; Diagnosis, Differential; Glucocorticoids; Humans; Male; | 2015 |
A 13-Year-Old Boy with Pancytopenia and a Sacrococcygeal Abscess.
Topics: Abscess; Adolescent; Anti-Bacterial Agents; Diagnosis, Differential; Glucocorticoids; Humans; Male; | 2015 |
A 13-Year-Old Boy with Pancytopenia and a Sacrococcygeal Abscess.
Topics: Abscess; Adolescent; Anti-Bacterial Agents; Diagnosis, Differential; Glucocorticoids; Humans; Male; | 2015 |
Clinical and molecular genetic characterization of wild-type MLL infant acute lymphoblastic leukemia identifies few recurrent abnormalities.
Topics: Antineoplastic Agents, Hormonal; B-Lymphocytes; Comparative Genomic Hybridization; DNA Copy Number V | 2016 |
Clinical and molecular genetic characterization of wild-type MLL infant acute lymphoblastic leukemia identifies few recurrent abnormalities.
Topics: Antineoplastic Agents, Hormonal; B-Lymphocytes; Comparative Genomic Hybridization; DNA Copy Number V | 2016 |
Clinical and molecular genetic characterization of wild-type MLL infant acute lymphoblastic leukemia identifies few recurrent abnormalities.
Topics: Antineoplastic Agents, Hormonal; B-Lymphocytes; Comparative Genomic Hybridization; DNA Copy Number V | 2016 |
[Clinical and Prognostic analysis of 43 Children with Mature B-cell Non-Hodgkin's Lymphoma/Acute Lymphoblastic Leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Cyclophosphamide; Cytarabin | 2016 |
[Clinical and Prognostic analysis of 43 Children with Mature B-cell Non-Hodgkin's Lymphoma/Acute Lymphoblastic Leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Cyclophosphamide; Cytarabin | 2016 |
[Clinical and Prognostic analysis of 43 Children with Mature B-cell Non-Hodgkin's Lymphoma/Acute Lymphoblastic Leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Cyclophosphamide; Cytarabin | 2016 |
Some GCR Polymorphisms (N363S, ER22/23EK, and Bcl-1) May Influence Steroid-induced Toxicities and Survival Rates in Children With ALL.
Topics: Adolescent; Child; Child, Preschool; Cyclin D1; Disease-Free Survival; Glucocorticoids; Humans; Infa | 2016 |
Some GCR Polymorphisms (N363S, ER22/23EK, and Bcl-1) May Influence Steroid-induced Toxicities and Survival Rates in Children With ALL.
Topics: Adolescent; Child; Child, Preschool; Cyclin D1; Disease-Free Survival; Glucocorticoids; Humans; Infa | 2016 |
Some GCR Polymorphisms (N363S, ER22/23EK, and Bcl-1) May Influence Steroid-induced Toxicities and Survival Rates in Children With ALL.
Topics: Adolescent; Child; Child, Preschool; Cyclin D1; Disease-Free Survival; Glucocorticoids; Humans; Infa | 2016 |
The impact of dexamethasone and prednisone on sleep in children with acute lymphoblastic leukemia.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Child; Child, Preschool; Dexamethasone; Female; H | 2016 |
The impact of dexamethasone and prednisone on sleep in children with acute lymphoblastic leukemia.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Child; Child, Preschool; Dexamethasone; Female; H | 2016 |
The impact of dexamethasone and prednisone on sleep in children with acute lymphoblastic leukemia.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Child; Child, Preschool; Dexamethasone; Female; H | 2016 |
Slower early response to treatment and distinct expression profile of childhood high hyperdiploid acute lymphoblastic leukaemia with DNA index < 1.16.
Topics: Antineoplastic Agents, Hormonal; Child; Child, Preschool; Chromosome Aberrations; DNA, Neoplasm; Fem | 2016 |
Slower early response to treatment and distinct expression profile of childhood high hyperdiploid acute lymphoblastic leukaemia with DNA index < 1.16.
Topics: Antineoplastic Agents, Hormonal; Child; Child, Preschool; Chromosome Aberrations; DNA, Neoplasm; Fem | 2016 |
Slower early response to treatment and distinct expression profile of childhood high hyperdiploid acute lymphoblastic leukaemia with DNA index < 1.16.
Topics: Antineoplastic Agents, Hormonal; Child; Child, Preschool; Chromosome Aberrations; DNA, Neoplasm; Fem | 2016 |
The Impact of Socioeconomic Factors on the Outcome of Childhood Acute Lymphoblastic Leukemia (ALL) Treatment in a Low/Middle Income Country (LMIC).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 2016 |
The Impact of Socioeconomic Factors on the Outcome of Childhood Acute Lymphoblastic Leukemia (ALL) Treatment in a Low/Middle Income Country (LMIC).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 2016 |
The Impact of Socioeconomic Factors on the Outcome of Childhood Acute Lymphoblastic Leukemia (ALL) Treatment in a Low/Middle Income Country (LMIC).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 2016 |
Development-associated immunophenotypes reveal the heterogeneous and individualized early responses of adult B-acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Anthracyclines; Antigens, CD19; Antigens, CD20; Antigens, CD34; Antineoplastic Co | 2016 |
Development-associated immunophenotypes reveal the heterogeneous and individualized early responses of adult B-acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Anthracyclines; Antigens, CD19; Antigens, CD20; Antigens, CD34; Antineoplastic Co | 2016 |
Development-associated immunophenotypes reveal the heterogeneous and individualized early responses of adult B-acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Anthracyclines; Antigens, CD19; Antigens, CD20; Antigens, CD34; Antineoplastic Co | 2016 |
The treatment of childhood acute lymphoblastic leukemia in Guatemala: Biologic features, treatment hurdles, and results.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 2017 |
The treatment of childhood acute lymphoblastic leukemia in Guatemala: Biologic features, treatment hurdles, and results.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 2017 |
The treatment of childhood acute lymphoblastic leukemia in Guatemala: Biologic features, treatment hurdles, and results.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 2017 |
Lymphoblastic Lymphoma Presenting as Bilateral Ovarian Mass in an Adolescent Girl.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biopsy; Daunorubici | 2017 |
Lymphoblastic Lymphoma Presenting as Bilateral Ovarian Mass in an Adolescent Girl.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biopsy; Daunorubici | 2017 |
Lymphoblastic Lymphoma Presenting as Bilateral Ovarian Mass in an Adolescent Girl.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biopsy; Daunorubici | 2017 |
Hyper-CVAD Compared With BFM-like Chemotherapy for the Treatment of Adult Acute Lymphoblastic Leukemia. A Retrospective Single-Center Analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophospham | 2017 |
Hyper-CVAD Compared With BFM-like Chemotherapy for the Treatment of Adult Acute Lymphoblastic Leukemia. A Retrospective Single-Center Analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophospham | 2017 |
Hyper-CVAD Compared With BFM-like Chemotherapy for the Treatment of Adult Acute Lymphoblastic Leukemia. A Retrospective Single-Center Analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophospham | 2017 |
Survival Outcome of Filipino Children With Acute Lymphoblastic Leukemia Treated With Modified Berlin-Frankfurt-Muenster/Hong Kong Acute Lymphoblastic Leukemia (BFM95/HKALL97) Protocol in a Tertiary General Hospital From January 2005 to December 2009: A Re
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2017 |
Survival Outcome of Filipino Children With Acute Lymphoblastic Leukemia Treated With Modified Berlin-Frankfurt-Muenster/Hong Kong Acute Lymphoblastic Leukemia (BFM95/HKALL97) Protocol in a Tertiary General Hospital From January 2005 to December 2009: A Re
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2017 |
Survival Outcome of Filipino Children With Acute Lymphoblastic Leukemia Treated With Modified Berlin-Frankfurt-Muenster/Hong Kong Acute Lymphoblastic Leukemia (BFM95/HKALL97) Protocol in a Tertiary General Hospital From January 2005 to December 2009: A Re
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2017 |
Unilateral facial nerve palsy as an early presenting symptom of relapse in a paediatric patient with acute lymphoblastic leukaemia.
Topics: Acyclovir; Adolescent; Antiviral Agents; Bell Palsy; Central Nervous System Neoplasms; Facial Nerve; | 2017 |
Unilateral facial nerve palsy as an early presenting symptom of relapse in a paediatric patient with acute lymphoblastic leukaemia.
Topics: Acyclovir; Adolescent; Antiviral Agents; Bell Palsy; Central Nervous System Neoplasms; Facial Nerve; | 2017 |
Unilateral facial nerve palsy as an early presenting symptom of relapse in a paediatric patient with acute lymphoblastic leukaemia.
Topics: Acyclovir; Adolescent; Antiviral Agents; Bell Palsy; Central Nervous System Neoplasms; Facial Nerve; | 2017 |
Initial leukemic gene expression profiles of patients with poor in vivo prednisone response are similar to those of blasts persisting under prednisone treatment in childhood acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blast Crisis; Child; Daunorubicin; Gen | 2008 |
Initial leukemic gene expression profiles of patients with poor in vivo prednisone response are similar to those of blasts persisting under prednisone treatment in childhood acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blast Crisis; Child; Daunorubicin; Gen | 2008 |
Initial leukemic gene expression profiles of patients with poor in vivo prednisone response are similar to those of blasts persisting under prednisone treatment in childhood acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blast Crisis; Child; Daunorubicin; Gen | 2008 |
Treatment of pediatric acute lymphoblastic leukemia.
Topics: Antineoplastic Agents; Blast Crisis; Child; Child, Preschool; Humans; Injections, Spinal; Meningeal | 2008 |
Treatment of pediatric acute lymphoblastic leukemia.
Topics: Antineoplastic Agents; Blast Crisis; Child; Child, Preschool; Humans; Injections, Spinal; Meningeal | 2008 |
Treatment of pediatric acute lymphoblastic leukemia.
Topics: Antineoplastic Agents; Blast Crisis; Child; Child, Preschool; Humans; Injections, Spinal; Meningeal | 2008 |
Clinical problem-solving. Fool's Gold.
Topics: Adult; Bundle-Branch Block; Dyspnea; Echocardiography; Electrocardiography; False Negative Reactions | 2008 |
Clinical problem-solving. Fool's Gold.
Topics: Adult; Bundle-Branch Block; Dyspnea; Echocardiography; Electrocardiography; False Negative Reactions | 2008 |
Clinical problem-solving. Fool's Gold.
Topics: Adult; Bundle-Branch Block; Dyspnea; Echocardiography; Electrocardiography; False Negative Reactions | 2008 |
Role of the erythropoietin receptor in ETV6/RUNX1-positive acute lymphoblastic leukemia.
Topics: Animals; Antineoplastic Agents, Hormonal; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proli | 2008 |
Role of the erythropoietin receptor in ETV6/RUNX1-positive acute lymphoblastic leukemia.
Topics: Animals; Antineoplastic Agents, Hormonal; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proli | 2008 |
Role of the erythropoietin receptor in ETV6/RUNX1-positive acute lymphoblastic leukemia.
Topics: Animals; Antineoplastic Agents, Hormonal; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proli | 2008 |
Kinetics of the in vivo expression of glucocorticoid receptor splice variants during prednisone treatment in childhood acute lymphoblastic leukaemia.
Topics: Antineoplastic Agents, Hormonal; Case-Control Studies; Child; Child, Preschool; Female; Gene Express | 2009 |
Kinetics of the in vivo expression of glucocorticoid receptor splice variants during prednisone treatment in childhood acute lymphoblastic leukaemia.
Topics: Antineoplastic Agents, Hormonal; Case-Control Studies; Child; Child, Preschool; Female; Gene Express | 2009 |
Kinetics of the in vivo expression of glucocorticoid receptor splice variants during prednisone treatment in childhood acute lymphoblastic leukaemia.
Topics: Antineoplastic Agents, Hormonal; Case-Control Studies; Child; Child, Preschool; Female; Gene Express | 2009 |
Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; B-Lymphocytes; Child; Child, Preschool | 2009 |
Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; B-Lymphocytes; Child; Child, Preschool | 2009 |
Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; B-Lymphocytes; Child; Child, Preschool | 2009 |
Changes in bone mineral density during therapy in childhood acute lymphoblastic leukemia.
Topics: Absorptiometry, Photon; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineop | 2009 |
Changes in bone mineral density during therapy in childhood acute lymphoblastic leukemia.
Topics: Absorptiometry, Photon; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineop | 2009 |
Changes in bone mineral density during therapy in childhood acute lymphoblastic leukemia.
Topics: Absorptiometry, Photon; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineop | 2009 |
Prevalence of transient hyperglycemia during induction chemotherapy for pediatric acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Body Mass Index; Child; Ch | 2009 |
Prevalence of transient hyperglycemia during induction chemotherapy for pediatric acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Body Mass Index; Child; Ch | 2009 |
Prevalence of transient hyperglycemia during induction chemotherapy for pediatric acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Body Mass Index; Child; Ch | 2009 |
Additional chromosomal abnormalities and their prognostic significance in adult Philadelphia-positive acute lymphoblastic leukemia: with or without imatinib in chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Benzamides; Chromos | 2009 |
Additional chromosomal abnormalities and their prognostic significance in adult Philadelphia-positive acute lymphoblastic leukemia: with or without imatinib in chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Benzamides; Chromos | 2009 |
Additional chromosomal abnormalities and their prognostic significance in adult Philadelphia-positive acute lymphoblastic leukemia: with or without imatinib in chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Benzamides; Chromos | 2009 |
Hyperglycemia during induction therapy is associated with poorer survival in children with acute lymphocytic leukemia.
Topics: Antineoplastic Agents; Asparaginase; Blood Glucose; Child; Child, Preschool; Daunorubicin; Dexametha | 2009 |
Hyperglycemia during induction therapy is associated with poorer survival in children with acute lymphocytic leukemia.
Topics: Antineoplastic Agents; Asparaginase; Blood Glucose; Child; Child, Preschool; Daunorubicin; Dexametha | 2009 |
Hyperglycemia during induction therapy is associated with poorer survival in children with acute lymphocytic leukemia.
Topics: Antineoplastic Agents; Asparaginase; Blood Glucose; Child; Child, Preschool; Daunorubicin; Dexametha | 2009 |
Good early treatment response in childhood acute lymphoblastic leukemia is associated with Bax nuclear accumulation and PARP cleavage.
Topics: Adolescent; bcl-2-Associated X Protein; Cell Nucleus; Child; Child, Preschool; Female; Fluorescein-5 | 2009 |
Good early treatment response in childhood acute lymphoblastic leukemia is associated with Bax nuclear accumulation and PARP cleavage.
Topics: Adolescent; bcl-2-Associated X Protein; Cell Nucleus; Child; Child, Preschool; Female; Fluorescein-5 | 2009 |
Good early treatment response in childhood acute lymphoblastic leukemia is associated with Bax nuclear accumulation and PARP cleavage.
Topics: Adolescent; bcl-2-Associated X Protein; Cell Nucleus; Child; Child, Preschool; Female; Fluorescein-5 | 2009 |
Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Münster protocols.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Brain Neoplasms; Child; Child, Prescho | 2009 |
Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Münster protocols.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Brain Neoplasms; Child; Child, Prescho | 2009 |
Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Münster protocols.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Brain Neoplasms; Child; Child, Prescho | 2009 |
A comparison of neurocognitive functioning in children previously randomized to dexamethasone or prednisone in the treatment of childhood acute lymphoblastic leukemia.
Topics: Antineoplastic Agents, Hormonal; Child; Child, Preschool; Cognition; Cross-Sectional Studies; Dexame | 2009 |
A comparison of neurocognitive functioning in children previously randomized to dexamethasone or prednisone in the treatment of childhood acute lymphoblastic leukemia.
Topics: Antineoplastic Agents, Hormonal; Child; Child, Preschool; Cognition; Cross-Sectional Studies; Dexame | 2009 |
A comparison of neurocognitive functioning in children previously randomized to dexamethasone or prednisone in the treatment of childhood acute lymphoblastic leukemia.
Topics: Antineoplastic Agents, Hormonal; Child; Child, Preschool; Cognition; Cross-Sectional Studies; Dexame | 2009 |
[Prophylaxis and treatment of modified BFM-90 regimen for lymphoblastic lymphoma in children and adolescents accompanied with infection].
Topics: Adolescent; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols | 2009 |
[Prophylaxis and treatment of modified BFM-90 regimen for lymphoblastic lymphoma in children and adolescents accompanied with infection].
Topics: Adolescent; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols | 2009 |
[Prophylaxis and treatment of modified BFM-90 regimen for lymphoblastic lymphoma in children and adolescents accompanied with infection].
Topics: Adolescent; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols | 2009 |
Weight patterns in children with higher risk ALL: A report from the Children's Oncology Group (COG) for CCG 1961.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Body Mass Ind | 2009 |
Weight patterns in children with higher risk ALL: A report from the Children's Oncology Group (COG) for CCG 1961.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Body Mass Ind | 2009 |
Weight patterns in children with higher risk ALL: A report from the Children's Oncology Group (COG) for CCG 1961.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Body Mass Ind | 2009 |
Philadelphia-negative acute lymphoblastic leukemia in a chronic myeloid leukemia patient receiving dasatinib.
Topics: Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Dasatinib; Hematopoietic Stem Cell Transplant | 2010 |
Philadelphia-negative acute lymphoblastic leukemia in a chronic myeloid leukemia patient receiving dasatinib.
Topics: Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Dasatinib; Hematopoietic Stem Cell Transplant | 2010 |
Philadelphia-negative acute lymphoblastic leukemia in a chronic myeloid leukemia patient receiving dasatinib.
Topics: Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Dasatinib; Hematopoietic Stem Cell Transplant | 2010 |
Hyperammonemic encephalopathy after induction chemotherapy for acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Daunorubicin; Humans; Hyperammonemia; | 2009 |
Hyperammonemic encephalopathy after induction chemotherapy for acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Daunorubicin; Humans; Hyperammonemia; | 2009 |
Hyperammonemic encephalopathy after induction chemotherapy for acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Daunorubicin; Humans; Hyperammonemia; | 2009 |
Methylene tetrahydrofolate reductase gene polymorphism in Egyptian children with acute lymphoblastic leukemia.
Topics: Alleles; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Chemical and Drug Induced Liv | 2010 |
Methylene tetrahydrofolate reductase gene polymorphism in Egyptian children with acute lymphoblastic leukemia.
Topics: Alleles; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Chemical and Drug Induced Liv | 2010 |
Methylene tetrahydrofolate reductase gene polymorphism in Egyptian children with acute lymphoblastic leukemia.
Topics: Alleles; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Chemical and Drug Induced Liv | 2010 |
[Comparison of the efficiency of CHOP-based regimen with or without high dose consolidation treatment combined with hematopoietic stem cell transplantation in 63 lymphoblastic lymphoma patients].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Child, | 2009 |
[Comparison of the efficiency of CHOP-based regimen with or without high dose consolidation treatment combined with hematopoietic stem cell transplantation in 63 lymphoblastic lymphoma patients].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Child, | 2009 |
[Comparison of the efficiency of CHOP-based regimen with or without high dose consolidation treatment combined with hematopoietic stem cell transplantation in 63 lymphoblastic lymphoma patients].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Child, | 2009 |
Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia.
Topics: Cell Survival; Child; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulati | 2010 |
Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia.
Topics: Cell Survival; Child; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulati | 2010 |
Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia.
Topics: Cell Survival; Child; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulati | 2010 |
Concurrent treatment of steroid-related mood and psychotic symptoms with risperidone.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents, Hormonal; Antipsychotic Agents; Child; Dexa | 2010 |
Concurrent treatment of steroid-related mood and psychotic symptoms with risperidone.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents, Hormonal; Antipsychotic Agents; Child; Dexa | 2010 |
Concurrent treatment of steroid-related mood and psychotic symptoms with risperidone.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents, Hormonal; Antipsychotic Agents; Child; Dexa | 2010 |
Prospective study of hemostatic alterations in children with acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Antithrombins; Asparaginase; Case-Contro | 2010 |
Prospective study of hemostatic alterations in children with acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Antithrombins; Asparaginase; Case-Contro | 2010 |
Prospective study of hemostatic alterations in children with acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Antithrombins; Asparaginase; Case-Contro | 2010 |
Central nervous system complications during treatment of acute lymphoblastic leukemia in a single pediatric institution.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Central Nervous System; Ce | 2010 |
Central nervous system complications during treatment of acute lymphoblastic leukemia in a single pediatric institution.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Central Nervous System; Ce | 2010 |
Central nervous system complications during treatment of acute lymphoblastic leukemia in a single pediatric institution.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Central Nervous System; Ce | 2010 |
Schistocytic hemolytic anemia owing to central venous catheter in a child with acute lymphoblastic leukemia.
Topics: Anemia, Hemolytic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Catheterization, Ce | 2010 |
Schistocytic hemolytic anemia owing to central venous catheter in a child with acute lymphoblastic leukemia.
Topics: Anemia, Hemolytic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Catheterization, Ce | 2010 |
Schistocytic hemolytic anemia owing to central venous catheter in a child with acute lymphoblastic leukemia.
Topics: Anemia, Hemolytic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Catheterization, Ce | 2010 |
Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Membrane; Cells, Cultured; Coculture Techniq | 2011 |
Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Membrane; Cells, Cultured; Coculture Techniq | 2011 |
Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Membrane; Cells, Cultured; Coculture Techniq | 2011 |
Puffiness of the eyelids and lips with multiple subcutaneous masses in 2-month-old infant.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Common Cold; Daunorubicin; Eyelids; Fe | 2010 |
Puffiness of the eyelids and lips with multiple subcutaneous masses in 2-month-old infant.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Common Cold; Daunorubicin; Eyelids; Fe | 2010 |
Puffiness of the eyelids and lips with multiple subcutaneous masses in 2-month-old infant.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Common Cold; Daunorubicin; Eyelids; Fe | 2010 |
Simultaneous assessment of p53 and MDM2 expression in leukemic cells in response to initial prednisone therapy in children with acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Child; Child, Preschool; Female; Hum | 2010 |
Simultaneous assessment of p53 and MDM2 expression in leukemic cells in response to initial prednisone therapy in children with acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Child; Child, Preschool; Female; Hum | 2010 |
Simultaneous assessment of p53 and MDM2 expression in leukemic cells in response to initial prednisone therapy in children with acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Child; Child, Preschool; Female; Hum | 2010 |
Second neoplasm in children treated in EORTC 58881 trial for acute lymphoblastic malignancies: low incidence of CNS tumours.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Central Nervous System Neo | 2011 |
Second neoplasm in children treated in EORTC 58881 trial for acute lymphoblastic malignancies: low incidence of CNS tumours.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Central Nervous System Neo | 2011 |
Second neoplasm in children treated in EORTC 58881 trial for acute lymphoblastic malignancies: low incidence of CNS tumours.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Central Nervous System Neo | 2011 |
Significant 25-hydroxyvitamin D deficiency in child and adolescent survivors of acute lymphoblastic leukemia: treatment with chemotherapy compared with allogeneic stem cell transplant.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; | 2011 |
Significant 25-hydroxyvitamin D deficiency in child and adolescent survivors of acute lymphoblastic leukemia: treatment with chemotherapy compared with allogeneic stem cell transplant.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; | 2011 |
Significant 25-hydroxyvitamin D deficiency in child and adolescent survivors of acute lymphoblastic leukemia: treatment with chemotherapy compared with allogeneic stem cell transplant.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; | 2011 |
The influence of Bcl-2 and myeloid antigen expression on response to therapy in childhood acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers, Tumor; CD13 Antigens; Chil | 2011 |
The influence of Bcl-2 and myeloid antigen expression on response to therapy in childhood acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers, Tumor; CD13 Antigens; Chil | 2011 |
The influence of Bcl-2 and myeloid antigen expression on response to therapy in childhood acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers, Tumor; CD13 Antigens; Chil | 2011 |
Prognostic impact of t(1;19)/ TCF3-PBX1 in childhood acute lymphoblastic leukemia in the context of Berlin-Frankfurt-Münster-based protocols.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Basic Helix-Loop-Helix Tra | 2011 |
Prognostic impact of t(1;19)/ TCF3-PBX1 in childhood acute lymphoblastic leukemia in the context of Berlin-Frankfurt-Münster-based protocols.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Basic Helix-Loop-Helix Tra | 2011 |
Prognostic impact of t(1;19)/ TCF3-PBX1 in childhood acute lymphoblastic leukemia in the context of Berlin-Frankfurt-Münster-based protocols.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Basic Helix-Loop-Helix Tra | 2011 |
Neurobehavioral side effects of corticosteroids during active treatment for acute lymphoblastic leukemia in children are age-dependent: report from Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Age Factors; Behavior; Child; Child, Preschool; Data Col | 2011 |
Neurobehavioral side effects of corticosteroids during active treatment for acute lymphoblastic leukemia in children are age-dependent: report from Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Age Factors; Behavior; Child; Child, Preschool; Data Col | 2011 |
Neurobehavioral side effects of corticosteroids during active treatment for acute lymphoblastic leukemia in children are age-dependent: report from Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Age Factors; Behavior; Child; Child, Preschool; Data Col | 2011 |
Activation of NF-ĸB in leukemic cells in response to initial prednisone therapy in children with acute lymphoblastic leukaemia: relation to other prognostic factors.
Topics: Adolescent; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Child; Child, Preschool; Female; Hum | 2011 |
Activation of NF-ĸB in leukemic cells in response to initial prednisone therapy in children with acute lymphoblastic leukaemia: relation to other prognostic factors.
Topics: Adolescent; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Child; Child, Preschool; Female; Hum | 2011 |
Activation of NF-ĸB in leukemic cells in response to initial prednisone therapy in children with acute lymphoblastic leukaemia: relation to other prognostic factors.
Topics: Adolescent; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Child; Child, Preschool; Female; Hum | 2011 |
Bone mineral density in adult survivors of childhood acute leukemia: impact of hematopoietic stem cell transplantation and other treatment modalities.
Topics: Absorptiometry, Photon; Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; B | 2011 |
Bone mineral density in adult survivors of childhood acute leukemia: impact of hematopoietic stem cell transplantation and other treatment modalities.
Topics: Absorptiometry, Photon; Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; B | 2011 |
Bone mineral density in adult survivors of childhood acute leukemia: impact of hematopoietic stem cell transplantation and other treatment modalities.
Topics: Absorptiometry, Photon; Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; B | 2011 |
Numb chin syndrome in acute lymphoblastic leukemia.
Topics: Antineoplastic Agents; Child; Chin; Cytarabine; Female; Humans; Hypesthesia; Magnetic Resonance Imag | 2011 |
Numb chin syndrome in acute lymphoblastic leukemia.
Topics: Antineoplastic Agents; Child; Chin; Cytarabine; Female; Humans; Hypesthesia; Magnetic Resonance Imag | 2011 |
Numb chin syndrome in acute lymphoblastic leukemia.
Topics: Antineoplastic Agents; Child; Chin; Cytarabine; Female; Humans; Hypesthesia; Magnetic Resonance Imag | 2011 |
Homozygosity for the rs9939609T allele of the FTO gene may have protective effect on becoming overweight in survivors of childhood acute lymphoblastic leukaemia.
Topics: Adolescent; Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Antineoplastic Combined Chemotherapy Prot | 2011 |
Homozygosity for the rs9939609T allele of the FTO gene may have protective effect on becoming overweight in survivors of childhood acute lymphoblastic leukaemia.
Topics: Adolescent; Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Antineoplastic Combined Chemotherapy Prot | 2011 |
Homozygosity for the rs9939609T allele of the FTO gene may have protective effect on becoming overweight in survivors of childhood acute lymphoblastic leukaemia.
Topics: Adolescent; Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Antineoplastic Combined Chemotherapy Prot | 2011 |
Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials.
Topics: Adolescent; Adult; Antibodies; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 2011 |
Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials.
Topics: Adolescent; Adult; Antibodies; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 2011 |
Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials.
Topics: Adolescent; Adult; Antibodies; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 2011 |
Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials.
Topics: Adolescent; Adult; Antibodies; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 2011 |
Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials.
Topics: Adolescent; Adult; Antibodies; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 2011 |
Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials.
Topics: Adolescent; Adult; Antibodies; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 2011 |
Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials.
Topics: Adolescent; Adult; Antibodies; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 2011 |
Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials.
Topics: Adolescent; Adult; Antibodies; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 2011 |
Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials.
Topics: Adolescent; Adult; Antibodies; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 2011 |
Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials.
Topics: Adolescent; Adult; Antibodies; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 2011 |
Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials.
Topics: Adolescent; Adult; Antibodies; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 2011 |
Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials.
Topics: Adolescent; Adult; Antibodies; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 2011 |
Acute lymphoblastic leukemia in a 10-year-old boy with cystic fibrosis - improvement of pulmonary function during chemotherapy in spite of intermittent Pseudomonas aeruginosa colonisation.
Topics: Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Comorbidity; Cystic Fi | 2011 |
Acute lymphoblastic leukemia in a 10-year-old boy with cystic fibrosis - improvement of pulmonary function during chemotherapy in spite of intermittent Pseudomonas aeruginosa colonisation.
Topics: Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Comorbidity; Cystic Fi | 2011 |
Acute lymphoblastic leukemia in a 10-year-old boy with cystic fibrosis - improvement of pulmonary function during chemotherapy in spite of intermittent Pseudomonas aeruginosa colonisation.
Topics: Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Comorbidity; Cystic Fi | 2011 |
Medication induced diabetes during induction in pediatric acute lymphoblastic leukemia: prevalence, risk factors and characteristics.
Topics: Adolescent; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Asparagine; Child; C | 2012 |
Medication induced diabetes during induction in pediatric acute lymphoblastic leukemia: prevalence, risk factors and characteristics.
Topics: Adolescent; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Asparagine; Child; C | 2012 |
Medication induced diabetes during induction in pediatric acute lymphoblastic leukemia: prevalence, risk factors and characteristics.
Topics: Adolescent; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Asparagine; Child; C | 2012 |
Posterior reversible encephalopathy syndrome in an adult patient with acute lymphoblastic leukemia after remission induction chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; Daunorubicin; | 2012 |
Posterior reversible encephalopathy syndrome in an adult patient with acute lymphoblastic leukemia after remission induction chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; Daunorubicin; | 2012 |
Posterior reversible encephalopathy syndrome in an adult patient with acute lymphoblastic leukemia after remission induction chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; Daunorubicin; | 2012 |
Elevated S100A8/S100A9 expression causes glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia.
Topics: Apoptosis; Blotting, Western; Calgranulin A; Calgranulin B; Drug Resistance, Neoplasm; Flow Cytometr | 2012 |
Elevated S100A8/S100A9 expression causes glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia.
Topics: Apoptosis; Blotting, Western; Calgranulin A; Calgranulin B; Drug Resistance, Neoplasm; Flow Cytometr | 2012 |
Elevated S100A8/S100A9 expression causes glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia.
Topics: Apoptosis; Blotting, Western; Calgranulin A; Calgranulin B; Drug Resistance, Neoplasm; Flow Cytometr | 2012 |
[Blastic plasmacytoid dendritic cell neoplasm: report of a case].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CD4 Antigens; CD56 Antigen; Cyclophosphamide; | 2011 |
[Blastic plasmacytoid dendritic cell neoplasm: report of a case].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CD4 Antigens; CD56 Antigen; Cyclophosphamide; | 2011 |
[Blastic plasmacytoid dendritic cell neoplasm: report of a case].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CD4 Antigens; CD56 Antigen; Cyclophosphamide; | 2011 |
Orbital plasmablastic lymphoma with remission following chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Fil | 2011 |
Orbital plasmablastic lymphoma with remission following chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Fil | 2011 |
Orbital plasmablastic lymphoma with remission following chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Fil | 2011 |
Management of hypertriglyceridemia in children with acute lymphoblastic leukemia under persistent therapy with glucocorticoids and L-asparaginase during induction chemotherapy.
Topics: Antineoplastic Agents; Asparaginase; Child; Female; Glucocorticoids; Humans; Hypertriglyceridemia; M | 2012 |
Management of hypertriglyceridemia in children with acute lymphoblastic leukemia under persistent therapy with glucocorticoids and L-asparaginase during induction chemotherapy.
Topics: Antineoplastic Agents; Asparaginase; Child; Female; Glucocorticoids; Humans; Hypertriglyceridemia; M | 2012 |
Management of hypertriglyceridemia in children with acute lymphoblastic leukemia under persistent therapy with glucocorticoids and L-asparaginase during induction chemotherapy.
Topics: Antineoplastic Agents; Asparaginase; Child; Female; Glucocorticoids; Humans; Hypertriglyceridemia; M | 2012 |
Clinical features, early treatment responses, and outcomes of pediatric acute lymphoblastic leukemia in China with or without specific fusion transcripts: a single institutional study of 1,004 patients.
Topics: Antineoplastic Agents, Hormonal; Child; Child, Preschool; China; Cohort Studies; Cytogenetic Analysi | 2012 |
Clinical features, early treatment responses, and outcomes of pediatric acute lymphoblastic leukemia in China with or without specific fusion transcripts: a single institutional study of 1,004 patients.
Topics: Antineoplastic Agents, Hormonal; Child; Child, Preschool; China; Cohort Studies; Cytogenetic Analysi | 2012 |
Clinical features, early treatment responses, and outcomes of pediatric acute lymphoblastic leukemia in China with or without specific fusion transcripts: a single institutional study of 1,004 patients.
Topics: Antineoplastic Agents, Hormonal; Child; Child, Preschool; China; Cohort Studies; Cytogenetic Analysi | 2012 |
Glucocorticoid withdrawal - heterozygous carriers of congenital adrenal hyperplasia at risk?
Topics: Adrenal Hyperplasia, Congenital; Adrenocorticotropic Hormone; Adrenogenital Syndrome; Antineoplastic | 2012 |
Glucocorticoid withdrawal - heterozygous carriers of congenital adrenal hyperplasia at risk?
Topics: Adrenal Hyperplasia, Congenital; Adrenocorticotropic Hormone; Adrenogenital Syndrome; Antineoplastic | 2012 |
Glucocorticoid withdrawal - heterozygous carriers of congenital adrenal hyperplasia at risk?
Topics: Adrenal Hyperplasia, Congenital; Adrenocorticotropic Hormone; Adrenogenital Syndrome; Antineoplastic | 2012 |
Acute lymphoblastic leukemia presenting as bilateral serous macular detachment and lacrimal gland enlargement.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Coloring Agents; Daunorubicin; Eye Neopl | 2012 |
Acute lymphoblastic leukemia presenting as bilateral serous macular detachment and lacrimal gland enlargement.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Coloring Agents; Daunorubicin; Eye Neopl | 2012 |
Acute lymphoblastic leukemia presenting as bilateral serous macular detachment and lacrimal gland enlargement.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Coloring Agents; Daunorubicin; Eye Neopl | 2012 |
The evaluation of protein Z levels of children with acute lymphoblastic leukaemia during induction therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blood Proteins; Case-Control Studies; | 2013 |
The evaluation of protein Z levels of children with acute lymphoblastic leukaemia during induction therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blood Proteins; Case-Control Studies; | 2013 |
The evaluation of protein Z levels of children with acute lymphoblastic leukaemia during induction therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blood Proteins; Case-Control Studies; | 2013 |
Symptomatic hypoglycemia in children receiving oral purine analogues for treatment of childhood acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blood Glucose; Child, Preschool; Cyclo | 2002 |
Symptomatic hypoglycemia in children receiving oral purine analogues for treatment of childhood acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blood Glucose; Child, Preschool; Cyclo | 2002 |
Symptomatic hypoglycemia in children receiving oral purine analogues for treatment of childhood acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blood Glucose; Child, Preschool; Cyclo | 2002 |
Variant translocations of 11q23 in infant acute lymphoblastic leukemia (ALL): do outcomes differ from t(4;11)?
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Chromosomes, Human, Pair 11; Chromosom | 2002 |
Variant translocations of 11q23 in infant acute lymphoblastic leukemia (ALL): do outcomes differ from t(4;11)?
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Chromosomes, Human, Pair 11; Chromosom | 2002 |
Variant translocations of 11q23 in infant acute lymphoblastic leukemia (ALL): do outcomes differ from t(4;11)?
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Chromosomes, Human, Pair 11; Chromosom | 2002 |
Increased factor VIII activity and dural sinus thrombosis.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Cyclophosphamide; C | 2002 |
Increased factor VIII activity and dural sinus thrombosis.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Cyclophosphamide; C | 2002 |
Increased factor VIII activity and dural sinus thrombosis.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Cyclophosphamide; C | 2002 |
Association of initial response to prednisone treatment in childhood acute lymphoblastic leukaemia and polymorphisms within the tumour necrosis factor and the interleukin-10 genes.
Topics: Adolescent; Alleles; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Child; Ch | 2002 |
Association of initial response to prednisone treatment in childhood acute lymphoblastic leukaemia and polymorphisms within the tumour necrosis factor and the interleukin-10 genes.
Topics: Adolescent; Alleles; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Child; Ch | 2002 |
Association of initial response to prednisone treatment in childhood acute lymphoblastic leukaemia and polymorphisms within the tumour necrosis factor and the interleukin-10 genes.
Topics: Adolescent; Alleles; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Child; Ch | 2002 |
Tuberculosis and immune thrombocytopenia.
Topics: Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Antitubercular Agents; Aspa | 2002 |
Tuberculosis and immune thrombocytopenia.
Topics: Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Antitubercular Agents; Aspa | 2002 |
Tuberculosis and immune thrombocytopenia.
Topics: Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Antitubercular Agents; Aspa | 2002 |
The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease-Free | 2002 |
The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease-Free | 2002 |
The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease-Free | 2002 |
The role of posttransplantation maintenance chemotherapy in improving the outcome of autotransplantation in adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Diseas | 2002 |
The role of posttransplantation maintenance chemotherapy in improving the outcome of autotransplantation in adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Diseas | 2002 |
The role of posttransplantation maintenance chemotherapy in improving the outcome of autotransplantation in adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Diseas | 2002 |
Improvement over time in outcome for children with acute lymphoblastic leukemia in second remission given hematopoietic stem cell transplantation from unrelated donors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2002 |
Improvement over time in outcome for children with acute lymphoblastic leukemia in second remission given hematopoietic stem cell transplantation from unrelated donors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2002 |
Improvement over time in outcome for children with acute lymphoblastic leukemia in second remission given hematopoietic stem cell transplantation from unrelated donors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2002 |
Determination of the in vivo effects of prednisone on Bcl-2 family protein expression in childhood acute lymphoblastic leukemia.
Topics: Adolescent; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Child; Child, Preschool; Female; H | 2003 |
Determination of the in vivo effects of prednisone on Bcl-2 family protein expression in childhood acute lymphoblastic leukemia.
Topics: Adolescent; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Child; Child, Preschool; Female; H | 2003 |
Determination of the in vivo effects of prednisone on Bcl-2 family protein expression in childhood acute lymphoblastic leukemia.
Topics: Adolescent; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Child; Child, Preschool; Female; H | 2003 |
Dental abnormalities in children after chemotherapy treatment for acute lymphoid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Combined Moda | 2003 |
Dental abnormalities in children after chemotherapy treatment for acute lymphoid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Combined Moda | 2003 |
Dental abnormalities in children after chemotherapy treatment for acute lymphoid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Combined Moda | 2003 |
[Primary renal non-Hodgkin lymphoma].
Topics: Abdominal Pain; Acute Kidney Injury; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bio | 2002 |
[Primary renal non-Hodgkin lymphoma].
Topics: Abdominal Pain; Acute Kidney Injury; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bio | 2002 |
[Primary renal non-Hodgkin lymphoma].
Topics: Abdominal Pain; Acute Kidney Injury; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bio | 2002 |
Successful reintroduction of methotrexate after acute pneumonitis in a patient with acute lymphoblastic leukemia.
Topics: Acute Disease; Female; Humans; Mercaptopurine; Methotrexate; Middle Aged; Pneumonia; Precursor Cell | 2003 |
Successful reintroduction of methotrexate after acute pneumonitis in a patient with acute lymphoblastic leukemia.
Topics: Acute Disease; Female; Humans; Mercaptopurine; Methotrexate; Middle Aged; Pneumonia; Precursor Cell | 2003 |
Successful reintroduction of methotrexate after acute pneumonitis in a patient with acute lymphoblastic leukemia.
Topics: Acute Disease; Female; Humans; Mercaptopurine; Methotrexate; Middle Aged; Pneumonia; Precursor Cell | 2003 |
Induction of long-term remission of a relapsed childhood B-acute lymphoblastic leukemia with rituximab chimeric anti-CD20 monoclonal antibody and autologous stem cell transplantation.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigens, Neoplasm; | 2003 |
Induction of long-term remission of a relapsed childhood B-acute lymphoblastic leukemia with rituximab chimeric anti-CD20 monoclonal antibody and autologous stem cell transplantation.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigens, Neoplasm; | 2003 |
Induction of long-term remission of a relapsed childhood B-acute lymphoblastic leukemia with rituximab chimeric anti-CD20 monoclonal antibody and autologous stem cell transplantation.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigens, Neoplasm; | 2003 |
Imatinib Mesylate (Gleevec) is a useful agent in the salvage treatment of adults with relapsed/refractory Philadelphia positive acute leukemias.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Benzamides; Cytarabine; D | 2003 |
Imatinib Mesylate (Gleevec) is a useful agent in the salvage treatment of adults with relapsed/refractory Philadelphia positive acute leukemias.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Benzamides; Cytarabine; D | 2003 |
Imatinib Mesylate (Gleevec) is a useful agent in the salvage treatment of adults with relapsed/refractory Philadelphia positive acute leukemias.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Benzamides; Cytarabine; D | 2003 |
Treatment outcome of adult acute lymphocytic leukemia with VPD(L) regimen: analysis of prognostic factors.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspar | 2003 |
Treatment outcome of adult acute lymphocytic leukemia with VPD(L) regimen: analysis of prognostic factors.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspar | 2003 |
Treatment outcome of adult acute lymphocytic leukemia with VPD(L) regimen: analysis of prognostic factors.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspar | 2003 |
[De novo acute lymphocytic leukemia with t(14;18) complicated by tumor lysis syndrome].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2003 |
[De novo acute lymphocytic leukemia with t(14;18) complicated by tumor lysis syndrome].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2003 |
[De novo acute lymphocytic leukemia with t(14;18) complicated by tumor lysis syndrome].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2003 |
Plasmapheresis as treatment for transient iatrogenic severe hyperlipidemia in a child with leukemia.
Topics: Adolescent; Antineoplastic Agents; Asparaginase; Female; Humans; Hyperlipidemias; Iatrogenic Disease | 2003 |
Plasmapheresis as treatment for transient iatrogenic severe hyperlipidemia in a child with leukemia.
Topics: Adolescent; Antineoplastic Agents; Asparaginase; Female; Humans; Hyperlipidemias; Iatrogenic Disease | 2003 |
Plasmapheresis as treatment for transient iatrogenic severe hyperlipidemia in a child with leukemia.
Topics: Adolescent; Antineoplastic Agents; Asparaginase; Female; Humans; Hyperlipidemias; Iatrogenic Disease | 2003 |
Expression and structural analysis of glucocorticoid receptor isoform gamma in human leukaemia cells using an isoform-specific real-time polymerase chain reaction approach.
Topics: Apoptosis; Base Sequence; Case-Control Studies; Child; Dexamethasone; DNA Primers; Glucocorticoids; | 2003 |
Expression and structural analysis of glucocorticoid receptor isoform gamma in human leukaemia cells using an isoform-specific real-time polymerase chain reaction approach.
Topics: Apoptosis; Base Sequence; Case-Control Studies; Child; Dexamethasone; DNA Primers; Glucocorticoids; | 2003 |
Expression and structural analysis of glucocorticoid receptor isoform gamma in human leukaemia cells using an isoform-specific real-time polymerase chain reaction approach.
Topics: Apoptosis; Base Sequence; Case-Control Studies; Child; Dexamethasone; DNA Primers; Glucocorticoids; | 2003 |
Analysis of single nucleotide polymorphism C3435T of the multidrug resistance gene MDR1 in acute lymphoblastic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Case-Control St | 2003 |
Analysis of single nucleotide polymorphism C3435T of the multidrug resistance gene MDR1 in acute lymphoblastic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Case-Control St | 2003 |
Analysis of single nucleotide polymorphism C3435T of the multidrug resistance gene MDR1 in acute lymphoblastic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Case-Control St | 2003 |
Expression of heat-shock protein 90 in glucocorticoid-sensitive and -resistant childhood acute lymphoblastic leukaemia.
Topics: Adolescent; Blotting, Western; Case-Control Studies; Child; Child, Preschool; Drug Resistance, Neopl | 2003 |
Expression of heat-shock protein 90 in glucocorticoid-sensitive and -resistant childhood acute lymphoblastic leukaemia.
Topics: Adolescent; Blotting, Western; Case-Control Studies; Child; Child, Preschool; Drug Resistance, Neopl | 2003 |
Expression of heat-shock protein 90 in glucocorticoid-sensitive and -resistant childhood acute lymphoblastic leukaemia.
Topics: Adolescent; Blotting, Western; Case-Control Studies; Child; Child, Preschool; Drug Resistance, Neopl | 2003 |
ITP and empiric steroid treatment.
Topics: Antineoplastic Agents, Hormonal; Bone Marrow Examination; Child; Diagnosis, Differential; Diagnostic | 2003 |
ITP and empiric steroid treatment.
Topics: Antineoplastic Agents, Hormonal; Bone Marrow Examination; Child; Diagnosis, Differential; Diagnostic | 2003 |
ITP and empiric steroid treatment.
Topics: Antineoplastic Agents, Hormonal; Bone Marrow Examination; Child; Diagnosis, Differential; Diagnostic | 2003 |
Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia.
Topics: Base Sequence; Child; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; DNA, Neoplasm; Etoposi | 2004 |
Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia.
Topics: Base Sequence; Child; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; DNA, Neoplasm; Etoposi | 2004 |
Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia.
Topics: Base Sequence; Child; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; DNA, Neoplasm; Etoposi | 2004 |
Lymphoblastic lymphoma of childhood and the LSA2-L2 protocol: the 30-year experience at Memorial-Sloan-Kettering Cancer Center.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 2003 |
Lymphoblastic lymphoma of childhood and the LSA2-L2 protocol: the 30-year experience at Memorial-Sloan-Kettering Cancer Center.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 2003 |
Lymphoblastic lymphoma of childhood and the LSA2-L2 protocol: the 30-year experience at Memorial-Sloan-Kettering Cancer Center.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 2003 |
Polyneuritis preceding lymphoblastic lymphoma.
Topics: Humans; Lymphoma; Lymphoma, Non-Hodgkin; Neuritis; Polyradiculopathy; Precursor Cell Lymphoblastic L | 1963 |
Polyneuritis preceding lymphoblastic lymphoma.
Topics: Humans; Lymphoma; Lymphoma, Non-Hodgkin; Neuritis; Polyradiculopathy; Precursor Cell Lymphoblastic L | 1963 |
Polyneuritis preceding lymphoblastic lymphoma.
Topics: Humans; Lymphoma; Lymphoma, Non-Hodgkin; Neuritis; Polyradiculopathy; Precursor Cell Lymphoblastic L | 1963 |
SERUM COMPLEMENT LEVELS IN CHILDREN WITH ACUTE LYMPHOCYTIC LEUKEMIA.
Topics: Adolescent; Antineoplastic Agents; Blood; Child; Complement System Proteins; Cyclophosphamide; Human | 1964 |
SERUM COMPLEMENT LEVELS IN CHILDREN WITH ACUTE LYMPHOCYTIC LEUKEMIA.
Topics: Adolescent; Antineoplastic Agents; Blood; Child; Complement System Proteins; Cyclophosphamide; Human | 1964 |
SERUM COMPLEMENT LEVELS IN CHILDREN WITH ACUTE LYMPHOCYTIC LEUKEMIA.
Topics: Adolescent; Antineoplastic Agents; Blood; Child; Complement System Proteins; Cyclophosphamide; Human | 1964 |
INTRACRANIAL EXTRACEREBRAL HEMORRHAGES IN ACUTE LYMPHOCYTIC LEUKEMIA. A PROBLEM RESULTING FROM THE CHEMOTHERAPEUTIC MODIFICATIONS OF ACUTE LEUKEMIA.
Topics: Adolescent; Child; Hematoma; Hematoma, Epidural, Cranial; Hematoma, Subdural; Humans; Hydrocephalus; | 1964 |
INTRACRANIAL EXTRACEREBRAL HEMORRHAGES IN ACUTE LYMPHOCYTIC LEUKEMIA. A PROBLEM RESULTING FROM THE CHEMOTHERAPEUTIC MODIFICATIONS OF ACUTE LEUKEMIA.
Topics: Adolescent; Child; Hematoma; Hematoma, Epidural, Cranial; Hematoma, Subdural; Humans; Hydrocephalus; | 1964 |
INTRACRANIAL EXTRACEREBRAL HEMORRHAGES IN ACUTE LYMPHOCYTIC LEUKEMIA. A PROBLEM RESULTING FROM THE CHEMOTHERAPEUTIC MODIFICATIONS OF ACUTE LEUKEMIA.
Topics: Adolescent; Child; Hematoma; Hematoma, Epidural, Cranial; Hematoma, Subdural; Humans; Hydrocephalus; | 1964 |
EXTREME HYPERURICEMIA ASSOCIATED WITH PREDNISONE THERAPY FOR ACUTE LYMPHOBLASTIC LEUKEMIA.
Topics: Adolescent; Blood; Blood Urea Nitrogen; Humans; Hyperuricemia; Leukemia; Leukemia, Lymphoid; Lymphoc | 1964 |
EXTREME HYPERURICEMIA ASSOCIATED WITH PREDNISONE THERAPY FOR ACUTE LYMPHOBLASTIC LEUKEMIA.
Topics: Adolescent; Blood; Blood Urea Nitrogen; Humans; Hyperuricemia; Leukemia; Leukemia, Lymphoid; Lymphoc | 1964 |
EXTREME HYPERURICEMIA ASSOCIATED WITH PREDNISONE THERAPY FOR ACUTE LYMPHOBLASTIC LEUKEMIA.
Topics: Adolescent; Blood; Blood Urea Nitrogen; Humans; Hyperuricemia; Leukemia; Leukemia, Lymphoid; Lymphoc | 1964 |
Protein expression of the glucocorticoid receptor in childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Case-Control Studies; Chil | 2003 |
Protein expression of the glucocorticoid receptor in childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Case-Control Studies; Chil | 2003 |
Protein expression of the glucocorticoid receptor in childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Case-Control Studies; Chil | 2003 |
Role of macrophages and stellate cells in the pathogenesis of veno-occlusive disease: an electron microscopic case study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Female; Hepatic Veno-Occlusive | 2003 |
Role of macrophages and stellate cells in the pathogenesis of veno-occlusive disease: an electron microscopic case study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Female; Hepatic Veno-Occlusive | 2003 |
Role of macrophages and stellate cells in the pathogenesis of veno-occlusive disease: an electron microscopic case study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Female; Hepatic Veno-Occlusive | 2003 |
[Iatrogenic hyperlipidemia after l-asparaginase and glucocorticoid treatment in two children with acute lymphoblastic leukemia].
Topics: Adolescent; Anti-Inflammatory Agents; Asparagine; Female; Humans; Hyperlipidemias; Iatrogenic Diseas | 2003 |
[Iatrogenic hyperlipidemia after l-asparaginase and glucocorticoid treatment in two children with acute lymphoblastic leukemia].
Topics: Adolescent; Anti-Inflammatory Agents; Asparagine; Female; Humans; Hyperlipidemias; Iatrogenic Diseas | 2003 |
[Iatrogenic hyperlipidemia after l-asparaginase and glucocorticoid treatment in two children with acute lymphoblastic leukemia].
Topics: Adolescent; Anti-Inflammatory Agents; Asparagine; Female; Humans; Hyperlipidemias; Iatrogenic Diseas | 2003 |
Glucocorticoids induce G1 arrest of lymphoblastic cells through retinoblastoma protein Rb1 dephosphorylation in childhood acute lymphoblastic leukemia in vivo.
Topics: Blast Crisis; Cell Cycle Proteins; Child; Cyclins; Female; G1 Phase; Glucocorticoids; Humans; Male; | 2004 |
Glucocorticoids induce G1 arrest of lymphoblastic cells through retinoblastoma protein Rb1 dephosphorylation in childhood acute lymphoblastic leukemia in vivo.
Topics: Blast Crisis; Cell Cycle Proteins; Child; Cyclins; Female; G1 Phase; Glucocorticoids; Humans; Male; | 2004 |
Glucocorticoids induce G1 arrest of lymphoblastic cells through retinoblastoma protein Rb1 dephosphorylation in childhood acute lymphoblastic leukemia in vivo.
Topics: Blast Crisis; Cell Cycle Proteins; Child; Cyclins; Female; G1 Phase; Glucocorticoids; Humans; Male; | 2004 |
Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Benzamides; Doxorubicin; Drug R | 2004 |
Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Benzamides; Doxorubicin; Drug R | 2004 |
Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Benzamides; Doxorubicin; Drug R | 2004 |
Evolution of BFM trials for childhood ALL.
Topics: Bone Marrow Transplantation; Child; Child, Preschool; Clinical Trials as Topic; Humans; Infant; Neop | 2004 |
Evolution of BFM trials for childhood ALL.
Topics: Bone Marrow Transplantation; Child; Child, Preschool; Clinical Trials as Topic; Humans; Infant; Neop | 2004 |
Evolution of BFM trials for childhood ALL.
Topics: Bone Marrow Transplantation; Child; Child, Preschool; Clinical Trials as Topic; Humans; Infant; Neop | 2004 |
Chemotherapy-induced leukonychia.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Daunorub | 2004 |
Chemotherapy-induced leukonychia.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Daunorub | 2004 |
Chemotherapy-induced leukonychia.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Daunorub | 2004 |
Prolonged fever of unknown origin and hemophagocytosis evolving into acute lymphoblastic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2004 |
Prolonged fever of unknown origin and hemophagocytosis evolving into acute lymphoblastic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2004 |
Prolonged fever of unknown origin and hemophagocytosis evolving into acute lymphoblastic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2004 |
Osteonecrosis: a treatment related toxicity in childhood acute lymphoblastic leukemia (ALL)--experiences from trial ALL-BFM 95.
Topics: Adolescent; Child; Child, Preschool; Dexamethasone; Female; Glucocorticoids; Hip Joint; Humans; Infa | 2005 |
Osteonecrosis: a treatment related toxicity in childhood acute lymphoblastic leukemia (ALL)--experiences from trial ALL-BFM 95.
Topics: Adolescent; Child; Child, Preschool; Dexamethasone; Female; Glucocorticoids; Hip Joint; Humans; Infa | 2005 |
Osteonecrosis: a treatment related toxicity in childhood acute lymphoblastic leukemia (ALL)--experiences from trial ALL-BFM 95.
Topics: Adolescent; Child; Child, Preschool; Dexamethasone; Female; Glucocorticoids; Hip Joint; Humans; Infa | 2005 |
The analysis of correlations between drug resistance and clinical/laboratory measures found in a group of children with all treated by ALL-BFM 90 protocol.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, | 2004 |
The analysis of correlations between drug resistance and clinical/laboratory measures found in a group of children with all treated by ALL-BFM 90 protocol.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, | 2004 |
The analysis of correlations between drug resistance and clinical/laboratory measures found in a group of children with all treated by ALL-BFM 90 protocol.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, | 2004 |
Cerebrospinal fluid excitatory amino acids and tau protein in children with acute lymphoblastic leukemia treated according to the BFM protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Aspartic Acid; Child; Daunorubicin; Ex | 2004 |
Cerebrospinal fluid excitatory amino acids and tau protein in children with acute lymphoblastic leukemia treated according to the BFM protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Aspartic Acid; Child; Daunorubicin; Ex | 2004 |
Cerebrospinal fluid excitatory amino acids and tau protein in children with acute lymphoblastic leukemia treated according to the BFM protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Aspartic Acid; Child; Daunorubicin; Ex | 2004 |
[Primary study of relationship between serum level of VEGF and non-Hodgkin's lymphoma in children and adolescent patients].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; C | 2004 |
[Primary study of relationship between serum level of VEGF and non-Hodgkin's lymphoma in children and adolescent patients].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; C | 2004 |
[Primary study of relationship between serum level of VEGF and non-Hodgkin's lymphoma in children and adolescent patients].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; C | 2004 |
[Analysis of 32 cases of acute leukemia with abnormality of chromosome 7].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Chromosome Aberratio | 2004 |
[Analysis of 32 cases of acute leukemia with abnormality of chromosome 7].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Chromosome Aberratio | 2004 |
[Analysis of 32 cases of acute leukemia with abnormality of chromosome 7].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Chromosome Aberratio | 2004 |
[Efficacy of modified BFM-90 regimen on children and adolescents with T cell lymphoblastic lymphoma: a report of 20 cases].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2004 |
[Efficacy of modified BFM-90 regimen on children and adolescents with T cell lymphoblastic lymphoma: a report of 20 cases].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2004 |
[Efficacy of modified BFM-90 regimen on children and adolescents with T cell lymphoblastic lymphoma: a report of 20 cases].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2004 |
[Results of treatment of children with acute lymphoblastic leukemia with a modified BFM protocol].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 2004 |
[Results of treatment of children with acute lymphoblastic leukemia with a modified BFM protocol].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 2004 |
[Results of treatment of children with acute lymphoblastic leukemia with a modified BFM protocol].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 2004 |
[Immunologic monitoring in children with acute lymphoblastic leukemia during maintenance treatment with regard to co-existing infections].
Topics: Adolescent; Antigens; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers; Chil | 2004 |
[Immunologic monitoring in children with acute lymphoblastic leukemia during maintenance treatment with regard to co-existing infections].
Topics: Adolescent; Antigens; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers; Chil | 2004 |
[Immunologic monitoring in children with acute lymphoblastic leukemia during maintenance treatment with regard to co-existing infections].
Topics: Adolescent; Antigens; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers; Chil | 2004 |
Severe hyperlipidemia in a child with acute lymphoblastic leukemia treated with L-asparaginase and prednisone.
Topics: Asparaginase; Blood Chemical Analysis; Child; Drug Therapy, Combination; Female; Follow-Up Studies; | 2004 |
Severe hyperlipidemia in a child with acute lymphoblastic leukemia treated with L-asparaginase and prednisone.
Topics: Asparaginase; Blood Chemical Analysis; Child; Drug Therapy, Combination; Female; Follow-Up Studies; | 2004 |
Severe hyperlipidemia in a child with acute lymphoblastic leukemia treated with L-asparaginase and prednisone.
Topics: Asparaginase; Blood Chemical Analysis; Child; Drug Therapy, Combination; Female; Follow-Up Studies; | 2004 |
[Treatment results in children with standard-risk acute lymphoblastic leukemia. Report of the Polish Pediatric Leukemia/Lymphoma Study Group].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Bone Neoplasm | 2004 |
[Treatment results in children with standard-risk acute lymphoblastic leukemia. Report of the Polish Pediatric Leukemia/Lymphoma Study Group].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Bone Neoplasm | 2004 |
[Treatment results in children with standard-risk acute lymphoblastic leukemia. Report of the Polish Pediatric Leukemia/Lymphoma Study Group].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Bone Neoplasm | 2004 |
Second induction in pediatric patients with recurrent acute lymphoid leukemia using DFCI-ALL protocols.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2005 |
Second induction in pediatric patients with recurrent acute lymphoid leukemia using DFCI-ALL protocols.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2005 |
Second induction in pediatric patients with recurrent acute lymphoid leukemia using DFCI-ALL protocols.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2005 |
Immunodeficiency in children with acute lymphoblastic leukemia after completion of modern aggressive chemotherapeutic regimens.
Topics: Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Pres | 2005 |
Immunodeficiency in children with acute lymphoblastic leukemia after completion of modern aggressive chemotherapeutic regimens.
Topics: Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Pres | 2005 |
Immunodeficiency in children with acute lymphoblastic leukemia after completion of modern aggressive chemotherapeutic regimens.
Topics: Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Pres | 2005 |
An adult case of acute lymphoblastic leukaemia presenting as hepatic dysfunction.
Topics: Antineoplastic Agents; Asparaginase; Bone Marrow; Drug Therapy, Combination; Female; Glucocorticoids | 2005 |
An adult case of acute lymphoblastic leukaemia presenting as hepatic dysfunction.
Topics: Antineoplastic Agents; Asparaginase; Bone Marrow; Drug Therapy, Combination; Female; Glucocorticoids | 2005 |
An adult case of acute lymphoblastic leukaemia presenting as hepatic dysfunction.
Topics: Antineoplastic Agents; Asparaginase; Bone Marrow; Drug Therapy, Combination; Female; Glucocorticoids | 2005 |
HRQOL implications of treatment with dexamethasone for children with acute lymphoblastic leukemia (ALL).
Topics: Anti-Inflammatory Agents; Child; Child Behavior; Child, Preschool; Dexamethasone; Female; Health Sta | 2006 |
HRQOL implications of treatment with dexamethasone for children with acute lymphoblastic leukemia (ALL).
Topics: Anti-Inflammatory Agents; Child; Child Behavior; Child, Preschool; Dexamethasone; Female; Health Sta | 2006 |
HRQOL implications of treatment with dexamethasone for children with acute lymphoblastic leukemia (ALL).
Topics: Anti-Inflammatory Agents; Child; Child Behavior; Child, Preschool; Dexamethasone; Female; Health Sta | 2006 |
[Lymphoproliferative disease following kidney transplantation].
Topics: Abdominal Pain; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, | 2005 |
[Lymphoproliferative disease following kidney transplantation].
Topics: Abdominal Pain; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, | 2005 |
[Lymphoproliferative disease following kidney transplantation].
Topics: Abdominal Pain; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, | 2005 |
Decreased numbers of CD4+ T lymphocytes in peripheral blood after treatment of childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; CD4 Lymphocy | 2006 |
Decreased numbers of CD4+ T lymphocytes in peripheral blood after treatment of childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; CD4 Lymphocy | 2006 |
Decreased numbers of CD4+ T lymphocytes in peripheral blood after treatment of childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; CD4 Lymphocy | 2006 |
Herpes simplex virus pneumonia during standard induction chemotherapy for acute leukemia: case report and review of literature.
Topics: Acyclovir; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Daunorubicin; Female; H | 2005 |
Herpes simplex virus pneumonia during standard induction chemotherapy for acute leukemia: case report and review of literature.
Topics: Acyclovir; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Daunorubicin; Female; H | 2005 |
Herpes simplex virus pneumonia during standard induction chemotherapy for acute leukemia: case report and review of literature.
Topics: Acyclovir; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Daunorubicin; Female; H | 2005 |
Treatment reduction in highly selected standard-risk childhood acute lymphoblastic leukemia. The AIEOP ALL-9501 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Daunorubicin; | 2005 |
Treatment reduction in highly selected standard-risk childhood acute lymphoblastic leukemia. The AIEOP ALL-9501 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Daunorubicin; | 2005 |
Treatment reduction in highly selected standard-risk childhood acute lymphoblastic leukemia. The AIEOP ALL-9501 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Daunorubicin; | 2005 |
[Mediastinal (thymic) large B-cell lymphoma: three cases reports].
Topics: Adolescent; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Diffe | 2005 |
[Mediastinal (thymic) large B-cell lymphoma: three cases reports].
Topics: Adolescent; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Diffe | 2005 |
[Mediastinal (thymic) large B-cell lymphoma: three cases reports].
Topics: Adolescent; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Diffe | 2005 |
Recent steroid therapy increases severity of varicella infections in children with acute lymphoblastic leukemia.
Topics: Chickenpox; Child; Female; Glucocorticoids; Humans; Immunocompromised Host; Male; Precursor Cell Lym | 2005 |
Recent steroid therapy increases severity of varicella infections in children with acute lymphoblastic leukemia.
Topics: Chickenpox; Child; Female; Glucocorticoids; Humans; Immunocompromised Host; Male; Precursor Cell Lym | 2005 |
Recent steroid therapy increases severity of varicella infections in children with acute lymphoblastic leukemia.
Topics: Chickenpox; Child; Female; Glucocorticoids; Humans; Immunocompromised Host; Male; Precursor Cell Lym | 2005 |
The MIF-173G/C polymorphism does not contribute to prednisone poor response in vivo in childhood acute lymphoblastic leukemia.
Topics: Case-Control Studies; Drug Resistance, Neoplasm; Gene Frequency; Genotype; Humans; Macrophage Migrat | 2005 |
The MIF-173G/C polymorphism does not contribute to prednisone poor response in vivo in childhood acute lymphoblastic leukemia.
Topics: Case-Control Studies; Drug Resistance, Neoplasm; Gene Frequency; Genotype; Humans; Macrophage Migrat | 2005 |
The MIF-173G/C polymorphism does not contribute to prednisone poor response in vivo in childhood acute lymphoblastic leukemia.
Topics: Case-Control Studies; Drug Resistance, Neoplasm; Gene Frequency; Genotype; Humans; Macrophage Migrat | 2005 |
Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; C | 2005 |
Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; C | 2005 |
Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; C | 2005 |
Could Candida dubliniensis be involved in lung fungus balls?
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bronchoalveolar Lavage Fluid; Candida; C | 2005 |
Could Candida dubliniensis be involved in lung fungus balls?
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bronchoalveolar Lavage Fluid; Candida; C | 2005 |
Could Candida dubliniensis be involved in lung fungus balls?
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bronchoalveolar Lavage Fluid; Candida; C | 2005 |
West Nile virus infection in a teenage boy with acute lymphocytic leukemia in remission.
Topics: Acyclovir; Adolescent; Animals; Antibodies, Viral; Antineoplastic Combined Chemotherapy Protocols; A | 2005 |
West Nile virus infection in a teenage boy with acute lymphocytic leukemia in remission.
Topics: Acyclovir; Adolescent; Animals; Antibodies, Viral; Antineoplastic Combined Chemotherapy Protocols; A | 2005 |
West Nile virus infection in a teenage boy with acute lymphocytic leukemia in remission.
Topics: Acyclovir; Adolescent; Animals; Antibodies, Viral; Antineoplastic Combined Chemotherapy Protocols; A | 2005 |
p16 inactivation associated with aggressive clinical course and fatal outcome in TEL/AML1-positive acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Child; Ch | 2005 |
p16 inactivation associated with aggressive clinical course and fatal outcome in TEL/AML1-positive acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Child; Ch | 2005 |
p16 inactivation associated with aggressive clinical course and fatal outcome in TEL/AML1-positive acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Child; Ch | 2005 |
bcr-abl-positive T-cell acute lymphoblastic leukemia associated with parvovirus B19 infection.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Cerebral Hemo | 2006 |
bcr-abl-positive T-cell acute lymphoblastic leukemia associated with parvovirus B19 infection.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Cerebral Hemo | 2006 |
bcr-abl-positive T-cell acute lymphoblastic leukemia associated with parvovirus B19 infection.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Cerebral Hemo | 2006 |
Roles of protein C, protein S, and antithrombin III in acute leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antithrombin III; Asparaginase; Cyclophosphamide; Cy | 2006 |
Roles of protein C, protein S, and antithrombin III in acute leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antithrombin III; Asparaginase; Cyclophosphamide; Cy | 2006 |
Roles of protein C, protein S, and antithrombin III in acute leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antithrombin III; Asparaginase; Cyclophosphamide; Cy | 2006 |
Unsupervised proteome analysis of human leukaemia cells identifies the Valosin-containing protein as a putative marker for glucocorticoid resistance.
Topics: Adenosine Triphosphatases; Biomarkers, Tumor; Blotting, Western; Case-Control Studies; Catalase; Cel | 2006 |
Unsupervised proteome analysis of human leukaemia cells identifies the Valosin-containing protein as a putative marker for glucocorticoid resistance.
Topics: Adenosine Triphosphatases; Biomarkers, Tumor; Blotting, Western; Case-Control Studies; Catalase; Cel | 2006 |
Unsupervised proteome analysis of human leukaemia cells identifies the Valosin-containing protein as a putative marker for glucocorticoid resistance.
Topics: Adenosine Triphosphatases; Biomarkers, Tumor; Blotting, Western; Case-Control Studies; Catalase; Cel | 2006 |
Acute lymphoblastic leukemia in adolescents between 10 and 19 years of age in Denmark--secondary publication.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; | 2006 |
Acute lymphoblastic leukemia in adolescents between 10 and 19 years of age in Denmark--secondary publication.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; | 2006 |
Acute lymphoblastic leukemia in adolescents between 10 and 19 years of age in Denmark--secondary publication.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; | 2006 |
Treatment of cavitary pulmonary zygomycosis with surgical resection and posaconazole.
Topics: Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Ben | 2006 |
Treatment of cavitary pulmonary zygomycosis with surgical resection and posaconazole.
Topics: Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Ben | 2006 |
Treatment of cavitary pulmonary zygomycosis with surgical resection and posaconazole.
Topics: Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Ben | 2006 |
[Acute lymphoblastic leukaemia in Danish children and young people 10 to 19 years of age. Should young adults with acute lymphoblastic leukaemia be treated in the same way as children?].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Daunorub | 2006 |
[Acute lymphoblastic leukaemia in Danish children and young people 10 to 19 years of age. Should young adults with acute lymphoblastic leukaemia be treated in the same way as children?].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Daunorub | 2006 |
[Acute lymphoblastic leukaemia in Danish children and young people 10 to 19 years of age. Should young adults with acute lymphoblastic leukaemia be treated in the same way as children?].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Daunorub | 2006 |
[Acute lymphoblastic leukemia in children with initial leucocytosis above 50,000/mm3: summary of treatment results of Polish Pediatric Leukemia/Lymphoma Study Group].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2006 |
[Acute lymphoblastic leukemia in children with initial leucocytosis above 50,000/mm3: summary of treatment results of Polish Pediatric Leukemia/Lymphoma Study Group].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2006 |
[Acute lymphoblastic leukemia in children with initial leucocytosis above 50,000/mm3: summary of treatment results of Polish Pediatric Leukemia/Lymphoma Study Group].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2006 |
Oral outpatient chemotherapy medication errors in children with acute lymphoblastic leukemia.
Topics: Administration, Oral; Adolescent; Child; Child, Preschool; Dexamethasone; Humans; Infant; Medication | 2006 |
Oral outpatient chemotherapy medication errors in children with acute lymphoblastic leukemia.
Topics: Administration, Oral; Adolescent; Child; Child, Preschool; Dexamethasone; Humans; Infant; Medication | 2006 |
Oral outpatient chemotherapy medication errors in children with acute lymphoblastic leukemia.
Topics: Administration, Oral; Adolescent; Child; Child, Preschool; Dexamethasone; Humans; Infant; Medication | 2006 |
[Twenty years of treating childhood acute lymphoblastic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophospham | 2006 |
[Twenty years of treating childhood acute lymphoblastic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophospham | 2006 |
[Twenty years of treating childhood acute lymphoblastic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophospham | 2006 |
Avascular necrosis--an antineoplastic-treatment-related toxicity: the experiences of two institutions.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; Cytarabi | 2006 |
Avascular necrosis--an antineoplastic-treatment-related toxicity: the experiences of two institutions.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; Cytarabi | 2006 |
Avascular necrosis--an antineoplastic-treatment-related toxicity: the experiences of two institutions.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; Cytarabi | 2006 |
[Infection status and clinical significance of Epstein-Barr virus in pediatric leukemia---a report of 35 cases].
Topics: Antineoplastic Agents, Hormonal; Child; Child, Preschool; DNA, Viral; Epstein-Barr Virus Infections; | 2007 |
[Infection status and clinical significance of Epstein-Barr virus in pediatric leukemia---a report of 35 cases].
Topics: Antineoplastic Agents, Hormonal; Child; Child, Preschool; DNA, Viral; Epstein-Barr Virus Infections; | 2007 |
[Infection status and clinical significance of Epstein-Barr virus in pediatric leukemia---a report of 35 cases].
Topics: Antineoplastic Agents, Hormonal; Child; Child, Preschool; DNA, Viral; Epstein-Barr Virus Infections; | 2007 |
Possible increase of the neurotoxicity of vincristine by the concurrent use of posaconazole in a young adult with leukemia.
Topics: Adult; Antifungal Agents; Antineoplastic Agents; Demyelinating Diseases; Electromyography; Fever; Hu | 2007 |
Possible increase of the neurotoxicity of vincristine by the concurrent use of posaconazole in a young adult with leukemia.
Topics: Adult; Antifungal Agents; Antineoplastic Agents; Demyelinating Diseases; Electromyography; Fever; Hu | 2007 |
Possible increase of the neurotoxicity of vincristine by the concurrent use of posaconazole in a young adult with leukemia.
Topics: Adult; Antifungal Agents; Antineoplastic Agents; Demyelinating Diseases; Electromyography; Fever; Hu | 2007 |
[Reults of treatment with protocols BFM 90 and BFM 95].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophospham | 2006 |
[Reults of treatment with protocols BFM 90 and BFM 95].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophospham | 2006 |
[Reults of treatment with protocols BFM 90 and BFM 95].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophospham | 2006 |
Air-leak syndrome associated with bronchiolitis obliterans after allogeneic peripheral blood stem cell transplantation.
Topics: Acute Disease; Adult; Anti-Inflammatory Agents; Bronchiolitis Obliterans; Cyclosporine; Cytomegalovi | 2007 |
Air-leak syndrome associated with bronchiolitis obliterans after allogeneic peripheral blood stem cell transplantation.
Topics: Acute Disease; Adult; Anti-Inflammatory Agents; Bronchiolitis Obliterans; Cyclosporine; Cytomegalovi | 2007 |
Air-leak syndrome associated with bronchiolitis obliterans after allogeneic peripheral blood stem cell transplantation.
Topics: Acute Disease; Adult; Anti-Inflammatory Agents; Bronchiolitis Obliterans; Cyclosporine; Cytomegalovi | 2007 |
Gene expression shift towards normal B cells, decreased proliferative capacity and distinct surface receptors characterize leukemic blasts persisting during induction therapy in childhood acute lymphoblastic leukemia.
Topics: Adolescent; B-Lymphocytes; Blast Crisis; CD11b Antigen; Cell Cycle; Cell Proliferation; Child; Child | 2007 |
Gene expression shift towards normal B cells, decreased proliferative capacity and distinct surface receptors characterize leukemic blasts persisting during induction therapy in childhood acute lymphoblastic leukemia.
Topics: Adolescent; B-Lymphocytes; Blast Crisis; CD11b Antigen; Cell Cycle; Cell Proliferation; Child; Child | 2007 |
Gene expression shift towards normal B cells, decreased proliferative capacity and distinct surface receptors characterize leukemic blasts persisting during induction therapy in childhood acute lymphoblastic leukemia.
Topics: Adolescent; B-Lymphocytes; Blast Crisis; CD11b Antigen; Cell Cycle; Cell Proliferation; Child; Child | 2007 |
High body mass index increases the risk for osteonecrosis in children with acute lymphoblastic leukemia.
Topics: Adolescent; Adrenal Cortex Hormones; Age Distribution; Analysis of Variance; Body Mass Index; Causal | 2007 |
High body mass index increases the risk for osteonecrosis in children with acute lymphoblastic leukemia.
Topics: Adolescent; Adrenal Cortex Hormones; Age Distribution; Analysis of Variance; Body Mass Index; Causal | 2007 |
High body mass index increases the risk for osteonecrosis in children with acute lymphoblastic leukemia.
Topics: Adolescent; Adrenal Cortex Hormones; Age Distribution; Analysis of Variance; Body Mass Index; Causal | 2007 |
Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-Associated Death Protein; Blotti | 2007 |
Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-Associated Death Protein; Blotti | 2007 |
Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-Associated Death Protein; Blotti | 2007 |
Vincristine-induced acute neurotoxicity versus Guillain-Barré syndrome: a diagnostic dilemma.
Topics: Action Potentials; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; | 2007 |
Vincristine-induced acute neurotoxicity versus Guillain-Barré syndrome: a diagnostic dilemma.
Topics: Action Potentials; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; | 2007 |
Vincristine-induced acute neurotoxicity versus Guillain-Barré syndrome: a diagnostic dilemma.
Topics: Action Potentials; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; | 2007 |
Disseminated intravascular coagulation in acute leukemia at presentation and during induction therapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Presc | 2007 |
Disseminated intravascular coagulation in acute leukemia at presentation and during induction therapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Presc | 2007 |
Disseminated intravascular coagulation in acute leukemia at presentation and during induction therapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Presc | 2007 |
Coenzyme Q10 concentration in the plasma of children suffering from acute lymphoblastic leukaemia before and during induction treatment.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Asparaginase; Child; Child | 2007 |
Coenzyme Q10 concentration in the plasma of children suffering from acute lymphoblastic leukaemia before and during induction treatment.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Asparaginase; Child; Child | 2007 |
Coenzyme Q10 concentration in the plasma of children suffering from acute lymphoblastic leukaemia before and during induction treatment.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Asparaginase; Child; Child | 2007 |
[Comparative study on clinical features between TEL-AML1 positive and negative childhood acute lymphoblastic leukemia].
Topics: Adolescent; Bone Marrow; Child; Child, Preschool; Core Binding Factor Alpha 2 Subunit; ETS Transloca | 2007 |
[Comparative study on clinical features between TEL-AML1 positive and negative childhood acute lymphoblastic leukemia].
Topics: Adolescent; Bone Marrow; Child; Child, Preschool; Core Binding Factor Alpha 2 Subunit; ETS Transloca | 2007 |
[Comparative study on clinical features between TEL-AML1 positive and negative childhood acute lymphoblastic leukemia].
Topics: Adolescent; Bone Marrow; Child; Child, Preschool; Core Binding Factor Alpha 2 Subunit; ETS Transloca | 2007 |
[Primary esophageal lymphoma in a acquired immunodeficiency syndrome: a case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Esophageal Neo | 2007 |
[Primary esophageal lymphoma in a acquired immunodeficiency syndrome: a case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Esophageal Neo | 2007 |
[Primary esophageal lymphoma in a acquired immunodeficiency syndrome: a case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Esophageal Neo | 2007 |
Incidence and outcome of TCF3-PBX1-positive acute lymphoblastic leukemia in Austrian children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Austria; Basic Helix-Loop- | 2007 |
Incidence and outcome of TCF3-PBX1-positive acute lymphoblastic leukemia in Austrian children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Austria; Basic Helix-Loop- | 2007 |
Incidence and outcome of TCF3-PBX1-positive acute lymphoblastic leukemia in Austrian children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Austria; Basic Helix-Loop- | 2007 |
The NQO1 C609T polymorphism is associated with risk of secondary malignant neoplasms after treatment for childhood acute lymphoblastic leukemia: a matched-pair analysis from the ALL-BFM study group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Daunorubicin; | 2007 |
The NQO1 C609T polymorphism is associated with risk of secondary malignant neoplasms after treatment for childhood acute lymphoblastic leukemia: a matched-pair analysis from the ALL-BFM study group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Daunorubicin; | 2007 |
The NQO1 C609T polymorphism is associated with risk of secondary malignant neoplasms after treatment for childhood acute lymphoblastic leukemia: a matched-pair analysis from the ALL-BFM study group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Daunorubicin; | 2007 |
[Clinical, morphologic immunologic and cytogenetic characteristics of childhood acute lymphoblastic leukemia: a comparison between prednisone poor responders and good responders].
Topics: Anti-Inflammatory Agents; Child, Preschool; Humans; Infant; Infant, Newborn; Precursor Cell Lymphobl | 2007 |
[Clinical, morphologic immunologic and cytogenetic characteristics of childhood acute lymphoblastic leukemia: a comparison between prednisone poor responders and good responders].
Topics: Anti-Inflammatory Agents; Child, Preschool; Humans; Infant; Infant, Newborn; Precursor Cell Lymphobl | 2007 |
[Clinical, morphologic immunologic and cytogenetic characteristics of childhood acute lymphoblastic leukemia: a comparison between prednisone poor responders and good responders].
Topics: Anti-Inflammatory Agents; Child, Preschool; Humans; Infant; Infant, Newborn; Precursor Cell Lymphobl | 2007 |
Effects of prednisolone on specifically expressed genes in pediatric acute B-lymphoblastic leukemia.
Topics: Gene Expression Regulation, Neoplastic; Humans; Infant; Lymphoma, B-Cell; Neoplasm Staging; Oligonuc | 2008 |
Effects of prednisolone on specifically expressed genes in pediatric acute B-lymphoblastic leukemia.
Topics: Gene Expression Regulation, Neoplastic; Humans; Infant; Lymphoma, B-Cell; Neoplasm Staging; Oligonuc | 2008 |
Effects of prednisolone on specifically expressed genes in pediatric acute B-lymphoblastic leukemia.
Topics: Gene Expression Regulation, Neoplastic; Humans; Infant; Lymphoma, B-Cell; Neoplasm Staging; Oligonuc | 2008 |
Outcomes of a modified CALGB 19802 regimen in adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Daunorubi | 2008 |
Outcomes of a modified CALGB 19802 regimen in adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Daunorubi | 2008 |
Outcomes of a modified CALGB 19802 regimen in adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Daunorubi | 2008 |
Obesity after successful treatment of acute lymphoblastic leukemia in childhood.
Topics: Adolescent; Age Factors; Antineoplastic Agents, Hormonal; Child; Child, Preschool; Dexamethasone; Fe | 1995 |
Obesity after successful treatment of acute lymphoblastic leukemia in childhood.
Topics: Adolescent; Age Factors; Antineoplastic Agents, Hormonal; Child; Child, Preschool; Dexamethasone; Fe | 1995 |
Obesity after successful treatment of acute lymphoblastic leukemia in childhood.
Topics: Adolescent; Age Factors; Antineoplastic Agents, Hormonal; Child; Child, Preschool; Dexamethasone; Fe | 1995 |
Lymphoma-associated pancreatitis as a presenting manifestation of immunoblastic lymphoma.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Diagnosi | 1994 |
Lymphoma-associated pancreatitis as a presenting manifestation of immunoblastic lymphoma.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Diagnosi | 1994 |
Lymphoma-associated pancreatitis as a presenting manifestation of immunoblastic lymphoma.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Diagnosi | 1994 |
CD34 expression is associated with major adverse prognostic factors in adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Amsacrine; Aneuploidy; Antibiotics, Antineoplastic; Antigens, CD; Antigens, | 1995 |
CD34 expression is associated with major adverse prognostic factors in adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Amsacrine; Aneuploidy; Antibiotics, Antineoplastic; Antigens, CD; Antigens, | 1995 |
CD34 expression is associated with major adverse prognostic factors in adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Amsacrine; Aneuploidy; Antibiotics, Antineoplastic; Antigens, CD; Antigens, | 1995 |
[The significance of preventive CNS irradiation during antineoplastic therapy in childhood with regard to late odontogenic and mandibulofacial injuries].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cephalometry; Child, Preschool; Combin | 1995 |
[The significance of preventive CNS irradiation during antineoplastic therapy in childhood with regard to late odontogenic and mandibulofacial injuries].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cephalometry; Child, Preschool; Combin | 1995 |
[The significance of preventive CNS irradiation during antineoplastic therapy in childhood with regard to late odontogenic and mandibulofacial injuries].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cephalometry; Child, Preschool; Combin | 1995 |
Acute lymphoblastic leukemia in the elderly: results of two different treatment approaches in 49 patients during a 25-year period.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Daunorubicin; | 1995 |
Acute lymphoblastic leukemia in the elderly: results of two different treatment approaches in 49 patients during a 25-year period.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Daunorubicin; | 1995 |
Acute lymphoblastic leukemia in the elderly: results of two different treatment approaches in 49 patients during a 25-year period.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Daunorubicin; | 1995 |
[Electrolytic changes in children with acute lymphoblastic leukemia during remission induction].
Topics: Adolescent; Allopurinol; Anions; Antineoplastic Combined Chemotherapy Protocols; Bicarbonates; Blood | 1995 |
[Electrolytic changes in children with acute lymphoblastic leukemia during remission induction].
Topics: Adolescent; Allopurinol; Anions; Antineoplastic Combined Chemotherapy Protocols; Bicarbonates; Blood | 1995 |
[Electrolytic changes in children with acute lymphoblastic leukemia during remission induction].
Topics: Adolescent; Allopurinol; Anions; Antineoplastic Combined Chemotherapy Protocols; Bicarbonates; Blood | 1995 |
Prognosis and treatment of seizures in children with acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Daunorubicin; Epile | 1995 |
Prognosis and treatment of seizures in children with acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Daunorubicin; Epile | 1995 |
Prognosis and treatment of seizures in children with acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Daunorubicin; Epile | 1995 |
The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocol | 1995 |
The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocol | 1995 |
The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocol | 1995 |
MACOP-B +/- radiation therapy for diffuse large cell lymphoma. Analysis of the Stanford results according to prognostic indices.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality The | 1993 |
MACOP-B +/- radiation therapy for diffuse large cell lymphoma. Analysis of the Stanford results according to prognostic indices.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality The | 1993 |
MACOP-B +/- radiation therapy for diffuse large cell lymphoma. Analysis of the Stanford results according to prognostic indices.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality The | 1993 |
[High dose chemoradiotherapy and autologous bone marrow transplantation (ABMT) as a first line therapy to treat advanced adult high-grade malignant T-cell non-Hodgkin's lymphoma--a pilot clinical study].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplant | 1993 |
[High dose chemoradiotherapy and autologous bone marrow transplantation (ABMT) as a first line therapy to treat advanced adult high-grade malignant T-cell non-Hodgkin's lymphoma--a pilot clinical study].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplant | 1993 |
[High dose chemoradiotherapy and autologous bone marrow transplantation (ABMT) as a first line therapy to treat advanced adult high-grade malignant T-cell non-Hodgkin's lymphoma--a pilot clinical study].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplant | 1993 |
The frequency of micronuclei in bone-marrow erythroblasts during the treatment of childhood acute lymphoblastic leukaemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Child; Child, | 1993 |
The frequency of micronuclei in bone-marrow erythroblasts during the treatment of childhood acute lymphoblastic leukaemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Child; Child, | 1993 |
The frequency of micronuclei in bone-marrow erythroblasts during the treatment of childhood acute lymphoblastic leukaemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Child; Child, | 1993 |
Treatment of poor prognosis non-Hodgkin's lymphoma with intensive, inpatient combination chemotherapy of brief duration: long-term followup.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1993 |
Treatment of poor prognosis non-Hodgkin's lymphoma with intensive, inpatient combination chemotherapy of brief duration: long-term followup.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1993 |
Treatment of poor prognosis non-Hodgkin's lymphoma with intensive, inpatient combination chemotherapy of brief duration: long-term followup.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1993 |
[DNA index and proliferative activity of blastic cells in childhood ALL].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Child; Child, Preschool; | 1995 |
[DNA index and proliferative activity of blastic cells in childhood ALL].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Child; Child, Preschool; | 1995 |
[DNA index and proliferative activity of blastic cells in childhood ALL].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Child; Child, Preschool; | 1995 |
Recurrent lymphoma in a cardiac allograft recipient.
Topics: Azathioprine; Cyclosporine; Follow-Up Studies; Graft Rejection; Heart Transplantation; Humans; Lung | 1994 |
Recurrent lymphoma in a cardiac allograft recipient.
Topics: Azathioprine; Cyclosporine; Follow-Up Studies; Graft Rejection; Heart Transplantation; Humans; Lung | 1994 |
Recurrent lymphoma in a cardiac allograft recipient.
Topics: Azathioprine; Cyclosporine; Follow-Up Studies; Graft Rejection; Heart Transplantation; Humans; Lung | 1994 |
Aggressive chemotherapy for acute leukemia relapsed after transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cyta | 1994 |
Aggressive chemotherapy for acute leukemia relapsed after transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cyta | 1994 |
Aggressive chemotherapy for acute leukemia relapsed after transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cyta | 1994 |
Childhood acute lymphoblastic leukemia (ALL): sister chromatid exchange (SCE) frequency and lymphocyte subpopulations during therapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 1995 |
Childhood acute lymphoblastic leukemia (ALL): sister chromatid exchange (SCE) frequency and lymphocyte subpopulations during therapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 1995 |
Childhood acute lymphoblastic leukemia (ALL): sister chromatid exchange (SCE) frequency and lymphocyte subpopulations during therapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 1995 |
Transient, severe hyperlipidemia in patients with acute lymphoblastic leukemia treated with prednisone and asparaginase.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Female; Humans; Hyp | 1994 |
Transient, severe hyperlipidemia in patients with acute lymphoblastic leukemia treated with prednisone and asparaginase.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Female; Humans; Hyp | 1994 |
Transient, severe hyperlipidemia in patients with acute lymphoblastic leukemia treated with prednisone and asparaginase.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Female; Humans; Hyp | 1994 |
A dental complication involving Pseudomonas during chemotherapy for acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Cytarabine; Dental Care for Chr | 1994 |
A dental complication involving Pseudomonas during chemotherapy for acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Cytarabine; Dental Care for Chr | 1994 |
A dental complication involving Pseudomonas during chemotherapy for acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Cytarabine; Dental Care for Chr | 1994 |
Treatment of acute lymphoblastic leukaemia in adults with modified BFM regimen.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymph | 1994 |
Treatment of acute lymphoblastic leukaemia in adults with modified BFM regimen.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymph | 1994 |
Treatment of acute lymphoblastic leukaemia in adults with modified BFM regimen.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymph | 1994 |
Poor outcome of intensive chemotherapy for adult acute lymphoblastic leukemia: a possible dose effect.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; Cytarab | 1994 |
Poor outcome of intensive chemotherapy for adult acute lymphoblastic leukemia: a possible dose effect.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; Cytarab | 1994 |
Poor outcome of intensive chemotherapy for adult acute lymphoblastic leukemia: a possible dose effect.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; Cytarab | 1994 |
Teratogenicity and carcinogenicity in a twin exposed in utero to cyclophosphamide.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Adrenal Gland Neoplasms; Adult; Aminopterin; A | 1993 |
Teratogenicity and carcinogenicity in a twin exposed in utero to cyclophosphamide.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Adrenal Gland Neoplasms; Adult; Aminopterin; A | 1993 |
Teratogenicity and carcinogenicity in a twin exposed in utero to cyclophosphamide.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Adrenal Gland Neoplasms; Adult; Aminopterin; A | 1993 |
Successful treatment of acute lymphoblastic leukemia in a child with cystic fibrosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child, Preschool; Cystic Fibrosis; Cyt | 1994 |
Successful treatment of acute lymphoblastic leukemia in a child with cystic fibrosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child, Preschool; Cystic Fibrosis; Cyt | 1994 |
Successful treatment of acute lymphoblastic leukemia in a child with cystic fibrosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child, Preschool; Cystic Fibrosis; Cyt | 1994 |
Incidence and prognostic significance of immunophenotypic subgroups in childhood acute lymphoblastic leukemia: the experience of the AIEOP Cooperative Study. Associazione Italiana Ematologia Oncologia Pediatrica.
Topics: Child; Humans; Immunophenotyping; Incidence; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednis | 1993 |
Incidence and prognostic significance of immunophenotypic subgroups in childhood acute lymphoblastic leukemia: the experience of the AIEOP Cooperative Study. Associazione Italiana Ematologia Oncologia Pediatrica.
Topics: Child; Humans; Immunophenotyping; Incidence; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednis | 1993 |
Incidence and prognostic significance of immunophenotypic subgroups in childhood acute lymphoblastic leukemia: the experience of the AIEOP Cooperative Study. Associazione Italiana Ematologia Oncologia Pediatrica.
Topics: Child; Humans; Immunophenotyping; Incidence; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednis | 1993 |
Excessive hepatitis-B surface antigen production after corticosteroids and the development of immunoblastic lymphoma.
Topics: Breast Neoplasms; Fatal Outcome; Female; Gene Expression Regulation, Viral; Glomerulonephritis, Memb | 1993 |
Excessive hepatitis-B surface antigen production after corticosteroids and the development of immunoblastic lymphoma.
Topics: Breast Neoplasms; Fatal Outcome; Female; Gene Expression Regulation, Viral; Glomerulonephritis, Memb | 1993 |
Excessive hepatitis-B surface antigen production after corticosteroids and the development of immunoblastic lymphoma.
Topics: Breast Neoplasms; Fatal Outcome; Female; Gene Expression Regulation, Viral; Glomerulonephritis, Memb | 1993 |
Relapses after termination of therapy of acute lymphoblastic leukemia in children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 1993 |
Relapses after termination of therapy of acute lymphoblastic leukemia in children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 1993 |
Relapses after termination of therapy of acute lymphoblastic leukemia in children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 1993 |
Late relapse after allogeneic bone marrow transplantation for Philadelphia-positive acute lymphoblastic leukaemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Co | 1993 |
Late relapse after allogeneic bone marrow transplantation for Philadelphia-positive acute lymphoblastic leukaemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Co | 1993 |
Late relapse after allogeneic bone marrow transplantation for Philadelphia-positive acute lymphoblastic leukaemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Co | 1993 |
[Acute lymphoblastic leukemia in infants--results of treatment according to infant leukemia protocol--POG 8493].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cortisone; Cyclophosphamide; Cytarabin | 1993 |
[Acute lymphoblastic leukemia in infants--results of treatment according to infant leukemia protocol--POG 8493].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cortisone; Cyclophosphamide; Cytarabin | 1993 |
[Acute lymphoblastic leukemia in infants--results of treatment according to infant leukemia protocol--POG 8493].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cortisone; Cyclophosphamide; Cytarabin | 1993 |
Ten years' experience with LSA2-L2 therapy for childhood advanced lymphoblastic lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclopho | 1993 |
Ten years' experience with LSA2-L2 therapy for childhood advanced lymphoblastic lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclopho | 1993 |
Ten years' experience with LSA2-L2 therapy for childhood advanced lymphoblastic lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclopho | 1993 |
Hemorrhagic cystitis associated with BKV in patients with refractory acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; BK Virus; Cyclophosphamide; Cystitis; Cytarabine; He | 1996 |
Hemorrhagic cystitis associated with BKV in patients with refractory acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; BK Virus; Cyclophosphamide; Cystitis; Cytarabine; He | 1996 |
Hemorrhagic cystitis associated with BKV in patients with refractory acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; BK Virus; Cyclophosphamide; Cystitis; Cytarabine; He | 1996 |
Influence of treatment modalities on body weight in acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cranial Irradia | 1996 |
Influence of treatment modalities on body weight in acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cranial Irradia | 1996 |
Influence of treatment modalities on body weight in acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cranial Irradia | 1996 |
True histiocytic lymphoma following therapy for lymphoblastic neoplasms.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Neoplasms; Child; Cisplati | 1996 |
True histiocytic lymphoma following therapy for lymphoblastic neoplasms.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Neoplasms; Child; Cisplati | 1996 |
True histiocytic lymphoma following therapy for lymphoblastic neoplasms.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Neoplasms; Child; Cisplati | 1996 |
A T cell lymphoblastic lymphoma patient with two malignant cell populations carrying different 9p deletions including the p16INK4 and p15INK4B genes: Clinical response to interferon-alpha therapy in one of the subclones.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carrier Proteins; Cell Cycle Proteins; C | 1996 |
A T cell lymphoblastic lymphoma patient with two malignant cell populations carrying different 9p deletions including the p16INK4 and p15INK4B genes: Clinical response to interferon-alpha therapy in one of the subclones.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carrier Proteins; Cell Cycle Proteins; C | 1996 |
A T cell lymphoblastic lymphoma patient with two malignant cell populations carrying different 9p deletions including the p16INK4 and p15INK4B genes: Clinical response to interferon-alpha therapy in one of the subclones.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carrier Proteins; Cell Cycle Proteins; C | 1996 |
Childhood acute lymphoblastic leukemia relapse in the uterine cervix.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Brain Neoplasms; Child; | 1996 |
Childhood acute lymphoblastic leukemia relapse in the uterine cervix.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Brain Neoplasms; Child; | 1996 |
Childhood acute lymphoblastic leukemia relapse in the uterine cervix.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Brain Neoplasms; Child; | 1996 |
Pyomyositis during induction chemotherapy for acute lymphocytic leukemia.
Topics: Abscess; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bacterial Infections; Child; | 1996 |
Pyomyositis during induction chemotherapy for acute lymphocytic leukemia.
Topics: Abscess; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bacterial Infections; Child; | 1996 |
Pyomyositis during induction chemotherapy for acute lymphocytic leukemia.
Topics: Abscess; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bacterial Infections; Child; | 1996 |
Effectiveness of intensified rotational combination chemotherapy for late hematologic relapse of childhood acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Combined Mod | 1996 |
Effectiveness of intensified rotational combination chemotherapy for late hematologic relapse of childhood acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Combined Mod | 1996 |
Effectiveness of intensified rotational combination chemotherapy for late hematologic relapse of childhood acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Combined Mod | 1996 |
[Paraplegia following intrathecal chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cisplatin; | 1996 |
[Paraplegia following intrathecal chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cisplatin; | 1996 |
[Paraplegia following intrathecal chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cisplatin; | 1996 |
Post-transplantation complications of unrelated bone marrow.
Topics: Adult; Antilymphocyte Serum; Bone Marrow Transplantation; Graft vs Host Disease; Humans; Immunosuppr | 1996 |
Post-transplantation complications of unrelated bone marrow.
Topics: Adult; Antilymphocyte Serum; Bone Marrow Transplantation; Graft vs Host Disease; Humans; Immunosuppr | 1996 |
Post-transplantation complications of unrelated bone marrow.
Topics: Adult; Antilymphocyte Serum; Bone Marrow Transplantation; Graft vs Host Disease; Humans; Immunosuppr | 1996 |
Expression and prognostic value of the retinoblastoma tumour suppressor gene (RB-1) in childhood acute lymphoblastic leukaemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Base Sequence; beta 2-Micr | 1996 |
Expression and prognostic value of the retinoblastoma tumour suppressor gene (RB-1) in childhood acute lymphoblastic leukaemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Base Sequence; beta 2-Micr | 1996 |
Expression and prognostic value of the retinoblastoma tumour suppressor gene (RB-1) in childhood acute lymphoblastic leukaemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Base Sequence; beta 2-Micr | 1996 |
Serum levels of insulin-like growth factor-I, -II and insulin-like growth factor binding proteins -2 and -3 in children with acute lymphoblastic leukaemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cell Division; Chil | 1996 |
Serum levels of insulin-like growth factor-I, -II and insulin-like growth factor binding proteins -2 and -3 in children with acute lymphoblastic leukaemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cell Division; Chil | 1996 |
Serum levels of insulin-like growth factor-I, -II and insulin-like growth factor binding proteins -2 and -3 in children with acute lymphoblastic leukaemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cell Division; Chil | 1996 |
Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Fema | 1996 |
Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Fema | 1996 |
Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Fema | 1996 |
Modified BFM protocol for childhood acute lymphoblastic leukemia: a retrospective analysis.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 1997 |
Modified BFM protocol for childhood acute lymphoblastic leukemia: a retrospective analysis.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 1997 |
Modified BFM protocol for childhood acute lymphoblastic leukemia: a retrospective analysis.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 1997 |
Nutritional state alterations in children with acute lymphoblastic leukemia during induction and consolidation of chemotherapy.
Topics: Adolescent; Anthropometry; Antineoplastic Combined Chemotherapy Protocols; Arm; Asparaginase; Body C | 1997 |
Nutritional state alterations in children with acute lymphoblastic leukemia during induction and consolidation of chemotherapy.
Topics: Adolescent; Anthropometry; Antineoplastic Combined Chemotherapy Protocols; Arm; Asparaginase; Body C | 1997 |
Nutritional state alterations in children with acute lymphoblastic leukemia during induction and consolidation of chemotherapy.
Topics: Adolescent; Anthropometry; Antineoplastic Combined Chemotherapy Protocols; Arm; Asparaginase; Body C | 1997 |
Deoxycytidine kinase mRNA expression in childhood acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cells, Cultured; Child; Daunorubicin; | 1997 |
Deoxycytidine kinase mRNA expression in childhood acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cells, Cultured; Child; Daunorubicin; | 1997 |
Deoxycytidine kinase mRNA expression in childhood acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cells, Cultured; Child; Daunorubicin; | 1997 |
Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster groups.
Topics: Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combine | 1997 |
Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster groups.
Topics: Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combine | 1997 |
Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster groups.
Topics: Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combine | 1997 |
Neurophysiological findings in long-term survivors of acute lymphoblastic leukaemia in childhood treated with the BFM protocol 81 SR-A/B.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cerebral Cortex; Child; Ch | 1997 |
Neurophysiological findings in long-term survivors of acute lymphoblastic leukaemia in childhood treated with the BFM protocol 81 SR-A/B.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cerebral Cortex; Child; Ch | 1997 |
Neurophysiological findings in long-term survivors of acute lymphoblastic leukaemia in childhood treated with the BFM protocol 81 SR-A/B.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cerebral Cortex; Child; Ch | 1997 |
Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Apoptosis; Arginine; Aspergillosis | 1998 |
Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Apoptosis; Arginine; Aspergillosis | 1998 |
Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Apoptosis; Arginine; Aspergillosis | 1998 |
Acute lymphoblastic leukemia: dental health of children in maintenance therapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Case-Control Studies; Chil | 1998 |
Acute lymphoblastic leukemia: dental health of children in maintenance therapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Case-Control Studies; Chil | 1998 |
Acute lymphoblastic leukemia: dental health of children in maintenance therapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Case-Control Studies; Chil | 1998 |
Immunophenotypic and clinical features of T-cell receptor gammadelta+ T-lineage acute lymphoblastic leukaemia.
Topics: Acute Disease; Antigens, CD; Antineoplastic Agents, Hormonal; Disease-Free Survival; Humans; Immunop | 1998 |
Immunophenotypic and clinical features of T-cell receptor gammadelta+ T-lineage acute lymphoblastic leukaemia.
Topics: Acute Disease; Antigens, CD; Antineoplastic Agents, Hormonal; Disease-Free Survival; Humans; Immunop | 1998 |
Immunophenotypic and clinical features of T-cell receptor gammadelta+ T-lineage acute lymphoblastic leukaemia.
Topics: Acute Disease; Antigens, CD; Antineoplastic Agents, Hormonal; Disease-Free Survival; Humans; Immunop | 1998 |
[Peripheral blood stem cell transplantation in adult acute lymphoblastic leukemia as postremission therapy].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclop | 1998 |
[Peripheral blood stem cell transplantation in adult acute lymphoblastic leukemia as postremission therapy].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclop | 1998 |
[Peripheral blood stem cell transplantation in adult acute lymphoblastic leukemia as postremission therapy].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclop | 1998 |
Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia--implications for treatment of infants.
Topics: Adolescent; Adult; Age Distribution; Age Factors; Antineoplastic Agents; Child; Child, Preschool; Cy | 1998 |
Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia--implications for treatment of infants.
Topics: Adolescent; Adult; Age Distribution; Age Factors; Antineoplastic Agents; Child; Child, Preschool; Cy | 1998 |
Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia--implications for treatment of infants.
Topics: Adolescent; Adult; Age Distribution; Age Factors; Antineoplastic Agents; Child; Child, Preschool; Cy | 1998 |
Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study.
Topics: Administration, Oral; Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemother | 1998 |
Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study.
Topics: Administration, Oral; Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemother | 1998 |
Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study.
Topics: Administration, Oral; Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemother | 1998 |
Childhood acute lymphoblastic leukaemia: outcomes of 54 consecutive patients treated in Auckland 1985-1991.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 1998 |
Childhood acute lymphoblastic leukaemia: outcomes of 54 consecutive patients treated in Auckland 1985-1991.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 1998 |
Childhood acute lymphoblastic leukaemia: outcomes of 54 consecutive patients treated in Auckland 1985-1991.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 1998 |
Changes in adhesion molecule expression on lymphoblasts during acute lymphoblastic leukemia treatment.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cell Adhesion Molec | 1999 |
Changes in adhesion molecule expression on lymphoblasts during acute lymphoblastic leukemia treatment.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cell Adhesion Molec | 1999 |
Changes in adhesion molecule expression on lymphoblasts during acute lymphoblastic leukemia treatment.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cell Adhesion Molec | 1999 |
Neurodevelopmental outcome of infants with acute lymphoblastic leukemia: a Children's Cancer Group report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Brain Damage, Chronic; Cognition Disor | 1999 |
Neurodevelopmental outcome of infants with acute lymphoblastic leukemia: a Children's Cancer Group report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Brain Damage, Chronic; Cognition Disor | 1999 |
Neurodevelopmental outcome of infants with acute lymphoblastic leukemia: a Children's Cancer Group report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Brain Damage, Chronic; Cognition Disor | 1999 |
Wilms' tumour gene (wt1) expression at diagnosis has no prognostic relevance in childhood acute lymphoblastic leukaemia treated by an intensive chemotherapy protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Cyclophosphamide; Cytarab | 1999 |
Wilms' tumour gene (wt1) expression at diagnosis has no prognostic relevance in childhood acute lymphoblastic leukaemia treated by an intensive chemotherapy protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Cyclophosphamide; Cytarab | 1999 |
Wilms' tumour gene (wt1) expression at diagnosis has no prognostic relevance in childhood acute lymphoblastic leukaemia treated by an intensive chemotherapy protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Cyclophosphamide; Cytarab | 1999 |
Degree of fatness after treatment for acute lymphoblastic leukemia in childhood.
Topics: Absorptiometry, Photon; Adipose Tissue; Adolescent; Adrenal Cortex Hormones; Antineoplastic Agents; | 1999 |
Degree of fatness after treatment for acute lymphoblastic leukemia in childhood.
Topics: Absorptiometry, Photon; Adipose Tissue; Adolescent; Adrenal Cortex Hormones; Antineoplastic Agents; | 1999 |
Degree of fatness after treatment for acute lymphoblastic leukemia in childhood.
Topics: Absorptiometry, Photon; Adipose Tissue; Adolescent; Adrenal Cortex Hormones; Antineoplastic Agents; | 1999 |
Non-Hodgkin's lymphoma protocols in the treatment of patients with Burkitt's lymphoma and lymphoblastic lymphoma: a report on 58 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophos | 1999 |
Non-Hodgkin's lymphoma protocols in the treatment of patients with Burkitt's lymphoma and lymphoblastic lymphoma: a report on 58 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophos | 1999 |
Non-Hodgkin's lymphoma protocols in the treatment of patients with Burkitt's lymphoma and lymphoblastic lymphoma: a report on 58 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophos | 1999 |
[Acute leukemia in Jehovah's Witnesses].
Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blood Transfusion; Chri | 1999 |
[Acute leukemia in Jehovah's Witnesses].
Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blood Transfusion; Chri | 1999 |
[Acute leukemia in Jehovah's Witnesses].
Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blood Transfusion; Chri | 1999 |
Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Child; Child, | 2000 |
Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Child; Child, | 2000 |
Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Child; Child, | 2000 |
[The efficacy of BFM-90 program in the treatment of acute lymphoblastic leukemia in children in the studies of Polish pediatric leukemia/lymphoma group].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantatio | 1998 |
[The efficacy of BFM-90 program in the treatment of acute lymphoblastic leukemia in children in the studies of Polish pediatric leukemia/lymphoma group].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantatio | 1998 |
[The efficacy of BFM-90 program in the treatment of acute lymphoblastic leukemia in children in the studies of Polish pediatric leukemia/lymphoma group].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantatio | 1998 |
[The analysis of failures in the treatment of children with non-B non-Hodgkin's lymphoma. Polish pediatric leukemia/lymphoma study group report].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 1998 |
[The analysis of failures in the treatment of children with non-B non-Hodgkin's lymphoma. Polish pediatric leukemia/lymphoma study group report].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 1998 |
[The analysis of failures in the treatment of children with non-B non-Hodgkin's lymphoma. Polish pediatric leukemia/lymphoma study group report].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 1998 |
Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Presc | 2000 |
Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Presc | 2000 |
Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Presc | 2000 |
Circulating CD4+ T lymphocytes with intracellular but no surface CD3 antigen in five of seven patients consecutively diagnosed with angioimmunoblastic T-cell lymphoma.
Topics: Adult; Aged; Antigens, CD7; Antigens, Surface; Antineoplastic Combined Chemotherapy Protocols; Bone | 2000 |
Circulating CD4+ T lymphocytes with intracellular but no surface CD3 antigen in five of seven patients consecutively diagnosed with angioimmunoblastic T-cell lymphoma.
Topics: Adult; Aged; Antigens, CD7; Antigens, Surface; Antineoplastic Combined Chemotherapy Protocols; Bone | 2000 |
Circulating CD4+ T lymphocytes with intracellular but no surface CD3 antigen in five of seven patients consecutively diagnosed with angioimmunoblastic T-cell lymphoma.
Topics: Adult; Aged; Antigens, CD7; Antigens, Surface; Antineoplastic Combined Chemotherapy Protocols; Bone | 2000 |
Precursor B-cell lymphoblastic lymphoma in childhood and adolescence: clinical features, treatment, and results in trials NHL-BFM 86 and 90.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Austria; B-Lymphocytes; Ch | 2000 |
Precursor B-cell lymphoblastic lymphoma in childhood and adolescence: clinical features, treatment, and results in trials NHL-BFM 86 and 90.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Austria; B-Lymphocytes; Ch | 2000 |
Precursor B-cell lymphoblastic lymphoma in childhood and adolescence: clinical features, treatment, and results in trials NHL-BFM 86 and 90.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Austria; B-Lymphocytes; Ch | 2000 |
Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli asparaginase (COALL-92 and 97 protocols).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2000 |
Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli asparaginase (COALL-92 and 97 protocols).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2000 |
Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli asparaginase (COALL-92 and 97 protocols).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2000 |
[A study on apoptotic cell death during chemotherapy of patients with acute leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Daunorubicin; Humans; Leukemia, Myeloid, | 1998 |
[A study on apoptotic cell death during chemotherapy of patients with acute leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Daunorubicin; Humans; Leukemia, Myeloid, | 1998 |
[A study on apoptotic cell death during chemotherapy of patients with acute leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Daunorubicin; Humans; Leukemia, Myeloid, | 1998 |
Molecular and clinical prognostic factors in BFM-treated childhood acute lymphoblastic leukemia patients: a single institution series.
Topics: Adolescent; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers, Tu | 2000 |
Molecular and clinical prognostic factors in BFM-treated childhood acute lymphoblastic leukemia patients: a single institution series.
Topics: Adolescent; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers, Tu | 2000 |
Molecular and clinical prognostic factors in BFM-treated childhood acute lymphoblastic leukemia patients: a single institution series.
Topics: Adolescent; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers, Tu | 2000 |
Acute lymphoblastic leukemia presenting as acute hepatic failure in childhood.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Child; Diagnosis, Differential; Etoposi | 2000 |
Acute lymphoblastic leukemia presenting as acute hepatic failure in childhood.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Child; Diagnosis, Differential; Etoposi | 2000 |
Acute lymphoblastic leukemia presenting as acute hepatic failure in childhood.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Child; Diagnosis, Differential; Etoposi | 2000 |
Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2000 |
Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2000 |
Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2000 |
Acute lymphoblastic leukemia in infants: a decade of experience in the Czech Republic.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Chromosomes, Hum | 2000 |
Acute lymphoblastic leukemia in infants: a decade of experience in the Czech Republic.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Chromosomes, Hum | 2000 |
Acute lymphoblastic leukemia in infants: a decade of experience in the Czech Republic.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Chromosomes, Hum | 2000 |
[Changes in gonadal function in post-pubertal male survivors of acute lymphoblastic leukemia and Hodgkin's disease].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Child; Cycl | 2000 |
[Changes in gonadal function in post-pubertal male survivors of acute lymphoblastic leukemia and Hodgkin's disease].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Child; Cycl | 2000 |
[Changes in gonadal function in post-pubertal male survivors of acute lymphoblastic leukemia and Hodgkin's disease].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Child; Cycl | 2000 |
Dose-response analysis for radiotherapy delivered to patients with intermediate-grade and large-cell immunoblastic lymphomas that have completely responded to CHOP-based induction chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined | 2001 |
Dose-response analysis for radiotherapy delivered to patients with intermediate-grade and large-cell immunoblastic lymphomas that have completely responded to CHOP-based induction chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined | 2001 |
Dose-response analysis for radiotherapy delivered to patients with intermediate-grade and large-cell immunoblastic lymphomas that have completely responded to CHOP-based induction chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined | 2001 |
Polymorphisms within glutathione S-transferase genes and initial response to glucocorticoids in childhood acute lymphoblastic leukaemia.
Topics: Adolescent; Adult; Case-Control Studies; Child; Child, Preschool; Female; Glucocorticoids; Glutathio | 2000 |
Polymorphisms within glutathione S-transferase genes and initial response to glucocorticoids in childhood acute lymphoblastic leukaemia.
Topics: Adolescent; Adult; Case-Control Studies; Child; Child, Preschool; Female; Glucocorticoids; Glutathio | 2000 |
Polymorphisms within glutathione S-transferase genes and initial response to glucocorticoids in childhood acute lymphoblastic leukaemia.
Topics: Adolescent; Adult; Case-Control Studies; Child; Child, Preschool; Female; Glucocorticoids; Glutathio | 2000 |
[Life threatening hypercalcemia in a young man with ALL].
Topics: Adolescent; Biopsy, Needle; Bone Marrow; Calcitonin; Combined Modality Therapy; Diagnosis, Different | 2001 |
[Life threatening hypercalcemia in a young man with ALL].
Topics: Adolescent; Biopsy, Needle; Bone Marrow; Calcitonin; Combined Modality Therapy; Diagnosis, Different | 2001 |
[Life threatening hypercalcemia in a young man with ALL].
Topics: Adolescent; Biopsy, Needle; Bone Marrow; Calcitonin; Combined Modality Therapy; Diagnosis, Different | 2001 |
Outcome of relapsed or refractory childhood B-cell acute lymphoblastic leukaemia and B-cell non-Hodgkin's lymphoma treated with the UKCCSG 9003/9002 protocols.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Burkitt Lymphoma; Child | 2001 |
Outcome of relapsed or refractory childhood B-cell acute lymphoblastic leukaemia and B-cell non-Hodgkin's lymphoma treated with the UKCCSG 9003/9002 protocols.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Burkitt Lymphoma; Child | 2001 |
Outcome of relapsed or refractory childhood B-cell acute lymphoblastic leukaemia and B-cell non-Hodgkin's lymphoma treated with the UKCCSG 9003/9002 protocols.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Burkitt Lymphoma; Child | 2001 |
Killer T-cell induction in patients with blastic natural killer cell lymphoma/leukaemia: implications for successful treatment and possible therapeutic strategies.
Topics: Aged; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy | 2001 |
Killer T-cell induction in patients with blastic natural killer cell lymphoma/leukaemia: implications for successful treatment and possible therapeutic strategies.
Topics: Aged; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy | 2001 |
Killer T-cell induction in patients with blastic natural killer cell lymphoma/leukaemia: implications for successful treatment and possible therapeutic strategies.
Topics: Aged; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy | 2001 |
Bony morbidity in children treated for acute lymphoblastic leukemia.
Topics: Adolescent; Analysis of Variance; Antineoplastic Agents, Hormonal; Boston; Child; Child, Preschool; | 2001 |
Bony morbidity in children treated for acute lymphoblastic leukemia.
Topics: Adolescent; Analysis of Variance; Antineoplastic Agents, Hormonal; Boston; Child; Child, Preschool; | 2001 |
Bony morbidity in children treated for acute lymphoblastic leukemia.
Topics: Adolescent; Analysis of Variance; Antineoplastic Agents, Hormonal; Boston; Child; Child, Preschool; | 2001 |
Magnetic resonance imaging detection of avascular necrosis of the bone in children receiving intensive prednisone therapy for acute lymphoblastic leukemia or non-Hodgkin lymphoma.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Arthroplasty, R | 2001 |
Magnetic resonance imaging detection of avascular necrosis of the bone in children receiving intensive prednisone therapy for acute lymphoblastic leukemia or non-Hodgkin lymphoma.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Arthroplasty, R | 2001 |
Magnetic resonance imaging detection of avascular necrosis of the bone in children receiving intensive prednisone therapy for acute lymphoblastic leukemia or non-Hodgkin lymphoma.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Arthroplasty, R | 2001 |
Intact T-cell regenerative capacity in childhood acute lymphoblastic leukemia after remission induction therapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 2001 |
Intact T-cell regenerative capacity in childhood acute lymphoblastic leukemia after remission induction therapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 2001 |
Intact T-cell regenerative capacity in childhood acute lymphoblastic leukemia after remission induction therapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 2001 |
Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 2001 |
Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 2001 |
Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 2001 |
[Acute lymphoblastic leukemia complicated with tumor lysis syndrome--four cases report].
Topics: Adult; Allopurinol; Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; F | 1999 |
[Acute lymphoblastic leukemia complicated with tumor lysis syndrome--four cases report].
Topics: Adult; Allopurinol; Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; F | 1999 |
[Acute lymphoblastic leukemia complicated with tumor lysis syndrome--four cases report].
Topics: Adult; Allopurinol; Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; F | 1999 |
Adult lymphoblastic lymphoma in Taiwan: an analysis of treatment results of 26 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow T | 2001 |
Adult lymphoblastic lymphoma in Taiwan: an analysis of treatment results of 26 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow T | 2001 |
Adult lymphoblastic lymphoma in Taiwan: an analysis of treatment results of 26 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow T | 2001 |
Late effects of anticancer therapy on kidney function in children with acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2001 |
Late effects of anticancer therapy on kidney function in children with acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2001 |
Late effects of anticancer therapy on kidney function in children with acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2001 |
[Effective treatment with Lamivudine of patients with reactivation of hepatitis B following chemotherapy administration].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Doxo | 2001 |
[Effective treatment with Lamivudine of patients with reactivation of hepatitis B following chemotherapy administration].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Doxo | 2001 |
[Effective treatment with Lamivudine of patients with reactivation of hepatitis B following chemotherapy administration].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Doxo | 2001 |
Diversity of the apoptotic response to chemotherapy in childhood leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; b | 2002 |
Diversity of the apoptotic response to chemotherapy in childhood leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; b | 2002 |
Diversity of the apoptotic response to chemotherapy in childhood leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; b | 2002 |
Childhood acute lymphoblastic leukemia: prognostic value of initial peripheral blast count in good responders to prednisone.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Child; Child, Preschool; D | 2001 |
Childhood acute lymphoblastic leukemia: prognostic value of initial peripheral blast count in good responders to prednisone.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Child; Child, Preschool; D | 2001 |
Childhood acute lymphoblastic leukemia: prognostic value of initial peripheral blast count in good responders to prednisone.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Child; Child, Preschool; D | 2001 |
Epstein-Barr virus-negative precursor B cell lymphoblastic lymphoma after liver transplantation: a unique form of posttransplant lymphoproliferative disease.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; D | 2002 |
Epstein-Barr virus-negative precursor B cell lymphoblastic lymphoma after liver transplantation: a unique form of posttransplant lymphoproliferative disease.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; D | 2002 |
Epstein-Barr virus-negative precursor B cell lymphoblastic lymphoma after liver transplantation: a unique form of posttransplant lymphoproliferative disease.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; D | 2002 |
No major cognitive impairment in young children with acute lymphoblastic leukemia using chemotherapy only: a prospective longitudinal study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Attention; Child, Preschool; Cognition | 2002 |
No major cognitive impairment in young children with acute lymphoblastic leukemia using chemotherapy only: a prospective longitudinal study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Attention; Child, Preschool; Cognition | 2002 |
No major cognitive impairment in young children with acute lymphoblastic leukemia using chemotherapy only: a prospective longitudinal study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Attention; Child, Preschool; Cognition | 2002 |
Pediatric acute lymphoblastic leukemia: redefining outcomes.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Attention; Child; Child, Preschool; Cogn | 2002 |
Pediatric acute lymphoblastic leukemia: redefining outcomes.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Attention; Child; Child, Preschool; Cogn | 2002 |
Pediatric acute lymphoblastic leukemia: redefining outcomes.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Attention; Child; Child, Preschool; Cogn | 2002 |
CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 2002 |
CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 2002 |
CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 2002 |
Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Daunoru | 2002 |
Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Daunoru | 2002 |
Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Daunoru | 2002 |
[High risk acute lymphoblastic leukaemia in children. Preliminary report after introducing a new version of New York (1997) protocol adjusted to the age of the patients. Report of the Polish Paediatric Leukaemia/Lymphoma Study Group].
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, | 2000 |
[High risk acute lymphoblastic leukaemia in children. Preliminary report after introducing a new version of New York (1997) protocol adjusted to the age of the patients. Report of the Polish Paediatric Leukaemia/Lymphoma Study Group].
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, | 2000 |
[High risk acute lymphoblastic leukaemia in children. Preliminary report after introducing a new version of New York (1997) protocol adjusted to the age of the patients. Report of the Polish Paediatric Leukaemia/Lymphoma Study Group].
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, | 2000 |
[Preliminary results of BFM 96 protocol in treatment of childhood ALL relapse in the experience of the Polish Paediatric Leukaemia /Lymphoma Study Group].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantatio | 2000 |
[Preliminary results of BFM 96 protocol in treatment of childhood ALL relapse in the experience of the Polish Paediatric Leukaemia /Lymphoma Study Group].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantatio | 2000 |
[Preliminary results of BFM 96 protocol in treatment of childhood ALL relapse in the experience of the Polish Paediatric Leukaemia /Lymphoma Study Group].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantatio | 2000 |
Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Société Française d'Oncologie Pédiatrique LMB89 protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide | 2002 |
Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Société Française d'Oncologie Pédiatrique LMB89 protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide | 2002 |
Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Société Française d'Oncologie Pédiatrique LMB89 protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide | 2002 |
Fifteen-year secondary leukaemia risk observed in 761 patients with Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy plus high-dose irradiation.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbaz | 2002 |
Fifteen-year secondary leukaemia risk observed in 761 patients with Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy plus high-dose irradiation.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbaz | 2002 |
Fifteen-year secondary leukaemia risk observed in 761 patients with Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy plus high-dose irradiation.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbaz | 2002 |
Cytomegalovirus infection in children with blood diseases.
Topics: Adolescent; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; C | 1992 |
Cytomegalovirus infection in children with blood diseases.
Topics: Adolescent; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; C | 1992 |
Cytomegalovirus infection in children with blood diseases.
Topics: Adolescent; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; C | 1992 |
Analyses of salivary components in leukemia patients receiving chemotherapy.
Topics: Adolescent; Adult; Aged; Amylases; Analysis of Variance; Antibiotics, Antineoplastic; Antineoplastic | 1992 |
Analyses of salivary components in leukemia patients receiving chemotherapy.
Topics: Adolescent; Adult; Aged; Amylases; Analysis of Variance; Antibiotics, Antineoplastic; Antineoplastic | 1992 |
Analyses of salivary components in leukemia patients receiving chemotherapy.
Topics: Adolescent; Adult; Aged; Amylases; Analysis of Variance; Antibiotics, Antineoplastic; Antineoplastic | 1992 |
[Treatment of elderly patients with hematological malignancies].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modalit | 1992 |
[Treatment of elderly patients with hematological malignancies].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modalit | 1992 |
[Treatment of elderly patients with hematological malignancies].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modalit | 1992 |
[Treatment of various types of acute leukemia in adult. An analysis of 98 cases. The Leukemia Cooperation Group of Beijing City].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabin | 1992 |
[Treatment of various types of acute leukemia in adult. An analysis of 98 cases. The Leukemia Cooperation Group of Beijing City].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabin | 1992 |
[Treatment of various types of acute leukemia in adult. An analysis of 98 cases. The Leukemia Cooperation Group of Beijing City].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabin | 1992 |
Incidence of thrombotic complications in adult patients with acute lymphoblastic leukaemia receiving L-asparaginase during induction therapy: a retrospective study. The GIMEMA Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Antithrombins; Asparaginase | 1992 |
Incidence of thrombotic complications in adult patients with acute lymphoblastic leukaemia receiving L-asparaginase during induction therapy: a retrospective study. The GIMEMA Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Antithrombins; Asparaginase | 1992 |
Incidence of thrombotic complications in adult patients with acute lymphoblastic leukaemia receiving L-asparaginase during induction therapy: a retrospective study. The GIMEMA Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Antithrombins; Asparaginase | 1992 |
Relation of 5'-nucleotidase and phosphatase activities with immunophenotype, drug resistance and clinical prognosis in childhood leukemia.
Topics: 5'-Nucleotidase; Acid Phosphatase; Adolescent; Alkaline Phosphatase; Antineoplastic Combined Chemoth | 1992 |
Relation of 5'-nucleotidase and phosphatase activities with immunophenotype, drug resistance and clinical prognosis in childhood leukemia.
Topics: 5'-Nucleotidase; Acid Phosphatase; Adolescent; Alkaline Phosphatase; Antineoplastic Combined Chemoth | 1992 |
Relation of 5'-nucleotidase and phosphatase activities with immunophenotype, drug resistance and clinical prognosis in childhood leukemia.
Topics: 5'-Nucleotidase; Acid Phosphatase; Adolescent; Alkaline Phosphatase; Antineoplastic Combined Chemoth | 1992 |
[Disparity of the bone marrow involvement in a 5-year-old boy with primary non-Hodgkin's malignant lymphoma of the bone].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Bone Neoplasms; Child, Pr | 1992 |
[Disparity of the bone marrow involvement in a 5-year-old boy with primary non-Hodgkin's malignant lymphoma of the bone].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Bone Neoplasms; Child, Pr | 1992 |
[Disparity of the bone marrow involvement in a 5-year-old boy with primary non-Hodgkin's malignant lymphoma of the bone].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Bone Neoplasms; Child, Pr | 1992 |
Childhood acute lymphoblastic leukemia immunophenotypes and their prognostic significance: experience of the IGCI-study in 389 children. International Society for Chemo-immunotherapy (IGCI-Vienna) Cooperative Group.
Topics: Adolescent; Age Factors; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; | 1992 |
Childhood acute lymphoblastic leukemia immunophenotypes and their prognostic significance: experience of the IGCI-study in 389 children. International Society for Chemo-immunotherapy (IGCI-Vienna) Cooperative Group.
Topics: Adolescent; Age Factors; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; | 1992 |
Childhood acute lymphoblastic leukemia immunophenotypes and their prognostic significance: experience of the IGCI-study in 389 children. International Society for Chemo-immunotherapy (IGCI-Vienna) Cooperative Group.
Topics: Adolescent; Age Factors; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; | 1992 |
Growth after radiotherapy and chemotherapy in children with leukemia or lymphoma.
Topics: Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparag | 1992 |
Growth after radiotherapy and chemotherapy in children with leukemia or lymphoma.
Topics: Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparag | 1992 |
Growth after radiotherapy and chemotherapy in children with leukemia or lymphoma.
Topics: Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparag | 1992 |
[Anemia and recurrences in acute lymphoblastic leukemia in children after the treatment and the frequency of the erythroblasts with micronuclei].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; beta-Thalassemia; Bone Mar | 1992 |
[Anemia and recurrences in acute lymphoblastic leukemia in children after the treatment and the frequency of the erythroblasts with micronuclei].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; beta-Thalassemia; Bone Mar | 1992 |
[Anemia and recurrences in acute lymphoblastic leukemia in children after the treatment and the frequency of the erythroblasts with micronuclei].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; beta-Thalassemia; Bone Mar | 1992 |
Corticosteroid induced tumor lysis syndrome in acute lymphoblastic leukemia.
Topics: Adrenal Cortex Hormones; Adult; Female; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pred | 1992 |
Corticosteroid induced tumor lysis syndrome in acute lymphoblastic leukemia.
Topics: Adrenal Cortex Hormones; Adult; Female; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pred | 1992 |
Corticosteroid induced tumor lysis syndrome in acute lymphoblastic leukemia.
Topics: Adrenal Cortex Hormones; Adult; Female; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pred | 1992 |
[High dose cinobufocini in attenuation and treatment of infection and granulocytopenia during combined chemotherapy of malignant blood diseases].
Topics: Adolescent; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Bufanolide | 1992 |
[High dose cinobufocini in attenuation and treatment of infection and granulocytopenia during combined chemotherapy of malignant blood diseases].
Topics: Adolescent; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Bufanolide | 1992 |
[High dose cinobufocini in attenuation and treatment of infection and granulocytopenia during combined chemotherapy of malignant blood diseases].
Topics: Adolescent; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Bufanolide | 1992 |
Cellular immunosuppression in children with acute lymphoblastic leukemia: effect of consolidation chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; | 1992 |
Cellular immunosuppression in children with acute lymphoblastic leukemia: effect of consolidation chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; | 1992 |
Cellular immunosuppression in children with acute lymphoblastic leukemia: effect of consolidation chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; | 1992 |
[Tactics of adjuvant therapy in the treatment of acute lymphoblastic leukemia according to the BFM program].
Topics: Adolescent; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined | 1992 |
[Tactics of adjuvant therapy in the treatment of acute lymphoblastic leukemia according to the BFM program].
Topics: Adolescent; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined | 1992 |
[Tactics of adjuvant therapy in the treatment of acute lymphoblastic leukemia according to the BFM program].
Topics: Adolescent; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined | 1992 |
Management of children with acute lymphoblastic leukemia by the Dana-Farber Cancer Institute protocols. An update of the Ontario experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cohort Studie | 1992 |
Management of children with acute lymphoblastic leukemia by the Dana-Farber Cancer Institute protocols. An update of the Ontario experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cohort Studie | 1992 |
Management of children with acute lymphoblastic leukemia by the Dana-Farber Cancer Institute protocols. An update of the Ontario experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cohort Studie | 1992 |
Therapeutic adherence to oral medication regimens by adolescents with cancer. I. Laboratory assessment.
Topics: Administration, Oral; Adolescent; Adult; Ambulatory Care; Biological Assay; Dehydroepiandrosterone; | 1992 |
Therapeutic adherence to oral medication regimens by adolescents with cancer. I. Laboratory assessment.
Topics: Administration, Oral; Adolescent; Adult; Ambulatory Care; Biological Assay; Dehydroepiandrosterone; | 1992 |
Therapeutic adherence to oral medication regimens by adolescents with cancer. I. Laboratory assessment.
Topics: Administration, Oral; Adolescent; Adult; Ambulatory Care; Biological Assay; Dehydroepiandrosterone; | 1992 |
Therapeutic adherence to oral medication regimens by adolescents with cancer. II. Clinical and psychologic correlates.
Topics: Administration, Oral; Adolescent; Adult; Ambulatory Care; Attitude to Health; Denial, Psychological; | 1992 |
Therapeutic adherence to oral medication regimens by adolescents with cancer. II. Clinical and psychologic correlates.
Topics: Administration, Oral; Adolescent; Adult; Ambulatory Care; Attitude to Health; Denial, Psychological; | 1992 |
Therapeutic adherence to oral medication regimens by adolescents with cancer. II. Clinical and psychologic correlates.
Topics: Administration, Oral; Adolescent; Adult; Ambulatory Care; Attitude to Health; Denial, Psychological; | 1992 |
[Late recurrence (11 years) in a case of ALL. Recurrence or a second disease?].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Central Nervous System Neo | 1992 |
[Late recurrence (11 years) in a case of ALL. Recurrence or a second disease?].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Central Nervous System Neo | 1992 |
[Late recurrence (11 years) in a case of ALL. Recurrence or a second disease?].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Central Nervous System Neo | 1992 |
Use of a synthetic protease inhibitor for the treatment of L-asparaginase-induced acute pancreatitis complicated by disseminated intravascular coagulation.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Benz | 1992 |
Use of a synthetic protease inhibitor for the treatment of L-asparaginase-induced acute pancreatitis complicated by disseminated intravascular coagulation.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Benz | 1992 |
Use of a synthetic protease inhibitor for the treatment of L-asparaginase-induced acute pancreatitis complicated by disseminated intravascular coagulation.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Benz | 1992 |
Intensive chemotherapy for adult lymphoblastic lymphomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dexamethasone; D | 1991 |
Intensive chemotherapy for adult lymphoblastic lymphomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dexamethasone; D | 1991 |
Intensive chemotherapy for adult lymphoblastic lymphomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dexamethasone; D | 1991 |
Behavioral effects of corticosteroids in children with acute lymphoblastic leukemia.
Topics: Age Factors; Analysis of Variance; Attention; Child; Child Behavior; Child, Preschool; Cytarabine; D | 1992 |
Behavioral effects of corticosteroids in children with acute lymphoblastic leukemia.
Topics: Age Factors; Analysis of Variance; Attention; Child; Child Behavior; Child, Preschool; Cytarabine; D | 1992 |
Behavioral effects of corticosteroids in children with acute lymphoblastic leukemia.
Topics: Age Factors; Analysis of Variance; Attention; Child; Child Behavior; Child, Preschool; Cytarabine; D | 1992 |
Bone marrow necrosis and thrombotic complications in childhood acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blood Proteins; Bone Marrow; Child; Ch | 1992 |
Bone marrow necrosis and thrombotic complications in childhood acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blood Proteins; Bone Marrow; Child; Ch | 1992 |
Bone marrow necrosis and thrombotic complications in childhood acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blood Proteins; Bone Marrow; Child; Ch | 1992 |
Treatment of relapsed or refractory adult acute lymphocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Cy | 1992 |
Treatment of relapsed or refractory adult acute lymphocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Cy | 1992 |
Treatment of relapsed or refractory adult acute lymphocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Cy | 1992 |
Results of the LMT81 protocol, a modified LSA2L2 protocol with high dose methotrexate, on 84 children with non-B-cell (lymphoblastic) lymphoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Child, Preschool; Cy | 1992 |
Results of the LMT81 protocol, a modified LSA2L2 protocol with high dose methotrexate, on 84 children with non-B-cell (lymphoblastic) lymphoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Child, Preschool; Cy | 1992 |
Results of the LMT81 protocol, a modified LSA2L2 protocol with high dose methotrexate, on 84 children with non-B-cell (lymphoblastic) lymphoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Child, Preschool; Cy | 1992 |
Prognostic factors and outcome of therapy in adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Doxorubicin; | 1991 |
Prognostic factors and outcome of therapy in adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Doxorubicin; | 1991 |
Prognostic factors and outcome of therapy in adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Doxorubicin; | 1991 |
Laboratory correlates and prognostic significance of granular acute lymphoblastic leukemia in children. A Pediatric Oncology Group study.
Topics: Azure Stains; Child; Child, Preschool; Cytoplasmic Granules; Histocytochemistry; Humans; Immunopheno | 1991 |
Laboratory correlates and prognostic significance of granular acute lymphoblastic leukemia in children. A Pediatric Oncology Group study.
Topics: Azure Stains; Child; Child, Preschool; Cytoplasmic Granules; Histocytochemistry; Humans; Immunopheno | 1991 |
Laboratory correlates and prognostic significance of granular acute lymphoblastic leukemia in children. A Pediatric Oncology Group study.
Topics: Azure Stains; Child; Child, Preschool; Cytoplasmic Granules; Histocytochemistry; Humans; Immunopheno | 1991 |
Effect of corticoid therapy on growth hormone secretion.
Topics: Arginine; Child; Child, Preschool; Female; Growth; Growth Hormone; Growth Hormone-Releasing Hormone; | 1991 |
Effect of corticoid therapy on growth hormone secretion.
Topics: Arginine; Child; Child, Preschool; Female; Growth; Growth Hormone; Growth Hormone-Releasing Hormone; | 1991 |
Effect of corticoid therapy on growth hormone secretion.
Topics: Arginine; Child; Child, Preschool; Female; Growth; Growth Hormone; Growth Hormone-Releasing Hormone; | 1991 |
[The fate of children after discontinuation of treatment for acute lymphoblastic leukemia].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 1991 |
[The fate of children after discontinuation of treatment for acute lymphoblastic leukemia].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 1991 |
[The fate of children after discontinuation of treatment for acute lymphoblastic leukemia].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 1991 |
Skin manifestation of extramedullary relapse in adult with acute lymphoblastic leukaemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; C | 1991 |
Skin manifestation of extramedullary relapse in adult with acute lymphoblastic leukaemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; C | 1991 |
Skin manifestation of extramedullary relapse in adult with acute lymphoblastic leukaemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; C | 1991 |
Immunization response varies with intensity of acute lymphoblastic leukemia therapy.
Topics: Antibodies, Bacterial; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bacterial Capsu | 1991 |
Immunization response varies with intensity of acute lymphoblastic leukemia therapy.
Topics: Antibodies, Bacterial; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bacterial Capsu | 1991 |
Immunization response varies with intensity of acute lymphoblastic leukemia therapy.
Topics: Antibodies, Bacterial; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bacterial Capsu | 1991 |
The F-MACHOP regimen in advanced diffuse aggressive lymphomas: summary of ten years' experience at a single institution.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Fluoroura | 1991 |
The F-MACHOP regimen in advanced diffuse aggressive lymphomas: summary of ten years' experience at a single institution.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Fluoroura | 1991 |
The F-MACHOP regimen in advanced diffuse aggressive lymphomas: summary of ten years' experience at a single institution.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Fluoroura | 1991 |
Acute tumour lysis syndrome in a patient with acute lymphoblastic leukemia after a single dose of prednisone.
Topics: Acute Disease; Adolescent; Humans; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; | 1991 |
Acute tumour lysis syndrome in a patient with acute lymphoblastic leukemia after a single dose of prednisone.
Topics: Acute Disease; Adolescent; Humans; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; | 1991 |
Acute tumour lysis syndrome in a patient with acute lymphoblastic leukemia after a single dose of prednisone.
Topics: Acute Disease; Adolescent; Humans; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; | 1991 |
Decreased cytotoxic potential of fresh and recombinant interleukin 2-cultured large granular lymphocytes in childhood acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cells, Cultured; Child; Cytotoxicity, | 1991 |
Decreased cytotoxic potential of fresh and recombinant interleukin 2-cultured large granular lymphocytes in childhood acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cells, Cultured; Child; Cytotoxicity, | 1991 |
Decreased cytotoxic potential of fresh and recombinant interleukin 2-cultured large granular lymphocytes in childhood acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cells, Cultured; Child; Cytotoxicity, | 1991 |
[Granular CALLA-positive acute lymphoblastic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers, Tumor; Child, Preschool; C | 1990 |
[Granular CALLA-positive acute lymphoblastic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers, Tumor; Child, Preschool; C | 1990 |
[Granular CALLA-positive acute lymphoblastic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers, Tumor; Child, Preschool; C | 1990 |
Prognosis of acute lymphoblastic leukaemia in Ibadan, Nigeria.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Drug Combinations; Hos | 1990 |
Prognosis of acute lymphoblastic leukaemia in Ibadan, Nigeria.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Drug Combinations; Hos | 1990 |
Prognosis of acute lymphoblastic leukaemia in Ibadan, Nigeria.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Drug Combinations; Hos | 1990 |
Multiagent chemotherapy in relapsed acute lymphoblastic leukemia in children.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Presc | 1990 |
Multiagent chemotherapy in relapsed acute lymphoblastic leukemia in children.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Presc | 1990 |
Multiagent chemotherapy in relapsed acute lymphoblastic leukemia in children.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Presc | 1990 |
Osteonecrosis in pediatric patients with acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Dexamethasone; Female; Femur; Fem | 1990 |
Osteonecrosis in pediatric patients with acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Dexamethasone; Female; Femur; Fem | 1990 |
Osteonecrosis in pediatric patients with acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Dexamethasone; Female; Femur; Fem | 1990 |
[Successful induction chemotherapy after colectomy in a case of acute lymphoblastic leukemia associated with obstructive ileus caused by sigmoid colon carcinoma].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Colectomy; Combined Modality | 1990 |
[Successful induction chemotherapy after colectomy in a case of acute lymphoblastic leukemia associated with obstructive ileus caused by sigmoid colon carcinoma].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Colectomy; Combined Modality | 1990 |
[Successful induction chemotherapy after colectomy in a case of acute lymphoblastic leukemia associated with obstructive ileus caused by sigmoid colon carcinoma].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Colectomy; Combined Modality | 1990 |
[Transverse leukonychia and anti-leukemia chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child, Preschool; Cyclophosphamide | 1990 |
[Transverse leukonychia and anti-leukemia chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child, Preschool; Cyclophosphamide | 1990 |
[Transverse leukonychia and anti-leukemia chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child, Preschool; Cyclophosphamide | 1990 |
Successful treatment of adult acute lymphoblastic leukemia after relapse with prednisone, intermediate-dose cytarabine, mitoxantrone, and etoposide (PAME) chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Comb | 1990 |
Successful treatment of adult acute lymphoblastic leukemia after relapse with prednisone, intermediate-dose cytarabine, mitoxantrone, and etoposide (PAME) chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Comb | 1990 |
Successful treatment of adult acute lymphoblastic leukemia after relapse with prednisone, intermediate-dose cytarabine, mitoxantrone, and etoposide (PAME) chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Comb | 1990 |
Dehydroepiandrosterone sulfate levels are not suppressible by glucocorticoids before adrenarche.
Topics: Adolescent; Adrenal Cortex Hormones; Child, Preschool; Dehydroepiandrosterone; Dehydroepiandrosteron | 1989 |
Dehydroepiandrosterone sulfate levels are not suppressible by glucocorticoids before adrenarche.
Topics: Adolescent; Adrenal Cortex Hormones; Child, Preschool; Dehydroepiandrosterone; Dehydroepiandrosteron | 1989 |
Dehydroepiandrosterone sulfate levels are not suppressible by glucocorticoids before adrenarche.
Topics: Adolescent; Adrenal Cortex Hormones; Child, Preschool; Dehydroepiandrosterone; Dehydroepiandrosteron | 1989 |
Immunoreactive beta-endorphin levels in cerebrospinal fluid of children with acute lymphoblastic leukemia: relationship with glucocorticoid therapy and neurological complications.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; beta-Endorphin; Child; Child, Preschool; | 1989 |
Immunoreactive beta-endorphin levels in cerebrospinal fluid of children with acute lymphoblastic leukemia: relationship with glucocorticoid therapy and neurological complications.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; beta-Endorphin; Child; Child, Preschool; | 1989 |
Immunoreactive beta-endorphin levels in cerebrospinal fluid of children with acute lymphoblastic leukemia: relationship with glucocorticoid therapy and neurological complications.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; beta-Endorphin; Child; Child, Preschool; | 1989 |
Maintenance chemotherapy for childhood acute lymphoblastic leukemia: relation of bone-marrow and hepatotoxicity to the concentration of methotrexate in erythrocytes.
Topics: Administration, Oral; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child | 1989 |
Maintenance chemotherapy for childhood acute lymphoblastic leukemia: relation of bone-marrow and hepatotoxicity to the concentration of methotrexate in erythrocytes.
Topics: Administration, Oral; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child | 1989 |
Maintenance chemotherapy for childhood acute lymphoblastic leukemia: relation of bone-marrow and hepatotoxicity to the concentration of methotrexate in erythrocytes.
Topics: Administration, Oral; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child | 1989 |
[Study of reinduction chemotherapy in bone marrow relapse of childhood acute lymphoblastic leukemia].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Child; | 1989 |
[Study of reinduction chemotherapy in bone marrow relapse of childhood acute lymphoblastic leukemia].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Child; | 1989 |
[Study of reinduction chemotherapy in bone marrow relapse of childhood acute lymphoblastic leukemia].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Child; | 1989 |
Attenuation of asparaginase-induced hyperglycemia after substitution of the Erwinia carotovora for the Escherichia coli enzyme preparation.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child, Preschool; Erwinia; | 1989 |
Attenuation of asparaginase-induced hyperglycemia after substitution of the Erwinia carotovora for the Escherichia coli enzyme preparation.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child, Preschool; Erwinia; | 1989 |
Attenuation of asparaginase-induced hyperglycemia after substitution of the Erwinia carotovora for the Escherichia coli enzyme preparation.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child, Preschool; Erwinia; | 1989 |
Reinduction therapy for advanced or refractory acute lymphoblastic leukemia of childhood.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transpl | 1989 |
Reinduction therapy for advanced or refractory acute lymphoblastic leukemia of childhood.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transpl | 1989 |
Reinduction therapy for advanced or refractory acute lymphoblastic leukemia of childhood.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transpl | 1989 |
Pharmacokinetics of prednisolone in children with acute lymphoblastic leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female; Half-Life; Humans; | 1989 |
Pharmacokinetics of prednisolone in children with acute lymphoblastic leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female; Half-Life; Humans; | 1989 |
Pharmacokinetics of prednisolone in children with acute lymphoblastic leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female; Half-Life; Humans; | 1989 |
Management of Ontario children with acute lymphoblastic leukemia by the Dana-Farber Cancer Institute protocols.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Boston; Child; Clinical Protocols; Fem | 1989 |
Management of Ontario children with acute lymphoblastic leukemia by the Dana-Farber Cancer Institute protocols.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Boston; Child; Clinical Protocols; Fem | 1989 |
Management of Ontario children with acute lymphoblastic leukemia by the Dana-Farber Cancer Institute protocols.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Boston; Child; Clinical Protocols; Fem | 1989 |
Inappropriate increase in erythropoietin titers during chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Asparaginase; Cyclophosphamide; Cytarabine; Daunorubicin; Erythr | 1989 |
Inappropriate increase in erythropoietin titers during chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Asparaginase; Cyclophosphamide; Cytarabine; Daunorubicin; Erythr | 1989 |
Inappropriate increase in erythropoietin titers during chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Asparaginase; Cyclophosphamide; Cytarabine; Daunorubicin; Erythr | 1989 |
Avascular necrosis of the femoral head in acute leukemia patients treated with combination therapy including steroids.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Femur Head Necrosis; Huma | 1989 |
Avascular necrosis of the femoral head in acute leukemia patients treated with combination therapy including steroids.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Femur Head Necrosis; Huma | 1989 |
Avascular necrosis of the femoral head in acute leukemia patients treated with combination therapy including steroids.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Femur Head Necrosis; Huma | 1989 |
[Intravenous immunoglobulin preparations in the adjuvant treatment of acute lymphoblastic leukemia in children].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 1988 |
[Intravenous immunoglobulin preparations in the adjuvant treatment of acute lymphoblastic leukemia in children].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 1988 |
[Intravenous immunoglobulin preparations in the adjuvant treatment of acute lymphoblastic leukemia in children].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 1988 |
High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Cytarabin | 1987 |
High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Cytarabin | 1987 |
High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Cytarabin | 1987 |
Changes in the EEG background activity of children with acute lymphoblastic leukemia during cytotoxic therapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Brain Diseases; Child; Chi | 1987 |
Changes in the EEG background activity of children with acute lymphoblastic leukemia during cytotoxic therapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Brain Diseases; Child; Chi | 1987 |
Changes in the EEG background activity of children with acute lymphoblastic leukemia during cytotoxic therapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Brain Diseases; Child; Chi | 1987 |
Convulsions and intracranial calcifications in a leukemic infant receiving only intrathecal methotrexate as central nervous system prophylaxis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Brain Diseases; Calcinosis; Cyclophosp | 1987 |
Convulsions and intracranial calcifications in a leukemic infant receiving only intrathecal methotrexate as central nervous system prophylaxis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Brain Diseases; Calcinosis; Cyclophosp | 1987 |
Convulsions and intracranial calcifications in a leukemic infant receiving only intrathecal methotrexate as central nervous system prophylaxis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Brain Diseases; Calcinosis; Cyclophosp | 1987 |
Fungal pneumonias masquerading as thromboses during induction therapy of acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Aspergillosis; Child, Preschool; Dauno | 1986 |
Fungal pneumonias masquerading as thromboses during induction therapy of acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Aspergillosis; Child, Preschool; Dauno | 1986 |
Fungal pneumonias masquerading as thromboses during induction therapy of acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Aspergillosis; Child, Preschool; Dauno | 1986 |
Childhood non-Hodgkin's lymphoma and "leukemia-lymphoma syndrome": long-term results with the modified LSA2-L2 protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Cranial Irradiatio | 1986 |
Childhood non-Hodgkin's lymphoma and "leukemia-lymphoma syndrome": long-term results with the modified LSA2-L2 protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Cranial Irradiatio | 1986 |
Childhood non-Hodgkin's lymphoma and "leukemia-lymphoma syndrome": long-term results with the modified LSA2-L2 protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Cranial Irradiatio | 1986 |
An overdose of vincristine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Epilepsy, Tonic-Clonic; Humans; Ma | 1987 |
An overdose of vincristine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Epilepsy, Tonic-Clonic; Humans; Ma | 1987 |
An overdose of vincristine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Epilepsy, Tonic-Clonic; Humans; Ma | 1987 |
Reinduction therapy in 297 children with acute lymphoblastic leukemia in first bone marrow relapse: a Pediatric Oncology Group Study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Child; Daunorubici | 1988 |
Reinduction therapy in 297 children with acute lymphoblastic leukemia in first bone marrow relapse: a Pediatric Oncology Group Study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Child; Daunorubici | 1988 |
Reinduction therapy in 297 children with acute lymphoblastic leukemia in first bone marrow relapse: a Pediatric Oncology Group Study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Child; Daunorubici | 1988 |
Secondary mania with steroid withdrawal.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bipolar Disorder; Dose-Response Relationship, | 1988 |
Secondary mania with steroid withdrawal.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bipolar Disorder; Dose-Response Relationship, | 1988 |
Secondary mania with steroid withdrawal.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bipolar Disorder; Dose-Response Relationship, | 1988 |
[Long-term survival following acute lymphoblastic leukemia (ALL) in childhood].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 1988 |
[Long-term survival following acute lymphoblastic leukemia (ALL) in childhood].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 1988 |
[Long-term survival following acute lymphoblastic leukemia (ALL) in childhood].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 1988 |
Short-term intensive treatment (V.A.A.P.) of adult acute lymphoblastic leukemia and lymphoblastic lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytara | 1988 |
Short-term intensive treatment (V.A.A.P.) of adult acute lymphoblastic leukemia and lymphoblastic lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytara | 1988 |
Short-term intensive treatment (V.A.A.P.) of adult acute lymphoblastic leukemia and lymphoblastic lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytara | 1988 |
[Acute lymphoblastic leukemia in adults: results of the DATOP-79 protocol].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; D | 1988 |
[Acute lymphoblastic leukemia in adults: results of the DATOP-79 protocol].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; D | 1988 |
[Acute lymphoblastic leukemia in adults: results of the DATOP-79 protocol].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; D | 1988 |
The influence of corticosteroids on human erythropoiesis. An in vivo study.
Topics: Child; Erythropoiesis; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Purpura, | 1988 |
The influence of corticosteroids on human erythropoiesis. An in vivo study.
Topics: Child; Erythropoiesis; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Purpura, | 1988 |
The influence of corticosteroids on human erythropoiesis. An in vivo study.
Topics: Child; Erythropoiesis; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Purpura, | 1988 |
[Preliminary evaluation of the treatment of recurrences of acute lymphoblastic leukemia by the BFM (Henze) method].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 1988 |
[Preliminary evaluation of the treatment of recurrences of acute lymphoblastic leukemia by the BFM (Henze) method].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 1988 |
[Preliminary evaluation of the treatment of recurrences of acute lymphoblastic leukemia by the BFM (Henze) method].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 1988 |
[Effect of prognostic factors on the course of acute lymphoblastic leukemia in children].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 1988 |
[Effect of prognostic factors on the course of acute lymphoblastic leukemia in children].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 1988 |
[Effect of prognostic factors on the course of acute lymphoblastic leukemia in children].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 1988 |
Deoxycoformycin treatment for childhood T-cell acute lymphoblastic leukemia early in second remission: a Pediatric Oncology Group Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Coformycin; Cytarabine; Daunoru | 1988 |
Deoxycoformycin treatment for childhood T-cell acute lymphoblastic leukemia early in second remission: a Pediatric Oncology Group Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Coformycin; Cytarabine; Daunoru | 1988 |
Deoxycoformycin treatment for childhood T-cell acute lymphoblastic leukemia early in second remission: a Pediatric Oncology Group Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Coformycin; Cytarabine; Daunoru | 1988 |
Plasma protein fractions and alpha 1-acidglycoprotein as tumor markers in acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers, Tumor; Blood Proteins; Bra | 1987 |
Plasma protein fractions and alpha 1-acidglycoprotein as tumor markers in acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers, Tumor; Blood Proteins; Bra | 1987 |
Plasma protein fractions and alpha 1-acidglycoprotein as tumor markers in acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers, Tumor; Blood Proteins; Bra | 1987 |